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Iminosugars, carbohydrate mimetics that feature a nitrogen atom substituting the 
furanose/pyranose ring oxygen in the parent sugar they emulate (Figure 1), are widely spread 
in nature.1 Iminosugars are highly sought-after commodities because of their potential to 
inhibit glycoprocessing enzymes, with potential application in buffering diet polysaccharide 
degradation and in modulating glycoconjugate metabolism.2 Today, iminosugars are in clinical 
use, or are considered as suitable leads for clinical development, for a range of human 
disorders including lysosomal storage disorders, type 2 diabetes, cancer, bacterial infections 
and viral infections.3 




Natural occurrence and biological activities 
The naturally occurring iminosugars can be classified in several structural classes, 
including pyrrolidines, piperidines, indolizidines, pyrrolizidines and nortropanes (Figure 1). 
The first iminosugar discovered from natural sources is nojirimycin (NJ, 2), which was isolated 
in 1966.4 Nojirimycin is a close glucopyranose analogue that only differs from glucose in the 
nature of the heteroatom within the ring: nitrogen instead of oxygen (Figure 1).  Nojirimycin is 
a potent inhibitor of various glucosidases, however the highly acid-labile hemi-aminal moiety 
that characterizes nojirimycin also renders the compound relatively unstable in physiological 
conditions. 1-Deoxynojirimycin (DNJ, 1) is a comparably much more stable compound that 
however possesses very similar biological properties. DNJ was synthesized in 19685 and 
isolated from plants in 1976,6 and is a potent inhibitor of a large number of α-glucosidases as 
well as β-glucosidases.7,-8 1,4-Dideoxy-1,4-imino-D-arabinitol (DAB, 3), and 2R,5R- 
dihydroxymethyl-3R,4R-dihydroxy-pyrrolidine (DMDP, 4) are representative examples of 
naturally occurring pyrrolidine iminosugars and have been isolated from tropical and 
temperate plants.9 Pyrrolidine 3 is a potent inhibitor of α-glucosidases, β-glucosidases and α-
mannosidases,10 and its close structural analogue 4 inhibits a wide range of glycosidases as 
well.11 
Figure 1: Structures of different classes of iminosugars 
 
Bicyclic iminosugars abound in nature as well and are also often quite potent glycosidase 
inhibitors. The archetypal indolizidine iminosugar, castanospermine (5), isolated from 
Leguminosae, is an inhibitor of both α-glucosidases and β-glucosidases, thus resembling the 
activity profile of DNJ 1.12-16 Swainsoine (6), isolated from leaves, stems and seeds of various 





inhibitor.19 A relevant pyrrolizidine iminosugar comprises australine (7), an inhibitor of both 
α-glucosidases and β-glucosidases that is found in Leguminosae seeds and leaves.20 Calystegine 
B1 (8) is a tetra-hydroxyl nortropanes alkaloids isolated from Convolvulaceae, and found to be 
a strong inhibitor of glucocerebrosidase.21 
Clinical relevance 
Iminosugars have long been regarded as promising starting points for drug development 
and today several iminosugars are in clinical use for the treatment of a number of human 
diseases. One early example of the therapeutic use of iminosugar-containing material 
comprises the application of mulberry leaves and bark, in Asia many years ago, for the 
treatment of diabetes. Several decades ago, both NJ and DNJ were isolated from mulberry 
leaves, and subsequently shown to inhibit of intestinal digestive glycosidases, thus affecting 
the digestion and absorption of carbohydrates. On the basis of DNJ, the antidiabetic agent, 
Miglitol (9), which has a better activity and selectivity compared with DNJ, was developed. 
Today, Miglitol is in clinical use for the oral treatment of type II diabetes. 
Figure 2: Structures of Miglitol and isofagomine 
 
 
Another glycoprocessing enzyme associated with diabetes is hepatic glycogen 
phosphorylase. Hepatic glucose levels are increased in type II diabetes patients22 and it is 
thought that buffering glucose levels can be effected through inhibition of hepatic glycogen 
phosphorylase. DAB (3, Figure 1) proved to be a potent hepatic glycogen phosphorylase 
inhibitor and by this virtue lowers gluconeogenesis from hepatic glycogen.23 Isofagomine (10) 
is another potent hepatic glycogen phosphorylase inhibitor, and is also able to partially 
prevent gluconeogenesis in animal models.24 
Perhaps the most successful application of iminosugars in therapy is found in the area of 
lysosomal storage disorders, in particular Gaucher disease. Lysosomal storage disorders (LSD) 
comprise about 50 inherited diseases, each caused by inherited, genetic mutations in 
particular lysosomal proteins, most commonly hydrolytic enzymes. Gaucher disease is a 




perhaps the best studied member of the LSD family and several therapeutic intervention 
strategies are in clinical practice or are in clinical development. Gaucher disease is 
characterized by partial or complete (depending on the nature of the mutation) dysfunctional 
lysosomal glucosylceramidase (GBA1). GBA1 hydrolyses the interglycosidic linkage in 
glucosylceramide and (partial) deficiency in GBA1 leads to accumulation of this substrate as 
well as the unusual lysolipid, glucosylsphingosine. Gaucher pathology likely is partially caused 
by accumulation of these lipids. Gaucher patients (at least those suffering from relatively mild 
Gaucher as the result of partial, but not complete, impairment in GBA1) can be treated 
intravenously with recombinant GBA1 in what is termed enzyme replacement therapy (ERT). 
Alternatively, the enzyme responsible for the synthesis of the primary storage material in 
Gaucher disease, glucosylceramide synthase (GCS, producing glucosylceramide from UDP-
glucose and ceramide) can be partially inhibited by N-butyl-deoxynojirimycin (13, marketed as 
Zavesca) in what has become known as substrate reduction therapy (SRT). Not clinical practice 
yet but an approach receiving considerable attention from academia and pharmaceutical 
industry alike is termed pharmacological chaperone therapy (PCT), which aims at stabilizing 
genetically impaired GBA1 to such an extent that (close to) normal glucosylceramide levels are 
reached. N-Nonyl-deoxynojirimycin (12) is a competitive GBA1 inhibitor that is under 
investigation as a pharmacological chaperone.25 Its mode of action relies on its inhibitory 
activity: by active site occupation the enzyme ‘folds’ around the inhibitor and thus retains its 
active conformation. CMT has in fact reached the clinic for another LSD: Fabry disease 
(characterized by genetic deficiency in lysosomal alpha-galactosidase). N-Butyl-
deoxygalactonojirimycin, or migalastat (11) is an α-galactosidase inhibitor and patients 
suffering from Fabry disease26 can be treated with this compound, in combination with 
recombinant α-galactosidase (thus, a combined ERT/PCT treatment regime). 
Figure 3: Structures of migalastat, NN-DNJ and Zavesca 
 
 
The anti-viral activity of iminosugars is generally thought to be related to their ability to 
inhibit endoplasmic reticulum (ER) α-glucosidases. Blocking ER α-glucosidases affects the 





as DNJ (1), NN-DNJ (12) and castanospermine (5) have been subjected to clinical studies in 
relation to HIV infections, though no clinical drug has emerged from these studies. 
In a recent publication, the anti-influenza activity of iminosugars was reported. In assays 
on infected cells both NN-DNJ and NB-DNJ were found to display antiviral activity against 
human influenza A, with NN-DNJ being the more potent compound. This activity is also thought 
to be related to ER α-glucosidase inhibition, since, upon treatment with 12 levels of viral 
hemagglutinin and neuraminidase proteins were found to be reduced.28 Related studies have 
shown that iminosugars may block intracellular proliferation of yet another pathogenic virus: 
hepatitis B virus (HBV). 
Outline of the thesis: 
The research executed in the context of this Thesis comprises the design and synthesis of 
focused libraries of unprecedented iminosugars. Chapter 2 reviews one of the most effective 
routes of synthesis towards deoxynojirimycin derivatives that is also central to parts of this 
Thesis: double reductive amination on an appropriately functionalized 5-keto-aldehyde. 
Application of this strategy in the synthesis of glycosylated DNJ derivatives is presented in 
Chapter 3. In Chapter 4, a series of N-alkyl iminosugars was designed and synthesized as 
selective inhibitors of the neutral glucosylceramidase, GBA2. In Chapter 5, and based on the 
dual GCS/GBA2 inhibitor described in the literature, biphenyl-L-ido-DNJ, a series of modified 
biphenyl-L-ido DNJ iminosugars are designed and synthesized and evaluated on their activity 
and selectivity on the three glucosylceramide processing enzymes, GCS, GBA1 and GBA2. In 
Chapter 6, a focused library of iminosugars characterized by the presence of a geminal 
bis(hydroxymethyl) motif is described, and Chapter 7 summarizes the results described in 
this Thesis, presents plans for future research and details some initial steps that have been 
taken in this direction. 
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Following the first synthesis of nojirimycin (NJ) and deoxynojirimycin (DNJ) reported by 
Paulsen and co-workers in 1967,1 many studies on the synthesis of iminosugar derivatives have 
emerged.2-7 In the course of these studies, many conceptually different strategies have been 
developed. Most of these synthesis strategies can be classified as being part of two overarching 
strategies, namely, those starting from simple, often achiral starting materials (de novo 
synthesis) and those starting from an abundant natural compound (chiral pool synthesis). 
Perhaps not surprisingly, carbohydrates often feature as the chiral pool starting material: many 
monosaccharides are abundant in nature, and a wealth of chemical transformations is known 






by means of which the individual functional groups of a carbohydrate can be addressed 
individually. Last but not least, many of these functional groups present in the target 
iminosugar are also found in the parent sugar and therefore ‘just’ need to be retained in a 
synthesis campaign. In this chapter, a literature survey of some of the most versatile de novo 
synthesis and chiral pool-based synthesis strategies towards the archetypal iminosugar, 1-
deoxynojirimycin (DNJ) will be given, with a focus on reductive amination chemistry as a key 
step in the synthesis. 
Synthesis from achiral compounds 
Scheme 1: Synthesis of DNJ featuring consecutive Sharpless asymmetric dihydroxylation 
and Sharpless asymmetric epoxidation steps 
 
 The synthesis of DNJ, which has four consecutive chiral centers, from non-chiral starting 
materials can be time-consuming and requires both the introduction (through for instance the 
use of chiral auxiliaries or the application of asymmetric catalysis strategies) and the transfer of 
chirality.5, 8-13 One of the earliest examples of an asymmetric synthesis of DNJ was reported by 
Somfai and co-workers in 1998 (Scheme 1).14 In the first step of this synthesis p-
methyloxybenzyl (PMB) protected diene 2 was subjected to a Sharpless asymmetric 
dihydroxylation reaction (treatment with AD-α-mix), giving diol 3 in high enantiomeric excess. 
Protection of the secondary alcohols in 3 was followed by reduction of the ethyl ester to 




generate allylic alcohol 4, which was converted to epoxide 5 by means of a Sharpless 
asymmetric epoxidation. Swern oxidation of the primary alcohol 5 to the aldehyde was 
followed by Wittig olefination, yielding vinyl epoxide 6 as a key intermediate bearing four 
consecutive chiral carbon centers.  
Oxidative removal of the PMB group in 6 was followed by reaction of the thus liberated 
primary alcohol with methanesulfonyl chloride and diisopropylethyl amine to provide mesylate 
7. Treatment of 7 with benzylamine gave regioselective opening of the epoxide to in situ form 
compound 8, after which intramolecular substitution of the mesylate in 8 provided piperidine 
9. Dihydroxylation of the vinyl moiety in 9 followed by oxidative cleavage and reduction of the 
resulting aldehyde gave partially protected DNJ 10 and ensuing global deprotection finally 
yielded DNJ 1. 
Synthesis from amino acids 
Compared with de novo synthesis strategies relying on the introduction of chirality during 
chemical transformations and that start with achiral starting materials, routes starting with 
chiral pool compounds are often more concise. Amino acids are sometimes used as starting 
points in the synthesis of iminosugars, and several routes of synthesis starting from (S)-
isoserine,15 serine16-21 and alanine22 have been reported. A relevant example of such a strategy 
is depicted in Scheme 2 and comprises the use of Garner’s aldehyde 12, itself easily prepared 
from D-serine, in the preparation of a variety of protected and functionalized piperideines.4 
These chiral piperideines (13 - 15) function as advanced intermediates in the preparation of 
DNJ (1) and some configurational analogues. D-Fagomine and its isomers were generated from 
methoxypiperideine 13,23, 24 DNJ and its D-allo, D-altro and D-manno congeners are synthesized 
via the dioxanyl piperideine intermediate 15,25 while D-gal, D-gulo, D-ido and D-talo isomers are 
generated from 14.26 






As an example of how piperideines can serve as advanced intermediates towards 
iminosugars, the transformation of 15 to DNJ 1 is depicted in Scheme 3. Treatment of 15 with 
oxone gave a near equimolar amount of the two epoxides 16 and 17 (44% and 45% yield, 
respectively). Acid hydrolysis of 16 gave a mixture of DNJ (1) and its D-altro epimer (19), again 
in a 1:1 ratio. Under the same conditions 17 was transformed to the D-altro epimer as the sole 
product. 
Scheme 3: Synthesis of DNJ from piperideine 15 
 
Takahata and co-workers revealed the use of the D-serine-derived piperideines in the 
synthesis of both configurational DNJ isomers and configurational fagomine isomers 
resembling naturally occurring D-configured monosaccharides. Moreover, by switching to the 
Garner’s aldehyde derived from L-serine the corresponding enantiomeric isomers can be 
prepared following the same sequence of reactions. A recent route reported by Singh et al. 
describes such a synthesis of L-DNJ starting from L-serine-derived Garner’s aldehyde.21,27 
Synthesis from carbohydrates 
Carbohydrates are often used as starting point for the chemical synthesis of iminosugar 
derivatives. Mannitol,28,_29 D-ribose,30 D-fructose31 as well as a number of other 
monosaccharides all feature in iminosugar synthesis strategies, and a reductive amination 
event (single or double) often is applied to create the piperidine core structure.32-48 
Owing to the structural similarity of DNJ and glucose, the use of glucose and its derivatives 
as chiral pool starting compounds is obvious, and many groups have devoted efforts to the 
synthesis of DNJ using glucose as starting material. One popular approach that starts from D-
glucose is to prepare DNJ via a 5-azido intermediate.32-40 A representative example is given in 
Scheme 4.39 The synthesis scheme starts with diacetone glucose, and after a series of standard 
protective group and functional group transformations compound 21 featuring a mesylate at C-
5 is obtained. SN2 substitution of the mesylate by sodium azide yielded 22, after which 




Staudinger reduction (22 to 23), Cbz protection of the amine in 23 followed by acidolysis 
provided lactol 24. Compound 24 was subjected to catalytic hydrogenation, resulting in 
deprotection of the amino group, intramolecular nucleophilic attack of the amine on the 
aldehyde (masked in 24 as the hemi-acetal) and dehydration to in situ form the imine, which is 
reduced in one pot to form DNJ (1). The last steps – imine formation followed by reduction, in 
other words a reductive amination, is found in many DNJ synthesis schemes. 
Scheme 4: Synthesis of DNJ via C-5 azido intermediate  
 
 
Two closely related DNJ syntheses that start from perbenzylated D-gluconolactone was 
reported independently by two groups about 25 years ago.41-43 In a representative procedure 
(see in Scheme 5), 2,3,4,6-tetra-O-benzyl-α-glucopyranose was oxidized to lactone 25. 
Treatment of 25 with methanolic ammonia gave 5-hydroxylamide 26. The C-5 hydroxyl group 
was then oxidized to the ketone (27), after which ring closure provided hydroxylactam 28. 
Reduction of the hydroxylactam under acidic conditions (in situ formation of an N-acyliminium 
ion, which is then reduced thanks to the presence in the reaction mixture of sodium 
cyanoborohydride) provided lactam 29. Lithium aluminum hydride reduction of the lactam to 
the piperidine followed by catalytic hydrogenation to remove the benzyl protective groups 







Scheme 5: Synthesis of DNJ from gluco-δ-lactone  
 
 
Synthesis via double reductive amination 
Baxter and Reitz reported in 199044,  45 the first synthesis of DNJ featuring as key step a 
stereoselective intramolecular reductive amination of a 1,5-dicarbonyl derivative (33) (scheme 
6). The synthesis of 33 started from acetone-D-glucose 31. In the first step, the free secondary 
alcohol in 31 is oxidized with dibutyltin oxide and bromine, after which the isopropylidene 
group was removed with acid resin to give dicarbonyl compound 33. This intermediate was 
subjected to a double reductive amination procedure using sodium cyanoborohydride and the 
appropriate primary amine to form N-substituted piperidines (34 and 35) with a high 
stereoselectivity (34:35 = 96:4). The yield and stereoselectivity in the formation of the N-alkyl 
DNJ derivatives described in this report was found to depend on the primary amine used.44 
Application of the double reductive amination protocol to either peracetylated or 
perbenzylated 33 gave much lower yields.45 Due to the high stereoselectivity and because 
hydroxyl protecting groups are not required, the double reductive amination procedure is very 
attractive and is widely applied in the preparation of different iminosugars and iminosugar 
derivatives. 
 




Scheme 6: Double reductive amination procedure towards DNJ 
 
Different synthesis strategies have been developed to prepare hexos-5-uloses (33) for 
ensuing application in double reductive amination protocols.46 For example, exo-glucal 38 can 
be transformed into 1,5-dicarbonyl 33 as depicted in scheme 7.47 Compound 38 was generated 
from fully protected 6-deoxy-6-iodoglucopyranose 37, which in turn was obtained in 2 steps 
from α-methyl glucose following treatment with DBU and ensuing protective group 
manipulations. Oxidation of 38 with 1,1,1-trifluoroacetone and oxone generated oxirane 39, 
which was in situ hydrolyzed to give D-hexos-5-ulose 40, after which subsequent silylation gave 
41. Removal of the protecting groups yielded 5-oxo-aldehyde 33, which was converted into DNJ 
following conditions essentially as described by Baxter and Reitz.45  
This strategy – generation of an exo-glucal and conversion to the keto-aldehyde – can be 
carried out on appropriately functionalized disaccharide derivatives as well. Steiner et al. 
developed a route to synthesize glucosyl-4-β-DNJ from cellobiose via a 5,6-glucal intermediate 
(Scheme 8).48 In this synthesis, cellobiose was converted to its methyl cellobioside and the 4’, 6’ 
hydroxyl groups protected to give benzylidene acetal 42. Following treatment with PPh3 and 
iodine, the remaining free hydroxyl groups were acetylated to provide 43. Silver fluoride 
mediated elimination of hydrogen iodide formed 5,6-enone 44, the alkene moiety of which was 
epoxidized (treatment with mCPBA) after which in situ hydrolysis of the anomeric acetal 





benzylidene protective group is removed under the applied conditions as well). This 
methodology can also be applied for the synthesis of glucosyl-4-α-DNJ from maltose.48 
Scheme 7: Synthesis of DNJ via a 5,6-exo-glucal intermediate 
 
 
Scheme 8: Synthesis of gluco-4-β-DNJ via 5,6-intermediate intermediate  
 
A related 5-ulose compound proved also to be a versatile intermediate in the synthesis of 
galactyl-4-β-DNJ 51 as depicted in Scheme 9.49 Lactose was transformed into partially 
protected disaccharide 48 in a series of standard transformations,50 after which 6-O-benzyl 
protected ketone 49 was obtained through regioselective benzylation and oxidation of the 
remaining secondary alcohol. Treatment of 49 with 90% aqueous TFA gave 1,5-di-carbonyl 




disaccharide 50, which was subjected to double reductive amination. Finally, catalytic 
hydrogenation of the thus obtained partially protected aza-disaccharide gave target iminosugar 
51. 
Scheme 9: Synthesis of galacto-4-β-D-DNJ from lactose  
 
As a last example, returning to the synthesis of DNJ 1, a concise synthetic route with 
perbenzylated 5-keto-aldehyde intermediate 54 as key intermediate is depicted in Scheme 10. 
The synthesis starts from commercially available 2,3,4,6-tert-O-benzyl-glucose (52).51 Lactol 52 
was reduced by lithium aluminum hydride to give 1,5-diol 53. Swern oxidation of both primary 
and secondary alcohol in 53 and subsequent double reductive amination of crude 53 yielded 
2,3,4,6-tetra-O-benzyl-DNJ 30. Palladium-catalyzed hydrogenolysis of the benzyl ethers in 30 
yielded DNJ. The overall yield in this procedure is up to 65% starting from 52 and moreover the 
procedure can be executed on a multi-gram scale.52 








This chapter details some representative and versatile routes of synthesis to obtain DNJ 1 
and some structural and configurational analogues. Amongst the routes presented, those 
starting from carbohydrates, and in particular those featuring double reductive amination steps, 
are arguably the most versatile for the construction of DNJ type iminosugars. Such routes 
proceed through the synthesis of a 5-keto-aldehyde intermediate, and thus the stereocenter at 
C-5 is lost during the synthesis. This stereocenter however is in almost all examples presented 
close to completely recovered during reduction of the intermediate imine. Thus the strategy is 
particularly suited for the construction of DNJ-configured iminosugars, although it should be 
noted that the synthesis of differently configured iminosugars by means of a double reductive 
amination step is likely to be less effective. 
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Iminosugars have received considerable interest in the past decades because of their 
potential to inhibit glycosidases and glycosyl transferases. A relatively unexplored class of 
iminosugars comprises the glycosylated deoxynojirimycin derivatives. Whereas 
monosaccharide analogues act as exoglycosidase inhibitors and sometimes also as glycosyl 
transferase inhibitors, iminosugars functionalized with a monosaccharide or an oligosaccharide 
may well act as inhibitors of another major class of glycoprocessing enzymes: endoglycosidases. 
3 Synthesis of Glycosylated 1-Deoxynojirimycin   




The glycosylated iminosugar, MDL25637 (2), is a relevant example of the potential of this 
class of compounds. It is a potent trehalase inhibitor (which is an established target for the 
treatment of type 2 diabetes), in contrast to the corresponding monosaccharide iminosugar, α-
homonojirimycin (1), which does not inhibit this endoglycosidase activity.1  
Figure 1: Structure of α-homonojirimycin and MDL25637 
 
 
Glycosylated iminosugars have been isolated from plants and microorganisms, often 
organisms that also produce DNJ. However, their natural abundance is usually rather low. For 
instance, in order to isolate 50 mg of α-glucosylated deoxynojirimycin 4 (Figure 2), 50 kg of 
mulberry tree root bark is required.2 The synthesis of glycosylated DNJ derivatives is therefore 
an attractive alternative. Three conceptual approaches can be discerned by means of which 
glycosylated DNJ have been prepared. These are 1) enzymatic glycosylation of DNJ derivatives, 
2) chemical glycosylation of DNJ derivatives and 3) strategies based on disaccharide entities as 
starting material. 
Figure 2: Structure of DNJ and glucosylated DNJ derivatives 
 
 
The enzymatic glycosylation of DNJ derivatives has been accomplished using 
glycohydrolases as catalysts in transglycosylation events using an appropriate donor glycoside. 




using α-cyclodextrin as glucose donor and bacillus macerans amylase as transglycosylase.3 
Following these studies, it was shown that a variety of alternative glycosides including p-
nitrophenyl-α-D-galactose,4 UDP-glucose,5 and lactose6 are effective donor glycosides as well, 
expanding the methodology to yield a variety of glycosylated DNJ derivatives. Besides 
glycosidases also glycosyl transferases have been recruited in the enzymatic synthesis of 
glycosylated DNJ derivatives. Enzymatic approaches hold several advantages, including mild 
reaction conditions, readily available starting material and short reaction sequences. However, 
enzymatic synthesis also has its limitations, including structural diversity that can be obtained 
in general and, in particular in the use of transglycosylations, the potential formation of 
structural isomers. For example, when cellobiose was chosen as glycosyl donor and yeast β-
glucosidase as the transglycosylase catalyst, 4, 6, 7 and 8 (Figure 2) as well as a number of 
other oligosaccharides were formed as a mixture.7 Because of their similar chemical and 
physical properties, separation of such a mixture of glycosylated iminosugars can be a 
challenge. 
Scheme 1:  Examples of chemical glycosylations of DNJ 
 
Chemical glycosylation forms an attractive alternative for enzymatic glycosylation of DNJ. 
In chemical glycosylation approaches, part of the hydroxyl groups in the acceptor (in this case, 
DNJ) are selectively protected, leaving the hydroxyl to be modified free for glycosylation using 
an appropriate donor (1-trichloroacetimidate 9,8 1-thioglycoside 109 or 1-bromoglycoside 
11,10 scheme 1) and activation strategy. Since the synthesis of a donor and acceptor may take 
quite a few protection and deprotection steps, this strategy may be – compared to enzymatic 
synthesis - somewhat lengthy and tedious. 




Scheme 2: Synthesis of DNJ11 and proposed synthesis of melibio-DNJ via double reductive 
amination. 
 
The third conceptual strategy towards glycosylated DNJ derivatives that has been studied 
to some extent comprises the use of disaccharides as starting material. In this strategy 
multistep preparation of the donor and acceptor moieties is avoided, but the caveat is that 
appropriate disaccharide starting materials should be available. The transformation of 
disaccharides into glycosylated DNJ derivatives described in this chapter is rooted in the double 
reductive amination strategy (Scheme 2, melibio-DNJ as example) by means of which a partially 
protected glucitol, in which the C-1 and C-5 alcohols are free for modification, can be 
transformed into DNJ (see for details on this strategy also Chapter 2). In this strategy, the 
anomeric center of a partially protected disaccharide is selectively exposed, and the hemi-acetal 
reduced to generate the key 1,5-diol intermediate. This diol is oxidized to the keto-aldehyde, 
which in a double reductive amination event to produce the target glycosylated DNJ derivative. 
An important feature of this scheme is the recovery of the stereocenter at C-5 of the newly 
formed iminosugar, which works well when the glucopyranose configuration is the desired one. 
Results and discussion 
Synthesis of 6-O-(α-D-galactopyranosyl)-1-deoxynojirimycin (24)  
The synthesis of 6-O-(α-D-galactopyranosyl)-1-deoxynojirimycin 24 (melibio-DNJ) 
commences from melibiose 16, which is commercially available. Treatment of 16 with sodium 
acetate in refluxing acetic anhydride afforded peracetylated melibiose 17, which was reacted 




steps. Zémplen deacetylation followed by benzylation yielded perbenzylated thiomelibiose 20, 
the thiolphenyl group in which could be removed using literature conditions13 (treatment with 
N-iodosuccinimide and trifluoroacetic acid) to yield lactol 21 as the key intermediate in 39% 
yield over the three steps. 
Scheme 3: Syntheses of 24 from melibiose 
 
Reagents and conditions: [a] Ac2O, NaOAc, reflux, 90%; [b] BF3∙Et2O, PhSH, DCM, 82%; [c] NaOMe, 
MeOH; [d] BnBr, NaH, DMF, 50% 2 steps; [e] NIS, TFA, DCM, 77%; [f] LiAlH4, THF, 74%; [g] 1) (COCl)2, 
DMSO; 2) HCOONH4, Na2SO4, NaBH3CN, 71% 2 steps; [h] 10% Pd/C, DMF/MeOH, 1M HCl, 75%. 
In the next step, the hemiacetal moiety in 21 was reduced (lithium aluminum hydride) to 
give diol 22, which was oxidized to the corresponding keto-aldehyde using Swern conditions. 
Double reductive amination with concomitant regeneration of the chiral center at C-5 was 
accomplished using ammonium formate and sodium cyanoborohydride to yield protected 1- 
melibio-deoxynojirimycin 23 (52% yield, three steps). The chirality of carbon C-5 in 23 was 
unambiguously established by proton NMR, revealing that, as expected, the iminosugar moiety 
in 23 has the D-gluco-configuration (as in DNJ). The coupling constants between H-4 and H-5 
(9.5 Hz) and between H-2 and H-3 (9.1 Hz) are in full agreement with the presented 
stereochemistry of 23, and the stereochemical outcome of the double reductive amination step 
is therefore as was observed previously for the synthesis of DNJ using the same sequence of 
events (reduction of the hemi-acetal in 2,3,4,6-tetra-O-benzyl-glucopyranose, followed by 
Swern oxidation of both primary and secondary alcohol and finally double reductive amination 
of the intermediate 5-keto-aldehyde, Figure 3, inserted box).11 Removal of the benzyl groups in 




23 by palladium-catalyzed hydrogenation gave the target imino-disaccharide 24 in 11% overall 
yield starting from 16. 
Figure 3: Part of the 400 MHz proton NMR spectra of 23  
 
 
Synthesis of 4-O-(α-D-glucopyranosyl)-1-deoxynojirimycin (33) 
 
Scheme 4: Synthesis of 33 from maltose 
Reagents and conditions: [a] Ac2O, NaOAc, reflux, 94%; [b] BF3.Et2O, PhSH, DCM, 61%; [c] NaOMe, 
MeOH; [d] BnBr, NaH, DMF, 89%; [e] NIS, TFA, DCM, 93%; [f] LiAlH4, THF, 74%; [g] 1) (COCl)2, DMSO; 2) 




The synthesis strategy applied for the assembly of 4-O-(α-D-glucopyranosyl)-1-
deoxynojirimycin 33 (malto-DNJ) was identical as that described for the synthesis of 24 
(melibio-DNJ, scheme 3), but now starting from maltose (25). Lactol 30 was uneventfully 
obtained from maltose 25 in a yield of 47% over the five steps. Lithium aluminum hydride 
reduction of 30 followed by Swern oxidation and double reductive amination produced fully 
protected malto-DNJ 32 (33% yield, three steps). The stereochemical outcome in synthesizing 
32 was revealed by proton NMR spectroscopy (Figure 4). The benzyl groups were removed by 
palladium-catalyzed hydrogenolysis to form target iminosugar 33 in 11% overall yield starting 
from (25). 
Figure 4: Part of the 400 MHz proton NMR spectra of 32 
                                  
 
 
Synthesis of 4-O-(β-D-galactopyranosyl)-1-deoxynojirimycin (34) 
The synthesis of 4-O-(β-D-galactopyranosyl)-1-deoxynojirimycin 40 (lacto-DNJ) starts with 
lactose, which is one of the cheapest disaccharide known and is a side product of the dairy 
industry.14 Hepta-acetyl thiolactoside 34 was prepared following the sequence of events as 
described for hepta-acetyl thiomelibioside 18, but starting from lactose. Compound 34 
underwent deacetylation, benzyl protection and NIS/TFA thioglycoside hydrolysis as described 
before to obtain lactol 37, and was reduced (lithium aluminum hydride), subjected to Swern 
oxidation followed by double reductive amination to obtain protected imino-disaccharide 39. 
Compound 39 was treated with palladium on carbon and hydrogen gas to give the desired 
imino-disaccharide 40 in 14% overall yield starting from 34.  




Scheme 5: Synthesis of 34  
 
Reagents and conditions: [a] NaOMe, MeOH; [b] BnBr, NaH, DMF, 100% 2 steps; [c] NIS, TFA, DCM, 85%; 
[d] LiAlH4, THF, 77%; [e] 1) (COCl)2, DMSO; 2) HCOONH4, Na2SO4, NaBH3CN, 22%; [f] Pd/C, H2, 
DMF/MeOH, 64%.  
The stereochemistry of carbon C-5 was established by NMR to be as in the parent 
compound. For comparison, the J values between H-2 and H-3 (not changed during the 
syntheses) and those of H-4 and H-5 (destroyed during Swern oxidation and recovered during 
reductive amination) of a number of aza-disaccharides discussed in this chapter is given in 
Table 1. 
Table 1: J2,3 and J4,5 of DNJ moiety from different molecules 
Molecule J2,3 (Hz) J4,5 (Hz) 
1-Deoxynojirimycin (DNJ), 3 9.1 9.1 
Protected melibio-DNJ, 23 9.1 9.5 
Protected malto-DNJ, 32 8.6 9.5 
Lacto-DNJ, 40 8.6 9.5 
Protected cellobio-DNJ, 48 8.8 9.7 
Protected 2-O-(α-gal)-DNJ, 68 9.2 9.3 
 
Synthesis of 4-O-(β-D-glucopyranosyl)-1-deoxynojirimycin (49)  
Starting from disaccharide cellobiose (41), 4-O-(β-D-glucopyranosyl)-1-deoxynojirimycin 
49 (cellobio-DNJ) was obtained in 10% overall yield following the sequence of events as 
described for the synthesis of 24 (melobio-DNJ). The nature of the stereochemistry at C-5 of the 





Scheme 6: Synthesis of 49 from cellobiose 
 
Reagents and conditions: [a] Ac2O, NaOAc, reflux, 98%; [b] BF3.Et2O, PhSH, DCM, 91%; [c] NaOMe, 
MeOH; [d] BnBr, NaH, DMF, 89%; [e] NIS, TFA, DCM, 90%; [f] LiAlH4, THF, 74%; [g] 1) (COCl)2, DMSO; 2) 
HCOONH4, Na2SO4, NaBH3CN, 44% 2 steps; [h] 10% Pd/C, DMF/MeOH, 1M HCl, 65%. 
Synthesis of 2-O-(α-galactopyranosyl)-1-deoxynojirimycin (69) 
 Scheme 7: Synthesis of acceptor 54 
 
Reagents and conditions: [a] BF3∙Et2O, PhSH, DCM, 91%; [b] NaOMe, MeOH; [c] PhCH(OMe)2, p-TsOH, 
DMF, 59% 2 steps; [d] Bu2SnO, TBAI, BnBr, 73%. 
The examples described above comprise the use of cheap, readily available disaccharides 
featuring a glucopyranose moiety at the reducing end as starting material. Obviously, many 
other disaccharides other than the ones used can be envisaged as starting material and that 
have a similar lay-out: a glycosylated glucopyranose. Besides making use of available 
disaccharides of this nature, one can also synthesize these by chemical glycosylation of a 
partially protected glucopyranose moiety. As an example, partially protected 1-phenylthio-
glucopyranoside 54, with O-2 free for chemical glycosyation, can be prepared following a 
number of protective group manipulations starting from peracetylated glucopyranose 50 
(scheme 7). 




Treatment of 50 with borontrifluoride diethyl etherate and thiophenol yielded 
thiophenylglycoside 51, the acetyl groups in which were then removed using sodium 
methoxide to give 52. The C-4 and C-6 hydroxyls in 52 were protected as the benzylidene 
acetal, after which regioselective benzylation (dibutyltin oxide, tetrabutylammonion iodide, 
benzyl bromide) gave 54 in 44% yield over the five steps.  
Galactose donor 61 was selected as glycosylating species to functionalize O-2 in 54 prior to 
its transformation into a DNJ derivative. The synthesis of 61 starts from D-galactose and was 
accomplished in 7 steps. In the first step, all hydroxyl groups in D-galactose were transformed 
into the acetates using acetic anhydride and sodium acetate, yielding peracetylated 
galactopyranose 55. Treatment of 55 with thiophenol and Lewis acid yielded 56, which after 
treatment with sodium methoxide gave thiogalactoside 57. The C-4 and C-6 hydroxyls in 57 
were protected as the di-tert-butylsilylene acetal, to yield 58. The free hydroxyls in 58 were 
protected as the benzyl ethers (treatment with benzyl bromide and sodium hydride) giving 59. 
The thio-acetal linkage in 59 was cleaved (NIS/TFA, 59 to 60), after which treatment with 
trifluoro-phenylacetimidoyl chloride gave donor galactoside 61 in an overall yield of 16% 
starting from galactose. 
 Scheme 8: Synthesis of donor 61 
 
Reagents and conditions: [a] BF3.Et2O, PhSH, DCM, 100%; [b] NaOMe, MeOH; [c] tBuSi(OTf)2, 53% 2 steps; 
[d] BnBr, NaH, DMF, 56%; [e] NIS, TFA, DCM, 88%; [f] trifluoro-phenylacetimidoyl chloride, 
Cs2CO3, acetone, 65%. 
Glucose acceptor 54 was next coupled with donor galactoside 61 using trimethylsilyl 
trifluoromethanesulfonate as the activating agent at 0 °C. Following this methodology, 




yield of 69%. However, when the glycosylation was carried out at -78 °C, the main product 
proved to be thiophenyl galactopyranoside 59 (yield more than 70%), with no formation of the 
desired disaccharide 62 observed. When conducting this reaction at -20 °C, 62 was obtained in 
a yield of 35%, together with a considerable amount of 59 (30%). 
Scheme 9: Synthesis of 69 
 
 
Reagents and conditions: [a] TMSOTf, DCM, 0 °C, 69%; [b] TBAF, THF, 82%; [c] p-TsOH, DCM, 90%; [d] 
BnBr, NaH, DMF, 92%; [e] NIS, TFA, DCM, 71%; [f] LiAlH4, THF, 88%; [f] (COCl)2, DMSO, HCOONH4, 
Na2SO4, NaBH3CN, 24%; [g] Pd/C, H2, EtOH, 1M HCl, 52%. 
The generation of 59 at low temperature might be due to the side reaction mechanism 
visualised in Figure 6. The sulfur and hydroxyl groups on the acceptor can both react with the 
activated donor, and whether the reaction goes through pathway I or pathway II depends on 
the relative reactivity of the sulfur and the hydroxyl groups.15 There exists literature precedents 
reporting that lowering the temperature favors reaction pathway II and thus avoids the aglycon 
transfer product.16-18 However, this is inconsistent with the findings presented here. Arguably, 
upon formation of oxycarbenium ion 70, S-glycosylation (pathway I) to give sulfonium ion 71 




proceeds easier (thus at lower temperature) than O-glycosylation (pathway II) to give 
protonated disaccharide 73. Once 73 is formed, however, deprotonation yields the final 
disaccharide as the thermodynamic end point. Assuming the occurrence of an equilibrium 
between sulfonium ion 71 and in situ formed oxycarbenium ion 70 (and acceptor 54), and by 
allowing the formation of 73 as well (by elevating the temperature) the reaction will then 
proceed towards disaccharide 62. In case the temperature is insufficiently high to overcome the 
barrier towards 73, and therefore allowing only pathway I to occur, eventually expulsion of 
oxycarbenium ion 72 (which will deteriorate during work-up) may occur as the main 
conclusive event, delivering phenylthiogalactoside 59.  
Figure 6: Chemical glycosylation products at different temperatures 
 
With disaccharide 62 in hand, the corresponding aza-disaccharide was readily prepared 
using the sequence of events also used for the preparation of the other aza-disaccharides 
described in this chapter. In the first instance, the di-tert-butylsilylene ester in 62 was removed 
using tetra-N-butylammoniumfluoride (TBAF) to afford 63. Removal (with p-toluenesulfonic 
acid) of the benzylidene in 63 gave 64 as white crystals (90%) and the free hydroxyls in 64 
were benzylated (sodium hydride and benzyl bromide) to give 65. NIS/TFA mediated 
hydrolysis of the phenyltio acetal yielded hemi-acetal 66, which was subjected to LiAlH4 
mediated reduction to give diol 67 in a yield of 88%. Subsequent oxidation of both alcohols in 




Proton NMR spectroscopy of 68 confirmed that the DNJ configuration was obtained also in this 
instance (see table 1). The benzyl protecting groups in 68 were finally removed to give aza-
disaccharide 69 in an overall yield of 7% based on 62. 
Conclusion 
This Chapter reports on the synthesis of five glycosylated 1-deoxynojimycin derivatives. 
Four of these, namely 6-O-(α-D-galactopyranosyl)-1-deoxynojirimycin (24), 4-O-(α-D-
glucopyranosyl)-1-deoxynojirimycin (33), 4-O-(β-D-glucopyranosyl)-1-deoxynojirimycin (49) 
and 4-O-(β-D-galactopyranosyl)-1-deoxynojirimycin (40) were synthesized from their 
commercially available disaccharide (melibiose, maltose, cellobiose and lactose, respectively) 
as precursor. As a further example, 2-O-(α-galactopyranosyl)-1-deoxynojirimycin (69) was also 
successfully synthesized via the same methodology from its corresponding disaccharide, and 
the precursor disaccharide for this transformation was synthesized via chemical glycosylation. 
Thus the methodology presented appears general and, though yields vary between the 
individual examples, glycosylated DNJ derivatives can be prepared without difficulties from 
their glycosylated glucose counterparts, as long as the latter are synthetically tractable. 
Experimental Section 
General methods: All solvents and reagents were obtained commercially and used as received 
unless stated otherwise. Reactions were executed at room temperature unless stated 
otherwise. Moisture sensitive reactions were performed under argon atmosphere. Water was 
removed from starting compounds by coevaporation with toluene. Solvents were removed by 
evaporation under reduced pressure. DCM, DMF, and THF were dried over activated 4Å 
molecular sieves for at least 12 hours before use. Compounds were visualized during TLC 
analyses by UV (254 nm), and with the following staining solutions: aqueous solution of KMnO4 
(5 g/ L) and K2CO3 (25 g/ L). Visualization of hemiacetals and glycosides was achieved by 
spraying with a solution of 20% H2SO4 in ethanol followed by charring at ≈ 200 ℃. Column 
chromatography was performed on silica gel (40 - 63 µm). 1H and 13C-APT NMR spectra were 
recorded on a Bruker AV 400 (400/100 MHz) or Bruker 600 (600/150 MHz) spectrometer in 
CDCl3, MeOD or D2O. Chemical shifts are given in ppm (δ) relative to TMS as internal standard 
(1H NMR in CDCl3) or the signal of the deuterated solvent.19 Coupling constants (J) are given in 
Hz. High resolution mass spectra were recorded by direct injection (2 µL of a 2 µM solution in 
water/acetonitrile/tert-butanol 1:1:1 v/v) on a mass spectrometer (Thermo Finnigan LTQ 
Orbitrap) equipped with an electrospray ion source with resolution R = 60000 at m/z 400 
(mass range m/z = 150 - 2000). IR spectra were recorded on a Shimadzu FTIR-8300 and are 
reported in cm-1. Optical rotation were measured on an automatic polarimeter of sodium D-line, 
at λ = 589 nm. Size-exclusion purifications were performed on an ÄKTA-explorer provided by 
GE-Healthcare polymere HW-40S from Toyopearl, column size  d = 26 mm; l = 60 mm, mobile 
phase NH4HCO3 (0.15 M) in H2O, flow 1.5 mL/min. Purification on HPLC were performed on a 
Prep LCMS, Gemini from Phenomenex B.V. (C-18, 110 Å, 5 µm, 19 x 150 mm column). 
 




Figure 7: Proton and carbon NMR numbering of iminosugars: 
 
Synthesis of 6-O-(α-D-galactopyranosyl)-1-deoxynojirimycin (24) 
1,2,3,4-Tetra-O-acetyl-6-O-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)-β-
glucopyranose (17): 
A suspension of Ac2O (59.0 mL, 0.625 mol) and NaOAc (4.21 g, 51.3 
mmol) were heated to reflux. When refluxing began the heat source 
was removed and melibiose (10.0 g, 29.2 mmol), which was co-
evaporated with toluene (3 x), was added in small portions. The 
mixture was heated to reflux for 1 hour. TLC analysis confirmed 
complete consumption of the starting material 16 (1:1, PE:EtOAc, RF = 
0.39). The mixture was poured into ice water (400 mL) which was 
vigorously stirred. DCM (150 mL) was added and the layers were separated. The organic layer 
was washed with cold water (150 mL), sat. aq. NaHCO3 solution (2 x 150 mL) and brine (150 
mL). After the organic layer was dried (Na2SO4), filtered, and concentrated. The residue was 
purified with silica gel column chromatography (2:1 → 1:1 → 1:2, PE:EtOAc) to give 17 in 90% 
yield (17.8 g, 26.2 mmol). RF = 0.39 (1:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 5.70 (d, J = 8.3 
Hz, 1H, H-1), 5.45 (d, J = 2.9 Hz, 1H, H-4’), 5.34 (dd, J = 10.8, 3.3 Hz, 1H, H-3’), 5.27 (t, J = 9.4 Hz, 
1H, H-4), 5.16 (m, 1H, H-1), 5.07 (m, 2H, H-2, H-3), 4.21 (dd, J = 11.4, 5.0 Hz, 1H, H-5’), 4.15 – 
4.02 (m, 3H, H-2’, H2-6), 3.83 (ddd, J = 9.9, 3.9, 2.6 Hz, 1H, H-5), 3.74 (dd, J = 11.7, 4.3 Hz, 1H, H-
6’a), 3.65 (dd, J = 11.8, 2.3 Hz, 1H, H-6’b), 2.24 – 1.96 (m, 24H, 8 x CH3). 13C NMR (100 MHz, 
CDCl3) 170.7 – 169.1 (C=O), 96.5 (C-1’), 91.7 (C-1), 73.6 (C-5), 70.3 (C-3), 68.4 (C-4), 68.2 (C-
4’), 68.1 (C-2), 67.6 (C-3’), 66.6 (C-5’), 65.8 (C-6), 61.9 (C-6’), 20.9 – 20.7 (8 x CH3). 
 
2,3,4-Tri-O-acetyl-6-O-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)-1-thio-D-
glucopyranose (18):  
PhSH (5.2 mL, 51.0 mmol) was added to a stirred solution of 17 (17.8 g, 
26.2 mmol) in dry DCM (50 mL) and kept under argon atmosphere. After 
cooling the solution (0 ℃), BF3∙Et2O (4.9 mL, 39.7 mmol) was added 
dropwise, turning the solution to orange. The mixture was stirred for 4 
hours at r.t., after which TLC analysis showed complete consumption of 
the starting material. DCM (50 mL) was added to the reaction mixture 
and the solution was washed with sat. aq. NaHCO3 solution (100 mL, 2 x). The organic layer was 
dried (Na2SO4). After filtering, concentrating and evaporating of the volatiles, the crude product 
was purified with silica gel column chromatography (3:1 → 7:3 → 5:3 → 1:1, PE:EtOAc), to give 
18 as a pure white solid product in 82% yield (15.6 g, 21.4 mmol), RF = 0.43 (1:1, PE:EtOAc). 1H 
NMR (400 MHz, CDCl3) 7.45 (dd, J = 8.0, 1.4 Hz, 2H, HAr SPh), 7.40 – 7.30 (m, 3H, HAr SPh), 5.35 
(dd, J = 3.5, 1.2 Hz, 1H, H-4’), 5.32 (dd, J = 10.2, 3.4 Hz, 1H, H-3’), 5.24 (t, J = 9.4 Hz, 1H, H-3), 5.14 
(d, J = 3.7 Hz, 1H, H-1’), 5.11 (dd, J = 10.2, 3.7 Hz, 1H, H-2’), 5.03 (t, J = 9.6 Hz, 1H, H-4), 4.96 (dd, 
J = 10.1, 9.2 Hz, 1H, H-2), 4.78 (d, J = 10.1 Hz, 1H, H-1), 4.21 (td, J = 6.6, 1.3 Hz, 1H, H-5’), 4.03 (d, 
J = 6.9 Hz, 2H, H2-6’), 3.77 (dd, J = 10.6, 5.8 Hz, 1H, H-6b), 3.71 (dd, J = 5.8, 2.0 Hz, 1H, H-5), 3.56 
(dd, J = 10.7, 1.9 Hz, 1H, H-6a), 2.15 – 1.99 (m, 21H, 7 x CH3). 13C NMR (100 MHz, CDCl3) 170.6 
–  169.4 (C=O), 132.2 (CAr Ph), 132.1 (Cq SPh), 129.3, 128.4 (CAr SPh), 96.4 (C-1’), 85.7 (C-1), 76.8 
(C-5), 74.1 (C-3), 70.1 (C-2), 68.8 (C-4), 68.2 (C-2’), 68.2 (C-4’), 67.5 (C-3’), 66.9 (C-6),  66.6 (C-
5’), 61.8 (C-6’), 21.0 – 20.7 (7 x CH3). [α]20D = +73.3 (c = 1.14, CHCl3).  IR/cm-1: 1750, 1734, 1373, 






glucopyranose (20):  
18 (15.0 g, 20.6 mmol) was co-evaporated with toluene (3 x), after 
which it was dissolved in dry MeOH (100 mL). A catalytic amount of 
NaOMe was added and the reaction mixture was stirred for two hours. 
TLC-MS analysis showed complete conversion of the starting material 
into a polar product. The mixture was diluted with MeOH after which 
amberlite H+ was added until pH was adjusted to 7. After filtering and 
concentrating the deprotected sugar (19) was co-evaporated with toluene (3 x). 19 was 
dissolved in DMF (100 mL), BnBr (20.9 mL, 176 mmol) was added, the solution was cooled (0 
℃). NaH (14.5 g, 360 mmol) was added in small portions, after which the solution was stirred 
overnight under argon atmosphere. TLC analysis showed complete consumption of the starting 
compound (1:1, PE:EtOAc). After cooled down to 0 ℃, the reaction mixture was sequently 
quenched by the addition of MeOH, the volatiles evaporated and EtOAc (200 mL) was added. 
The mixture was washed with HCl solution (1M, 100 mL, 2 x). After being dried (Na2SO4), 
filtered, and concentrated, the crude product was purified with silica gel column 
chromatography (17:3 → 4:1 → 1:1, PE:EtOAc) to give 20 in 50% yield over the 2 steps (11.0 g, 
10.3 mmol). RF = 0.88 (1:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) 7.54 – 7.12 (m, 40H, HAr 
SPh/Bn), 5.03 (d, J = 3.5 Hz, 1H, H-1’), 4.66 (d, J = 9.9 Hz, 1H, H-1), 4.97 – 4.37 (m, 14H, 7 x CH2 
Bn), 4.05 (dd, J = 9.7, 3.5 Hz, 1H, H-2’), 3.99 (t, J = 6.5 Hz, 1H, H-5), 3.89 (m, 1H, H-3’), 3.86 (d, J = 
2.9 Hz, 1H, H-4’), 3.78 (qd, J = 11.7, 3.5 Hz, 2H, H2-6’), 3.68 – 3.59 (m, 2H, H-3, H-4), 3.54 (dd, J = 
9.3, 5.9 Hz, 1H, H-5’), 3.49 (dd, J = 9.5, 6.5 Hz, 2H, H2-6), 3.26 (dd, J = 9.9, 8.5 Hz, 1H, H-2). 13C 
NMR (100 MHz, CDCl3) 139.0 – 138.1 (Cq Bn), 134.2  (Cq SPh), 131.9 – 127.5 (CHAr Bn), 97.9 
(C-1’), 87.8 (C-1), 86.8 (C-3), 81.2 (C-2),  79.0 (C-5), 78.5 (C-4’), 78.0 (C-4), 76.9 (C-2), 75.8, 75.6 
(2 x CH2 Bn), 75.3 (C-3’), 75.1, 74.9, 73.4, 73.2, 72.8 (5 x CH2 Bn), 72.8, 69.3 (C-5), 69.1 (C-6), 




NIS (22 mg, 97 µmol) and 30 μL of TFA were added to a cooled solution 
of 20 (94 mg, 88 µmol) in 2 mL DCM at 0 °C. After an hour of stirring 
TLC, analysis (4:1, toluene:EtOAc) showed complete consumption of the 
starting material. Sat. aq. Na2S2O3 solution (7 mL) followed by sat. aq. 
NaHCO3 solution (7 mL) was added. The mixture was diluted with DCM, 
after 30 minutes of stirring the layers were separated. The organic layer 
was dried (MgSO4) and after filtering and concentrating the crude product was purified on 
silica gel column chromatography (9:1 → 7:3 → 6:4, PE:EtOAc) to give 21 in 77% yield (70 mg, 
68 µmol). RF = 0.30 and 0.40 (7:3, PE:EtOAc). For the major anomer: 1H NMR (400 MHz, CDCl3) 
7.41 – 7.19 (m, 35H, HAr Bn), 5.09 (d, J = 3.6 Hz, 1H, H-1’), 4.98 (d, J = 3.5 Hz, 1H, H-1), 4.95 – 
4.28 (m, 14H, 7 x CH2 Bn), 4.13 (dt, J = 14.3, 6.8 Hz, 1H, H-5’), 4.07 – 3.98 (m, 2H, H-4, H-5), 3.96 
– 3.88 (m, 3H, H-2’, H-3, H-4’), 3.85 (d, J = 11.7 Hz, 1H, H-6’a), 3.72 (dd, J = 12.0, 5.5 Hz, 1H, H-
6’b), 3.64 – 3.43 (m, 3H, H-2, H2-6), 3.39 (dd, J = 9.4, 3.5 Hz, 1H, H-2), 3.26 (dd, J = 8.6, 7.3 Hz, 1H, 
H-3’). 13C NMR (100 MHz, CDCl3) 138.9, 138.8, 138.4, 138.3, 138.1, 137.9, 137.8 (7 x Cq Bn), 
128.6 – 127.6 (CHAr Bn), 98.5 (C-1’), 91.1 (C-1), 83.6 (C-3’), 81.9 (C-3), 80.4 (C-4),  78.6 (C-2), 
78.2 (C-2’), 76.7 (C-4’), 75.8 – 72.7 (7 x CH2 Bn), 70.8 (C-5’), 69.6 (C-5), 69.6 (C-6), 67.8 (C-6’). 
[α]20D = +38.1 (c = 1.03, CHCl3). IR/cm-1: 3030, 2920, 2868, 2247, 1497, 1454, 1357, 1090, 1026. 
HRMS: found 995.43431 [C61H64O11+Na]+, calculated for [C61H64O11+Na]+ 995.43408. 
 
2,3,4-Tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-D-glucitol (22): 
LiAlH4 in THF (6.0 mL, 2 M, 12.0 mmol) was slowly added to a cooled (0 ℃) solution of 21 (3.91 
g, 4.02 mmol, co-evaporated 3 x with toluene), in dry THF (40 mL) under argon atmosphere. 




The mixture was stirred overnight allowing the temperature to reach 
r.t. TLC analysis showed absent of the starting compound (7:3, 
PE:EtOAc). The mixture was cooled in an ice-bath, after which it was 
slowly quenched by addition of H2O. Then NaOH solution (3M, 40 mL) 
was added followed by Celite. The solution was stirred until a 
homogenous mixture was formed and after which it was filtered and 
the filter cake rinsed with Et2O. H2O (50 mL) and EtOAc (50 mL) was added and the organic 
layer was dried (Na2SO4), filtered and concentrated, the residue was purified with silica gel 
column chromatography (4:1 → 7:3 → 3:2, PE:EtOAc) to give 22 as an yellow oil in 74% yield 
(2.88 g, 2.95 mmol). RF = 0.22 (7:3, PE:EtOAc). 1H NMR (400 MHz, CDCl3) 7.41 – 7.19 (m, 35H, 
HAr  Bn), 4.88 (d, J = 3.7 Hz, 1H, H-1’), 5.03 – 4.29 (m, 14H, 7 x CH2 Bn), 4.06 (dd, J = 10.0, 3.6 Hz, 
1H, H-2’), 4.02 – 3.93 (m, 3H, H-4’, H-5, H-5’), 3.92 – 3.86 (m, 2H, H-3, H-3’), 3.82 (dd, J = 11.1, 
5.3 Hz, 1H, H-6a), 3.73 (ddd, J = 20.7, 12.0, 4.8 Hz, 4H, H-4, H-1a, H-2, H-4’, H-6b), 3.55 (dd, J = 
11.3, 4.3 Hz, 1H, H-1b), 3.49 (d, J = 6.5 Hz, 2H, H2-6’). 13C NMR (100 MHz, CDCl3) 138.7 – 138.0 
(Cq Bn), 128.6-127.5 (CHAr Bn), 99.0 (C-1’), 79.6 (C-3), 79.4 (C-4), 79.2 (C-2), 78.5 (C-3’), 76.5 (C-
2’), 74.9, 74.9 (2 x CH2 Bn), 74.8 (C-4’), 73.9 – 72.9 (5 x CH2 Bn), 70.6 (C-6), 70.4 (C-5’), 69.8 (C-
5), 69.0 (C-6’), 61.9 (C-1). [α]20D = +34.4 (c = 1.02, CHCl3). IR/cm-1: 3335, 2974, 2289, 1636, 
1456, 1418, 1088, 1045. HRMS: found 997.44913 [C61H64O11+Na]+, calculated for 
[C61H64O11+Na]+ 997.44973. 
 
2,3,4-Tri-O-benzyl-6-O-(2,3,4,6-tetra-α-D-galactopyranosyl)-1-deoxynojirimycin (23):  
A solution of (COCl)2 (1.2 mL, 14.0 mmol) in dry DCM (15 mL) under argon 
atmosphere, was cooled to -78 ℃. DMSO (1.2 mL, 16.9 mmol) dissolved in 
dry DCM (12 mL) was added dropwise. After 40 minutes 22 (4.28 g, 3.22 
mmol), which was co-evaporated with toluene (3 x), in dry DCM (18 mL), 
was added dropwise to the mixture. The reaction was stirred for 2 hours at -
70 ℃, after which Et3N (5.4 mL, 38.7 mmol) was added dropwise. The 
mixture was gradually warmed to -5 ℃ after which it was poured into a cooled (0 ℃) MeOH 
solution (200 mL) containing NaCNBH3 (0.813 g, 12.3 mmol), HCOONH4 (4.07 g, 64.5 mmol), 
and Na2SO4 (1.37 g, 9.67 mmol). The mixture was stirred overnight allowing the reaction to 
reach r.t. TLC analysis showed the formation of the product. After filtering, the solvents were 
evaporated, after which the residue was dissolved in EtOAc (200 mL). The solution was washed 
with sat. aq. NaHCO3 solution (200 mL). The organic layer was dried (Na2SO4), filtered and 
concentrated, the crude product was purified with silica gel column chromatography (4:1 → 7:3 
→ 3:2 → 1:1, PE:EtOAc) to give the 23 in 71% yield (2.17 g, 2.27 mmol). 1H NMR (400 MHz, 
CDCl3) 7.45 – 7.16 (m, 35H, HAr Bn), 4.91 (d, J = 3.7 Hz, 1H, H-1’), 5.05 – 4.26 (m, 14H, 7 x CH2 
Bn), 4.06 (dd, J = 10.0, 3.6 Hz, 1H H-2’), 3.97 (d, J = 2.7 Hz, 1H, H-4’), 3.94 – 3.87 (m, 2H, H-3’, H-
5’), 3.86 (dd, J = 10.5, 5.3 Hz, 1H, H-6a), 3.64 (dd, J = 10.5, 2.6 Hz, 1H, H-6b), 3.54 (dd, J = 9.1, 2.5 
Hz, 1H, H-6’a), 3.53 (t, J = 9.0 Hz, 1H, H-3), 3.49 (dd, J = 9.3, 6.1 Hz, 1H, H-6’b), 3.32 (t, J = 9.2 Hz, 
1H, H-2), 3.31 (t, J = 9.5, 1H, H-4), 2.95 (dd, J = 12.5, 5.1, 1H, H-1’a), 2.68 (ddd, J = 9.6, 5.2, 2.6, 
1H, H-5), 2.37 (dd, J = 12.4, 10.7, 1H, H-1’b). 13C NMR (100 MHz, CDCl3) 138.8 – 137.9 (Cq Bn), 
128.4 – 127.4 (CHAr Bn), 99.0 (C-1’), 87.2 (C-3), 80.9 (C-4), 80.0 (C-2), 78.8 (C-3’), 76.8 (C-2’), 
75.6, 75.1, 74.7 (3 x CH2 Bn), 74.7 (C-4’), 73.6, 73.4, 72.6, 72.6 (4 x CH2 Bn), 69.6 (C-5’), 69.4 (C-
6), 68.8 (C-6’), 59.5 (C-5), 47.7 (C-1). IR/cm-1: 3032, 2899, 2872, 1497, 1453, 1354, 1208, 1093, 
1059, 1027. [α]20D = +58.2 (c = 0.5, CHCl3). HRMS: found 956.47363 [C61H66NO9+H]+, calculated 
for [C61H66NO9+H]+  956.47321. 
 
6-O-(α-D-Galactopyranosyl)-1-deoxynojirimycin (24): 
 A mixture of DMF/MeOH (1:1, 20 mL), HCl (2 mL, 1M) and 23 (2.00 g, 2.09 
mmol) was flushed with argon (3 x). Then a catalytic amount of Pd/C (20%) 
was added, after which H2 was flushed through the mixture, and the solution 




complete conversion of starting material into the desired product. Then the catalyst was 
filtered and the solution was concentrated. The crude product was purified on size-exclusion 
column (NH4HCO3 in water 0.15 M). After co-evaporating (3 x) with Milli-Q water, product 24 
was obtained as a white solid in 75% yield (326 mg, 1.00 mmol). 1H NMR (400 MHz, MeOD) δ 
4.84 (d, J = 3.4 Hz, 1H, H-1’), 4.01 (dd, J = 10.5, 4.7 Hz, 1H, H-6a), 3.90 (dd, J = 3.0, 1.2 Hz, 1H, H-
4’), 3.84 (td, J = 6.1, 1.1 Hz, 1H, H-5’), 3.80 (dd, J = 10.1, 3.4 Hz, 1H, H-2’), 3.76 (dd, J = 10.1, 3.0 
Hz, 1H, H-3’), 3.70 (d, J = 6.1 Hz, 2H, H2-6’), 3.59 (dd, J = 10.4, 2.5 Hz, 1H, H-6b), 3.52 (ddd, J = 
11.0, 9.1, 5.1 Hz, 1H, H-2), 3.38 (dd, J = 10.1, 9.0, 1H, H-4), 3.25 (t, J = 9.0 Hz, 1H, H-3), 3.20 (dd, J 
= 12.3, 5.1 Hz, 1H, H-1a), 2.82 (ddd, J = 10.0, 4.6, 2.6 Hz, 1H, H-5), 2.60 (dd, J = 12.3, 11.0 Hz, 1H, 
H-1b). 13C NMR (100 MHz, MeOD) δ 100.3 (C-1’), 79.9 (C-3), 72.4 (C-5’), 71.6 (C-4), 71.5 (C-2), 
71.2 (C-3’), 70.9 (C-4’), 70.4 (C-2’), 66.8 (C-6), 62.6 (C-6’), 60.5 (C-5), 49.9 (C-1). [α]20D = +92.8 
(c = 1.0, MeOH).  IR/cm-1: 3482, 2928, 2962, 1653, 1506, 1409, 1437, 1387, 1255, 1092, 1063. 
HRMS: found 326.14465 [C12H23NO9+H]+, calculated for [C12H23NO9+H]+  326.14456.  
 
Synthesis of 4-O-α-D-glucopyranosyl-1-deoxynojirimycin (33) 
1,2,3,6-Tetra-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)-β-
glucopyranose (26):                                                                                                                                                            
A suspension of Ac2O (59.0 mL, 0.625 mol) and NaOAc (4.33 g, 52.8 
mmol) was heated to reflux in an oil bath. When refluxing began the 
heat source was removed and maltose (9.94 g, 29.0 mmol, co-
evaporated with toluene 3 x) was added in small portions. The 
mixture was heated again to reflux and after an hour, TLC analysis 
confirmed the formation of the product (1:1, PE:EtOAc, RF = 0.36). The mixture was poured into 
ice water (400 mL) which was vigorously stirred. DCM (150 mL) was added and the layers 
were separated after which the organic layer was washed with water (200 mL), sat. aq. NaHCO3 
solution (2 x 150 mL) and brine (200 mL). After the organic layer was dried (Na2SO4), filtered, 
and concentrated, the residue was purified with silica gel column chromatography (1:1 → 1:2 → 
0:1, PE:EtOAc) to give the pure 26 in 94% yield (18.5 g, 27.3 mmol). 1H NMR (400 MHz, CDCl3) 
δ 5.74 (d, J = 8.2 Hz, 1H, H-1), 5.42 (dd, J = 12.4, 4.0 Hz, 1H, H-1’), 5.36 (dd, J = 9.8, 2.3 Hz, 1H, H-
3), 5.33 – 5.26 (m, 1H, H-3’), 5.11 – 4.94 (m, 2H, H-4’, H-2), 4.86 (ddd, J = 10.5, 6.2, 4.0 Hz, 1H, H-
2’), 4.45 (dd, J = 12.3, 2.4 Hz, 1H, H-6’a), 4.27 – 4.19 (m, 2H, H-6a, H-6’b), 4.14 – 4.08 (m, 1H, H-
6b), 4.04 (ddd, J = 8.9, 5.8, 3.8 Hz, 1H, H-4), 3.96 – 3.91 (m, 1H, H-5’), 3.84 (ddd, J = 9.6, 4.3, 2.5 
Hz, 1H, H-5), 2.26 – 1.96 (m, 24H, 8 x CH3). 13C NMR (100 MHz, CDCl3) δ 170.6 – 168.9 (8 x C=O), 
95.8 (C-1’), 91.3 (C-1), 75.3 (C-3’), 73.0 (C-5), 72.4 (C-4), 71.0 (C-2), 70.1 (C-2’), 69.3 (C-3), 68.6 
(C-5’), 68.0 (C-4’), 62.6 (C-6’), 61.5 (C-6), 20.9 – 20.6 (8 x CH3). 
 
2,3,6-Tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)-1-thio-D-
glucopyranose (27):  
27 was synthesised from 26 (18.5 g, 27.3 mmol) according to the 
procedure described for the preparation for compound 18, to gain 
27 (12.1 g, 16.5 mmol, 61% yield) as a colourless oil. RF = 0.43 (1:1, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.51 – 7.44 (m, 2H, HAr SPh), 
7.36 – 7.28 (m, 3H, HAr SPh), 5.39 (d, J = 4.0 Hz, 1H, H-1’), 5.34 (dd, J 
= 10.5, 9.6 Hz, 1H, H-3), 5.28 (t, J = 8.9 Hz, 1H, H-3’), 5.04 (t, J = 9.9 Hz, 1H, H-4’), 4.85 (dd, J = 
10.5, 4.0 Hz, 1H, H-2’), 4.79 (d, J = 9.0 Hz, 1H, H-2), 4.73 (d, J = 10.1 Hz, 1H, H-1), 4.54 (dd, J = 
12.1, 2.5 Hz, 1H, H-6’a), 4.24 (dd, J = 10.5, 4.5 Hz, 1H, H-6a), 4.21 (dd, J = 10.2, 4.4 Hz, 1H, H-6’b), 
4.04 (dd, J = 10.2, 4.4 Hz, 1H, H-6b), 3.95 (dd, J = 9.7, 9.0 Hz, 1H, H-4), 3.94 (ddd, J = 10.4, 4.0, 2.4 
Hz, 1H, H-5’), 3.72 (ddd, J = 9.8, 4.8, 2.6 Hz, 1H, H-5), 2.14 – 1.99 (m, 21H, 7 x CH3). 13C NMR 
(100 MHz, CDCl3) δ 170.7 – 169.6 (C=O), 133.5 (CAr SPh), 131.4 (Cq SPh), 129.0, 128.6 (CAr SPh), 
95.7 (C-1’), 85.2 (C-1), 76.6 (C-3’), 76.2 (C-5), 72.5 (C-4), 70.8 (C-2), 70.1 (C-2’), 69.4 (C-3), 68.6 




(C-5’), 68.1 (C-4’), 62.9 (C-6’), 61.6 (C-6), 21.1 – 20.7 (CH3). [α]20D = +30.6 (c = 1.0, CHCl3). 




29 was synthesised from 27 (11.9 g, 13.3 mmol) according to the 
procedure described for the preparation for compound 19, to gain 29 
(15.4 g, 14.5 mmol, 89% yield) as a light yellow oil. RF = 0.63 (4:1, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.60 (dd, J = 6.5, 3.0 Hz, 2H, 
HAr SPh), 7.33 – 7.16 (m, 32H, HAr Bn, HAr SPh), 7.13 – 7.08 (m, 6H, HAr 
Bn), 5.64 (d, J = 3.6 Hz, 1H, H-1’), 4.92 – 4.76 (m, 6H, 3 x CH2 Bn), 4.70 
(d, J = 9.7 Hz, 1H, H-1), 4.62 – 4.41 (m, 7H, 7 x CHH Bn), 4.31 (d, J = 12.1 Hz, 1H, CHH Bn), 4.12 (t, 
J = 9.2 Hz, 1H, H-4), 3.93 (dd, J = 9.9, 8.9 Hz, 1H, H-3’), 3.89 (dd, J = 11.3, 4.3 Hz, 1H, H-6’a), 3.83 
(dd, J = 6.5, 4.3 Hz, 1H, H-6’b), 3.82 (t, J = 8.8 Hz, 1H, H-3), 3.79 (dd, J = 7.3, 2.7 Hz, 1H, H-5’), 3.67 
(dd, J = 17.1, 8.0 Hz, 1H, H-4’), 3.60 (dd, J = 11.2, 1.8 Hz, 1H, H-6a), 3.59 (dd, J = 10.5, 3.3 Hz, 1H, 
H-5), 3.58 (t, J = 10.2 Hz, 1H, H-2), 3.51 (dd, J = 9.9, 3.7 Hz, 1H, H-2’), 3.45 (dd, J = 10.6, 1.8 Hz, 
1H, H-6b). 13C NMR (100 MHz, CDCl3) δ 138.7 – 137.8 (7 x Cq Bn), 133.7 (Cq SPh), 132.0 – 126.5 
(CAr SPh), 97.1 (C-1’), 87.2 (C-1), 86.7 (C-3), 82.0 (C-3’), 80.9 (C-2), 79.4 (C-2’), 78.8 (C-5), 77.7 
(C-4’), 75.5 – 73.3 (7 x CH2Bn), 72.7 (C-4), 71.1 (C-5’), 69.2 (C-6’), 68.3 (C-6). [α]20D = + 2.87 (c = 




 30 was synthesised from 29 (14.5 g, 13.6 mmol) according to the 
procedure described for the preparation for compound 21, to gain 30 
(12.3 g, 12.3 mmol, 93% yield) as a light yellow oil. RF = 0.40 and 0.30 
(7:3, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.07 (m, 35H, HAr 
Bn), 5.66 (dd, J = 8.6, 3.6 Hz, 1H, H-1’), 5.21 (t, J = 2.9 Hz, 1H, H-1), 
5.02 – 4.26 (m, 14H, 7 x CH2 Bn), 4.31 (dd, J = 12.2, 10.0 Hz, 1H, H-4), 4.13 (t, J = 8.8 Hz, 1H, H-3), 
4.03 – 3.82 (m, 2H, H-3’, H-5), 3.80 – 3.58 (m, 5H, H-2, H-4’, H-5’, H2-6’), 3.55 – 3.45 (m, 2H, H-2’, 
H-6a), 3.39 (ddd, J = 10.7, 3.6, 1.7 Hz, 1H, H-6b). 13C NMR (100 MHz, CDCl3) δ 138.9, 138.7, 
138.4, 138.2, 138.0, 137.9, 137.7 (7 x Cq Bn), 128.4 – 127.1 (CHAr Bn), 96.9 (C-1’), 90.7 (C-1), 
82.0 (C-3’), 81.4 (C-4), 80.0 (C-2), 79.4 (C-2’), 77.7 (C-4’), 75.6 – 72.9 (7 x CH2 Bn), 72.9 (C-3), 
71.1 (C-5), 69.6 (C-5’), 69.2 (C-6’), 68.1 (C-6). [α]20D = +32.8 (c = 1.0, CHCl3). IR/cm-1: 3418, 
3063, 3030, 2903, 2864, 1497, 1452, 1362, 1265, 1207, 1146, 1088, 1043, 1026.  
 
2,3,6-Tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl)-D-glucitol (31): 
31 was synthesised from 30 (11.3 g, 11.6 mmol) according to the 
procedure described for the preparation for compound 22, to gain 31 
(8.33 g, 8.55 mmol, 74% yield) as a light yellow oil. RF = 0.31 (7:3, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) 7.36 – 7.07 (m, 35H, HAr Bn), 
4.82 (d, J = 3.1 Hz, 1H, H-1’), 4.96 – 4.35 (m, 14H, 7 x CH2 Bn), 4.12 
(dd, J = 8.6, 4.0 Hz, 1H, H-3’), 3.98 (ddd, J = 10.2, 3.2, 2.1 Hz, 1H, H-5), 3.96 – 3.90 (m, 4H, H-5’, H-
4, H-3’, H-4’),  3.71 (dt, J = 29.8, 6.9 Hz, 2H, H-1), 3.60 – 3.53 (m, 6H, H2-6, H2-6’, H-2, H-2’). 13C 
NMR (100 MHz, CDCl3) 138.2 – 137.6 (Cq Bn), 129.1 – 125.4 (CHAr Bn), 99.2 (C-1’), 82.0 (C-3), 
79.9 (C-3’), 79.7 (C-4’), 79.4 (C-2), 78.8 (C-4), 77.8 (C-2’), 75.7 – 72.8 (7 x CH2 Bn), 71.8 (C-3’), 
71.6 (C-6), 71.2 (C-5), 68.3 (C-6’), 61.6 (C-1). [α]20D = +38.1 (c = 1.03, CHCl3). IR/cm-1: 3420, 
3063, 3030, 2862, 1454, 1207, 1086, 1070, 1028. HRMS: found 997.44970 [C61H64O11+Na]+, 








32 was synthesised from 31 (0.998 g, 1.02 mmol) according to the 
procedure described for the preparation for compound 23, to gain 32 
(0.428 g, 0.448 mmol, 44% yield) as a light yellow oil. RF = 0.38 (1:1, 
PE:EtOAc).  1H NMR (400 MHz, CDCl3) 7.49 – 7.26 (m, 35H, HAr Bn), 
5.94 (d, J = 3.6 Hz, 1H, H-1’), 5.30 – 4.46 (m, 14H, CH2 Bn), 4.11 (dd, J = 
9.8, 8.5 Hz, 1H, H-3’), 3.98 (dd, J = 9.5, 8.7 Hz, 1H, H-4), 3.93 – 3.87 (m, 2H, H-5’, H-6a), 3.88 (t, J 
= 8.7 Hz, 1H, H-3), 3.84 (dd, J = 8.7, 1.3 Hz, 1H, H-4’), 3.81 (dd, J = 8.7, 5.6 Hz, 1H, H-6b), 3.73 (dd, 
J = 10.6, 2.8 Hz, 1H, H-6’a), 3.73 – 3.70 (m, 1H, H-2), 3.67 (dd, J = 9.8, 3.6 Hz, 1H, H-2’), 3.61 (dd, J 
= 10.4, 1.3 Hz, 1H, H-6’b), 3.42 (dd, J = 12.3, 5.1 Hz, 1H, H-1a), 3.03 (ddd, J = 9.1, 5.8, 2.9, 1H, H-
5), 2.70 (dd, J = 12.3, 10.6 Hz, 1H, H-1b). 13C NMR (100 MHz, CDCl3) 139.1 – 137.9 (7 x Cq Bn), 
128.3 – 126.5 (CHAr Bn), 96.6 (C-1’), 87.0 (C-3), 82.0 (C-3’), 80.9 (C-2), 79.3 (C-2’), 77.7 (C-4’), 
75.5, 74.9 (2 x CH2 Bn), 74.2 (C-4), 73.8 – 72.5 (5 x CH2 Bn), 71.0 (C-5’), 70.5 (C-6), 68.1 (C-6’), 
59.0 (C-5), 47.8 (C-1). [α]20D = +26.0 (c = 0.7, CHCl3). IR/cm-1: 2918, 2866, 1454, 1362, 1740, 
1090, 1072, 1047, 1026. HRMS: found 956.47311 [C61H66NO9+H]+, calculated for 
[C61H66NO9+H]+  956.47321. 
 
 4-O-(α-D-Glucopyranosyl)-1-deoxynojirimycin (33): 
33 was synthesised from 32 (1.00 g, 1.04 mmol) according to the 
procedure described for the preparation for compound 24, to gain 33 
(0.24 g, 0.74 mmol, 71% yield) as a light yellow oil.  1H NMR (400 MHz, 
MeOD) δ 5.21 (d, J = 3.7 Hz, 1H, H-1’), 4.00 (dd, J = 12.1, 4.8 Hz, 1H, H-
6a), 3.91 (dd, J = 12.0, 3.0 Hz, 1H, H-6b), 3.88 – 3.83 (m, 1H, H-6’a), 3.77 
(ddd, J = 4.8, 8.9, 10.8 Hz, 1H, H-2). 3.81 – 3.66 (m, 4H, H-3’, H-4’, H-6’b, H-3), 3.62 (dd, J = 9.7, 
9.0 Hz, 1H, H-4) 3.49 (dd, J = 9.7, 3.8 Hz, 1H, H-2’), 3.35 (dd, J = 12.5, 5.0 Hz, 1H, H-1a), 3.30 – 
3.23 (m, 2H, H-5’, H-5), 2.91 (dd, J = 12.4, 10.9 Hz, 1H, H-1b).  13C NMR (100 MHz, MeOD) δ 
103.1 (C-1’), 79.3 (C-3’), 77.7 (C-3), 75.1 (C-4’), 74.9 (C-4), 73.9 (C-2’), 71.4 (C-5’), 68.2 (C-2), 
62.7 (C-6’), 60.5 (C-5), 58.8 (C-6), 47.1 (C-1). [α]20D = +25.0 (c =0.2, MeOH). IR/cm-1: 3303, 2967, 
1636, 1560, 1203, 1161, 1022. HRMS: found 326.14464 [C12H23NO9+H]+, calculated for 
[C12H23NO9+H]+  326.14456.  
 
Synthesis of β-D-galactopyranosyl-1-deoxynojirimycin (40) 
2,3,6-Tri-O-benzyl-4-(2’,3’,4’,6’-tetra-O-benzyl-β-D-galactopyranosyl)-1-thio-D-
glucopyranose (36): 
36 was synthesised from 34 (3.64 g, 5.00 mmol) according to the 
procedure described for the preparation for compound 20, to gain 
36 (5.32 g, 5.00 mmol, 100% yield) as a light yellow oil. RF = 0.67 
(4:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.61 – 7.04 (m, 40H, 
HAr Bn/SPh), 4.67 (d, J = 10.5 Hz, 1H, H-1), 5.13 – 4.20 (m, 14H, 7 x CH2 Bn), 4.45 (d, J = 7.7 Hz, 
1H, H-1’), 4.00 – 3.91 (m, 2H, H-4’, H-5’), 3.82 (dd, J = 11.0, 4.3 Hz, 1H, H-6’a), 3.79 – 3.73 (m, 2H, 
H-2’, H-6’b), 3.61 (t, J = 8.9 Hz, 1H, H-3’), 3.52 (t, J = 7.6 Hz, 1H, H-6a), 3.47 – 3.31 (m, 5H, H-2, H-
3, H-4, H-5 H-6b). 13C NMR (100 MHz, CDCl3) δ 139.2 – 138.2 (7 x Cq Bn), 133.8 (Cq SPh), 132.2 – 
127.3 (CHAr Bn/SPh), 103.0 (C-1’), 87.5 (C-1), 85.1 (C-3’), 82.7 (C-4), 80.2 (C-2), 80.1 (C-2’), 79.5 
(C-3), 76.6 (C-4’), 75.7, 75.6, 75.5, 74.5 (4 x CH2 Bn), 73.7 (C-5’), 73.5, 73.2 (2 x CH2 Bn), 73.1 (C-
5), 72.2 (CH2 Bn), 68.5 (C-6’), 68.2 (C-6). IR/cm-1: 3030, 2920, 2862, 1497, 1454, 1362, 1209, 
1088, 1076, 1028, 1001.  
 







37 was synthesised from 36 (0.12 g, 0.12 mmol) according to the 
procedure described for the preparation for compound 21, to gain 
37 (96.0 mg, 98.7 µmol, 85% yield) as a light yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 7.61 – 7.04 (m, 40H, HAr Bn/SPh), 5.16 (d, J = 3.7 
Hz, 1H, H-1), 5.10 – 4.17 (m, 14H, 7 x CH2 Bn), 4.33 (d, J = 9.4 Hz, 1H, H-1’), 3.99 – 3.87 (m, 3H, 
H-2’, H-3’, H-5’), 3.87 – 3.80 (m, 2H, H-4, H-3), 3.74 (ddd, J = 10.0, 7.5, 2.4 Hz, 1H, H-6’a), 3.65 
(dd, J = 10.5, 1.6 Hz, 1H, H-6’b), 3.52 (ddd, J = 12.7, 9.3, 6.7 Hz, 2H, H-2, H-6a), 3.42 – 3.29 (m, 
4H, H-3, H-4’, H-5, H-6b). 13C NMR (100 MHz, CDCl3) δ 139.3 – 138.1 (Cq Bn), 128.5 – 127.2 
(CHAr Bn), 103.0 (C-1’), 91.5 (C-1), 82.5 (C-3), 80.0 (C-2), 79.2 (C-2’), 76.6 (C-3’), 75.5, 72.3 (2 x 
CH2 Bn), 75.1 (C-4’), 74.8 (CH2 Bn), 73.8 (C-4), 73.7, 73.6, 73.2 (3 x CH2 Bn), 73.2 (C-5’), 72.7 
(CH2 Bn), 70.5 (C-5), 68.3 (C-6’), 68.1 (C-6). [α]20D = +12.4 (c = 1.07, CHCl3). IR/cm-1: 2920, 2864, 
1452, 1396, 1362, 1207, 1090. HRMS: found 995.43425 [C61H64O11+Na]+, calculated for 
[C61H64O11+Na]+  995.43408. 
 
2,3,6-Tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-D-glucitol (38): 
38 was synthesised from 37 (5.44 g, 5.59 mmol) according to the 
procedure described for the preparation for compound 22, to gain 
38 (4.17 g, 4.28 mmol, 77% yield) as a light yellow oil. RF   = 0.20 (7:3, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) 7.36 – 7.18 (m, 35H, HAr Bn), 
4.97 – 4.22 (m, 14H, 7 x CH2 Bn), 4.34 (dd, J = 7.2, 5.4 Hz, 1H, H-1’), 4.03 (dd, J = 7.4, 2.4 Hz, 1H, 
H-4), 3.99 (dt, J = 7.9, 3.8 Hz, 2H, H-2, H-5’), 3.95 (dd, J = 7.8, 2.4 Hz, 1H, H-3), 3.83 (d, J = 2.9 Hz, 
1H, H-4’), 3.77 (dd, J = 9.8, 7.7 Hz, 1H, H-2’), 3.71 (dd, J = 6.9, 3.7, 2H, H-1), 3.66 (dd, J = 9.9, 4.4 
Hz, 1H, H-6’a), 3.55 (dd, J = 9.8, 3.0 Hz, 1H, H-6’b), 3.48 (dd, J = 6.3, 2.5 Hz, 2H, H2-6), 3.42 (dd, J 
= 10.0, 6.4 Hz, 1H, H-5), 3.40 (dd, J = 9.7, 3.0 Hz, 1H, H-3’). 13C NMR (100 MHz, CDCl3) 138.8 – 
137.7 (Cq Bn), 128.5 – 127.3  (CHAr Bn), 103.8 (C-1’), 82.42 (C-3’), 79.9 (C-4), 79.8 (C-2), 79.4 (C-
2’), 77.5 (C-3), 75.4, 74.9, 74.7 (3 x CH2 Bn), 73.8 (C-4’), 73.6, 73.3 (2 x CH2 Bn), 73.3 (C-5), 73.2, 
73.0 (2 x CH2 Bn),  70.8 (C-5’), 70.8 (C-6’), 68.9 (C-6), 62.3 (C-1). IR/cm-1: 3028, 2922, 2864, 
1063, 1026, 1001. [α]20D = +6.6 (c = 1.0, CHCl3). HRMS: found 997.44976 [C61H66O11+Na]+, 




39 was synthesised from 38 (4.17 g, 4.28 mmol) according to the 
procedure described for the preparation for compound 23, to gain 39 
(0.90 g, 0.94 mmol, 22% yield) as a light yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 7.45 – 7.09 (m, 35H, HAr Bn), 5.05 (d, J = 10.7 Hz, 1H, CHH  Bn), 
4.98 (d, J = 11.4 Hz, 1H), 4.85 (d, J = 11.4 Hz, 1H, CHH  Bn), 4.83 (d, J = 2.6 Hz, 2H, CH2 Bn), 4.75 
(d, J = 11.9 Hz, 1H, CHH Bn), 4.71 (d, J = 11.6 Hz, 2H, CH2 Bn), 4.67 (d, J = 11.5 Hz, 1H, CHH  Bn), 
4.57 (d, J = 11.7 Hz, 1H, CHH  Bn), 4.44 (d, J = 11.7 Hz, 1H, CHH  Bn), 4.38 (d, J = 11.8 Hz, 1H, CHH  
Bn), 4.35 (d, J = 11.7 Hz, 1H, CHH  Bn), 4.34 (d, J = 7.7 Hz, 1H, H-1’), 4.30 (d, J = 11.9 Hz, 1H, CHH  
Bn), 3.92 (d, J = 3.0 Hz, 1H, H-4’), 3.78 (dd, J = 9.7, 7.7 Hz, 1H, H-2’), 3.70 (dd, J = 9.0, 2.8 Hz, 1H, 
H-6a), 3.65 (dd, J = 9.4, 6.1 Hz, 1H, H-6b), 3.57 (dd, J = 9.8, 5.0 Hz, 1H, H-2), 3.52 (dd, J = 14.3, 7.4 
Hz, 1H, H-6’a), 3.46 – 3.41 (m, 3H, H-5’, H-3, H-4). 3.42 (dd, J = 9.8, 2.9 Hz, 1H, H-3’), 3.35 (dd, J = 
14.0, 7.3 Hz, 1H, H-6’b), 3.20 (dd, J = 12.2, 4.5 Hz, 1H, H-1a), 2.71 (ddd, J = 9.2, 5.6, 2.6 Hz, 1H, H-
5), 2.50 (dd, J = 12.2, 10.0 Hz, 1H, H-1b). 13C NMR (100 MHz, CDCl3) δ 138.8 – 137.7 (Cq Bn), 
128.6 – 127.6 (CH2 Bn), 103.9 (C-1’), 82.5 (C-4’), 80.0 (C-5’), 79.8 (C-2’), 79.4 (C-3’), 77.6 – 74.7 
(3 x CH2 Bn), 73.7 (C-3), 73.6 (CH2 Bn), 73.3 (C-5), 73.3 – 72.9 (3 x CH2 Bn), 70.8 (C-2), 70.8 (C-




1028. [α]20D = +14.0 (c = 0.4, CHCl3). HRMS: found 956.47340 [C61H66O9N +Na]+, calculated for 
[C61H66O9N+H]+  956.47321. 
 
 4-(β-D-Galactopyranosyl)-1-deoxynojirimycin (40): 
40 was synthesised from 39 (0.932 g, 0.975 mmol) according to the 
procedure described for the preparation for compound 24, to gain 40 
(0.20 g, 0.621 mmol, 64% yield) as a light yellow oil. 1H NMR (400 MHz, 
MeOD) δ 4.44 (d, J = 7.6 Hz, 1H, H-1’), 3.92 (d, J = 3.7 Hz, 2H, H2-6), 3.92 
(d, J = 3.2, Hz, 1H, H-4’), 3.87 (dd, J = 11.4, 7.4 Hz, 1H, H-6’a), 3.79 (dd, J = 11.4, 4.7 Hz, 1H, H-
6’b), 3.67 (ddd, J = 7.4, 4.7, 1.1 Hz, 1H, H-5’), 3.65 (dd, J = 9.8, 7.6 Hz, 1H, H-2’), 3.58 (dd, J = 9.7, 
3.3 Hz, 1H, H-3’), 3.55 (ddd, J = 10.7, 9.1, 5.1 Hz, 1H, H-2), 3.50 (dd, J = 9.5, 8.8 Hz, 1H, H-4), 3.44 
(t, J = 8.7 Hz, 1H, H-3), 3.17 (dd, J = 12.4, 5.1 Hz, 1H, H-1a), 2.71 (dt, J = 9.6, 3.8 Hz, 1H, H-5), 2.54 
(dd, J = 12.5, 10.7 Hz, 1H, H-1b). 13C NMR (100 MHz, MeOD) δ 106.1 (C-1’), 83.6 (C-4), 79.6 (C-
3), 77.9 (C-5’), 75.7 (C-3’), 73.5 (C-2), 73.3 (C-2’), 71.1 (C-4’), 63.3 (C-6’), 62.8 (C-6), 62.5 (C-5), 
51.3 (C-1). [α]20D = +16.0 (c = 0.2, MeOH). IR/cm-1: 3306, 2945, 2833, 1653, 1448, 1410, 1113, 
1018. HRMS: found 326.14482 [C12H23NO9+H]+, calculated for [C12H23NO9+H]+  326.14456. 
 
Synthesis of 4-O-(β-D-glucopyranosyl)-1-deoxynojirimycin (49) 
2,3,6-Tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-1-thio-D-
glucopyranose (42): 
42 was synthesised from D-(+)-cellobiose (10.0 g, 29.2 mmol) 
according to the procedure described for the preparation for 
compound 17, to gain 42 (19.5 g, 28.8 mmol, 98% yield). RF = 0.36 
(1:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) 5.66 (d, J = 8.2 Hz, 1H, 
H-1), 5.23 (t, J = 9.2 Hz, 1H, H-3’), 5.18 – 4.99 (m, 3H, H-3, H-4, H-2), 4.97 – 4.87 (m, 1H, H-2’), 
4.52 – 4.47 (m, 2H, H-6’a, H-1’), 4.37 (dd, J = 12.3, 4.4 Hz, 1H, H-6a), 4.12 (dd, J = 12.2, 4.6 Hz, 
1H, H-6’b), 4.05 (dd, J = 12.5, 2.1 Hz, 1H, H-6b), 3.82 (dd, J = 15.6, 6.5 Hz, 1H, H-4’), 3.75 (ddd, J = 
9.8, 4.7, 1.8 Hz, 1H, H-5), 3.66 (ddd, J = 9.9, 4.4, 2.4 Hz, 1H, H-5’). 13C NMR (100 MHz, CDCl3) 
170.6 – 169.0 (8 x C=O), 100.8 (C-1’), 91.7 (C-1), 76.0 (C-5’), 73.6 (C-4’), 73.0 (C-3’), 72.5 (C-3), 




43 was synthesised from 42 (0.68 g, 1.00 mmol) according to the 
procedure described for the preparation for compound 18, to gain 
43 (0.67 g, 0.91 mmol, 91% yield) as a colourless oil. RF = 0.53 
(1:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) 5.20 (dd, J = 10.4, 8.0 
Hz, 1H, H-3’), 5.15 (dd, J = 9.4, 7.2 Hz, 1H, H-3), 5.06 (t, J = 9.7 Hz, 1H, H-4), 4.91 (ddd, J = 10.0, 
8.6, 3.7 Hz, 2H, H-2, H-2’), 4.70 (d, J = 10.1 Hz, 1H, H-1’), 4.56 (dd, J = 11.9, 2.0 Hz, 1H, H-6’a), 
4.54 (d, J = 7.9 Hz, 1H, H-1), 4.38 (dd, J = 12.5, 4.3 Hz, 1H, H-6a), 4.11 (td, J = 7.1, 1.9 Hz, 1H, H-
6’b), 4.03 (dd, J = 12.4, 2.0 Hz, 1H, H-6b), 3.75 (m, 1H, H-4’), 3.69 (ddd, J = 8.9, 3.9, 1.8 Hz, 1H, H-
5), 3.65 (dd, J = 5.7, 2.0 Hz, 1H, H-5’). 13C NMR (100 MHz, CDCl3) 170.3 – 168.8 (7 x C=O), 
132.8 (CAr SPh), 131.7 (Cq SPh), 128.7, 128.1 (CAr SPh), 100.5 (C-1’), 85.2 (C-1), 76.6 (C-5’), 76.2 
(C-4’), 73.4 (C-3’), 72.8 (C-3), 71.7 (C-5), 71.4 (C-2’), 70.0 (C-2), 67.6 (C-4), 61.9 (C-6’), 61.4 (C-
6), 20.9 – 20.3 (7 x CH3). [α]20D = +30.6 (c = 1.0, CHCl3). IR/cm-1: 2958, 2872, 1743, 1440, 1368, 
1216, 1168, 1038. HRMS: found 751.18783 [C32H40O17S+Na]+, calculated for [C32H40O17S+Na]+  
751.18784. 
 





glucopyranose (45):  
45 was synthesised from 43 (11.9 g, 13.3 mmol) according to the 
procedure described for the preparation for compound 19, to gain 
45 (15.4 g, 14.5 mmol, 89% yield) as a light yellow oil. RF = 0.63 
(4:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) 7.60 (dd, J = 6.5, 3.0 
Hz, 2H, HAr SPh), 7.33 – 7.16 (m, 32H, HAr Bn, HAr SPh), 7.13 – 7.08 (m, 6H, HAr Bn), 5.64 (d, J = 
3.6 Hz, 1H, H-1’), 4.92 – 4.76 (m, 6H, 3 x CH2 Bn), 4.70 (d, J = 9.7 Hz, 1H, H-1), 4.62 – 4.41 (m, 7H, 
7 x CHH Bn), 4.31 (d, J = 12.1 Hz, 1H, CHH Bn), 4.12 (t, J = 9.2 Hz, 1H, H-4), 3.93 (dd, J = 9.9, 8.9 
Hz, 1H, H-3’), 3.89 (dd, J = 11.3, 4.3 Hz, 1H, H-6a’), 3.83 (dd, J = 6.5, 4.3 Hz, 1H, H-6b’), 3.82 (t, J = 
8.8 Hz, 1H, H-3), 3.79 (dd, J = 7.3, 2.7 Hz, 1H, H-5’), 3.67 (dd, J = 17.1, 8.0 Hz, 1H, H-4’), 3.60 (dd, J 
= 11.2, 1.8 Hz, 1H, H-6a), 3.59 (dd, J = 10.5, 3.3 Hz, 1H, H-5), 3.58 (t, J = 10.2 Hz, 1H, H-2), 3.51 
(dd, J = 9.9, 3.7 Hz, 1H, H-2’), 3.45 (dd, J = 10.6, 1.8 Hz, 1H, H-6b). 13C NMR (100 MHz, CDCl3) 
138.7 – 137.8 (7 x Cq Bn), 133.7 (Cq SPh), 132.0-126.5 (CAr), 97.1 (C-1’), 87.2 (C-1), 86.7 (C-3), 
82.0 (C-3’), 80.9 (C-2), 79.4 (C-2’), 78.8 (C-5), 77.7 (C-4’), 75.5 – 73.3 (7 x CH2Bn), 72.7 (C-4), 
71.1 (C-5’), 69.2 (C-6’), 68.3 (C-6). [α]20D = + 2.87 (c = 2.31, CHCl3). IR/cm-1: 3063, 3030, 2904, 
2864, 1452, 1360, 1207, 1140, 1084, 1055, 1026. HRMS: found 1087.44289 [C61H64O11+Na]+, 




46 was synthesised from 45 (14.5 g, 13.6 mmol) according to the 
procedure described for the preparation for compound 21, to gain 
46 (12.3 g, 12.3 mmol, 90% yield) as a light yellow oil. RF = 0.40 
and 0.30 (7:3, PE:EtOAc). For the major anomer: 1H NMR (400 
MHz, CDCl3)  7.31 – 7.07 (m, 35H, HAr Bn), 5.66 (dd, J = 8.6, 3.6 Hz, 1H, H-1’), 5.21 (t, J = 2.9 Hz, 
1H, H-1), 5.02 – 4.26 (m, 14H, 7 x CH2 Bn), 4.31 (dd, J = 12.2, 10.0 Hz, 1H, H-4), 4.13 (t, J = 8.8 Hz, 
1H, H-3), 4.03 – 3.82 (m, 2H, H-3’, H-5), 3.80 – 3.58 (m, 5H, H-2, H-4’, H-5’, H2-6’), 3.55 – 3.45 (m, 
2H, H-2’, H-6a), 3.39 (ddd, J = 10.7, 3.6, 1.7 Hz, 1H, H-6b). 13C NMR (100 MHz, CDCl3) 138.9 – 
137.7 (7 x Cq Bn), 128.4 – 127.1 (CHAr Bn), 96.9 (C-1’), 90.7 (C-1), 82.0 (C-3’), 81.4 (C-4), 80.0 (C-
2), 79.4 (C-2’), 77.7 (C-4’), 75.6 – 72.9 (7 x CH2 Bn), 72.9 (C-3), 71.1 (C-5), 69.6 (C-5’), 69.2 (C-
6’), 68.1 (C-6). [α]20D = +32.8 (c = 1.0, CHCl3). IR/cm-1: 3418, 3063, 3030, 2903, 2864, 1497, 
1452, 1362, 1265, 1207, 1146, 1088, 1043, 1026. HRMS: found 995.43387 [C61H64O11+Na]+, 
calculated for [C61H64O11+Na]+  995.43408. 
 
2,3,6-Tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl)-D-glucitol (47): 
47 was synthesised from 46 (11.2 g, 11.6 mmol) according to the 
procedure described for the preparation for compound 22, to gain 
47 (8.33 g, 8.55 mmol, 74% yield) as a light yellow oil. RF = 0.31 
(7:3 PE:EtOAc). 1H NMR (400 MHz, CDCl3) 7.36 – 7.07 (m, 35H, 
HAr Bn), 4.82 (d, J = 3.1 Hz, 1H, H-1’), 4.96 – 4.35 (m, 14H, 7 x CH2 Bn), 4.12 (dd, J = 8.6, 4.0 Hz, 
1H, H-3’), 3.98 (ddd, J = 10.2, 3.2, 2.1 Hz, 1H, H-5), 3.96 – 3.90 (m, 4H, H-5’, H-4, H-3’, H-4’),  3.71 
(dt, J = 29.8, 6.9 Hz, 2H, H2-1), 3.52 – 3.62 (m, 6H, H2-6, H2-6’, H-2, H-2’). 13C-NMR (100 MHz, 
CDCl3) 138.2 – 137.6 (7 x Cq Bn), 129.1 – 125.4 (CHAr Bn), 99.2 (C-1’), 82.0 (C-3), 79.9 (C-3’), 
79.7 (C-4’), 79.4 (C-2), 78.8 (C-4), 77.8 (C-2’), 75.7 – 72.8 (7 x CH2 Bn), 71.8 (C-3’), 71.6 (C-6), 
71.2 (C-5), 68.3 (C-6’), 61.6 (C-1). IR/cm-1: 3420, 3063, 3030, 2862, 1454, 1207, 1086, 1070, 
1028. [α]20D = +38.1 (c = 1.03, CHCl3). HRMS: found 997.44972 [C61H66O11+Na]+, calculated for 







48 was synthesised from 47 (1.0 g, 1.02 mmo) according to the 
procedure described for the preparation for compound 23, to gain 
48 (0.43 g, 0.45 mmol, 44% yield) as a light yellow oil. RF = 0.38 (1:1 
PE, EtOAc).  1H NMR (400 MHz, CDCl3) 7.49 – 7.26 (m, 35H, HAr 
Bn), 5.94 (d, J = 3.6 Hz, 1H, H-1’), 5.30 – 4.46 (m, 14H, 7 x CH2 Bn), 4.11 (dd, J = 9.8, 8.5 Hz, 1H, 
H-3’), 3.98 (dd, J = 9.6, 8.7 Hz, 1H, H-4), 3.93 – 3.87 (m, 3H, H-5’, H-6a, H-3), 3.84 (dd, J = 8.7, 1.3 
Hz, 1H, H-4’), 3.81 (dd, J = 8.7, 5.6 Hz, 1H, H-6b), 3.73 (dd, J = 10.6, 2.8 Hz, 1H, H-6a’), 3.72 (td, J 
= 5.3, 2.2 Hz, 1H, H-2), 3.67 (dd, J = 9.8, 3.6 Hz, 1H, H-2’), 3.61 (dd, J = 10.4, 1.3 Hz, 1H, H-6b’), 
3.42 (dd, J = 12.3, 5.1 Hz, 1H, H-1a), 3.03 (ddd, J = 9.0, 5.7, 2.8, 1H, H-5), 2.70 (dd, J = 12.3, 10.6 
Hz, 1H, H-1b). 13C NMR (100 MHz, CDCl3) 139.1 – 137.9 (7 x Cq Bn), 128.3 – 126.5 (CHAr Bn), 
96.6 (C-1’), 87.0 (C-3), 82.0 (C-3’), 80.9 (C-2), 79.3 (C-2’), 77.7 (C-4’), 75.5, 74.9 (2 x CH2 Bn), 
74.2 (C-4), 73.8 – 72.5 (5 x CH2 Bn), 71.0 (C-5’), 70.5 (C-6), 68.1 (C-6’), 59.0 (C-5), 47.8 (C-1). 
[α]20D = +26.0 (c = 0.7, CHCl3). IR/cm-1: 2918, 2866, 1454, 1362, 1740, 1090, 1072, 1047, 1026. 
HRMS: found 956.47361 [C61H66NO9+Na]+, calculated for [C61H66NO9+Na]+  956.47321. 
 
4-O-(β-D-Glucopyranosyl)-1-deoxynojirimycin (49): 
49 was synthesised from 48 (1.00 g, 1.04 mmol) according to the 
procedure described for the preparation for compound 24, to gain 49 
(0.22 g, 0.67 mmol, 65% yield) as a light yellow oil. 1H NMR (600 MHz, 
D2O) δ 4.46 (d, J = 7.9 Hz, 1H, H-1’), 3.88 (dd, J = 12.3, 3.1 Hz, 1H, H-6a), 
3.84 (dd, J =12.4, 2.2 Hz, 1H, H-6’a), 3.66 (dd, J = 12.4, 5.7 Hz, 1H, H-6’b), 3.66 – 3.62 (m, 1H, H-
2), 3.62 (dd, J = 10.4, 8.9 Hz, H-5’), 3.49 (t, J = 9.1 Hz, 1H, H-3), 3.42 (t, J = 9.5 Hz, 1H, H-3’), 3.42 – 
3.39 (m, 1H, H-5), 3.35 (dd, J = 9.8, 9.1 Hz, H-4’), 3.26 (dd, J = 12.7, 5.0 Hz, H-1a), 3.26 (dd, J = 
9.4, 7.9 Hz, H-2’), 3.02 (ddd, J = 10.3, 5.0, 2.9 Hz, 1H, H-5), 2.70 (dd, J = 12.5, 11.2 Hz, 1H, H-1b). 
13C NMR (150 MHz, D2O) δ 102.6 (C-1), 78.5 (C-4), 76.0 (C-5’), 75.6 (C-3’), 75.5 (C-3), 73.2 (C-
2’), 69.4 (C-4’), 68.4 (C-2), 60.5 (C-6’), 59.2 (C-5), 58.4 (C-6), 46.6 (C-1). [α]20D = +25.3 (c = 1.0, 
MeOH). IR/cm-1: 3302, 2966, 1636, 1558, 1203, 1161, 1022. HRMS: found 326.14464 
[C12H23NO9+H]+, calculated for [C12H23NO9+H]+  326.14456.   
 
Synthesis of 2-O-(α-D-galactopyranpsyl-)-1-deoxynojirimycin (69) 
Phenyl-1-thio-2,3,4,6-tetra-(O-acetyl)-β-D-glucopyranoside (51): 
β-D-Glucose penta-acetate (0.996 g, 2.56 mmol) and PhSH (0.4 mL, 4 mmol) 
were dissolved in DCM (20 mL). The mixture was cooled to 0 ℃ and BF3∙Et2O 
(0.46 mL, 3.7 mmol) was added dropwise. After 5 hours, TLC analysis 
showed complete consumption of the starting compound. The mixture was 
washed with sat. aq. NaHCO3, organic layer was dried (Na2SO4), filtrated and concentrated.  The 
crude product was purified with silica gel column chromatography to gain 51 as white crystal 
(1.02 g, 2.33 mmol, yield 91%). RF = 0.7 (5:3, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.55 – 7.49 
(m, 2H, HAr SPh), 7.36 – 7.32 (m, 3H, HAr SPh), 5.24 (t, J = 9.3 Hz, 1H, H-3), 5.06 (t, J = 9.8 Hz, 1H, 
H-4), 4.99 (dd, J = 10.1, 9.2 Hz, 1H, H-2), 4.73 (d, J = 10.1 Hz, 1H, H-1), 4.24 (dd, J = 12.3, 5.0 Hz, 
1H, H-6a), 4.20 (dd, J = 12.3, 2.7 Hz, 1H, H-6b), 3.75 (ddd, J = 10.1, 5.0, 2.7 Hz, 1H, H-5), 2.11 (s, 
3H, CH3), 2.10 (s, 3H, CH3), 2.04 (s, 3H, CH3), 2.01 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 
170.6, 170.2, 169.4, 169.3 (4 x C=O), 131.6 (Cq SPh), 128.9 – 128.4 (CAr SPh), 85.7 (C-1), 75.8 (C-
5), 74.0 (C-3), 69.9 (C-2), 68.2 (C-4), 62.1 (C-6), 20.7 – 20.6 (4 x CH3). 
 
Phenyl-1-thio-β-D-glucopyranoside (52): 
NaOMe (0.276 g, 5.12 mmol) was added to a solution of 51 (2.56 mmol) in 
MeOH (20 mL). After 24 hours, TLC analysis showed complete consumption 
of 51. The solution was neutralized with amberlite H+ resin, filtrated and 




concentrated. The crude product was used for the next reaction step without further 
purification. RF = 0.6 (5:1, EtOAc:MeOH). 1H NMR (400 MHz, MeOD) δ 7.60 – 7.57 (m, 2H, HAr 
SPh), 7.35 – 7.26 (m, 3H, HAr  SPh), 4.63 (d, J = 9.6 Hz, 1H, H-1), 3.91 (dd, J = 12.4, 1.6 Hz, 1H, H-
6a), 3.71 (dd, J = 12.0, 5.6, 1H, H-6b), 3.43 (t, J = 8.8, 1H, H-4), 3.37 – 3.29 (m, 2H, H-3, H-5), 3.26 
(dd, J = 9.6, 8.8, 1H, H-2). 13C NMR (100 MHz, MeOD) δ 133.8 (Cq SPh), 131.3, 128.5, 127.0 (CAr 
SPh), 88.0 (C-1), 80.7 (C-3), 78.3 (C-4), 72.4 (C-2), 70.0 (C-5), 61.5 (C-6). 
 
Phenyl-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (53): 
PhCH(OMe)2 (5.7 mL, 38 mmol) was added to the solution of 52 (8.65 g, 
31.6 mmol) in DMF (20 mL). p-TsOH was added to adjust the pH to 4. The 
mixture was heated to 60 °C and the pressure was reduced to 20 mbar. 
After 4.5 hours, TLC analysis showed complete consumption of 52. The 
mixture was neutralized with TEA, diluted with EtOAc, washed successively with distilled water 
and brine, dried (Na2SO4), filtered, concentrated to get light yellow oil as crude product. The 
crude product was recrystallized from warm ethanol to get pure 53 as a white solid (19 mmol, 
yield 59% over two steps). RF = 0.67 (2:1, EtOAc:PE). 1H NMR (400 MHz, CDCl3) δ 7.58 – 7.55 
(m, 2H, HAr Ph), 7.59 – 7.57 (m, 3H, HAr Ph), 7.41 – 7.37 (m, 5H, HAr Ph), 5.57 (s, 1H, CH-
benzylidene), 4.69 (d, J = 9.6 Hz, 1H, H-1), 4.44 (dd, J = 10.4, 4.4 Hz, 1H, H-6a) 3.91 (t, J = 8.8 Hz, 
1H, H-3) 3.85 (dd, J = 7.2 Hz, 3.2 Hz, 1H, H-6b), 3.51 – 3.55 (m, 2H, H-4, H-5), 3.53 (dd, J = 11.8, 
8.4 Hz, 1H, H-2). 13C NMR (100 MHz, CDCl3) δ 136.8, 134.2 (Cq Ph), 133.1 – 126.3 (CAr Ph), 102.0 
(C-7), 88.7 (C-1), 80.2 (C-4), 74.6 (C-3), 72.6 (C-2), 70.6 (C-5), 68.6 (C-6). 
 
Phenyl-3-O-benzyl-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (54): 
Bu2SnO (0.35 g, 1.40 mmol) was added to a solution of 53 (0.48 g, 1.33 
mmol) in toluene (17 mL), the reaction mixture was stirred overnight at 
115 ℃. Then toluene was evaporated, the residue was dissolved in DMF 
(10 mL), and CsF (0.31 g, 2.04 mmol), BnBr (0.3 mL, 2.5 mmol) was added. 
The reaction mixture was stirred at 115 ℃ for 12 hours. After TLC analysis showed complete 
consumption of 53, the reaction mixture was diluted with ethyl acetate, washed successively 
with NaHCO3 solution and brine. The organic layer was dried (Na2SO4), concentrated and the 
residue was purified with a short column (8:1, PE:EtOAc) to gain 54 (0.44 g, yield 73.3%) as 
light yellow crystal. RF = 0.66 (4:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 5.60 (s, 1H,  CH-
benzylidene), 4.99 (d, J = 11.5 Hz, 1H, CHH Bn), 4.83 (d, J = 11.6 Hz, 1H, CHH Bn), 4.67 (d, J = 9.7 
Hz, 1H, H-1), 4.42 (dd, J = 10.5, 5.0 Hz, 1H, H-6a), 3.83 (t, J = 10.3 Hz, 1H, H-6b), 3.76-3.63 (m, 
2H, H-3, H-4), 3.58 – 3.53 (m, 2H, H-2, H-5). 13C NMR (100 MHz, CDCl3) δ 138.2, 137.2 (Cq Ph), 
133.2 – 126.0 (CAr Ph), 101.3 (CH-benzylidene), 88.5 (C-1), 81.7 (C-3), 81.1 (C-4), 74.8 (CH2 Bn), 
72.3 (C-2), 70.7 (C-5), 68.6 (C-6).  
 
Phenyl-1-thio-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (56):    
The title compound was synthesized from 55 (1.00 g, 2.56 mmol), thiophenol 
(0.4 mL, 3.91 mmol) and BF3∙Et2O (0.46 mL, 3.72 mmol) according to the 
procedure described for the preparation of 51 to gain 56 (1.2 g, 2.5 mmol, 
100%) as white crystal. RF = 0.68 (5:3, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 
7.52 – 7.52 (m, 2H, HAr), 7.34 – 7.32 (m, 3H, HAr), 5.44 (d, J = 3.2, 1H, H-1), 5.28 
(t, J = 10 Hz, 1H, H-2), 5.08 (dd, J = 10, 3.6 Hz, 1H, H-3), 4.75 (d, J = 10.0 Hz, 1H, H-4), 4.23 (dd, J 
= 11.2, 7.2 Hz, 1H, H-6a), 4.15 (dd, J = 11.6, 6 Hz, 1H, H-6b), 3.98 (t, J = 6.4 Hz, 1H, H-5), 2.14 (s, 
3H, CH3), 2.11 (s, 3H, CH3), 2.06 (s, 3H, CH3), 1.99 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 
170.4 – 169.5 (4 x C=O), 132.6 (CAr), 132.5 (Cq Ph), 129.0, 128.2 (CAr), 86.6 (C-1), 74.4 (C-5), 72.0 







The title compound was synthesized from 57 (59.00 g, 133.95 mmol), 
thiophenol (0.4 mL, 3.91 mmol) and BF3∙Et2O (0.46 mL, 3.72 mmol) according 
to the procedure described for the preparation of 52 to gain 57 as crude 
product and used in next step without further purification. RF = 0.5 (5:1, 
EtOAc:MeOH). 1H NMR (400 MHz, MeOD) δ 7.56 – 7.54 (m, 2H, HAr SPh), 7.31 – 
7.21 (m, 3H, HAr SPh), 4.59 (d, J = 8.0 Hz, 1H, H-1), 3.90 (d, J = 4.0 Hz, 1H, H=4), 3.76 (dd, J = 12.0, 
8.0 Hz, 1H, H-6a), 3.71 (dd, J = 12.0, 4 Hz, 1H, H-6b), 3.59 – 3.55 (m, 2H, H-5, H-2), 3.50 (dd, J = 
12.0, 4 Hz, 1H, H-3). 13C NMR (100 MHz, CDCl3) δ 130.1 (Cq SPh), 132.1 – 128.0 (CAr SPh), 90.3 
(C-1), 80.6 (C-3), 76.3 (C-4), 71.0 (C-2), 70.4 (C-5), 62.6 (C-6).  
 
Phenyl-4,6-O-di-tert-butylsilylene-1-thio-β-D-galactopyranoside (58): 
 57 (3.12 g, 11.5 mmol) was co-evaporated with DMF. The mixture was 
dissolved in pyridine (20 mL). The solution was cooled to -20 °C and 
tBuSi(OTf)2 (3.5 mL, 9.9 mmol) was added. After 2 hours, TLC analysis 
showed complete consumption of 57. Methanol was added to quench the 
reaction. The volatiles were evaporated and the residue was diluted with EtOAc, washed with 
HCl (1M) and sat. aq. NaHCO3. The organic layer was dried (Na2SO4), filtrated and concentrated. 
The residue was purified with silica gel column chromatography (1:4 → 1:3, EtOAc:PE) to gain 
52 (2.49 g, 6.04 mmol, yield 53%) as light yellow oil. RF = 0.34 (1:1, PE:EtOAc). 1H NMR (400 
MHz, CDCl3) δ 7.62 – 7.52 (m, 2H, HAr SPh), 7.39 – 7.30 (m, 3H, HAr SPh), 4.58 (d, J = 9.8 Hz, 1H, 
H-1), 4.46 (dd, J = 3.5, 1.1 Hz, 1H, H-4), 4.29 (dd, J = 2.0, 1.1 Hz, 2H, H2-6), 3.77 (dd, J = 9.8, 8.9 
Hz, 1H, H-2), 3.56 (dd, J = 8.9, 3.5 Hz, 1H, H-3), 3.50 (td, J = 2.0, 1.1 Hz, 1H, H-5), 1.08 (s, 9H, 3 x 
CH3, tert-Bu), 1.06 (s, 9H, 3 x CH3, tert-Bu). 13C NMR (100 MHz, CDCl3) δ 133.1 (Cq), 132.6 – 
127.9 (CAr SPh), 89.1 (C-1), 75.2 (C-5), 75.1 (C-3), 72.5 (C-4), 70.7 (C-2), 67.1 (C-6), 27.6 – 20.7 
(6 x CH3, tert-Bu). 
 
Phenyl-2,3-di-O-benzyl-4,6-O-di-tert-butylsilylene-1-thio-β-D-galactopyranoside (59): 
 58 (15.74 g, 38.15 mmol) was dissolved in DMF (20 mL). BnBr (9 mL, 76 
mmol) and TBAI (16.75 g, 68.68 mmol) were added. The mixture was 
cooled to 0 °C and NaH (8.2 g, 0.21 mmol) was added in small potions. 
After an overnight reaction, TLC analysis showed complete consumption 
of 58. The mixture was quenched by the addition of water, diluted with EtOAc and washed with 
brine. The organic layer was dried (Na2SO4), filtrated and concentrated. The residue was 
purified with silica gel column chromatography (20:1 → 10:1, PE:EtOAc) to gain 59 (12.66 g, 
21.35 mmol, yield 56%) as thick oil. RF = 0.4 (5:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.61 – 
7.27 (m, 12H, HAr Bn/SPh), 4.94 (s, 2H, CH2 Bn), 4.80 (q, J = 12 Hz, 2H, CH2 Bn), 4.71 (d, J = 9.6 
Hz, 1H, H-1), 4.53 (d, J = 2.8 Hz, 1H, H-4), 4.24 (m, 2H, H2-6), 3.89 (t, J = 9.6 Hz, 1H, H-2), 3.52 
(dd, J = 9.2, 3.2 Hz, 1H, H-3), 3.32 (s, 1H, H-5), 1.17 (s, 9H, 3 x CH3, tert-Bu), 1.12 (s, 9H, 3 x CH3, 
tert-Bu). 13C NMR (100 MHz, CDCl3) δ 138.4, 134.9 (Cq Bn), 132.1 – 127.3 (CHAr Bn/SPh), 88.7 
(C-1), 82.8 (C-3), 77.0 (C-2), 76.0 (CH2 Bn), 74.8 (C-5), 71.1 (CH2 Bn), 70.0 (C-4), 67.4 (C-6), 
27.7, 27.7 (CH3, tert-Bu), 23.5 (Cq, tert-Bu), 20.8 (Cq, tert-Bu).  
 
2,3-Di-O-benzyl-4,6-O-di-tert-butylsilylene-D-galactopyranoside (60): 
59 (0.61 g, 1.0 mmol) was co-evaporated with toluene (3 x) and dissolved 
in DCM (50 mL). The solution was cooled to 0 °C. N-Iodosuccinimide 
(0.227 g, 1.03 mmol) and TFA (77 µL, 1.0 mmol) were added to the 
solution. After 1 hour, TLC analysis showed complete consumption of 59. 
The reaction was quenched by adding TEA, and sat. aq. Na2S2O3 was added to the mixture. The 
mixture was extracted with EtOAc, and the organic layer was dried (Na2SO4), filtrated and 
concentrated. The resulting residue was purified with silica gel column chromatography (10:1 




→ 2:1, PE:EtOAc) to gain 60 (0.451 g, 0.903 mmol, yield 88%). RF = 0.28 (toluene). 1H NMR (400 
MHz, CDCl3) δ 7.37 – 7.29 (m, 10H, HAr Bn), 5.23 (d, J = 3.6 Hz, 1H, H-1), 4.92 (d, J = 11.6 Hz, 2H, 
CH2 Bn), 4.81 – 4.72 (m, 2H, CH2 Bn), 4.54 (d, J = 3.0 Hz, 1H, H-4), 4.21 – 4.12 (m, 2H, H2-6), 4.02 
(dd, J = 9.6, 3.6 Hz, 1H, H-2), 3.87 (d, J = 3.2 Hz, 1H, H-5), 3.84 (d, J = 2.8 Hz, 1H, H-3), 1.12 (s, 9H, 
3 x CH3, tert-Bu), 1.08 (s, 9H, 3 x CH3, tert-Bu). 13C NMR (100 MHz, CDCl3) δ 138.9, 138.3 (Cq Bn), 
128.4 – 127.6 (CHAr Bn), 92.1 (C-1), 77.5 (C-3), 74.8 (C-2), 74.8 (CH2 Bn), 71.0 (C-4), 71.0 (CH2 





Cs2CO3 (0.28 g, 0.85 mmol) and trifluoro-phenylacetimidoyl 
chloride (0.20 g, 0.96 mmol) was added to a solution of 60 (0.27 
g, 0.54 mmol) in acetone (3 mL). The reaction mixture was kept at 
0 ℃ under argon atmosphere. After 3 hours, the reaction mixture 
was filtrated through a pad of Celite. The filtrate was concentrated and purified on a short 
column (20:1 → 2:1, PE:EtOAc) to get 61 (0.22 g, 0.26 mmol, yield 65%) as anomeric mixture at 
ratio 1:1. RF = 0.56, 0.38 (10:1, PE:EtOAc). For the upper spot on TLC, 1H NMR (400 MHz, CDCl3) 
δ 7.52 – 6.78 (m, 15H, HAr Bn/Ph), 6.55 (br s, 1H, H-1), 4.89 (d, J = 11.8 Hz, 1H, CHH Bn), 4.85 – 
4.72 (m, 3H, 3 x CHH Bn ), 4.62 (br s, 1H, H-4), 4.33 – 4.18 (m, 3H, H2-6, H-2), 3.91 (d, J = 10.1 
Hz, 1H, H-3), 3.81 (br s, 1H, H-5), 1.10 (s, 9H, 3 x CH3, tert-Bu), 1.02 (s, 9H, 3 x CH3, tert-Bu). 13C 
NMR (100 MHz, CDCl3) δ 171.1 (C=N), 143.8, 138.6, 138.2 (Cq Bn), 129.1 – 120.6 (CHAr Bn), 
100.0 (CF3), 94.8 (H-1), 77.3 (C-3), 73.7 (CH2 Bn), 73.6 (C-2), 71.1 (CH2 Bn), 70.7 (C-4), 70.0 (C-




54 (0.405 g, 0.899 mmol) and 61 (1.201 g, 1.788 mmol) were co-
evaporated with toluene (3 x). The residue was dissolved in dried DCM 
(4 mL) and cooled to 0 ℃, followed by dropwise addition of 
trimethylsilyl trifluoromethanesulfonate (0.045 mL, 0.25 mmol). After 
an overnight reaction, TLC analysis showed complete consumption of 
61. The reaction was quenched by the addition of TEA and 
concentrated. The resulting residue was purified with silica gel column 
chromatography (40:1 → 10:1, PE:EtOAc). Yield 69% (0.56 g, 0. 61 
mmol). RF = 0.15 (10:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.04 (m, 25H, HAr), 5.89 
(d, J = 4 Hz, 1H, H-1’), 5.65 (s, 1H, CH-benzylidene), 5.09 (d, J = 10 Hz, 1H, CHH Bn), 4.97 (d, J = 
9.2 Hz, 1H, H-1), 4.89 (s, 2H, CH2 Bn), 4.81 (q, J = 12 Hz, 2H, CH2 Bn), 4.43 (dd, J = 10.8, 5.2 Hz, 
1H, H-6a), 4.33 (d, J = 10.4 Hz, 1H, CHH Bn), 4.07 (dd, J = 10.0, 3.6 Hz, 1H, H-2’), 4.02 (d, J = 8.0 
Hz, 1H, H-4’), 3.89 – 3.72 (m, 6H, H-3, H-2, H-5’, H-6b, H-3’, H-4), 3.56 (dd, J = 12.8, 1.6 Hz, 1H, H-
6’a), 3.60 – 3.53 (m, 1H, H-5), 3.02 (dd, J = 12.6, 2.2 Hz, 1H, H-6’b), 1.02 (s, 9H, CH3, tert-Bu), 0.99 
(s, 9H, CH3, tert-Bu). 13C NMR (100 MHz, CDCl3) δ 139.5 – 126.0 (CAr), 101.1 (CH-benzylidene), 
96.2 (C-1’), 87.6 (C-1’), 82.2 (C-3), 81.0 (C-4), 77.0 (C-3’), 76.2 (CH2 Bn), 74.2 (C-2’), 73.7 (CH2 
Bn), 72.7 (C-2), 71.2 (CH2 Bn), 71.0 (C-4’), 70.0 (C-5), 68.7 (C-6), 66.9 (C-3’), 66.5 (C-6’), 27.7, 




TBAF (1M in THF, 1.2 mL, 1.2 mmol) was added dropwise to a solution of 62 (0.16 g, 0.17 
mmol) in THF (2 mL) at 0 ℃, and the yellow solution was stirred at room temperature 
overnight. The reaction mixture was then diluted with EtOAc, washed with brine, dried 




chromatography (5:2 → 1:1, PE:EtOAc) to get pure 63 (0.11 g, 0.14 mmol, 
yield 82%). RF = 0.17 (5:2, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.52 – 
7.17 (m, 25H, HAr), 6.01 (d, J = 3.8 Hz, 1H, H-1’), 5.63 (s, 1H, CH-
benzylidene), 5.10 (d, J = 10.7 Hz, 1H, CHH Bn), 4.96 (d, J = 9.3 Hz, 1H, H-
1), 4.87 (d, J = 11.7 Hz, 1H, CHH Bn), 4.84 (d, J = 11.6 Hz, 1H, CHH Bn), 4.77 
(d, J = 11.7 Hz, 1H, CHH Bn), 4.71 (d, J = 11.6 Hz, 1H, CHH Bn), 4.48 (d, J = 
10.7 Hz, 1H, CHH Bn), 4.41 (dd, J = 10.5, 5.0 Hz, 1H, H-6a), 4.06 (t, J = 4.8 
Hz, 1H, H-5’), 3.96 – 3.90 (m, 3H, H-2, H-2’, H-3), 3.84 (d, J = 10.2 Hz, 1H, H-
6b), 3.81 – 3.78 (m, 1H, H-4), 3.75 (dd, J = 10.0, 3.2 Hz, 1H, H-3’), 3.59 (dd, J = 3.2, 1.5 Hz, 1H, H-
4’), 3.55 (dt, J = 9.8, 4.8 Hz, 1H, H-5), 3.30 (dd, J = 11.8, 5.4 Hz, 1H, H-6’a), 3.23 (dd, J = 11.8, 4.3 
Hz, 1H, H-6’b). 13C NMR (100 MHz, CDCl3) δ 137.9 – 125.9 (CAr), 101.1 (CH-benzylidene), 95.7 
(C-1’), 87.5 (C-1), 82.0 (C-4), 81.9 (C-3) 76.7 (C-3’), 76.0 (CH2 Bn), 75.4 (C-2’), 73.3 (CH2 Bn), 
73.2 (C-2), 72.8 (CH2 Bn), 70.0 (C-5), 69.9 (C-4’),68.6 (C-6), 68.4 (C-5’), 63.1 (C-6’). [α]20D = 





p-Toluenesulfonic acid monohydrate (0.065 g, 0.34 mmol) was added to 
a solution of 63 (0.10 g, 0.13 mmol) in methanol and DCM (10 mL, 1:1, 
v/v), and the reaction mixture was kept stirred at room temperature 
overnight. After quenching by the addition of TEA, the reaction mixture 
was concentrated and purified with silica gel column chromatography 
(1:1, pentane: EtOAc) to give 64 (0.08 g, yield 90%). RF = 0.1 (1:1, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.53 – 7.16 (m, 15H, HAr), 5.97 (d, 
J = 3.7 Hz, 1H, H-1’), 5.06 (d, J = 11.2 Hz, 1H, CHH Bn), 4.91 (d, J = 9.7 Hz, 
1H, H-1), 4.87 (d, J = 11.7 Hz, 1H, CHH Bn), 4.82 (d, J = 11.8 Hz, 1H, CHH Bn), 4.76 (d, J = 11.8 Hz, 
1H, CHH Bn), 4.71 (d, J = 11.7 Hz, 1H, CHH Bn), 4.58 (d, J = 11.2 Hz, 1H, CHH Bn), 4.05 (td, J = 5.2, 
4.7, 2.3 Hz, 1H, H-5’), 3.93 (dd, J = 10.1, 3.9 Hz, 1H, H-2’), 3.90 – 3.79 (m, 4H, H-6a, H-2, H-6b, H-
3), 3.76 (dd, J = 10.0, 3.2 Hz, 1H, H-3’), 3.66 (t, J = 9.0 Hz, 1H, H-4), 3.54 (d, J = 2.9 Hz, 1H, H-4’), 
3.42 – 3.34 (m, 2H, H-6’a, H-5), 3.26 (dd, J = 11.8, 4.0 Hz, 1H, H-6’b). 13C NMR (100 MHz, CDCl3) δ 
138.1 – 126.3 (CAr), 95.5 (C-1’), 87.4 (C-1), 85.4 (C-4), 79.3 (C-5), 76.6 (C-3’), 76.2 (CH2 Bn), 75.4 
(C-2’), 73.2 (CH2 Bn), 73.1 (C-2), 72.7 (CH2 Bn), 71.1 (C-3), 69.1 (C-4’), 68.6 (C-5’), 62.9 (C-6’), 
62.0 (C-6). [α]20D = +16.3 (c = 2.45, CHCl3). HRMS: found 727.25414 [C39H44O10+Na]+, calculated 




NaH (60% on mineral oil, 48.8 mg, 1.22mmol) was added to a solution of 
64 (0.08 g, 0.11 mmol) in DMF (1 mL) at 0 ℃ under argon atmosphere, 
the suspension was stirred at 0 ℃ for 1 hour. Then BnBr (0.067 mL, 0.56 
mmol) was added. The reaction mixture was kept stirred at room 
temperature overnight. After quenched by the addition of water, the 
reaction mixture was extracted with EtOAc, washed with water and 
brine, dried (Na2SO4), filtered, concentrated and purified with silica gel 
column chromatography (20:1, pentane:EtOAc) to get pure 65 (0.11g, 
0.10 mmol, yield 92%). RF = 0.62 (5:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.59 – 7.09 (m, 
40H, HAr), 6.01 (d, J = 3.7 Hz, 1H, H-1’), 4.98 (d, J = 11.6 Hz, 1H, CHH Bn), 4.92 – 4.53 (m, 10H, 5 x 
CH2 Bn), 4.49 (d, J = 11.4 Hz, 1H, CHH Bn), 4.33 (t, J = 6.5 Hz, 1H, H-5’), 4.30 (d, J = 12.0 Hz, 1H, 
CHH Bn), 4.22 (d, J = 11.8 Hz, 1H, CHH Bn), 4.12 (dd, J = 10.2, 3.6 Hz, 1H, H-2’), 3.97 (t, J = 9.1 Hz, 
1H, H-2), 3.89 (dd, J = 10.2, 2.7 Hz, 1H, H-3’), 3.81 – 3.72 (m, 3H, H2-6, H-4), 3.65 (t, J = 9.3 Hz, 
1H, H-3), 3.60 (dd, J = 2.9, 1.3 Hz, 1H, H-4’), 3.55 (ddd, J = 9.8, 4.5, 2.1 Hz, 1H, H-5), 3.44 (dd, J = 




9.5, 6.4 Hz, 1H, H-6’a), 3.28 – 3.23 (m, 1H, H-6’b). 13C NMR (100 MHz, CDCl3) δ 138.9 – 127.1 
(CAr), 95.6 (C-1’), 87.1 (C-1), 85.2 (C-4), 79.0 (C-5), 78.5 (C-3), 78.3 (C-3’), 76.3 (C-2’), 75.5 (CH2 
Bn), 75.2 (C-4’), 74.9 (CH2 Bn), 74.7 (CH2 Bn), 73.5 (CH2 Bn), 73.4 (C-2), 73.1 (CH2 Bn), 73.0 (CH2 




NIS (0.13 g, 0.53 mmol) and TFA (35 μL) was added to a solution of 65 
(0.44 g, 0.41 mmol) in dried DCM (5 mL) at 0 °C under argon 
atmosphere. The reaction was stirred at room temperature for 2 hours. 
Piperidine was added to quench the reaction at 0 °C, after which sat. aq. 
Na2S2O3 solution was added. The reaction mixture was extracted with 
EtOAc, washed with HCl solution (1M) and brine. The organic layer was 
dried (Na2SO4), filtered and concentrated. The crude product was 
purified with silica gel column chromatography (4:1 → 2:1, PE:EtOAc) to 
gain pure 66 (0.28 g, 0.29 mmol, yield 71%) as a mixture of two isomers (2:5). RF = 0.3 (4:1, 
PE:EtOAc). For the major isomer: 1H NMR (400 MHz, CDCl3) δ 5.34 (d, J = 3.4 Hz, 1H, H-1’), 4.99 
– 4.50 (m, 13H, 6 x CH2 Bn, H-1), 4.41 – 4.28 (m, 2H, CH2 Bn), 4.15 (d, J = 7.2 Hz, 1H, H-5), 4.12 – 
4.05 (m, 2H, H-5’, H-2), 4.00 – 3.89 (m, 3H, H-4, H-4’, H-3’), 3.85 (dd, J = 9.0, 3.4 Hz, 1H, H-2’), 
3.83 – 3.70 (m, 3H, H2-6’, H-3), 3.49 – 3.45 (m, 2H, H2-6). 13C NMR (100 MHz, CDCl3) δ 138.7 – 
127.5 (CAr), 96.5 (C-1), 90.3 (C-1’), 80.3 (C-4), 79.0 (C-4’), 77.5 (C-3), 77.3 (CH2 Bn), 75.4 (C-2’), 
75.3 (CH2 Bn), 74.8 (CH2 Bn), 74.5 (C-2), 74.3, 73.6, 73.2, 72.5 (4 x CH2 Bn), 70.9 (C-5’), 69.7 (C-
5), 68.6 (C-6’), 68.5 (C-6). 
 
2-O-(2,3,4,6-Tetra-O-benzyl-α-galactopyranosyl)-3,4,6-tri-O-benzyl-D-glucitol (67): 
LiAlH4 (0.5 mL, 2.4 M in THF, 1.2 mmol) was added dropwise into a 
solution of 66 (0.25 g, 0.26 mmol) in THF (3 mL) at 0 °C under argon 
atmosphere. After stirred overnight, the reaction mixture was slowly 
quenched by the addition of methanol, after which HCl (1M, 3 mL) was 
added. Then the mixture was diluted with ethyl acetate and washed with 
brine, the water layer was reextracted with EtOAc. The organic layers 
were combined, dried (Na2SO4), filtered and concentrated. The crude 
product was purified with silica gel column chromatography (2:1 → 1:1, 
PE:EtOAc) to gain 67 (0.22 g, 0.23 mmol, yield 88%). RF = 0.58 (1:1, PE:EtOAc). 1H NMR (400 
MHz, CDCl3) δ 5.05 (d, J = 3.5 Hz, 1H, H-1’), 4.96 – 4.86 (m, 2H, CH2 Bn), 4.79 – 4.51 (m, 6H, 3 x 
CH2 Bn), 4.45 (d, J = 12.0 Hz, 1H, CHH Bn), 4.35 (d, J = 12.0 Hz, 1H, CHH Bn ), 4.14 – 4.04 (m, 2H, 
H-2, H-5’), 4.11 (dd, J = 10.1, 3.7 Hz, 1H, H-2’), 4.00 – 3.98 (m, 1H, H-5), 3.98 (dd, J = 10.1, 2.6 Hz, 
1H, H-3’) 3.92 – 3.82 (m, 3H, H-3, H-4’, H-4), 3.81 – 3.76 (m, 1H, H-6a), 3.76 – 3.71 (m, 2H, H2-
6’), 3.69 – 3.64 (m, 1H, H-6b), 3.52 (dd, J = 9.3, 6.7 Hz, 1H, H-1a), 3.38 (dd, J = 9.4, 5.8 Hz, 1H, H-
1b). 13C NMR (100 MHz, CDCl3) δ 138.5 – 127.5 (CAr), 99.9 (C-1’), 81.8 (C-5), 79.3 (C-3’), 79.2 (C-
4’), 79.2 (C-3), 76.2 (C-2’), 74.7 (C-4), 74.6 – 72.6 (7 x CH2 Bn), 71.2 (C-6’), 70.7 (C-5’), 70.4 (C-
2), 69.4 (C-1), 62.5 (C-6). [α]20D = +39.1 (c = 1.17, CHCl3). HRMS: found 997.44983 
[C61H66O11+Na]+, calculated for [C61H66O11+Na]+ 997.44973. 
 
2-O-(2,3,4,6-Tetra-O-benzyl-α-galactopyranpsyl)-3,4,6-tri-O-benzyl-1-deoxynojirimycin 
(68):   
A solution of (COCl)2 (100 μL, 1.16 mmol) in dry DCM (1.5 mL) was cooled 
to -78 °C under argon atmosphere. DMSO (100 μL, 1.40 mmol) dissolved in 
dry DCM (1.5 mL) was added dropwise. After 40 minutes 67 (0.32 g, 0.33 
mmol, which was co-evaporated with toluene 3 x), in dry DCM (7.5 mL), 
was added dropwise to the mixture. The reaction was stirred for 2 hours at 




mixture was gradually warmed to -40  °C  in more than 1 hour, after which it was poured into a 
cooled (0 °C) MeOH solution (60 mL) containing NaCNBH3 (0.09 g, 1.44 mmol), HCOONH4 (0.49 
g, 7.76 mmol), and Na2SO4 (0.19 g, 1.34 mmol). The mixture was stirred overnight allowing the 
reaction to reach room temperature. TLC analysis showed the formation of the product (2:1, 
PE:EtOAc, RF = 0.37). After filtration, the volatiles were evaporated, as the residue was 
dissolved in EtOAc (100 mL). The solution was washed with sat. aq. NaHCO3 solution, dried 
(Na2SO4) filtered and concentrated. The residue was purified with silica gel column 
chromatography (5:1 → 2:3, PE:EtOAc) to give 62 in 24% yield (0.07 g, 0.073 mmol). RF = 0.37 
(2:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 4.95 – 4.80 (m, 7H, H-1’, 3 x CH2 Bn), 4.72 (d, J = 
11.8 Hz, 1H, CHH Bn), 4.67 (d, J = 12.1 Hz, 1H, CHH Bn), 4.57 – 4.44 (m, 4H, 2 x CH2 Bn), 4.31 (d, J 
= 6.2 Hz, 2H, CH2 Bn), 4.20 (td, J = 6.5, 1.3 Hz, 1H, H-5’), 4.05 (dd, J = 10.1, 3.6 Hz, 1H, H-2’), 3.89 
(dd, J = 10.1, 2.9 Hz, 1H, H-3’), 3.75 (dd, J = 9.2, 4.6 Hz, 1H, H-2), 3.72 – 3.69 (m, 2H, H-6a, H-4’), 
3.65 – 3.59 (m, 1H, H-6b), 3.60 (t, J = 9.2 Hz, 1H, H-3), 3.52 (dd, J = 9.6, 6.4 Hz, 1H, H-6’a), 3.41 (t, 
J = 9.3 Hz, 1H, H-4), 3.32 (dd, J = 9.6, 6.6 Hz, 1H, H-6’b), 3.25 (dd, J = 12.5, 4.8 Hz, 1H, H-1a), 2.76 
(ddd, J = 9.3, 5.0, 2.6 Hz, 1H, H-5), 2.56 (dd, J = 12.5, 10.4 Hz, 1H, H-1b). 13C NMR (100 MHz, 
CDCl3) δ 138.8 – 127.5 (CAr), 94.5 (C-1’), 85.9 (C-3), 80.4 (C-4), 78.7 (C-3’), 76.5 (C-2’), 75.6 (CH2 
Bn), 75.2 (C-4’), 75.2 (CH2 Bn), 74.8 (CH2 Bn), 74.8 (C-2), 73.7 (CH2 Bn), 73.5 – 72.9 (4 x CH2 Bn), 
69.8 (C-6), 68.9 (C-6’), 68.8 (C-5’), 59.7 (C-5), 46.5 (C-1). [α]20D = +76.9 (c = 0.32, CHCl3). HRMS: 
found 956.47350 [C61H65NO9+H]+, calculated for [C61H65NO9+H]+ 956.47321. 
 
2-O-(α-D-galactopyranpsyl-)-1-deoxynojirimycin (69): 
62 (0.2 g, 0.21 mmol) was dissolved in ethanol (6 mL), pH of the solution 
was adjusted to 2 with 1M HCl. Pd/C (10%) was added, the mixture was 
shaken under H2 atmosphere at 4 bar for 24 hours. The catalyst was filtered 
through a pad of Celite and the filtrate was concentrated. The residue was 
purified on size exclusion column chromatography (eluent: NH4Ac, 0.15 M, aq.) to get pure 69 
(35 mg, 0.11 mmol, yield 52%). 1H NMR (400 MHz, D2O) δ 4.93 (d, J = 3.8 Hz, 1H, H-1’), 4.05 (t, J 
= 6.4 Hz, 1H, H-5’), 3.85 (d, J = 3.2 Hz, 1H, H-4’), 3.80 (dd, J = 12.8, 3.1 Hz, 1H, H-6a), 3.77 – 3.70 
(m, 3H, H-6b, H-2, H-3’), 3.68 (dd, J = 10.5, 3.7 Hz, 1H, H-2’), 3.58 (d, J = 6.2 Hz, 2H, H-6’), 3.54 
(dd, J = 12.6, 5.0 Hz, 1H, H-1a), 3.52 – 3.49 (m, 2H, H-3, H-4), 3.06 (ddt, J = 8.0, 5.4, 3.1 Hz, 1H, H-
5), 2.84 (dd, J = 12.5, 11.5 Hz, 1H, H-1b). 13C NMR (100 MHz, D2O) δ 100.0 (C-1’), 74.4 (C-3), 71.6 
(C-3’), 70.9 (C-5’), 69.0 (C-2), 69.0 (C-4’), 67.8 (C-2’), 67.6 (C-4), 60.8 (C-6’), 59.8 (C-5), 57.6 (C-
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GBA2 (EC3.2.1.45, GH116) is a membrane-bound, non-lysosomal retaining β-glucosidase. 
GBA2 was first described by Matern et al. who annotated the enzyme as a bile acid active 
glycosidase,1 but is now widely known to partake in the degradation of glucosylceramide 
(GlcCer).2 GBA2 is associated with a number of physiological and pathological processes, such 
as neuronal development, lysosomal storage diseases (LSD), tumorigenicity and inflammatory 
diseases.3 
4 
Discovery of N-alkyl 
Deoxynojirimycin Derivatives as 
Potential GBA2 Inhibitors 




GlcCer is synthesized on the outer endoplasmic reticulum leaflet by glucosylceramide 
synthase (GCS) from UDP-glucose and ceramide (Figure 1), and degraded in lysosomes by 
lysosomal glucocerebrosidase (GBA1).4 In Gaucher disease and Niemann-Pick type C disease 
(caused by genetic deficiency of GBA1 and acid sphingomyelinase, respectively), GlcCer 
accumulates in lysosomes, from where it spills over into the cytoplasm where it is degraded by 
GBA2. This degradation leads to an increase of ceramide concentration in the cytoplasm, which 
may be responsible for several symptoms observed in patients suffering from Gaucher and 
Niemann-Pick type C.5 Mistry et al. reported6 that genetic deletion of the GBA2 gene can relieve 
clinical symptoms in Gaucher diseased mice, which indicates that GBA2 is a potential target for 
Gaucher disease treatment. This finding is consistent with the hypothesis that compensatory 
GBA2 overexpression in Gaucher disease has deleterious effects.7 
Figure 1: Glucosylceramide metabolism 
 
Although GBA2 has been identified to be present in various tissues,8 its expression and 
activity appears most abundant in the central nervous system.9 This indicates that GBA2 may 
play a role in neuronal development. Relevant evidence to support this observation was shown 
by Martin et al. who demonstrated that the loss of GBA2 function is responsible for motor 
neuron defects in hereditary spastic paraplegia.10 Also, mutations in the gene encoding for 
GBA2 were found in patients suffering from cerebella ataxia, spastic paraplegia, thin corpus 
callosum and cognitive impairment.11 These findings underscore the potential correlation 
between GBA2 and neurodegenerative diseases. GBA2 activity has been connected with tumor 
biology as well. Inducibly overexpressed GBA2 leads to a decreased anchorage-independent 
human melanoma cell growth, and thus to the decrease of in vivo melanoma tumor growth.12 In 
addition, GBA2 activity has also been associated with inflammatory responses. Mistry et al. 





inflammatory cytokines, which indicates that GBA2 may be a relevant target for drugs aiming 
for reducing inflammation.6 For all these reasons, the identification of inhibitors selective for 
GBA2 is a relevant research objective. 
Figure 2: Structure and IC50 values of the lead compounds.  
 
N-alkyl-deoxynojirimycin derivatives are potent GBA2 inhibitors that however display 
inhibitory activity against the other GlcCer-metabolizing enzymes, GCS and GBA1, as well 
(Figure 2). N-Butyl-deoxynojirimycin (N-butyl-DNJ, Zavesca, 1), a moderately potent GCS 
inhibitor that at lower concentrations also blocks GBA2 activity, is in clinical use for the 
treatment of non-neuronopathic Gaucher patients. Inspired by the clinical success of N-butyl-
DNJ (1), a large number of N-alkyl-DNJ derivatives have appeared in the literature and that vary 
in the nature of the N-alkyl group, in the configuration of the polyhydroxylated piperidine or a 
combination thereof.13-15 Amongst these compounds, N-adamantanemethyloxypentyl-DNJ (2, 
MZ-21) and its L-ido-configured isoster (3, MZ-31) were identified as very potent GCS inhibitors 
(much more than the clinical compound, Zavesca 1) that also strongly inhibit GBA2 and to a 
lesser extend GBA1. In the context of the studies that led to the identification of MZ-21 2 and 
MZ-31 3, it was observed that N-neopentyloxypentyl-DNJ 4 and N-neopentyloxypentyl-L-ido-
DNJ 5, compounds with comparatively (in relation to 2 and 3) smaller N-alkyl substituents, are 
potent GBA2 inhibitors with comparatively less activity against GCS and GBA1. Compared with 
MZ-21 (IC50 GCS / IC50 GBA2 = 235), compound 4 has a much better GBA2 selectivity (IC50 GCS / IC50 
GBA2 = 1020). Compounds 4 and 5 are nanomolar GBA2 inhibitors while inhibiting GCS and 
GBA1 only in the micromole range, if at all. 
 




Figure 3: Structure of the lead N-neopentyloxypentyl-DNJ derivatives 4 (D-glucose 




Taking compounds 4 and 5 as lead structures and with the aim to investigate whether 
GBA2 selective inhibitors could be designed, a series D-gluco and L-ido-DNJ derivatives bearing 
a variety of aliphatic and aromatic N-alkyl substituents (Figure 4) were prepared and evaluated 
on their potency and selectivity (as compared to GCS and GBA1) as GBA2 inhibitors. 
 Figure 4: D-Gluco and L-ido-DNJ derivatives subject of the here presented studies 
 
Results and discussion 
The synthesis of DNJ (9) was accomplished following the established procedure with as key 
step a double reductive amination of a glucose-derived 5-keto-aldehyde (scheme 1).16 In the 
first step, the commercially available 2,3,4,6-tetra-O-benzyl-D-glucopyranose (6) was reduced 
to give partially protected glucitol 7. Swern oxidation of both the primary and secondary 
alcohol in 7 followed by double reductive amination gave 2,3,4,6-tetra-O-benzyl-DNJ (8). 
Catalytic hydrogenation gave DNJ (9) in good yield and sufficient quantities for further 
elaboration. 
Treatment of glucitol 7 with excess methanesulfonyl chloride followed by treatment with 
allyl amine gave, with inversion of configuration at the carbon bearing the secondary alcohol, 
fully protected L-ido-DNJ 10 in good overall yield. The allyl protecting group in 10 was removed 





the obtained enamine to give 11 in excellent yield. Compound 11 was globally deprotected (H2, 
Pd/C) to give L-ido-DNJ 12 for ensuing N-alkylation. 
Scheme 1: Synthesis of 1-deoxynojirimycin and L-ido-1-deoxynojirimycin 
 
Reagents and conditions: [a] LiAlH4, THF; [b] 1) (COCl)2, DMSO, DCM; 2) HCOONH4, Na2SO4, NaBH3CN, 
MeOH, 12% 2 steps; [c] MsCl, pyridine, allyl amine, reflux, 78% 2 steps; [d] tBuOK, DMSO, HCl, 92%; [e] 
Pd/C, H2, 82% (9), 76% (12). 
The synthesis of appropriately functionalized alkylating agents for preparation of the target 
compounds was accomplished following established procedures. As an example, the synthesis 
of tetrahydrofuran-3-ylmethyloxypentyl bromide and its use in the N-alkylation of DNJ 9 and L-
ido-DNJ 12 is depicted in Scheme 2. Thus, 1,5-pentanediol (13) was treated with one equivalent 
of trityl chloride (TrtCl) and base, after which the remaining primary alcohol in 14 was 
transformed into the sulfonate after reacting with p-toluenesulfonyl chloride (p-TsCl). The 
tosylate in the thus produced compound 15 was substituted by tetrahydrofuran-3-ylmethyl 
alcohol, yielding ether 22. The trityl group in 22 was removed and the resulting alcohol 33 
subjected to Appel bromination (treatment with triphenylphosphine and tetrabromomethane) 
to give bromide 44. In a similar fashion, all compounds listed in Figure 5 were prepared. Finally, 
treatment of DNJ 9 with 44 and diisopropyl ethylamine in DMF gave N-alkyl-DNJ derivative 55, 
and in a similar vein L-ido-DNJ derivative 62 was prepared (see experimental for details on the 
alkyl bromide syntheses and ensuing N-alkylation of DNJ 9 and L-ido-DNJ 12). 
In a similar way, and in yields varying from 10% up to 88%, N-alkyl-DNJ derivatives 4, 49 - 
59 and N-alkyl-L-ido-DNJ 5, 60 - 65 were synthesized (Figure 6). 
 




Scheme 2: N-Alkylation strategy of DNJ 9 and L-ido-DNJ 12
 
Reagents and conditions: [a] TrtCl, TEA, EtOAc, 85 ℃, 3h, 99%; [b] p-TsCl, TEA, DMAP, DCM, 0 ℃ to r.t., 
2h, 70%; [c] 1) THF-3-ylmethanol, NaH, DMF, r.t., 90 min; 2) 15, 75 ℃, 1h, 56%; [d] BF3∙OEt2, 
toluene/MeOH (1:1), 1.5h, 72%; [e] 1) PPh3, DCM, r.t., 0 ℃; 2) CBr4, Ar, 2h, 91%; [f] DMF, K2CO3, 80 ℃, 88% 
(55), 30% (62). 









Figure 6: Isolated yields of the N-alkylated D-gluco and L-ido iminosugars 
 
Inhibition activity 
Table 1 shows the inhibitory results of lead structure 4 together with N-alkyl-DNJ 
derivatives (49 - 59) on the three enzymes involved in glycosylceramide metabolism: GCS, 
GBA1 and GBA2. From the results on the series of branched alkyl analogues (49 - 51), it can be 
observed that extending the neopentyl group in 4 with one carbon, as in 51, results in more 
potent GCS inhibitory activity. The absence (49) or presence (50) of an additional methyl 




moiety gave no significant difference in inhibitory potency towards GCS, compared to 4. Within 
the cycloalkyl series (52 - 54), the compound with the largest substituent proved to be the 
most potent GCS inhibitor (inhibitory activity: 54 > 53 > 52), whereas the tetrahydrofuran- and 
tetrahydropyran-modified DNJ derivatives 55 - 57 proved to be poor GCS inhibitors. The 
thiophene containing iminosugars (58 and 59) inhibit GCS almost as potently as the literature 
compound, MZ-21 (4). Amongst all the compounds, cyclopentyl-DNJ derivative 54 appeared the 
most potent GCS inhibitor (IC50 = 0.12), whereas compounds 51, 53, 58 and 59 are also potent 
GCS inhibitors with sub-micromolar IC50 values. Altogether, these results indicate that a 
sizeable hydrophobic nonpolar N-alkyl group is critical for GCS activity. 
Table 1: GCS, GBA1 and GBA2 IC50 values of the alkylated D-gluco iminosugars 
Compound IC50 GCS (µM) IC50 GBA1 (µM) IC50 GBA2 (nM) 
D-gluco-DNJ series    
4 5 ± 0.9 6 ± 0.4 5 ± 0.07 
49 4 ± 0.1 17 ± 1 7 ± 1 
50 6 ± 0.9 3 ± 0.2 4 ± 0.2 
51 0.8 ± 0.03 4 ± 0.009 5 ± 0.3 
52 7 ± 1 51 ± 2 18 ± 0.2 
53 0.6 ± 0.03 12 ± 0.2 9 ± 0.9 
54 0.1 ± 0.06 6 ± 0.4 4 ± 0.2 
55 >50 156 ± 6 42 ± 5 
56 >50 325 ± 14 120 ± 8 
57 10 ± 0.7 63 ± 2 35 ± 2 
58 0.4 ± 0.06 11 ± 0.2 4 ± 0.6 
59 0.4 ± 0.05 6 ± 0.2 2 ± 0.1 
 
With respect to GBA1 inhibitory activity, it was observed that with the exception of 
compounds 50, 51, 54 and 59, most compounds are less potent than lead compound 4. This 
may suggest that a nonpolar hydrophobic moiety of a certain size is essential for GBA1 
inhibitory activity. Looking at the nature of the alkyloxy substituent, branched alkyl moieties 
are favorable with respect to GBA1 inhibitory activity (inhibitory potency: 50 > 4 > 49). From 
the cycloalkyl series, it can be concluded that the larger the substituent is, the more potent the 
compound inhibits GBA1 (inhibitory potency: 54 > 53 > 52). As was observed for GCS 
inhibition, the tetrahydrofuranyl/tetrahydropyranyl-DNJ derivatives are poor GBA1 inhibitors 





54 with those obtained for tetrahydrofuranyl-DNJ derivatives 55 and 56). Another observed 
trend is that an extra methylene moiety (4 versus 51, 58 versus 59) is beneficial for GBA1 
inhibitory activity. The most potent GBA1 inhibitor of this series finally appeared to be 
compound 50. 
Table 2: GCS, GBA1 and GBA2 IC50 values of the alkylated L-ido iminosugars 
Compound IC50 GCS (µM) IC50 GBA1 (µM) IC50 GBA2 (nM) 
L-ido-DNJ series    
5 3 ± 0.1 >1000 10 ± 0.3 
60 5 ± 0.1 196 ± 15 7 ± 0.5 
61 0.12 ± 0.005 176 ± 16 3 ± 0.1 
62 1 ± 0.2 >1000 25 ± 0.7 
63 2.5 ± 0.4 >1000 21 ± 4 
64 0.05 ± 0.002 328 ± 26 2 ± 0.3 
65 0.12 ± 0.008 205 ± 0.4 11 ± 0.04 
 
Looking at GBA2 inhibitory activity, finally, it can be seen that all N-alkyl-DNJ derivatives 
tested are potent GBA2 inhibitors. Again, compounds 55, 56, and 57 featuring a 
tetrahydrofuranyl/tetrahydropyranyl moiety are the weakest inhibitors of the series. However, 
GBA2 inhibitory activity is less affected by the presence of an oxygen atom than GBA1 and GCS 
inhibitory activities. When comparing tetrahydrofuranyl-DNJ 55 with cyclopentyl-DNJ 54, it 
can be seen that substituting one of the cyclopentyl carbons (as in 54) for oxygen (as in 55) led 
to a 500-fold decrease in GCS inhibitory activity, a 25-fold decrease in GBA1 inhibitory activity, 
and a 10-fold decrease in GBA2 inhibitory activity. Thus, while compound 55 is less potent than 
carbon analogue 54, it is the more selective GBA2 inhibitor. Amongst the cycloalkyl-DNJ 
derivatives, compound 54 featuring a cyclopentane moiety appeared to be the most potent 
GBA2 inhibitor. 
In summary on this part, DNJ derivative 55 appears to be the most GBA2 selective 
compound (IC50 GCS / IC50 GBA2 = 1176, IC50 GBA1 / IC50 GBA2 = 3682), and while less active it is also 
more selective than compound 4, which served as the starting point of the here-presented 
studies (IC50 GCS / IC50 GBA2 = 1020, IC50 GBA1 / IC50 GBA2 = 1252). At the same time, all DNJ 
derivatives follow the general trend that, in case GCS is inhibited, also GBA1 is inhibited with 
considerable potency. As has been shown before, altering the configuration of the piperidine 
moiety from D-glucose to L-idose can abolish GBA1 inhibition.  




Accordingly, a number of alkyl substituents were selected and the corresponding N-alkyl-L-
ido-DNJ derivatives were prepared (Scheme 2) and evaluated (Table 2) as GCS/GBA1/GBA2 
inhibitors. As N-alkyl moieties, the most effective substituents from the D-gluco-DNJ series in 
terms of activity and selectivity were selected, leading to compounds 60 – 65, the inhibitory 
potency of which was compared with lead L-ido-DNJ derivative 5. All L-ido derivatives tested 
are more potent GCS inhibitors in comparison with their D-gluco congeners. This follows the 
trend witnessed in earlier studies, and the same holds true for GBA1 inhibition (all L-ido-DNJ 
derivatives tested are considerably weaker GBA1 inhibitors compared to the D-gluco-DNJ 
analogues). Finally and importantly, there is not much difference between GBA2 inhibitory 
potency when going from a D-gluco-DNJ derivative to its configurational L-ido-DNJ derivative 
(compare the GBA2 inhibitory potency of 60 with that of 50; 61 with 54; 62 with 55; 63 with 
56; 64 with 58; and 65 with 59). Hence all L-ido-DNJ derivatives tested are potent GCS/GBA2 
inhibitors with a considerable therapeutic window towards GBA1 – the enzyme one would like 
to avoid targeting when aiming for the development of new and improved substrate reduction 
therapies for Gaucher patients. Amongst the compounds tested thiophene-DNJ derivative 64 
appears to be the most potent analogue and further testing of this compound in relevant 
biological systems may be considered. 
Conclusion 
In this Chapter 17 new N-alkyl-DNJ derivatives are described, the structures of which are 
inspired by neopentyl-DNJ derivatives 4 and 5. From the compounds tested, DNJ derivative 55 
may well be the most selective, nanomolar GBA2 inhibitor reported to date. The most potent 
GBA2 inhibitors in turn appear to be 59 and 64. These compounds, as well as thiophene-L-ido-
DNJ derivative 58, which came out as the most most potent GCS inhibitor, deserves more in-
depth studies with respect to their in situ and even in vivo efficacy to modulate GlcCer 
metabolism through inhibition of GCS and/or GBA2. 
Experimental Section 
Enzyme inhibition assays:  The potencies (IC50 values) of the N-alkyl-DNJ derivatives as GCS, 
GBA1 and GBA2 inhibitors were determined by exposing cells or enzyme preparations to an 
appropriated range of iminosugar concentrations. 
 
GCS: IC50 values for GCS activity were measured using living cells with NBD-ceramide as 
substrate.17 Briefly, cells were incubated with 50 nmol C6-NBD-ceramide (6-[N-methyl-N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)aminododecanoyl]sphingosine) in the presence of increasing 
compound concentrations. The cells were harvested after 2h followed by lipid extraction. The 





phosphor imaging device. IC50 values were determined from the titration curves. The 
experiment was performed twice. 
 
GBA1: IC50 values for lysosomal GBA1 were measured using 4-methylumbeliferyl-β-D-glucoside 
as substrate.18 Briefly, recombinant GBA1 was incubated with increasing compound 
concentrations for 30 min at 0 ℃. Enzyme activity was determined with 3.7 mM 4-
methylumbelliferyl-β-D-glucopyranoside in McIlvaine buffer (0.1 M citrate and 0.2 M phosphate 
buffer), pH 5.2, 0.1% Triton X-100 (v/v) and sodium taurocholate (0.2%, w/v). Assays 
performed in triplicate were incubated at 37 ℃ for 30 min and quenched by the addition of 
glycine/NaOH (0.2 mL, pH 10.6). The amount of liberated 4-methylumbeliferyl was determined 
with a PerkinElmer Life Sciences LS30 fluorimeter, excitation wavelength 366 nm, emission 
wavelength 445 nm. 
 
GBA2: IC50 values for the non-lysosomal glucocerebrosidase (GBA2) were measured with 4-
methylumbeliferyl-β-D-glucoside as substrate.18 GBA2-rich membrane suspensions were 
prepared from enzyme-overexpressing HEK cells by sonicating, and the suspension was pre-
incubated for 30 min at 37 ℃ with conduritol-B-epoxide (1 mM, CBE, Sigma) to inhibit the 
lysosomal glucocerebrosidase (GBA1). The prepared GBA2-rich suspension was then incubated 
with increasing compound concentrations for another 30 min, and then incubated with 3.7 mM 
4-methylumbeliferyl-β-D-glucoside in McIlvaine buffer (0.1 M citrate and 0.2 M phosphate 
buffer), pH 5.8. Assays were incubated at 37 ℃ for 1 hour and quenched by the addition of 
glycine/NaOH (0.2 mL, pH 10.6). The amount of liberated 4-methylumbeliferyl was determined 
with a PerkinElmer Life Sciences LS30 fluorimeter, excitation wavelength 366 nm, emission 
wavelength 445 nm. Assays were performed in triplicate. 
 
General compound synthesis, purification and analysis methods: All solvents and reagents 
were obtained commercially and used as received unless stated otherwise. Reactions were 
executed at room temperature unless stated otherwise. Moisture sensitive reactions were 
performed under argon atmosphere. Water was removed from starting compounds by 
repetitive coevaporation with toluene. Solvents were removed by evaporation under reduced 
pressure. DCM, DMF, and THF were dried over activated 4Å molecular sieves for at least 12 
hours before use. Compounds were visualized during TLC analyses by UV (254 nm), and with 
the following staining solutions: aqueous solution of KMnO4 (5 g/L) and K2CO3 (25 g/L). 
Visualization of hemiacetals and glycosides was achieved by spraying with a solution of 20% 
H2SO4 in ethanol followed by charring at ≈ 200 ℃. Column chromatography purification was 
performed on silica gel (40-63 µm). 1H and 13C-APT NMR spectra were recorded on a Bruker AV 
400 (400/100 MHz) or Bruker 600 (600/150 MHz) spectrometer in CDCl3, MeOD or D2O. 
Chemical shifts are given in ppm (δ) relative to TMS as internal standard (1H NMR in CDCl3) or 
the signal of the deuterated solvent.19 Coupling constants (J) are given in Hz. High resolution 
mass spectra were recorded by direct injection (2 µL of a 2 µM solution in 
water/acetonitrile/tert-butanol 1:1:1 v/v/v) on a mass spectrometer (Thermo Finnigan LTQ 
Orbitrap) equipped with an electrospray ion source with resolution R = 60000 at m/z 400 
(mass range m/z = 150-2000). IR spectra were recorded on a Shimadzu FTIR-8300 and are 
reported in cm-1. Optical rotation were measured on an automatic polarimeter of sodium D-line, 
at λ =589 nm. Size-exclusion purifications were performed on an ÄKTA-explorer, column size d 
= 26 mm, l = 60 mm, mobile phase NH4HCO3 (0.15 M) in H2O, flow 1.5 mL/min. HPLC 
Purification were performed on a Prep LCMS, Gemini from Phenomenex B.V. (C-18, 110 Å, 5 µm, 
19 x 150 mm column). 
 
General procedure A: Substitution of the tosyl group. A dry solution of alcohol (5 mmol) in 
DMF (15 mL) was charged with NaH (10 mmol) and stirred for 90 min. Then a dry solution of 
15 (4.5 mmol) in DMF (15 mL) was added. The reaction mixture was heated to 75 ℃ for 1 h. 




After complete consumption of the starting material (TLC monitored), the mixture was cooled 
to room temperature, quenched by the addition of water (3 mL) and concentrated. The residue 
was dissolved in a mixture of TEAA (0.1 M), EtOAc and sat. aq. NaHCO3 (80 mL, 2:3:3) and 
extracted with EtOAc (3 x 30 mL). The organic phase was dried (MgSO4), filtered and 
concentrated. Purification by silica gel column chromatography (0 - 10% EtOAc in PE) gave the 
target compound. 
 
General Procedure B: Deprotection of the trityl-group. To a solution of alkyloxyl-1-
trityloxpentane (2.0 mmol) in toluene/MeOH (1:1, 20 mL, 0.1 M) was added BF3∙Et2O (3.0 
mmol, 1.5 eq). This mixture was stirred for 1.5 h at r.t. After complete consumption of the 
starting material (TLC monitored), the mixture was diluted with EtOAc (30 mL) and washed 
with sat. aq. NaHCO3 (50 mL). The water layer was extracted with EtOAc (3 x 30 mL) and the 
combined organic layers were dried (MgSO4), filtered, concentrated and the residue purified by 
silica gel column chromatography (1:9 → 1:4 → 1:1 → 1:0, EtOAc:PE) to give target alcohol 
chain. 
 
General Procedure C: Bromination. To a solution of alkyloxyl-1-pentanol (1 mmol) in DCM 
(100 mL, 0.01 M) was added PPh3 (0.40 g, 1.5 mmol, 1.5 eq) and cooled to 0 ℃. Then CBr4 (0.5 
g, 1.5 mmol, 1.5 eq) was added and the reaction mixture was stirred at 0 ℃ until TLC analysis 
monitored the complete consumption of starting compound. After which Celite was added and 
the volatiles were evaporated. The residue was purified with silica gel column chromatography 
(0 - 100% toluene in heptane → 2 - 20% EtOAc in toluene) to give the bromide spacer. 
 
General Procedure D: Alkylation of iminosugars. To a mixture of the 1-bromo-5-alkyloxy-
pentane (0.3 mmol, 1.5 eq) and di-isopropylethylamine  (DiPEA, 0.1 mL, 0.6 mmol, 3 eq) was 
added a solution of iminosugar (0.03 g, 0.2 mmol) in DMF (1 mL). The mixture was stirred 
overnight at 70 ℃. After cooling to r.t., the mixture was filtered and concentrated. The crude 
product was purified using HPLC. 
 
Synthesis of DNJ and L-ido-DNJ 
2,3,4,6-Tetra-O-benzyl-1-deoxynojirimycin (8): 
A solution of (COCl)2 (0.70 mL, 8.16 mmol) in dry DCM (5 mL) under argon 
atmosphere, was cooled to -78 ℃. DMSO (0.71 mL, 10.0 mmol) dissolved in 
dry DCM (5 mL) was added dropwise. After 40 minutes, 7 (1.02 g, 1.88 mmol, 
co-evaporated with toluene 3 x) in dry DCM (3 mL), was added dropwise to 
the mixture. The reaction was stirred for 2 hours at -78 ℃, after which Et3N 
(3.40 mL, 24.4 mmol) was added dropwise. The mixture was gradually warmed to -5 ℃ after 
which it was poured into a cooled (0 ℃) MeOH solution (50 mL) containing NaCNBH3 (0.50 g, 
8.00 mmol), HCOONH4 (2.53 g, 40.1 mmol), and Na2SO4 (0.89 g, 6.24 mmol). The mixture was 
stirred overnight during which the reaction mixture was allowed to warm up to r.t. TLC 
analysis showed complete consumption of the starting material (1:1, PE:EtOAc, RF = 0.36). After 
filtration, the volatiles were evaporated, and the residue was dissolved in EtOAc (70 mL), 
washed with sat. aq. NaHCO3 (70 mL). The organic layer was dried (Na2SO4) filtrated and 
concentrated. The residue was purified with silica gel column chromatography (2:1 → 1:2, 
PE:EtOAc) to give the pure product 8 in 12% overall yield (0.114 g, 0.218 mmol). RF = 0.36 (1:1, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) 7.41 – 7.13 (m, 20H, HAr Bn), 5.00 – 4.38 (m, 8H, 4 x CH2 
Bn), 3.66 (dd, J = 9.0, 2.5 Hz, 1H, H-6a), 3.58 – 3.44 (m, 3H, H-2, H-3, H-6b), 3.35 (t, J = 9.2 Hz, 
1H, H-4), 3.23 (dd, J = 12.3, 4.9 Hz, 1H, H-1a), 2.71 (ddd, J = 9.7, 5.9, 2.6 Hz, 1H, H-5), 2.49 (dd, J = 
12.2, 10.3 Hz, 1H, H-1b). 13C NMR (100 MHz, CDCl3) 138.9 – 138.0 (Cq Bn), 128.4 – 127.6 (CHAr 








8 (2.00 g, 3.82 mmol) was dissolved in EtOH (120 mL) and pH was adjusted to 
2 with HCl solution (1 M). The solution was flushed with argon (3 x), after 
which two spatula tips of Pd/C (20%) was added. Then the mixture was 
exposed to H2 atmosphere (4 bar) for 24 hours. The catalyst was filtered 
through a pad of Celite and the filtrate was concentrated. The residue was 
purified on silica gel column chromatography (4:1, EtOAc:MeOH + 1% NH4OH → 6:4:1, 
EtOH:H2O:NH4OH) to give  9 in 82% yield (511 mg, 3.13 mmol). 1H NMR (400 MHz, MeOD) δ 
3.92 (dd, J = 10.9, 3.1 Hz, 1H, H-6a), 3.67 (dd, J = 10.9, 6.5 Hz, 1H, H-6b), 3.49 (ddd, J = 10.6, 8.7, 
5.1 Hz, 1H, H-2), 3.28 (t, J = 8.1 Hz, 1H, H-3), 3.24 (t, J = 9.1 Hz, 1H, H-4), 3.18 (dd, J = 12.1, 5.1 
Hz, 1H, H-1a), 2.54 (ddd, J = 9.4, 6.4, 3.1 Hz, 1H, H-5), 2.52 (dd, J = 12.1, 10.7 Hz, 1H, H-1b). 13C 
NMR (100 MHz, MeOD) δ 81.5 (C-3), 74.2 (C-4), 73.5 (C-2), 64.0 (C-6), 63.7 (C-5), 51.9 (C-1). 
 
2,3,4,6-Tetra-O-benzyl-L-ido-N-allyl-1-deoxynojimycin (10): 
MsCl (4.2 mL, 53.1 mmol) was added dropwise to a cooled mixture (0 ℃) of 
pyridine (90 mL) and 7 (11.5 g, 21.2 mmol). The mixture was stirred for 3 
hours at r.t., after which TLC analysis (2:1, PE:EtOAc, RF = 0.13) showed 
complete consumption of the starting material. Water (60 mL) was added 
and the solution was concentrated. The residue was dissolved in EtOAc (130 
mL), and successively washed with HCl (100 mL, 1M, 2 x), sat. aq. NaHCO3 
(100 mL) and brine (100 mL). The organic layer was dried (Na2SO4), filtered and concentrated. 
The residue was co-evaporated with toluene (3 x). Allylamine (90 mL) was added to dissolve 
the methanesulfonylated product, and the solution was heated to reflux for 14 hours, until TLC 
analysis (2:1, PE:EtOAc) showed complete consumption of the starting material. After 
concentration, the residue was dissolved with EtOAc (110 mL), washed with sat. aq. NaHCO3 
(100 mL, 2 x) and brine (100 mL). The organic layer was dried (Na2SO4), filtered and 
concentrated. The residue was purified on silica gel column chromatography (17:3, PE:EtOAc) 
to give 10 in 78% yield (9.30 g, 16.5 mmol). RF = 0.76 (2:1, PE:EtOAc). 1H NMR (400 MHz, 
CDCl3) 7.42 – 7.27 (m, 20H, HAr Bn), 5.77 (ddt, J = 16.8, 10.3, 6.3 Hz, 1H, H-2’), 5.12 (dd, J = 
23.6, 6.2 Hz, 2H, H-3”), 4.90 – 4.46 (m, 8H, 4 x CH2 Bn), 3.84 (dd, J = 10.2, 6.8 Hz, 1H, H-1a’), 3.72 
(dd, J = 10.2, 2.5 Hz, 1H, H-1b”), 3.69 (dd, J = 7.6, 4.2 Hz, 1H, H-4), 3.60 – 3.50 (m, 2H, H-2, H-3), 
3.42 (ddd, J = 10.1, 5.8, 1.6 Hz, 1H, H-5), 3.37 (dd, J = 6.9, 2.0 Hz, 1H, H-6a), 3.18 (dd, J = 14.1, 6.9 
Hz, 1H. H-6b), 2.92 (dd, J = 11.9, 4.9 Hz, 1H, H-1a), 2.53 (dd, J = 11.8, 9.8 Hz, 1H, H-1b). 13C NMR 
(100 MHz, CDCl3) 139.3, 138.8, 138.7, 138.6 (4 x Cq Bn), 136.3 (C-2”), 128.5 – 127.6  (CHAr Bn), 
117.2 (C-3”), 83.1 (C-4), 80.2 (C-3), 78.9 (C-2), 75.5, 73.4, 73.1 72.8 (4 x CH2 Bn), 64.7 (C-1”), 
60.1 (C-5), 58.1 (C-6), 49.1 (C-1). 
 
2,3,4,6-Tetra-O-benzyl-L-ido-1-deoxynojimycin (11): 
A mixture of DMSO (35 mL), tBuOK (1.00 g, 8.91 mmol) and 10 (9.30 g, 16.5 
mmol, co-evaporated with toluene 3 x) was heated to 100 ℃ and stirred 
under argon atmosphere. After 1 hour stirring, HCl solution (30 mL, 1M) was 
added and the heating resource was removed. After 30 minutes, the mixture 
was poured into a mixture of sat. aq. NaHCO3 (100 mL) and Et2O (150 mL). 
The organic layer was separated and the water layer was re-extracted with Et2O (150 mL, 2 x). 
The combined organic layers were dried (Na2SO4), filtered and concentrated. The residue was 
purified with silica gel column chromatography (2:1 → 1:2 → 0:1, PE:EtOAc) to give the pure 
product 11 with a yield of 92% (7.93 g, 15.1 mmol). RF = 0.13 (1:1, PE:EtOAc). 1H NMR (400 
MHz, CDCl3) δ 7.38 – 7.22 (m, 20H, HAr Bn), 4.68 – 4.49 (m, 8H, 4 x CH2 Bn), 3.68 (t, J = 9.2 Hz, 
1H, H-6a), 3.62 (t, J = 5.3 Hz, 1H, H-3), 3.55 (dd, J = 9.5, 5.2 Hz, 1H, H-6b), 3.45 (td, J = 6.6, 4.1 Hz, 
1H, H-2), 3.38 (ddd, J = 8.7, 5.0, 3.6 Hz, 1H, H-5), 3.01 (dd, J = 12.9, 4.1 Hz, 1H, H-1a), 2.86 (dd, J = 
12.8, 6.7 Hz, 1H, H-1b). 13C NMR (100 MHz, CDCl3) δ 138.7 – 138.4 (Cq Bn), 128.5 – 127.7 (CHAr 




Bn), 77.3 (C-3), 77.0 (C-2), 74.2 (CH2 Bn), 73.5 (CH2 Bn), 72.7 (CH2 Bn), 72.2 (CH2 Bn), 67.3 (C-
6), 54.7 (C-5), 44.3 (C-1). 
 
 L-Ido-1-deoxynojimycin (12): 
11 (2.30 g, 4.39 mmol) was dissolved in EtOH (150 mL) and pH was adjusted to 
2 with HCl solution (1 M). The solution was flushed with argon for 3 times, 
after which two spatula tips of Pd/C (20%) was added. The suspension was 
exposed to H2 atmosphere (4 bar) and shaken for 24 hours. The catalyst was 
filtered through a pad of Celite and the filtrate was concentrated. The residue 
was purified with silica gel column chromatography (4:1 EtOAc:MeOH + 1% 
NH4OH → 6:4:1, EtOH: H2O:NH4OH) to give the 12 in 76% yield (840 mg, 3.32 mmol). 1H NMR 
(400 MHz, MeOD) δ 3.95  – 3.93 (m, 2H, H-2, H-3), 3.89 (dd, J = 5.7, 2.0 Hz, 1H, H-4), 3.85 (dd, J = 
11.0, 2.1 Hz, 1H, H-6a), 3.81 (dd, J = 11.7, 5.1 Hz, 1H, H-6b), 3.47 (ddd, J = 8.9, 5.0, 1.9 Hz, 1H, H-
5), 3.36 (dd, J = 13.2, 2.0 Hz, 1H, H-1a), 3.24 (dd, J = 13.2, 1.7 Hz, 1H, H-1b). 13C NMR (100 MHz, 
MeOD) δ 69.2 (C-4), 68.4 (C-3), 68.0 (C-2), 60.3 (C-6), 58.2 (C-5), 46.9 (C-1). 
 
Synthesis of the bromide-spacers 
Figure 7: Proton and carbon NMR numbering of the linker molecules (16- 48) 
 
5-Trityloxy-1-pentanol (14): 
Trityl chloride (55.82 g, 200 mmol), 1,5-pentanediol (100 mL, 954 mmol), 
EtOAc (500 mL) and TEA (56 mL, 396 mmol) were mixed. The mixture 
was stirred for 3h at 85 ℃. After complete conversion of the starting material (1:1, PE:EtOAc) 
the mixture was washed successively with HCl (4 x 100 mL, 1M) and sat. aq. NaHCO3 (4 x 100 
mL), dried (MgSO4) and concentrated to give compound 22 (68.67 g, 198.20 mmol, 99% yield). 
RF = 0.70 (1:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.36 (m, 6H, HAr Trt), 7.29 – 7.17 
(m, 9H, HAr Trt), 3.57 – 3.55 (m, 2H, H2-1), 3.07 – 3.05 (m, 2H, H2-5), 1.65 – 1.63 (m, 2H, H2-4), 
1.55 – 1.35 (m, 4H, H2-2, H2-3). 13C NMR (100 MHz, CDCl3) δ 144.4 (Cq Trt), 128.6 – 126.8 (CH 
Trt), 86.3 (Cq Trt), 63.4 (C-1), 62.7 (C-5), 32.5 (C-4), 29.7 (C-2), 22.4 (C-3).  
 
5-(Toluene-4-sulfonyl)-1-trityloxypentane (15):  
p-Toluenesulfonyl chloride (8.83 g, 46.3 mmol) was added to a dry and 
cooled (0 ℃) mixture of 14 (10.72 g, 30.94 mmol), TEA (7 mL, 49.5 mmol) 
and DMAP (0.19 g, 1.56 mmol) in DCM (93 mL). The mixture was stirred for 2h while warming 
to r.t. The mixture was washed successively with HCl (100 mL, 1M), sat. aq. NaHCO3 (100 mL) 
and sat. aq. NaCl (100 mL). The organic phase was dried (MgSO4), filtered and concentrated. 
Purification of the residue with silica gel column chromatography (10 – 16% EtOAc in PE) gave 
compound 15 (10.9 g, 21.7 mmol, 70%) as a white solid. RF = 0.78 (25% EtOAc in PE). 1H NMR 
(400 MHz, CDCl3) δ 7.75 (d, 2H, HAr Ts), 7.42 (d, 6H, HAr Trt), 7.24 – 7.19 (m, 10H, HAr Trt/Ts), 
7.16 – 7.13 (m, 3H, HAr Trt), 3.94 (t, 2H, H-5), 3.00 (t, 2H, H2-1), 1.94 (s, 3H, CH3 Ts), 1.54 – 1.49 
(m, 4H, H2-2, H2-4), 1.35 – 1.33 (m, 2H, H2-3). 13C NMR (100 MHz, CDCl3) δ 144.8 (Cq Ts), 
144.5(Cq Trt), 133.3(Cq Ts), 130.0 (CH, Ts), 128.9 – 127.1 (CH Trt), 86.5 (Cq Trt), 70.7 (C-5), 
63.2(C-1), 29.4 (C-2), 28.7 (C-4), 22.4 (C-3), 21.7 (CH3 Ts). 
 
5-(2-Methyl-1-propyloxy)-1-trityloxypentane (16): 
Compound 15 (4.60 mmol) was subjected to the general procedure A, 





mmol) in a yield of 42%, as thick oil, after silica gel column chromatography purification. RF = 
0.65 (10% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ 7.44 (m, J = 8.6, 2.2, 1.6 Hz, 6H, HAr Trt), 
7.32 – 7.14 (m, 9H, HAr Trt), 3.37 (t, J = 6.5 Hz, 2H, H2-5), 3.14 (d, J = 6.8 Hz, 2H, H2-6), 3.06 (t, J = 
6.6 Hz, 2H, H2-1), 1.84 (dp, J = 6.7 Hz, 1H, H-7), 1.71 – 1.60 (m, 2H, H2-2), 1.59 – 1.50 (m, 2H, H2-
4), 1.50 – 1.37 (m, 2H, H2-3), 0.89 (d, J = 6.7 Hz, 6H, 2 x CH3). 13C NMR (100 MHz, CDCl3) δ 144.6 
(Cq Trt), 128.8 (CH Trt), 127.7 (CH Trt), 126.9 (CH Trt), 86,4 (Cq Trt), 77.9 (C-6), 71.0 (C-5), 63.6 
(C-1), 30.0 (C-2), 29.7 (C-4), 28.5 (C-7), 23.1 (C-3), 19.5 (2 x CH3). IR/cm-1: 3061, 2930, 2901, 
2866, 1597, 1489, 1448, 1392, 1364, 1176, 1072. 
 
5-(3,3-Dimethyl-2-butoxy)-1-trityloxypentane (17): 
Compound 15 (4.43 mmol) was subjected to the general procedure 
A, using 3,3-dimethyl-2-butanol (5.06 mmol)  to provide 17 (0.95 g, 
2.21 mmol) in a 50% yield, as thick oil, after silica gel column 
chromatography purification. RF = 0.79 (5% EtOAc in PE).  1H NMR 
(400 MHz, CDCl3) δ 7.48 – 7.36 (m, 6H, HAr Trt), 7.28 – 7.11 (m, 
12H, HAr Trt), 3.53 (dt, J = 9.4, 5.8 Hz, 1H, H-5a), 3.21 (dd, J = 9.2, 6.2 Hz, 1H, H-5b), 3.06 (t, J = 
6.6 Hz, 2H, H2-1), 2.93 (q, J = 6.3 Hz, 1H, H-6), 1.74 – 1.35 (m, 6H, H2-2, H2-3, H2-4), 1.01 (d, J = 
6.3 Hz, 3H, H3-7), 0.87 (s, 9H, H3-9, H3-10, H3-11). 13C NMR (100 MHz, CDCl3) δ 144.7 (Cq  Trt), 
128.8 (CH Trt), 127.9 (CH Trt), 126.9 (CH Trt), 86.4 (Cq Trt), 83.4 (C-6), 69.8 (C-5), 63.7 (C-1), 
35.3 (C-8), 30.3 (C-2), 30.1 (C-4), 26.2 (C-7), 23.3 (C-3), 14.1 (C-9, C-10, C-11). IR/cm-1: 3059, 
3022, 2936, 2866, 1597, 1489, 1448, 1389, 1362, 1219, 1090, 1072. 
 
5-(3,3-Dimethyl-1-butoxy)-1-trityloxypentane (18): 
Compound 15 (4.41 mmol) was subjected to the general procedure 
A, using 3,3-dimethyl-1-butanol (5.07 mmol)  to provide 18 (1.02 g, 
2.36 mmol) in a 54% yield, as thick oil, after silica gel column 
chromatography purification. RF = 0.67 (5% EtOAc in PE). 1H NMR  (400 MHz, CDCl3) δ 7.44 
(dt, J = 8.3, 2.2 Hz, 6H, HAr Trt), 7.25 – 7.16 (m, 6H, HAr Trt), 7.16 – 7.10 (m, 3H, HAr Trt), 3.41 
(t, J = 7.4 Hz, 2H, H2-5), 3.34 (t, J = 6.4 Hz, 2H, H2-6), 3.06 (td, J = 6.9, 3.0 Hz, 2H, H2-1), 1.63 (p, J = 
6.8 Hz, 2H, H2-2), 1.52 (m, 4H, H2-4, H2-7), 1.48 - 1.38 (m, 2H, H2-3), 0.90 (s, 9H, H3-9, H3-10, H3-
11). 13C NMR (100 MHz, CDCl3) δ 144.5 (Cq Trt), 128.7 (CAr Trt), 127.7 (CH Trt), 126.8 (CH Trt), 
86.3 (Cq Trt), 70.8 (C-6), 68.1 (C-5), 63.5 (C-1), 43.0 (C-7), 29.8 (C-2), 29.7 (C-9,10,11), 29.6 (C-
4), 29.6 (C-8), 23.1 (C-3). IR/cm-1: 3057, 3022, 2936, 2864, 1597, 1489, 1448, 1364, 1219, 1111, 
1072. 
 
5-(Cyclopropylmethoxy)-1-trityloxypentane (19):  
Compound 15 (4.41 mmol) was subjected to the general procedure A, 
using cyclopropylmethanol (5.02 mmol) to provide 19 (0.10 g, 2.49 
mmol) in a 56% yield, as thick oil, after silica gel column chromatography purification. RF = 0.63 
(10% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ 7.48 – 7.41 (m, 6H, Trt), 7.28 - 7.19 (m, 6H, HAr 
Trt), 7.20 – 7.13 (m, 3H, HAr Trt), 3.38 (t, J = 6.6 Hz, 2H, H2-5), 3.20 (d, J = 6.9 Hz, 2H, H2-6), 3.06 
(t, J = 6.6 Hz, 2H, H2-1), 1.65 (p, J = 6.8 Hz, 2H, H2-2), 1.51 – 1.59 (m, 2H, H2-4), 1.47 – 1.38 (m, 
2H, H2-3), 1.08 – 0.97 (m, 1H, H-7), 0.52 – 0.45 (m, 2H, H2-8), 0.16 (dt, J = 6.0, 4.5 Hz, 2H, H2-9). 
13C NMR (100 MHz, CDCl3) δ 144.6 (Cq Trt), 128.8 (CH Trt), 127.8 (CH Trt), 126.9 (CH Trt), 86.4 
(Cq Trt), 75.7 (C-7), 70.7 (C-5), 63.7 (C-1), 30.1 (C-2), 29.8 (C-4), 23.1 (C-3), 10.8 (C-7), 3.2 (C-8, 
C-9). IR/cm-1: 3082, 3057, 3022, 2933, 2862, 1732, 1597, 1489, 1448, 1382, 1219, 1087, 1074. 
 
5-(Cyclobutylmethoxy)-1-trityloxypentane (20):  
Compound 15 (4.40 mmol) was subjected to the general procedure 
A, using cyclobutylmethanol (5.01 mmol) to provide 20 (0.79 g, 1.91 
mmol) in a 43% yield, as thick oil, after silica gel column chromatography purification. RF = 0.74 
(10% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.43 (m, 6H, HAr Trt) 7.22 – 7.17 (m, 6H, 




HAr Trt), 7.14 – 7.10 (m, 3H, HAr Trt), 3.37 – 3.32 (m, 4H, H2-5, H2-6), 3.07 (t, 2H, H2-1), 2.56 – 
2.49 (m, 1H, C-7), 2.04 – 1.97 (m, 2H, H2-10), 1.86 – 1.79 (m, 2H, H2-8), 1.75 – 1.40 (m, 8H, H2-9. 
H2-2, H2-4, H2-3). 13C NMR (100 MHz, CDCl3) δ 144.6 (Cq Trt), 128.9 (CH Trt), 127.9 (CH Trt), 
127.0 (CH Trt), 86.5 (Cq Trt), 75.6 (C-6), 71.1 (C-5), 63.7 (C-1), 35.4 (C-7), 29.9 (C-2), 29.8 (C-4), 
25.4 (C-8, C-10), 23.2 (C-3), 18.9 (C-9). IR/cm-1: 3084, 3059, 2934, 2862, 1597, 1489, 1448, 
1363, 1219, 1111, 1072. 
 
5-(Cyclopentylmethoxy)-1-trityloxypentane (21):  
Compound 15 (4.43 mmol) was subjected to the general procedure 
A, using cyclopentylmethanol (5.09 mmol) to provide 21 (1.29 g, 
3.02 mmol) in a 68% yield, as thick oil, after silica gel column 
chromatography purification. RF = 0.77 (10% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ 7.44 (m, 
6H, HAr Trt), 7.18 – 7.06 (m, 9H, HAr Trt), 3.39 – 3.29 (m, 2H, H2-5), 3.21 (dd, J = 7.0, 1.0 Hz, 2H, 
H2-6), 3.05 (dt, J = 11.1, 6.5 Hz, 2H, H2-1), 2.10 (q, J = 7.4 Hz, 1H, H2-7), 1.74 – 1.57 (m, 4H, H2-8, 
H2-11), 1.57 – 1.36 (m, 8H, H2-2, H2-3, H2-4, H2-9), 1.31 – 1.17 (m, 2H, H2-10). 13C NMR (100 
MHz, CDCl3) δ 144.4 – 125.6 (CH Trt), 75.2 (C-6), 70.6 (C-5), 63.3 (C-1), 38.4 (C-7), 29.4 – 28.7 
(C-8, C-9, C-10, C-11), 25.3, 25.1 (C-2, C-4), 22.8 (C-3). IR/cm-1: 3084, 3057, 3022, 2939, 2864, 
1597, 1489, 1448, 1367, 1176, 1072.  
 
5-(R/S-Tetrahydrofuran-3-ylmethoxy)-1-trityloxypentane (22):  
Compound 15 (4.61 mmol) was subjected to the general procedure 
A, using R/S tetrahydrofuran-3-ylmethanol (4.96 mmol) to provide 
22 (1.11 g, 2.58 mmol) in a 56% yield, as an oil, after silica gel 
column chromatography purification. RF = 0.40 (15% EtOAc in PE). 1H NMR (400 MHz,  CDCl3) δ 
7.48 – 7.40 (m, 6H, HAr Trt), 7.21 (dd, J = 8.5, 6.8 Hz, 6H, HAr Trt), 7.16 – 7.10 (m, 3H, HAr Trt), 
3.75 (ddd, J = 12.1, 8.3, 6.2 Hz, 2H, H-8a, H-9a), 3.68 - 3.55 (m, 1H, H-8b), 3.53 (dd, J = 8.7, 5.4 
Hz, 1H, H-9b), 3.40 – 3.18 (m, 4H, H2-5, H2-9), 3.07 (t, J = 6.5 Hz, 2H, H2-1), 2.49 – 2.35 (m, 1H, H-
7), 1.87 (ddt, J = 13.9, 8.1, 4.0 Hz, 1H, H-10a), 1.62 (p, J = 6.8 Hz, 2H, H2-2), 1.51 (m, 3H, H2-4, H-
10b), 1.46 – 1.37 (m, 2H, H2-3). 13C NMR (100 MHz, CDCl3) δ 144.6 (Cq Trt), 128.8 (CH Trt), 
127.0 (CH Trt), 86.4 (Cq Trt), 73.0 (C-8), 71.1 (C-5), 71.1 (C-9), 67.8 (C-7), 39.4 (C-1), 30.0 (C-




Compound 15 (5.03 mmol) was subjected to the general procedure 
A, using R/S tetrahydrofuran-1-ylmethanol (5.73 mmol) to provide 
23 (1.06 g, 2.46 mmol) in a yield of 49%, as an oil, after silica gel 
column chromatography purification. RF = 0.52 (15% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ 
7.48 – 7.37 (m, 6H, HAr Trt), 7.32 – 7.23 (m, 6H, HAr Trt), 7.23 – 7.16 (m, 3H, HAr Trt), 4.02 (tt, J = 
7.3, 5.3 Hz, 1H, H-7), 3.85 (ddd, J = 8.2, 6.9, 6.1 Hz, 1H, H-10a), 3.73 (ddd, J = 8.2, 7.2, 6.3 Hz, 1H, 
H-10b), 3.53 – 3.37 (m, 4H, H2-5, H2-6), 3.05 (t, J = 6.6 Hz, 2H, H2-1), 1.96 – 1.77 (m, 3H, H2-2, H-
9a), 1.69 – 1.60 (m, 2H, H2-2), 1.60 – 1.52 (m, 3H, H2-4, H-9b), 1.47 – 1.37 (m, 2H, H2-3). 13C NMR 
(100 MHz, CDCl3) δ 144.5 (Cq Trt), 128.7 (CH Trt), 127.7 (CH Trt), 126.9 (CH Trt), 86.3 (Cq Trt), 
77.9 (C-7), 73.6 (C-6), 71.6 (C-5), 68.4(C-10), 63.6 (C-1), 30.0 (C-9), 29.6 (C-4), 28.2 (C-8), 25.7 
(C-2), 22.9 (C-3). IR/cm-1: 3084, 3055, 3022, 2934, 2862, 1597, 1489, 1448, 1373, 1219, 1111, 
1074. 
 
5-(Tetrahydro-2H-pyran-4-ylmethoxy)-1-trityloxypentane (24):  
Compound 15 (4.68 mmol) was subjected to the general procedure 
A, using tetrahydro-2H-pyran-4-ylmethanol (4.34 mmol)  to 
provide 24 (0.79 g, 1.78 mmol) in a  yield of 38%, as an oil, after 





CDCl3) δ 7.48 – 7.35 (m, 6H, HAr Trt), 7.32 – 7.21 (m, 6H, HAr Trt), 7.25 – 7.13 (m, 3H, HAr Trt), 
3.99 – 3.89 (m, 2H, H2-10), 3.42 – 3.30 (m, 4H, H2-5, H2-9), 3.21 (d, J = 6.6 Hz, 2H, H2-1), 3.06 
(t, J = 6.5 Hz, 2H, H2-6), 1.88 – 1.74 (m, 1H, H-7), 1.70 – 1.57 (m, 4H, H2-2, H2-8), 1.57 – 1.47 (m, 
2H, H2-4), 1.47 – 1.38 (m, 2H, H2-3), 1.35 – 1.25 (m, 2H, H2-11). 13C NMR (100 MHz, CDCl3) δ 
144.5 (Cq Trt), 128.7 (CH Trt), 127.7 (CH Trt), 126.9 (CH Trt), 86.4 (Cq Trt), 75.9 (C-6), 71.1 (C-
1), 67.7 (C-9, C-10), 63.5 (C-5), 35.5 (C-7), 30.1 (C-8, C-11), 29.9 (C-2), 29.6 (C-4), 23.0 (C-3). 
IR/cm-1: 3085, 3056, 3023, 2932, 2849, 1558, 1506, 1506, 1489, 1227, 1163, 1097. 
 
5-(Thiophen-3-methoxy)-1-trityloxypentane (25):  
Compound 15 (4.56 mmol) was subjected to the general procedure 
A, using 3-thiophenmethanol (4.57 mmol) to provide 25 (0.73 g, 
2.13 mmol) in a 56% yield, as thick oil, after silica gel column 
chromatography purification. RF = 0.79 (15% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ 7.48 – 
7.38 (m, 6H, HAr Trt), 7.28 – 7.20 (m, 6H, HAr Trt), 7.20 - 7.14 (m, 3H, HAr Trt), 7.12 (dq, J = 3.0, 
1.0 Hz, 1H, H thio), 7.04 (dd, J = 4.9, 1.3 Hz, 1H, H thio), 7.02 (dd, J = 4.9, 1.3 Hz, 1H, H thio), 4.44 
(d, J = 0.8 Hz, 2H, H2-6), 3.40 (t, J = 6.5 Hz, 2H, H2-5), 3.05 (t, J = 6.6 Hz, 2H, H2-1), 1.70 – 1.49 (m, 
4H, H2-2, H2-4), 1.51 – 1.36 (m, 2H, H2-3). 13C NMR (100 MHz, CDCl3) δ 144.6 (Cq Trt), , 128.9 
(CH Trt), 127.9 (CH Trt), 127.4 (CH thio), 127.0 (Cq Trt), 126.0 (CH thio), 122.6 (CH thio), 114.7 
(Cq Thio), 86.5 (Cq Trt), 70.4 (C-5), 68.3 (C-6), 63.7 (C-1), 30.0 (C-2), 29.8 (C-4), 23.1 (C-3). 
IR/cm-1: 3501, 3088, 3059, 3024, 2938, 2864, 2316, 1734, 1448, 1364, 1242, 1068, 1034. 
 
5-(Thiophen-3-ethoxy)-1-trityloxypentane (26):  
Compound 15 (4.56 mmol) was subjected to the general 
procedure A, using 3-thiophenethanol (4.57 mmol) to provide 26 
(0.97 g, 1.65 mmol) in a 47% yield, as an oil, after silica gel 
column chromatography purification. RF = 0.70 (10% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ 
7.48 – 7.40 (m, 6H, HAr Trt), 7.30 – 7.24 (m, 6H, HAr Trt), 7.22 – 7.19 (m, 3H, HAr Trt), 7.18 – 7.16 
(m, 1H, H-thio), 6.97 (dq, J = 3.0, 1.0 Hz, 1H, H thio), 6.94 (dd, J = 4.9, 1.3 Hz, 1H, H thio), 3.59 
(t, J = 7.0 Hz, 2H, H2-2), 3.41 (t, J = 6.5 Hz, 2H, H2-5), 3.05 (t, J = 6.6 Hz, 2H, H2-1), 2.92 – 2.84 (m, 
2H, H2-1), 1.64 (p, J = 6.8 Hz, 2H, H2-2), 1.55 (dq, J = 8.7, 6.5 Hz, 2H, H2-4), 1.47 – 1.36 (m, 2H, H2-
3). 13C NMR (100 MHz, CDCl3) δ 144.5 (Cq Trt), 128.8 (CH Trt), 128.0 (CH thio), 127.8 (CH Trt), 
126.9 (CH Trt), 125.2 (CH thio), 121.1 (CH thio), 114.6 (Cq thio), 86.4 (Cq Trt), 71.1 (C-2), 71.0 
(C-5), 63.6 (C-1), 30.8 (C-1), 29.9 (C-2), 29.6 (C-4), 23.0 (C-3). IR/cm-1: 3524, 3086, 3057, 2934, 
2862, 1738, 1717, 1489, 1447, 1387, 1364, 1242, 1159, 1113, 1069, 1034. 
 
5-(2-Methyl-1-propyloxy)-1-pentanol (27): 
Compound 16 (3.56 mmol) was subjected to the general procedure B 
to provide 27 (0.33 g, 2.07 mmol) in a yield of 73%, as an oil, after 
silica gel column chromatography purification. RF = 0.24 (20% EtOAc in PE). 1H NMR (400 MHz, 
CDCl3) δ 3.49 (t, J = 6.6 Hz, 2H, H2-1), 3.31 (t, J = 6.5 Hz, 2H, H2-5), 3.07 (d, J = 6.8 Hz, 2H, H2-6), 
1.78 – 1.72 (m, 1H, H-7), 1.53 – 1.43 (m, 4H, H2-2, H2-4), 1.37 – 1.27 (m, 2H, H2-3), 0.81 (s, 3H, 
H3-8), 0.79 (s, 3H, H3-9). 13C NMR (100 MHz, CDCl3) δ 77.8 (C-6), 70.8 (C-5), 62.1 (C-1), 32.3 (C-
2), 29.3 (C-4), 28.2 (C-7), 22.3 (C-3), 19.3 (C-8, C-9). IR/cm-1: 3335, 2934, 2859, 1470, 1383, 
1366, 1115, 1055, 1007. 
 
5-(3,3-Dimethyl-2-butoxy)-1-pentanol (28):  
Compound 17(2.21 mmol) was subjected to the general procedure B 
to provide 28 (0.2089 g, 1.11 mmol) in a 50% yield, as an oil, after 
silica gel column chromatography purification. RF = 0.32 (20% EtOAc 
in PE). 1H NMR (400 MHz, CDCl3) δ 3.64 (t, J = 6.6 Hz, 2H, H2-1), 3.57 (dt, J = 9.2, 6.1 Hz, 1H, H-
5a), 3.26 (dt, J = 9.2, 6.6 Hz, 1H, H-5b), 2.95 (q, J = 6.3 Hz, 1H, H-6), 1.64 – 1.51 (m, 4H, H2-2, H2-
4), 1.50 – 1.36 (m, 2H, H2-3), 1.03 (d, J = 6.3 Hz, 3H, H3-7), 0.87 (s, 9H, H3-9, H3-10, H3-11). 13C 




NMR (100 MHz, CDCl3) δ 83.4 (C-6), 69.8 (C-5), 62.8 (C-1), 35.1 (C-8), 32.5 (C-2), 29.8 (C-4), 
26.0 (C-9, C-10, C-11), 22.5 (C-3), 14.0 (C-7). IR/cm-1: 3296, 2938, 2866, 1474, 1456, 1388, 
1371, 1339, 1209, 1099, 1057. 
 
5-(3,3-Dimethyl-1-butoxy)-1-pentanol (29):  
Compound 18 (2.36 mmol) was subjected to the general procedure B 
to provide 29 (0.2142 g, 1.14 mmol) in a yield of 48%, as an oil, after 
silica gel column chromatography purification. RF = 0.22 (20% EtOAc 
in PE). 1H NMR (400 MHz, CDCl3) δ 3.63 (t, J = 6.5 Hz, 2H, H2-1), 3.51 – 3.36 (m, 4H, H2-5, H2-2), 
1.60 (dq, J = 14.6, 6.6 Hz, 4H, H2-2, H2-4), 1.54 – 1.49 (m, 2H, H2-1), 1.48 – 1.37 (m, 2H, H2-3), 
0.92 (s, 9H, H3-9, H3-10, H3-11). 13C NMR (100 MHz, CDCl3) δ 70.9 (C-6), 68.2 (C-5), 62.6 (C-1), 
42.9 (C-1), 32.4 (C-2), 29.7 (C-9, C-10, C-11), 29.6 (C-8), 29.5 (C-4), 22.5 (C-3). IR/cm-1: 3345, 
2938, 2864, 1472, 1364, 1244, 1194, 1113, 1055. 
 
5-(Cyclopropylmethoxy)-1-pentanol (30):  
Compound 19 (2.49 mmol) was subjected to the general procedure B 
to provide 30 (0.19 g, 1.19 mmol) in a yield of 48%, as an oil, after 
silica gel column chromatography purification. RF = 0.27 (30% EtOAc in PE). 1H NMR (400 MHz, 
CDCl3) δ 3.63 (t, J = 6.5 Hz, 2H, H2-1), 3.45 (t, J = 6.6 Hz, 2H, H2-5), 3.25 (d, J = 6.9 Hz, 2H, H2-6), 
1.61 (m, 4H, H2-2, H2-4), 1.49 – 1.36 (m, 2H, H2-3), 1.12 – 0.98 (m, 1H, H-7), 0.59 – 0.47 (m, 4H, 
H2-8, H2-9). 13C NMR (100 MHz, CDCl3) δ 75.6 (C-6), 70.6 (C-5), 62.5 (C-1) 32.4 (C-2), 29.4 (C-4), 
22.4 (C-3), 10.6 (C-7), 3.0 (C-8, C-9). IR/cm-1: 3348, 2934, 2858, 1456, 1382, 1339, 1107, 1051. 
 
5-(Cyclobutylmethoxy)-1-pentanol (31):  
Compound 20 (1.91 mmol) was subjected to the general procedure B 
to provide 31 (0.18 g, 1.02 mmol) in a yield of 53%, as an oil, after 
silica gel column chromatography purification. RF = 0.41 (30% EtOAc in PE). 1H NMR (400 MHz, 
CDCl3) δ 3.61 (t, J = 6.6 Hz, 2H, H2-1), 3.42 (t, J = 6.5 Hz, 2H, H2-5), 3.27 (d, J = 7.2 Hz, 2H, H2-6), 
2.17 – 2.13 (m, 1H, H-7), 1.81 – 1.68 (m, 1H, H-8a), 1.64 – 1.50 (m, 7H, H2-2, H2-4, H2-10, H-8b), 
1.47 – 1.37 (m, 2H, H2-3), 1.26 – 1.15 (m, 2H, H2-9). 13C NMR (100 MHz, CDCl3) δ 75.6 (C-6), 70.9 
(C-5), 62.4 (C-1), 39.3 (C-7), 32.4 (C-2), 29.6 (C-8, C-10), 29.3 (C-4), 25.4 (C-9), 22.4 (C-3). 
IR/cm-1: 3360, 2933, 2858, 1456, 1364, 1113, 1057. 
 
5-(Cyclopentylmethoxy)-1-pentanol (32):  
Compound 21 (3.02 mmol) was subjected to the general procedure B 
to provide 32 (0.27 g, 1.43 mmol) in a yield of 47%, as an oil, after 
silica gel column chromatography purification. RF = 0.45 (30% EtOAc 
in PE). 1H NMR (400 MHz, CDCl3) δ 3.63 (t, J = 6.5 Hz, 2H, H2-1), 3.45 – 3.37 (m, 4H, H2-5, H2-6), 
2.56 (p, J = 7.5 Hz, 1H, H-7), 2.11 – 2.00 (m, 2H, H2-8), 1.97 – 1.79 (m, 2H, H2-11), 1.77 – 1.65 (m, 
2H, H2-9), 1.64 – 1.54 (m, 4H, H2-2, H2-4), 1.46 – 1.37 (m, 2H, H2-3). 13C NMR (100 MHz, CDCl3) δ 
75.7 (C-6), 70.9 (C-5), 62.6 (C-1), 35.1 (C-7), 32.4 (C-2), 29.7 (C-8, C-11)29.3 (C-4), 25.2 (C-9, C-
10), 22.4 (C-3). IR/cm-1: 3333, 2939, 2862, 1456, 1373, 1361, 1115, 1057. 
 
5-(R/S-Tetrahydrofuran-3-ylmethoxy)-1-pentanol (33):  
Compound 22 (3.56 mmol) was subjected to the general procedure 
B to provide 33 (0.48 g, 2.56 mmol) in a yield of 72%, as an oil, after 
silica gel column chromatography purification. RF = 0.33 (1:2, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 3.88 – 3.78 (m, 2H, H-8a,H-9a), 3.72 (dt, J = 8.4, 7.2 Hz, 
1H, H-8b), 3.65 – 3.52 (m, 3H, H2-1, H-9b), 3.47 – 3.27 (m, 4H, H2-5, H2-6), 2.58 – 2.45 (m, 1H, H-
7), 2.06 – 1.94 (m, 1H, H-10a), 1.66 – 1.51 (m, 5H, H2-2, H2-4, H-10b), 1.47 – 1.35 (m, 2H, H2-3). 





32.4 (C-2), 29.3 (C-4), 29.0 (C-10), 22.4 (C-3). IR/cm-1: 3385, 2934, 2858, 1456, 1375, 1211, 
1113, 1072, 1056. 
 
5-(R/S-Tetrahydrofuran-1-ylmethoxy)-1-pentanol (34):  
Compound 23 (2.46 mmol) was subjected to the general procedure B 
to provide 34 (0.35 g, 1.86 mmol) in a yield of 76%, as an oil, after 
silica gel column chromatography purification. RF = 0.28 (1:2, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 4.04 (ddd, J = 12.4, 6.9, 5.2 Hz, 1H, H-7), 3.87 (dt, J = 8.3, 
6.6 Hz, 1H, H-10a), 3.81 – 3.71 (m, 1H, H-10b), 3.61 (t, J = 6.5 Hz, 2H, H2-1), 3.48 (td, J = 6.6, 2.2 
Hz, 2H, H2-5), 3.44 – 3.39 (m, 2H, H2-6), 2.02 – 1.79 (m, 3H, H2-9, H-8a), 1.66 – 1.54 (m, 5H, H2-2, 
H2-4, H-8b), 1.48 – 1.36 (m, 2H, H2-3). 13C NMR (100 MHz, CDCl3) δ 77.8 (C-7), 73.4 (C-6), 71.4 
(C-5), 68.2 (C-10), 62.3 (C-1), 32.4 (C-2), 29.3 (C-4), 28.0 (C-9), 25.5 (C-8), 22.3 (C-3). IR/cm-1: 
3410, 2934, 2858, 1645, 1454, 1375, 1109, 1072, 1055. 
 
5-(Tetrahydro-2H-pyran-4-ylmethoxy)-1-pentanol (35): 
Compound 24 (1.78 mmol) was subjected to the general procedure 
B to provide 35 (0.14 g, 0.697 mmol) in a yield of 39%, as an oil, 
after silica gel column chromatography purification. RF = 0.31 (1:2, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 3.96 (m, 2H, H-9a, 10a), 3.60 (t, J = 6.6 Hz, 2H, H2-1), 
3.45 – 3.34 (m, 4H, H2-5, H-9b, H-10b), 3.25 (d, J = 6.6 Hz, 2H, H2-6), 1.83 (t, J = 3.4 Hz, 1H, H-7), 
1.70 – 1.51 (m, 6H, H2-2,H2-4, H-8a, H-11a), 1.46 – 1.36 (m, 2H, H2-3), 1.36 – 1.21 (m, 2H, H-8b, 
H-11b). 13C NMR (100 MHz, CDCl3) δ 75.9 (C-6), 71.0 (C-5), 67.6 (C-9, C-10), 62.3 (C-1), 35.3 (C-
7), 32.4 (C-2), 29.9 (C-8, C-11), 29.3 (C-4), 22.4 (C-3). IR/cm-1: 3445, 2931, 2851, 1437, 1364, 
1236, 1117, 1092, 1012. 
 
5-(Thiophen-3-methoxy)-1-pentanol (36): 
Compound 25 (2.13 mmol) was subjected to the general procedure B 
to provide 36 (0.23 g, 1.15 mmol) in a yield of 69%, as an oil, after 
silica gel column chromatography purification. RF = 0.27 (30% EtOAc 
in PE). 1H NMR (400 MHz, CDCl3) δ 7.28 (dd, J = 4.9, 3.0 Hz, 1H, H thio), 7.19 (ddt, J = 2.1, 1.5, 0.9 
Hz, 1H, H thio), 7.06 (dd, J = 4.9, 1.3 Hz, 1H, H thio), 4.49 (s, 2H, H2-6), 3.57 (t, J = 6.6 Hz, 2H, H2-
1), 3.46 (t, J = 6.5 Hz, 2H, H2-5), 1.66 – 1.57 (m, 2H, H2-4), 1.57 – 1.50 (m, 2H, H2-2), 1.45 – 1.36 
(m, 2H, H2-3). 13C NMR (100 MHz, CDCl3) δ 139.6 (Cq thio), 127.3 (CH thio), 125.9 (CH thio), 
122.7 (CH thio), 70.2 (C-5), 68.1 (C-6), 62.4 (C-1), 32.4 (C-2), 29.4 (C-4), 22.4 (C-3). 
 
5-(Thiophen-3-ethoxy)-1-pentanol (37): 
Compound 26 (1.65 mmol) was subjected to the general 
procedure B to provide 37 (0.3318 g, 1.55 mmol) in a 73% yield, 
as an oil, after silica gel column chromatography purification. RF = 
0.30 (30% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ 7.23 (dd, J = 4.9, 3.0 Hz, 1H, H thio), 7.01 
(dq, J = 3.0, 1.0 Hz, 1H, H thio), 6.97 (dd, J = 4.9, 1.3 Hz, 1H, H thio), 3.62 (m,4H, H2-6, H2-7), 3.45 
(t, J = 6.5 Hz, 2H, H2-5), 2.90 (td, J = 7.0, 0.8 Hz, 2H, H2-1), 1.65 – 1.52 (m, 4H, H2-2, H2-4), 1.45 – 
1.35 (m, 2H, H2-3). 13C NMR (100 MHz, CDCl3) δ 139.28 (Cq thio), 128.5 (CH thio), 125.2 (CH 
thio), 121.1 (CH thio), 71.0 (C-7), 70.9 (C-5), 62.6 (C-6), 32.4 (C-4), 30.7 (C-1), 29.4 (C-2), 22.4 
(C-3). IR/cm-1: 3360, 2934, 2860, 1456, 1418, 1348, 1250, 1225, 1155, 1094, 1053. 
 
1-Bromo-5-(2-methyl-1-propyloxy)pentane (38): 
Alcohol 27 (2.07 mmol) was subjected to the general procedure C to 
provide 38 (0.24 g, 1.08 mmol) in a yield of 52% after silica gel column 
chromatography purification. RF = 0.71 (100% toluene) 1H NMR (400 MHz, CDCl3) δ 3.41 (t, J = 
6.9 Hz, 2H, H2-5). 3.40 (t, J = 6.3 Hz, 2H, H2-1), 3.16 (d, J = 6.7 Hz, 2H, H2-6), 1.90 – 1.85 (m, 3H, 
H2-2, H-7), 1.65 – 1.56 (m, 2H, H2-4), 1.56 – 1.47 (m, 2H, H2-3), 0.92 (s, 3H, H3-8), 0.89(s, 3H, H3-




9). 13C NMR (100 MHz, CDCl3) δ 77.9 (C-6), 70.6 (C-5), 33.7 (C-1), 32.6 (C-2), 28.9 (C-4), 28.4 (C-
7), 25.0 (C-3), 19.4 (C-8, C-9).  IR/cm-1: 2940, 2863, 1473, 1363, 1332, 1100. 
 
1-Bromo-5-(3,3-dimethyl-2-butoxy)pentane (39):  
Alcohol 28 (1.11 mmol) was subjected to the general procedure C to 
provide 39 (0.25 g, 0.99 mmol) in a yield of 89% after silica gel column 
chromatography purification. RF = 0.71 (1:1, PE:toluene). 1H NMR (400 
MHz, CDCl3) δ 3.56 (dt, J = 9.5, 5.8 Hz, 1H, H-5a), 3.41 (t, J = 6.9 Hz, 2H, H2-1), 3.24 (dt, J = 9.5, 6.1 
Hz, 1H, H-5b), 2.94 (q, J = 6.3 Hz, 1H, H-6), 1.88 (p, J = 7.0 Hz, 2H, H2-2), 1.64 – 1.44 (m, 4H, H2-3, 
H2-4), 1.03 (d, J = 6.3 Hz, 3H, H3-7), 0.87 (s, 9H, H3-9, H3-10, H3-11). 13C NMR (100 MHz, CDCl3) δ 
83.3 (C-6), 69.3 (C-5), 35.1 (C-8), 33.8 (C-1), 32.7 (C-2), 29.3 (C-4), 26.0 (C-9, C-10, C-11), 25.1 
(C-3), 13.9 (C-7). IR/cm-1: 2938, 2866, 1477, 1369, 1335, 1099. 
 
1-Bromo-5-(3,3-dimethyl-1-butoxy)pentane (40):  
Alcohol 29 (1.14 mmol) was subjected to the general procedure C to 
provide 40 (0.14 g, 0.54 mmol) in a yield of 48% after silica gel 
column chromatography purification. RF = 0.71 (100% toluene). 1H 
NMR (400 MHz, CDCl3) δ 3.50 – 3.38 (m, 6H, H2-1, H2-5, H2-6), 1.96 – 1.84 (m, 2H, H2-7), 1.67 – 
1.56 (m, 2H, H2-2), 1.59 – 1.40 (m, 4H, H2-3, H2-4), 0.93 (s, 9H, H3-9, H3-10, H3-11). 13C NMR 
(100 MHz, CDCl3) δ 70.6 (C-6), 68.2 (C-5), 43.0 (C-7), 33.7 (C-1), 32.7 (C-2), 29.8 (C-9, C-10, C-
11), 29.6 (C-8), 29.0 (C-4), 25.0 (C-3). IR/cm-1: 2951, 2862, 1734, 1486, 1364, 1111. 
 
1-Bromo-5-(cyclopropylmethoxy)pentane (41):  
Alcohol 30 (1.19 mmol) was subjected to the general procedure C to 
provide 41 (0.12 g, 0.54 mmol) in a yield of 46% after silica gel column 
chromatography purification. RF = 0.52 (100% toluene). 1H NMR (400 MHz, CDCl3) δ 3.44 (t, J = 
6.4 Hz, 2H, H2-5), 3.42 (t, J = 6.8 Hz, 2H, H2-1), 3.25 (d, J = 6.9 Hz, 2H, H2-6), 1.89 (dt, J = 14.8, 7.0 
Hz, 2H, H2-2), 1.67 – 1.56 (m, 2H, H2-4), 1.58 – 1.47 (m, 2H, H2-3), 1.13 – 0.98 (m, 1H, H-7), 0.58 
– 0.49 (m, 2H, H2-8), 0.20 (dt, J = 6.1, 4.5 Hz, 2H, H2-9). 13C NMR (100 MHz, CDCl3) δ 75.6 (C-6), 
70.3 (C-5), 33.8 (C-1), 32.6 (C-2), 28.9 (C-4), 24.9 (C-3), 10.6 (C-7), 3.0 (C-8, C-9). IR/cm-1: 2934, 
2857, 1732, 1456, 1381, 1337, 1250, 1107, 1016. 
 
1-Bromo-5-(cyclobutylmethoxy)pentane (42): 
Alcohol 31 (1.02 mmol) was subjected to the general procedure C to 
provide 42 (0.1276 g, 0.54 mmol) in a yield of 53% after silica gel 
column chromatography purification. RF = 0.67 (100% toluene). 1H 
NMR (400 MHz, CDCl3) δ 3.41, (t, J = 6.7 Hz, 2H, H2-5), 3.41 (t, J = 6.9 Hz, 2H, H2-1), 3.38 (d, J = 
6.8 Hz, 2H, H2-6), 2.60 – 2.54 (m, 1H, H-7), 2.14 – 2.01 (m, 2H, H2-8), 1.97 – 1.81 (m, 4H, H2-2, 
H2-10), 1.80 – 1.67 (m, 2H, H2-9), 1.66 – 1.56 (m, 2H, H2-4), 1.56 – 1.45 (m, 2H, H2-3). 13C NMR 
(100 MHz, CDCl3) δ 75.6 (C-6), 70.7 (C-5), 35.2 (C-7), 33.8 (C-1), 32.6 (C-2), 28.9 (C-4), 25.2 (C-
8, C-10), 24.9 (C-3), 18.6 (C-9). IR/cm-1: 2932, 2855, 1732, 1456, 1364, 1246, 1111. 
 
1-Bromo-5-(cyclopentylmethoxy)pentane (43):  
Alcohol 32 (1.43 mmol) was subjected to the general procedure C to 
provide 43 (0.25 g, 1.01 mmol) in a yield of 71% after silica gel 
column chromatography purification. RF = 0.71 (100% toluene). 1H 
NMR (400 MHz, CDCl3) δ 3.43 (dd, J = 6.7, 6.0 Hz, 2H, H2-5), 3.43 (t, J = 6.8 Hz, 1H, H2-1), 3.27 (d, 
J = 7.1 Hz, 2H, H2-6), 2.17 – 2.11 (m, 1H, H-7), 1.89 (dt, J = 14.1, 7.0 Hz, 2H, H2-2), 1.79 – 1.66 (m, 
2H, H2-8), 1.64 – 1.45 (m, 8H, H2-3, H2-4, H2-11, H2-9), 1.29 – 1.16 (m, 2H, H2-10). 13C NMR (100 
MHz, CDCl3) δ 75.6 (C-6), 70.6 (C-5), 39.5 (C-7), 33.8 (C-1), 32.6 (C-2), 29.6 (C-8, C-11), 28.9 (C-






1-Bromo-5-(R/S-tetrahydrofuran-3-ylmethoxy)pentane (44):  
Alcohol 33 (1.86 mmol) was subjected to the general procedure C to 
provide 44 (0.58 g, 2.32 mmol) in a yield of 91% after silica gel 
column chromatography purification. RF = 0.33 (5% EtOAc in PE). 1H 
NMR (400 MHz, CDCl3) δ 3.87 – 3.78 (m, 2H, H-8a, H-9a), 3.78 – 3.66 (m, 1H, H-8b), 3.56 (dd, J = 
8.7, 5.4 Hz, 1H, H-9b), 3.46 – 3.25 (m, 6H, H2-1, H2-5, H2-6), 2.54 – 2.48 (m, 1H, H-7), 2.06 – 1.94 
(m, 1H, H-10a), 1.92 – 1.83 (m, 2H, H2-2), 1.65 – 1.54 (m, 3H, H2-4, H-10b), 1.54 – 1.45 (m, 2H, 
H2-3). 13C NMR (100 MHz, CDCl3) δ 73.0 (C-6), 71.0 (C-9), 70.8 (C-5), 67.7 (C-8), 39.2 (C-7), 33.7 
(C-1), 32.6 (C-2), 29.1 (C-10), 28.8 (C-4), 24.9 (C-3). IR/cm-1: 2934, 2857, 1486, 1111, 1076. 
 
1-Bromo-5-(R/S-tetrahydrofuran-1-ylmethoxy)pentane (45):  
Alcohol 34 (1.86 mmol) was subjected to the general procedure C to 
provide 45 (0.33 g, 1.30 mmol) in a yield of 70% after silica gel 
column chromatography purification. RF = 0.33 (5% EtOAc in PE). 1H 
NMR (400 MHz, CDCl3) δ 4.04 (m, 1H, H-7), 3.88 (m, 1H, H-10a), 3.75 (m, 1H, H-10b), 3.49 (m, 
2H, H2-5), 3.47-3.39 (m, 4H, H2-1, H2-6), 1.99 – 1.83 (m, 5H, H2-2. H-8a , H2-9), 1.66-1.62 (m, 3H, 
H-8b, H2-4), 1.61-1.53 (m, 2H, H2-3). 13C NMR (400 MHz, CDCl3) δ 77.9 (C-7), 73.6 (C-6), 71.2 (C-
5), 68.3 (C-10), 33.8 (C-1), 32.6 (C-2), 28.8 (C-4), 28.1 (C-8), 25.6 (C-9), 24.9 (C-3). IR/cm-1: 
2938, 2860, 1456, 1437, 1117, 1070. 
 
1-Bromo-5-(tetrahydro-2H-pyran-4-ylmethoxy)pentane (46):  
Alcohol 35 (0.31 mmol) was subjected to the general procedure C to 
provide 46 (0.061 g, 0.23 mmol) in a 33% yield after silica gel 
column chromatography purification. RF = 0.35 (5% EtOAc in PE). 
1H NMR (400 MHz, CDCl3) δ 4.00 – 3.94 (m, 2H, H-9a, H-10a), 3.45 – 3.35 (m, 6H, H2-1, H2-5, H-
9b, H-10b), 3.25 (d, J = 6.6 Hz, 2H, H2-6), 1.93 – 1.77 (m, 3H, H2-2, H-7), 1.68 – 1.55 (m, 4H, H2-4, 
H-8a, H-11a), 1.55 – 1.46 (m, 2H, H2-3), 1.42 – 1.19 (m, 2H, H-8b, H-11b). 13C NMR (100 MHz, 
CDCl3) δ 76.0 (C-6), 70.8 (C-5), 67.8 (C-9, C-10), 35.5 (C-7), 33.8 (C-1), 32.6 (C-2), 30.0 (C-8, C-
11), 28.9 (C-4), 24.9 (C-3). IR/cm-1: 2924, 2845, 1734, 1384, 1115, 1092. 
 
1-Bromo-5-(thiophen-3-methoxy)pentane (47):  
Alcohol 36 (1.15 mmol) was subjected to the general procedure C to 
provide 47 (0.19 g, 0.74 mmol) in a yield of 45% after silica gel 
column chromatography purification. RF = 0.67 (100% toluene). 1H 
NMR (400 MHz, CDCl3) δ 7.33 (dd, J = 5.0, 3.0 Hz, 1H, H thio), 7.23 (dd, J = 2.9, 1.2 Hz, 1H, H 
thio), 7.10 (dd, J = 5.0, 1.2 Hz, 1H, H thio), 4.56 – 4.51 (s, 2H, H2-6), 3.50 (t, J = 6.3 Hz, 2H, H2-5), 
3.44 (t, J = 6.8 Hz, 2H, H2-1), 1.90 (p, J = 7.0 Hz, 2H, H2-2), 1.72 – 1.59 (m, 2H, H2-4), 1.62 – 1.48 
(m, 2H, H2-3). 13C NMR (100 MHz, CDCl3) δ 139.7 (Cq thio), 127.3 (CH thio), 126.0 (CH thio), 
122.6 (CH thio), 70.0 (C-6), 68.2 (C-5), 33.8 (C-1), 32.6 (C-2), 28.9 (C-4), 25.0 (C-3). IR/cm-1:  
3000, 2934, 2857, 1732, 1153, 1096. 
 
1-Bromo-5-(thiophen-3-ethoxy)pentane (48):  
Alcohol 37 (1.55 mmol) was subjected to the general procedure C 
to provide 48 (0.28 g, 0.99 mmol) in a yield of 46% after silica gel 
column chromatography purification. RF = 0.67 (100% toluene). 
1H NMR (400 MHz, CDCl3) δ 7.25 – 7.21 (m, 1H, H thio), 7.02 – 6.98 (m, 1H, H thio), 6.97 (dd, J = 
4.9, 1.3 Hz, 1H, H thio), 3.62 (t, J = 7.0 Hz, 2H, H2-6), 3.44 (t, J = 6.3 Hz, 2H, H2-5), 3.39 (t, J = 6.8 
Hz, 2H, H2-1), 2.90 (td, J = 7.0, 0.8 Hz, 2H, H2-7), 1.92 – 1.79 (m, 2H, H2-2), 1.64 – 1.54 (m, 2H, H2-
4), 1.53 – 1.44 (m, 2H, H2-3). 13C NMR (100 MHz, CDCl3) δ 139.4 (Cq thio), 128.5 (CH thio), 125.2 
(CH thio), 121.1 (CH thio), 71.1 (C-6), 70.6 (C-5), 33.9 (C-1), 32.6 (C-2), 30.8 (C-7), 28.9 (C-4), 
25.0 (C-3). IR/cm-1: 3102, 2934, 2857, 1734, 1109. 
 




1-Bromo-5-(2,2-dimethyl-1-propoxy) pentane (66): 
68 (2.72 g, 11.46 mmol) was synthesized from corresponding alcohol 
(2.70 g, 15.49 mmol) according to the general procedure C in a yield of 
74%.  1H NMR (400 MHz, CDCl3) δ 3.42 (t, J = 6.8 Hz, 2H, H2-1), 3.41 (t, J = 6.2 Hz, 2H, H2-5), 3.04 
(s, 2H, H2-6), 1.91 – 1.87 (m, 2H, H2-2), 1.67 – 1.42 (m, 4H, H2-4, H2-3), 0.90 (s, 9H, H3-8, H3-9, 
H3-10). 13C NMR (100 MHz, CDCl3) δ 81.6 (C-6), 71.3 (C-5), 34.1 (C-1), 32.8 (C-2), 28.9 (C-5), 
26.9 (C-8, C-9, C-10), 25.1 (C-3). IR/cm-1: 2941, 2863, 1473, 1363, 1331, 1102. 
 
Synthesis of the alkylated iminosugars 
Figure 8: Proton and carbon NMR numbering of iminosugars (4, 5, 49 - 65) 
 
N-[5-(3,3-Dimethyl-1-propyloxy)pentyl]-1-deoxynojirimycin (4): 
Bromide 66 (0.30 mmol) was subjected to the general procedure 
D with 1-deoxynojirimycin (0.20 mmol) to provide 4 (30 mg, 
0.094 mmol, yield 77%). 1H NMR (400 MHz, MeOD) δ 4.01 (dd, J 
= 12.3, 2.0 Hz, 1H, H-6a), 3.89 (dd, J = 12.3, 3.0 Hz, 1H, H-6b), 
3.62 (ddd, J = 10.8, 9.2, 4.9 Hz, 1H, H-2), 3.52 (t, J = 9.6 Hz, 1H, H-
4), 3.44 (t, J = 6.2 Hz, 2H, H2-5’), 3.32 – 3.24 (m, 2H, H-3, H-1a), 
3.17 (td, J = 12.1, 11.5, 5.5 Hz, 1H, H-1’a), 3.08 (s, 2H, H2-6’), 3.00 (td, J = 12.7, 12.0, 5.4 Hz, 1H, 
H-1’b), 2.78 – 2.70 (m, 1H, H-1b), 2.72 (t, J = 11.4 Hz, 1H, H-5), 1.69  – 1.65 (m, 4H, H2-2’, H2-4’), 
1.44 (ddd, J = 17.2, 9.0, 5.9 Hz, 2H, H2-3’), 0.91 (s, 9H, H3-8’, H3-9’, H3-10’). 13C NMR (100 MHz, 
CDCl3) δ 82.5 (C-6’), 79.0 (C-3), 72.1 (C-5’), 69.9 (C-4), 68.8 (C-2), 67.4 (C-5), 56.5 (C-6), 55.7 (C-
1), 54.0 (C-1’), 32.9 (C-7’), 30.4 (C-4’), 27.1 (C-8’, C-9’, C-10’), 24.8 (C-3’), 24.4 (C-2’).  IR/cm−1: 




Bromide 38 (0.30 mmol) was subjected to the general procedure 
D with 1-deoxynojirimycin (0.20 mmol) to provide 49 (28 mg, 
0.092 mmol, yield 46%). 1H NMR (400 MHz, MeOD) δ 4.07 (d, J = 
12.4 Hz, 1H, H-6a), 3.93 (dd, J = 12.5, 2.9 Hz, 1H, H-6b), 3.67 (td, J 
= 10.1, 4.5 Hz, 1H, H-2), 3.58 (t, J = 9.6 Hz, 1H, H-4), 3.47 (t, J = 6.3 
Hz, 2H, H2-5’), 3.43 – 3.24 (m, 3H, H-1a, H-3, H-1’a), 3.22 (d, J = 
6.6 Hz, 2H, H2-6’), 3.10 (br s, 1H, H-1’b), 2.92 – 2.74 (m, 2H, H-5, H-1b), 1.89 – 1.81 (m, 1H, H-7’), 
1.80 – 1.72 (m, 2H, H2-2’), 1.71 – 1.62 (m, 2H, H2-4’), 1.54 – 1.41 (m, 2H, H2-3’), 0.93 (d, J = 6.7 
Hz, 6H, H3-8’, H3-9’). 13C NMR (100 MHz, MeOD) δ 77.6 (C-6’), 77.2 (C-3), 70.2 (C-5’), 68.1 (C-4), 
67.0 (C-2), 66.1 (C-5), 55.5 (C-6), 54.0 (C-1), 52.6 (C-1’), 28.9 (C-4’), 28.2 (C-7’), 23.3 (C-3’), 22.9 
(C-2’), 18.3 (C-8’, C-9’). [α]20D = -7.17 (c = 0.56, MeOH). IR/cm-1: 3333, 2871, 1670, 1432, 1383, 
1201, 1131, 1031. HRMS: found 306.22757 [C15H31NO5+H]+, calculated for [C15H31NO5+H]+ 
306.22750. 
 
 N-[5-(3,3-Dimethyl-2-butoxy)pentyl]-1-deoxynojirimycin  (50): 
Bromide 39 (0.32 mmol) was subjected to the general procedure D with 1-deoxynojirimycin 
(0.20 mmol) to provide 50 (31 mg, 0.094 mmol, yield 47%). 1H NMR (400 MHz, MeOD) δ 4.14 





3.68 – 3.58 (m, 3H, H-3, H-4, H-5’a), 3.48 (dd, J = 12.0, 4.9 Hz, 
1H, H-1a), 3.43 – 3.35 (m, 3H, H-1’a, H-3, H-5’b), 3.22 (td, J = 
12.2, 5.1 Hz, 1H, H-1’b), 3.07 (br d, J = 9.8 Hz, 1H, H-5), 3.03 (d, 
J = 6.3 Hz, 1H, H-6’), 3.01 (dd, J = 12.5, 10.9 Hz, 1H, H-1b), 1.81 
(dt, J = 11.1, 5.7 Hz, 2H, H2-2’), 1.65 (dt, J = 8.8, 5.8 Hz, 2H, H2-
4’), 1.57 – 1.44 (m, 2H, H2-3’), 1.07 (d, J = 6.3 Hz, 3H, H3-7’), 
0.90 (s, 9H, H3-9’, H3-10’, H3-11’). 13C NMR (100 MHz, MeOD) δ 83.3 (C-6’), 76.7 (C-3), 68.9 (C-
5’), 67.4 (C-4), 66.4 (C-2), 66.0 (C-5), 53.5 (C-6), 53.5 (C-1), 52.9 (C-1’), 34.6 (C-8’), 29.3 (C-4’), 
25.0 (C-9’, C-10’, C-11’), 23.2 (C-3’), 22.6 (C-2’), 12.8 (C-7’). [α]20D = -6.94 (c = 0.63, MeOH). 
IR/cm-1: 3330, 2956, 2875, 1672, 1439, 1203, 1134, 1029. HRMS: found 334.25885 
[C17H35NO5+H]+, calculated for [C17H35NO5+H]+ 334.25880. 
 
N-[5-(3,3-Dimethyl-1-butoxy)pentyl]-1-deoxynojirimycin (51):  
Bromide 40 (0.299 mmol) was subjected to the general 
procedure D with 1-deoxynojirimycin (0.20 mmol) to provide 
51 (28 mg, 0.085 mmol, yield 43%). 1H NMR (400 MHz, MeOD) 
δ 4.12 (d, J = 12.5 Hz, 1H, H-6a), 3.93 (dd, J = 12.3, 2.8 Hz, 1H, 
H-6b), 3.71 (td, J = 10.4, 10.0, 4.4 Hz, 1H, H-2), 3.62 (t, J = 9.7 
Hz, 1H, H-4), 3.50 (t, J = 7.3 Hz, 2H, H2-6’), 3.50 (dd, J = 9.0, 1.5 
Hz, 1H, H-1a), 3.46 (t, J = 6.3 Hz, 2H, H2-5’), 3.43 – 3.36 (m, 2H, H-3, H-1’a ), 3.22 (td, J = 12.1, 5.2 
Hz, 1H, H-1b), 3.07 (br d, J = 10.3 Hz, 1H, H-5), 3.00 (t, J = 11.7 Hz, 1H, H-1b), 1.90 – 1.71 (m, 2H, 
H2-2’), 1.65 (ddd, J = 13.7, 7.5, 6.0 Hz, 2H, H2-4’), 1.51 (t, J = 7.4 Hz, 2H, H2-7’), 1.53 – 1.43 (m, 2H, 
H2-3’), 0.94 (s, 9H, H3-9’, H3-10’, H3-11’). 13C NMR (100 MHz, MeOD) δ 76.7 (C-3), 70.0 (C-5’), 
67.9 (C-6’), 67.4 (C-4), 66.4 (C-2), 66.0 (C-5), 53.4 (C-6), 53.3 (C-1), 52.9 (C-1’), 42.6 (C-7’), 29.7 
(C-4), 28.7 (C-9’, C-10’, C-11’), 25.8 (C-3), 25.0 (C-2), 22.6 (C-8’). [α]20D = +0.56 (c = 0.57, MeOH). 
IR/cm-1: 3343, 2954, 2870, 1673, 1433, 1203, 1134. HRMS: found 334.25886 [C17H35NO5+H]+, 
calculated for [C17H35NO5+H]+ 334.25880. 
 
N-[5-(Cyclopropylmethoxy)pentyl]-1-deoxynojirimycin (52): 
Bromide 41 (0.30 mmol) was subjected to the general 
procedure D with 1-deoxynojirimycin (0.20 mmol) to provide 
52 (30 mg, 0.097 mmol, yield 49%). 1H NMR (400 MHz, MeOD) 
δ 4.13 (d, J = 12.6 Hz, 1H, H-6a), 3.94 (dd, J = 12.7, 3.1 Hz, 1H, H-
6b), 3.73 (td, J = 10.3, 4.7 Hz, 1H, H-2), 3.64 (t, J = 9.8 Hz, 1H, H-
4), 3.52 (t, J = 6.3 Hz, 2H, H2-5’), 3.51 – 3.46 (m, 1H, H-1a), 3.40 
(t, J = 9.2 Hz, 1H, H-3), 3.40 – 3.36 (m, 1H, H-1’a), 3.30 (d, J = 6.9 Hz, 2H, H2-6’), 3.23 (td, J = 12.3, 
5.3 Hz, 1H, H-1’b), 3.08 (br d, J = 10.1 Hz, 1H, H-5), 3.01 (t, J = 11.7 Hz, 1H, H-1b), 1.91 – 1.73 (m, 
2H, H2-2’), 1.72 – 1.63 (m, 2H, H2-4’), 1.55 – 1.45 (m, 2H, H2-3’), 1.10 – 1.00 (m, 1H, H-7’), 0.57 – 
0.51 (m, 2H, H2-8’), 0.22 (dt, J = 6.1, 4.4 Hz, 2H, H2-9’). 13C NMR (100 MHz, MeOD) δ 76.7 (C-3), 
75.3 (C-6’), 69.8 (C-5’), 67.4 (C-4), 66.4 (C-2), 66.0 (C-5), 53.6 (C-6), 53.4 (C-1), 52.9 (C-1’), 28.7 
(C-4’), 23.1 (C-3’), 22.5 (C-2’), 10.0 (C-7’), 2.1 (C-8’, C-9’). [α]20D = -6.08 (c = 0.59, MeOH). IR/cm-
1: 3346, 2866, 1672, 1430, 1202, 1134, 1032. HRMS: found 304.21194 [C15H29NO5+H]+, 
calculated for [C15H29NO5+H]+ 304.21185. 
 
N-[5-(Cyclobutylmethoxy)pentyl]-1-deoxynojirimycin (53):    
Bromide 42 (0.31 mmol) was subjected to the general 
procedure D with 1-deoxynojirimycin (0.20 mmol) to provide 
53 (25 mg, 0.079 mmol, yield 39%). 1H NMR (400 MHz, MeOD) 
δ 4.14 (d, J = 12.5 Hz, 1H, H-6a), 3.93 (dd, J = 12.7, 3.1 Hz, 1H, H-
6b), 3.71 (td, J = 10.7, 10.2, 4.7 Hz, 1H, H-2), 3.63 (t, J = 9.8 Hz, 
1H, H-4), 3.49 (t, J = 6.2 Hz, 2H, H2-5’), 3.48 (dd, J = 11.8, 5.2 Hz, 
1H, H-1a), 3.43 (d, J = 6.8 Hz, 2H, H2-6’), 3.43 – 3.36 (m, 1H, H-1’a), 3.39 (t, J = 9.4 Hz, 1H, H-3), 




3.22 (td, J = 12.3, 5.3 Hz, 1H, H-1’b), 3.06 (br d, J = 11.2 Hz, 1H, H-5), 3.01 (t, J = 11.7 Hz, 1H, H-
1b), 2.63 – 2.53 (m, 1H, H-7’), 2.14 – 2.03 (m, 2H, H2-8’), 2.03 – 1.91 (m, 2H, H2-10’), 1.91 – 1.72 
(m, 4H, H2-2’, H2-9’), 1.67 (ddd, J = 13.7, 7.5, 5.9 Hz, 2H, H2-4’), 1.51 – 1.47 (m, 2H, H2-3’). 13C 
NMR (100 MHz, MeOD) δ 76.7 (C-3), 75.2 (C-6’), 70.2 (C-5’), 67.4 (C-4), 66.4 (C-2), 66.0 (C-5), 
53.5 (C-6), 53.4 (C-1), 52.9 (C-1’), 35.1 (C-7’), 28.7 (C-4’), 24.6 (C-8’, C-9’), 23.1 (C-3’), 22.5 (C-
2’), 18.0 (C-10’). [α]20D = -6.02 (c = 0.50, MeOH). IR/cm-1: 3341, 2938, 2865, 1673, 1431, 1202, 




Bromide 43 (0.30 mmol) was subjected to the general 
procedure D with 1-deoxynojirimycin (0.20 mmol) to provide 
54 (23 mg, 0.069 mmol, yield 35%). 1H NMR (400 MHz, MeOD) 
δ 4.13 (d, J = 12.5 Hz, 1H, H-6a), 3.93 (dd, J = 12.6, 3.1 Hz, 1H, 
H-6b), 3.72 (dt, J = 14.7, 4.6 Hz, 1H, H-2), 3.63 (t, J = 9.7 Hz, 1H, 
H-4), 3.52 – 3.44 (m, 1H, H-1a), 3.49 (t, J = 6.2 Hz, 2H, H2-5’), 
3.43 – 3.35 (m, 2H, H-3, H-1’a), 3.33 (d, J = 7.1 Hz, 2H, H2-6’), 3.22 (td, J = 12.3, 5.3 Hz, 1H, H-1’b), 
3.07 (d, J = 9.5 Hz, 1H, H-5), 3.00 (t, J = 11.7 Hz, 1H, H-1b), 2.21 – 2.12 (m, 1H, H-7’), 1.88 – 1.71 
(m, 4H, H2-2’, H2-8’), 1.71 – 1.54 (m, 6H, H2-9’, H2-10’, H2-4’), 1.51 – 1.48 (m, 2H, H2-3’), 1.35 – 
1.22 (m, 2H, H2-11’). 13C NMR (100 MHz, MeOD) δ 76.7 (C-3), 75.3 (C-6’), 70.1 (C-5’), 67.4 (C-4), 
66.4 (C-2), 66.0 (C-5), 53.5 (C-6), 53.5 (C-1), 52.8 (C-1’), 39.3 (C-7’), 29.2 (C-8’, C-11’), 28.7 (C-9’, 
C-10’), 25.0 (C-4’), 23.1 (C-3’), 22.7 (C-2’). [α]20D = -4.76 (c = 0.46, MeOH). IR/cm-1: 3346, 2950, 
2867, 1673, 1433, 1203, 1133, 1032. HRMS: found 332.24323 [C17H33NO5+H]+, calculated for 
[C17H33NO5+H]+ 332.24315.  
 
N-[5-(R/S-Tetrahydrofuran-3-ylmethoxy)pentyl]-1-deoxynojirimycin (55): 
Bromide 44 (0.29 mmol) was subjected to the general 
procedure D with 1-deoxynojirimycin (0.20 mmol) to provide 
55 (58.5 mg, 0.17 mmol, yield 88%). 1H NMR (400 MHz, 
MeOD) δ 4.14 (d, J = 12.6 Hz, 1H, H-6a), 3.93 (dd, J = 12.4, 3.0 
Hz, 1H, H-6b), 3.85 (dd, J = 8.3, 5.5 Hz, 1H, H-9’a), 3.83 (dd, J = 
8.7, 7.2 Hz, 1H, H-10’a), 3.78 – 3.69 (m, 2H, H-9’b, H-2), 3.63 (t, 
J = 9.8 Hz, 1H, H-4), 3.58 (dd, J = 8.6, 5.5 Hz, 2H, H2-10’b), 3.52 – 3.47 (m,1H, H-1a), 3.50 (td, J = 
6.3, 1.7 Hz, 2H, H2-5’), 3.44 (dd, J = 9.2, 6.3 Hz, 1H, H-6’a), 3.43 – 3.35 (m, 3H, H-1’a, H-3, H-6’b), 
3.20 – 3.18 (m, 1H, H-1’b), 3.07 (br d, J = 9.9 Hz, 1H, H-5), 3.01 (t, J = 11.7 Hz, 1H, H-1b), 2.59 – 
2.48 (m, 1H, H-7’), 2.02 – 1.98 (m, 1H, H-8’a), 1.91 – 1.72 (m, 2H, H2-2’), 1.72 – 1.60 (m, 3H, H-
8’b, H2-4’), 1.53 – 1.47 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 76.7 (C-3), 72.5 (C-6’), 70.5 
(C-10’), 70.3 (C-5’), 67.4 (C-4), 67.3 (C-9’), 66.4 (C-2), 66.0 (C-5), 53.5 (C-6), 53.5 (C-1), 52.9 (C-
1’), 39.0 (C-7’), 28.7 (C-4’), 28.5 (C-8’), 23.1 (C-3’), 22.5 (C-2’). IR/cm-1: 3346, 2970, 2942, 1738, 
1070, 1430, 1366, 1199, 1132, 898. [α]20D = -1.89 (c = 1.17, MeOH). HRMS: found 334.22282 
[C16H31NO6+H]+, calculated for [C16H31NO6+H]+ 334.22241. 
 
N-[5-(R/S-Tetrahydrofuran-1-ylmethoxy)pentyl]-1-deoxynojirimycin (56): 
Bromide 45 (0.29 mmol) was subjected to the general 
procedure D with 1-deoxynojirimycin (0.20 mmol) to provide 
56 (10 mg, 0.030 mmol, yield 15%). 1H NMR (600 MHz, MeOD) 
δ 4.12 (d, J = 11.5 Hz, 1H, H-6a), 4.07 – 4.01 (m, 1H, H-7’), 3.91 
(dd, J = 12.5, 3.2 Hz, 1H, H-6b), 3.85 (dt, J = 8.2, 6.7 Hz, 1H, H-
10’a), 3.76 (td, J = 7.7, 6.1 Hz, 1H, H-10’b), 3.69 – 3.67 (m, 1H, 
H-2), 3.60 (dd, J = 12.7, 6.6 Hz, 1H, H-4), 3.51 (td, J = 6.2, 3.8 Hz, 1H, H-5’), 3.47 – 3.34 (m, 5H, 
H2-6’, H-1a, H-1’a, H-3), 3.20 (td, J = 12.4, 5.0 Hz, 1H, H-1b), 3.04 (d, J = 9.9 Hz, 1H, H-5), 2.99 (t, J 





H2-2’), 1.66 (tt, J = 7.5, 5.9 Hz, 2H, H2-4’), 1.63 – 1.57 (m, 1H, H-8’b), 1.54 – 1.43 (m, 2H, H2-3’). 
13C NMR (150 MHz, MeOD) δ 79.4 (C-7’), 78.2 (C-3), 74.6 (C-6’), 72.0 (C-5’), 69.2 (C-10’), 68.8 
(C-5), 67.8 (C-4), 67.4 (C-2), 54.9 (C-1), 54.8 (C-6), 54.3 (C-1’), 29.9 (C-4’), 28.9 (C-8’), 26.6 (C-
9’), 24.5 (C-3’), 23.9 (C-2’). IR/cm-1: 3367, 2964, 2902, 1674, 1396, 1066. [α]20D = -9.8 (c = 0.20, 
MeOH). HRMS: found 334.22266 [C16H31NO6+H]+, calculated for [C16H31NO6+H]+ 334.22241. 
 
N-[5-(Tetrahydro-2H-pyran-4-ylmethoxy)pentyl]-1-deoxynojirimycin (57): 
Bromide 46 (0.29 mmol) was subjected to the general 
procedure D with 1-deoxynojirimycin (0.20 mmol) to provide 
57 (35 mg, 0.10 mmol, yield 50%). 1H NMR (400 MHz, MeOD) 
δ 4.14 (d, J = 12.5 Hz, 1H, H-6a), 3.92 (dd, J = 11.8, 2.6 Hz, 1H, 
H-6b), 3.99 – 3.94 (m, 2H, H-9’a, H-10’a), 3.70 (ddd, J = 11.2, 
9.3, 4.9 Hz, 1H, H-2), 3.62 (dd, J = 10.4, 9.2 Hz, 1H, H-4), 3.49 
(t, J = 6.2 Hz, 2H, H2-5’), 3.48 – 3.35 (m, 5H, H-9’b, H-10’b, H-1a, H-1’a, H-3), 3.31 (d, J = 6.4 Hz, 
2H, H2-6’), 3.23 (dd, J = 12.1, 5.3 Hz, 1H, H-1’b), 3.06 (dd, J = 10.3, 2.7 Hz, 1H, H-5), 3.01(t, J = 
11.7 Hz, 1H, H-1b), 1.92 – 1.84 (m, 1H, H-7’), 1.84 – 1.72 (m, 2H, H2-2’), 1.72 – 1.62 (m, 4H, H2-4’, 
H-8’a, H-11’a), 1.57 – 1.45 (m, 2H, H2-3’), 1.34 – 1.32 (m, 2H, H-8’b, H-11’b). 13C NMR (100 MHz, 
MeOD) δ 76.8 (C-3), 75.5 (C-6’), 70.2 (C-5’), 67.3 (C-9’, C-10’), 67.3 (C-4), 66.4 (C-2), 66.0 (C-5), 
53.5 (C-6), 53.4 (C-1), 52.8 (C-1’), 35.2 (C-7’), 29.6 (C-8’, C-11’), 28.7 (C-4’), 23.1 (C-3’), 22.5 (C-
2’). [α]20D = -4.01 (c = 0.70, MeOH). IR/cm-1: 3333, 2923, 2859, 1671, 1433, 1387, 1200, 1136, 
1088, 1032. HRMS: found 348.23809 [C17H33NO6+H]+, calculated for [C17H33NO6+H]+ 
348.23806. 
 
N-[5-(Thiophen-3-methoxy)pentyl]-1-deoxynojirimycin  (58): 
Bromide 47 (0.29 mmol) was subjected to the general 
procedure D with 1-deoxynojirimycin (0.20 mmol) to provide 
58 (41 mg, 0.12 mmol, yield 59%). 1H NMR (400 MHz, MeOD) 
δ 7.41 (dd, J = 5.0, 3.0 Hz, 1H, H thio), 7.34 – 7.31 (m, 1H, H 
thio), 7.10 (dd, J = 5.0, 1.2 Hz, 1H, H thio), 4.54 (s, 2H, H2-6’), 
4.12 (d, J = 12.2 Hz, 1H, H-6a), 3.92 (dd, J = 12.7, 3.1 Hz, 1H, H-
6b), 3.71 (td, J = 10.1, 4.5 Hz, 1H, H-2), 3.62 (t, J = 9.8 Hz, 1H, H-4), 3.54 (t, J = 6.2 Hz, 2H, H2-5’), 
3.46 (dd, J = 12.1, 4.8 Hz, 1H, H-1a), 3.43 – 3.36 (m, 2H, H-1’a, H-3), 3.21 (td, J = 12.3, 5.2 Hz, 1H, 
H-1’b), 3.11 – 3.02 (m, 1H, H-5), 2.99 (t, J = 11.7 Hz, 1H, H-1b), 1.89 – 1.74 (m, 2H, H2-2’), 1.69 
(ddd, J = 13.6, 7.5, 6.0 Hz, 2H, H2-4’), 1.53 – 1.45 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 
139.5, 127.1, 125.6, 122.6 (C-thio), 76.7 (C-3), 69.3 (C-5’), 67.6 (C-6’), 67.4 (C-4), 66.4 (C-2), 
66.0 (C-5), 53.5 (C-6), 53.5 (C-1), 52.9 (C-1’), 28.6 (C-4’), 23.1 (C-3’), 22.5 (C-2’).  [α]20D = -3.16 
(c = 0.82, MeOH).  IR/cm-1: 3346, 2963, 2867, 1672, 1429, 1366, 1202, 1133, 1032. HRMS: 
found 346.16843 [C16H27NO5S+H]+, calculated for [C16H27NO5S+H]+ 346.16837. 
 
N-[5-(Thiophen-3-ethoxy)pentyl]-1-deoxynojirimycin (59): 
Bromide 48 (0.29 mmol) was subjected to the general 
procedure D with 1-deoxynojirimycin (0.20 mmol) to 
provide 59 (10 mg, 0.028 mmol, yield 14%). 1H NMR (400 
MHz, MeOD) δ 7.33 (dd, J = 5.0, 2.9 Hz, 1H, H thio), 7.11 (dd, J 
= 3.0, 1.1 Hz, 1H, H thio), 7.02 (dd, J = 4.9, 1.3 Hz, 1H,  H 
thio), 4.12 (d, J = 12.5 Hz, 1H, H-6a), 3.92 (d, J = 12.3 Hz, 1H, 
H-6b), 3.74 – 3.70 (m, 1H, H-2), 3.68 (t, J = 6.7 Hz, 2H, H2-6’), 3.62 (t, J = 9.7 Hz, 1H, H-4), 3.52 (t, 
J = 6.2 Hz, 2H, H2-5’), 3.45 (dd, J = 12.1, 4.8 Hz, 1H, H-1a), 3.42 – 3.34 (m, 2H, H-3, H-1’a), 3.23 – 
3.13 (m, 1H, H-1’b), 3.06 – 3.00 (m, 1H, H-5), 2.97 (t, J = 11.7 Hz, 1H, H-1b), 2.91 (dd, J = 7.1, 6.3 
Hz, 2H, H2-7’), 1.86 – 1.70 (m, 2H, H2-2’), 1.70 – 1.62 (m, 2H, H2-4’), 1.52 – 1.40 (m, 2H, H2-3’). 
13C NMR (100 MHz, MeOD) δ 139.3, 128.1, 124.7, 120.7 (C thio), 76.8 (C-3), 70.8 (C-6’), 69.9 (C-
5’), 67.5 (C-4), 66.4 (C-2), 66.0 (C-5), 53.4 (C-1), 53.0 (C-1’), 30.2 (C-7’), 28.7 (C-4’), 24.0 (C-3’), 




23.1 (C-2’). [α]20D = -9.09 (c = 0.20, MeOH). IR/cm-1: 3358, 3018, 2943, 2870, 1736, 1677, 1439, 




Bromide 66 (0.30 mmol) was subjected to the general procedure 
D with L-ido-1-deoxynojirimycin (0.20 mmol) to provide 5 (16 
mg, 0.049 mmol, yield 40%). 1H NMR (400 MHz, MeOD) δ 4.05 
(br s, 1H, H-3), 4.03 – 3.94 (m, 3H, H2-6, H-2), 3.71 – 3.64 (m, 1H, 
H-4), 3.56 (t, J = 7.0 Hz, 1H, H-5), 3.43 (t, J = 6.3 Hz, 1H, H-2), 3.27 
– 3.18 (m, 2H, H-5’), 3.07 (s, 2H, H2-6’), 3.10 – 2.87 (m, 4H, H2-1, 
H2-1’), 1.82 – 1.53 (m, 4H, H2-2’, H2-4’), 1.51 – 1.37 (m, 2H, H2-3’), 
0.90 (s, 9H, H3-8’, H3-9’, H3-10’). 13C NMR (100 MHz, MeOD) δ 82.4 (C-6’), 72.4 (C-3), 72.3 (C-5’), 
70.3 (C-4), 64.0 (C-2), 55.8 (C-6), 55.3 (C-1’), 53.3 (C-1), 32.9 (C-7’), 30.4 (C-4’), 26.7 (C-8’, C-9’, 
C-10’), 24.8 (C-2’), 13.3 (C-3’). IR/cm-1: 3369, 2935, 2860, 1066. HRMS: found 320.2431 
[C16H33NO5+H]+, calculated for [C16H33NO5+H]+ 320.2432. 
 
N-[5-(3,3-Dimethyl-2-butoxy)pentyl]-L-ido-1-deoxynojirimycin  (60): 
Bromide 39 (0.32 mmol) was subjected to the general 
procedure D with L-ido-1-deoxynojirimycin (0.20 mmol) to 
provide 60 (14 mg, 0.042 mmol, yield 21%). 1H NMR (400 
MHz, MeOD) δ 4.05 (br s, 1H, H-3), 4.03 – 3.95 (m, 3H, H2-6, H-
2), 3.93 – 3.86 (m, 1H, H-4), 3.64 (ddd, J = 8.9, 7.6, 4.7 Hz, 1H, 
H-5'a), 3.58 – 3.47 (m, 2H, H-1a, H-5), 3.41 – 3.30 (m, 4H, H-1a, 
H2-1’, H-5’b), 3.04 (q, J = 6.3 Hz, 1H, H-6’), 1.95 – 1.72 (m, 2H, H2-2’), 1.66 (dt, J = 12.9, 6.2 Hz, 
2H, H2-4’), 1.56 – 1.44 (m, 2H, H2-3’), 1.08 (d, J = 6.4 Hz, 3H, H3-7’), 0.91 (s, 9H, H3-9’, H3-10’, H3-
11’).  13C NMR (100 MHz, MeOD) δ 83.3 (C-6’), 70.9 (C-3), 68.9 (C-5’), 67.5 (C-2), 66.6 (C-4), 62.4 
(C-5), 60.0 (C-6), 53.7 (C-1’), 53.0 (C-1), 34.6 (C-8’), 29.4 (C-4’), 25.0 (C-9’, C-10’, C-11’), 23.3 (C-
3’), 22.0 (C-2’), 12.8 (C-7’). IR/cm-1: 3372, 2972, 1673, 1393, 1203, 1139, 1066. [α]20D = +1.44 (c 




Bromide 43 (0.30 mmol) was subjected to the general 
procedure D with L-ido-1-deoxynojirimycin (0.20 mmol) to 
provide 61 (23 mg, 0.069 mmol, yield 35%). 1H NMR (400 
MHz, MeOD) δ 4.05 (br s, 1H, H-3), 4.03 – 3.94 (m, 3H, H2-6, H-
2), 3.90 (br s, 1H, H-4), 3.60 – 3.51 (m, 2H, H-1a, H-5), 3.49 (t, J 
= 6.3 Hz, 2H, H2-5’), 3.40 – 3.33 (m, 5H, H-1b, H2-1’, H2-6’), 2.17 
(dt, J = 14.9, 7.6 Hz, 1H, H-7’), 1.96 – 1.72 (m, 4H, H2-2’, H-8’a, H-11’a), 1.71 – 1.54 (m, 6H, H2-9’, 
H2-10’, H2-4’), 1.48 (p, J = 7.7 Hz, 2H, H2-3’), 1.34 – 1.25 (m, 2H, H2-11’). 13C NMR (100 MHz, 
MeOD) δ 75.3 (C-6’), 70.9 (C-3), 70.2 (C-5’), 67.5 (C-2), 66.6 (C-4), 62.4 (C-5), 60.0 (C-6), 53.6 
(C-1’), 53.0 (C-1), 39.3 (C-7’), 29.2 (C-8’, C-11’), 28.7 (C-9’, C-10’), 25.0 (C-4’), 23.1 (C-3’), 21.9 
(C-2’). IR/cm-1: 3374, 2953, 2873, 1678, 1440, 1205, 1136, 1072. [α]20D = +4.33 (c = 0.46, 
MeOH). HRMS: found 332.24355 [C17H33NO5+H]+, calculated for [C17H33NO5+H]+ 332.24315.  
 
N-[5-(R/S-Tetrahydrofuran-3-ylmethoxy)pentyl]-L-ido-1-deoxynojirimycin (62): 
Bromide 44 (0.29 mmol) was subjected to the general 
procedure D with L-ido-1-deoxynojirimycin (0.20 mmol) to 
provide 62 (20 mg, 0.060 mmol, yield 30%). 1H NMR (400 
MHz, MeOD) δ 4.08 – 3.95 (m, 4H, H2-6, H-3, H-2), 3.90 (t, J = 





(m, 1H, H-9’b), 3.58 (dd, J = 8.6, 5.5 Hz, 1H, H-10’b), 3.56 – 3.52 (m, 2H, H-5, H-1a), 3.50 (td, J = 
6.3, 1.8 Hz, 2H, H2-5’), 3.44 (dd, J = 9.3, 6.2 Hz, 1H, H-6’), 3.41 – 3.32 (m, 4H, H-1b, H2-1’, H-6'b), 
2.59 – 2.49 (m, 1H, H-7’), 2.09 – 1.99 (m, 2H, H2-8’), 1.97 – 1.72 (m, 2H, H2-2’), 1.71 – 1.60 (m, 
2H, H2-4’), 1.48 (p, J = 7.6 Hz, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 72.5 (C-6’), 70.9 (C-3), 
70.5 (C-10’), 70.3 (C-5’), 67.5 (C-2), 67.3 (C-9’), 66.7 (C-4), 62.4 (C-5), 60.0 (C-6), 53.7 (C-1’), 
53.0 (C-1), 39.0 (C-7’), 28.7 (C-4’), 28.5 (C-8’), 23.1 (C-3’), 21.9 (C-2’). IR/cm-1: 3355, 2971, 
1674, 1201, 1132, 1066. [α]20D = +10.50 (c = 0.40, MeOH). HRMS: found 334.22299 
[C16H31NO6+H]+, calculated for [C16H31NO6+H]+ 334.22241. 
 
N-[5-(R/S-Tetrahydrofuran-1-ylmethoxy)pentyl]-L-ido-1-deoxynojirimycin (63): 
Bromide 45 (0.29 mmol) was subjected to the general 
procedure D with L-ido-1-deoxynojirimycin (0.20 mmol) to 
provide 63 (23 mg, 0.069 mmol, yield 34%). 1H NMR (400 
MHz, MeOD) δ 4.12 – 3.94 (m, 5H, H-3, H-7’, H-2, H2-6), 3.93 – 
3.83 (m, 2H, H-4, H-10’a), 3.82 – 3.74 (m, 1H, H-10’b), 3.58 – 
3.48 (m, 5H, H-1a, H-5, H2-5’, H-6’a), 3.48 – 3.29 (m, 3H, H-1b, 
H2-1’), 2.08 – 1.85 (m, 4H, H-8’a, H2-9’, H-2’a), 1.85 – 1.73 (m, 1H, H-2’b), 1.70 – 1.59 (m, 3H, H2-
4’, H-8’b), 1.50 (q, J = 7.5 Hz, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 78.0 (C-3), 73.1 (C-6’), 70.9 
(C-7’), 70.6 (C-5’), 67.8(C-10’), 67.6 (C-2), 66.7 (C-4), 62.4 (C-5), 59.9 (C-6), 53.7 (C-1’), 53.0 (C-
1), 28.6 (C-4’), 27.5 (C-8’), 25.2 (C-9’), 23.1 (C-3’), 21.8 (C-2’). IR/cm-1: 3346, 2871, 1673, 1432, 
1200, 1132, 1071. [α]20D = +12.5 (c = 0.46, MeOH). HRMS: found 334.22280 [C16H31NO6+H]+, 
calculated for [C16H31NO6+H]+ 334.22241. 
 
N-[5-(Thiophen-3-methoxy)pentyl]-L-ido-1-deoxynojirimycin (64): 
Bromide 47 (0.29 mmol) was subjected to the general 
procedure D with L-ido-1-deoxynojirimycin (0.20 mmol) to 
provide 64 (14 mg, 0.042 mmol, yield 21%). 1H NMR (400 
MHz, MeOD) δ 4.54 (d, J = 0.7 Hz, 2H, H2-6’), 4.04 (br s, 1H, H-
3), 4.01 – 3.93 (m, 3H, H2-6, H-2), 3.89 (t, J = 3.7 Hz, 1H, H-4), 
3.54 (t, J = 6.2 Hz, 2H, H2-5’), 3.55 – 3.44 (m, 2H, H-1a, H-5), 
3.39 – 3.28 (m, 3H, H-1b, H2-1’), 1.98 – 1.72 (m, 2H, H2-2’), 1.69 (dt, J = 8.3, 6.3 Hz, 2H, H2-4’), 
1.50 (q, J = 7.6 Hz, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 139.5(Cq thio), 127.1 , 125.6, 122.6 
(CH thio), 70.9 (C-3), 69.3 (C-5’), 67.6 (C-6’), 67.5 (C-2), 66.6 (C-4), 62.4 (C-5), 60.0 (C-6), 53.6 
(C-1’), 53.0 (C-1), 28.7 (C-4), 23.1 (C-2), 21.8 (C-3). IR/cm-1: 3346, 2970, 1673, 1409, 1201, 
1133, 1066.  [α]20D = +8.28 (c = 0.29, MeOH). HRMS: found 346.16823 [C16H27NO5S +H]+, 
calculated for [C16H27NO5S+H]+ 346.16827. 
 
N-[5-(Thiophen-3-ethoxy)pentyl]-L-ido-1-deoxynojirimycin  (65): 
Bromide 48 (0.29 mmol) was subjected to the general 
procedure D with L-ido-1-deoxynojirimycin (0.20 mmol) to 
provide 65 (36 mg, 0.099 mmol, yield 49%). 1H NMR (400 
MHz, MeOD) δ 7.33 (dd, J = 4.9, 3.0 Hz, 2H, H thio), 7.14 – 
7.09 (m, 1H, H thio), 7.02 (dd, J = 4.9, 1.3 Hz, 1H, H thio), 
4.05 (br s, 1H, H-3), 4.01 – 3.95 (m, 3H, H-2, H2-6), 3.90 (t, J = 
3.7 Hz, 1H, H-4), 3.68 (t, J = 6.7 Hz, 2H, H2-6’), 3.56 – 3.47 (m, 2H, H-1a, H-5), 3.52 (t, J = 6.2 Hz, 
2H, H2-5’), 3.38 – 3.28 (m, 3H, H-1b, H2-1’), 2.94 – 2.88 (m, 2H, H2-7’), 1.93 – 1.70 (m, 2H, H2-2’), 
1.70 – 1.64 (m, 2H, H2-4’), 1.53 – 1.37 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 139.3 (Cq  
thio), 128.1, 124.7, 120.7 (CH thio), 70.9 (C-3), 70.8 (C-6’), 70.0 (C-5’), 67.5 (C-2), 66.6 (C-4), 
62.4 (C-5), 60.0 (C-6), 53.7 (C-1’), 53.0 (C-1), 30.2 (C-7’), 28.7 (C-4’), 23.1 (C-3’), 21.8 (C-2’). 
IR/cm-1: 3355, 2971, 1674, 1394, 1202, 1066. [α]20D = +2.52 (c = 0.71, MeOH). HRMS: found 
360.18397 [C17H29NO5S +H]+, calculated for [C17H29NO5S+H]+ 360.18392. 
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N-alkyl-deoxynojiricin derivatives (N-alkyl iminosugars) are an important class of 
biologically active molecules that are applied both in fundamental glycobiology studies and in 
clinical settings.1 N-alkyl-DNJ derivatives are potent inhibitors of the glucosylceramide 
metabolizing enzymes, glucosylceramide synthase (GCS) and neutral glucosylceramidase 
(GBA2) as well as intestinal glucosidases. Literature reports suggest that this dual activity make 
such N-modified DNJs promising leads for the development of type 2 diabetes. In these studies, 
it was also shown that N-alkyl derivatives of the C-5 epimer of DNJ, the L-ido-configured 
5 
Biphenyl-L-ido DNJ Derivatives 






iminosugars are at least equally potent GCS and GBA2 inhibitors as their DNJ counterparts, but 
do not target intestinal glycosidases. Based on this comparative selectivity, L-ido-DNJ 
derivatives may be considered as starting point for the development of therapeutics for the 
treatment of lysosomal storage disorders, in particular those in which GCS (and possibly also 
GBA2) are involved, such as Gaucher disease.2 
As is described in Chapter 4, GCS, the enzyme responsible for the biosynthesis of 
glucosylceramide, is targeted in substrate reduction therapy for Gaucher disease. 
Compensatory overexpression of GBA2 in the cytoplasm has however been associated with 
LSDs symptoms as well.3 Therefore, dual GCS/GBA2 inhibitors that are otherwise clean with 
respect to other glycoprocessing enzymes are thought to be promising compounds for the 
development of new and more effective drugs for treatment of these LSDs. This in turn 
indicates that further perusal of diverse, N-alkyl-L-ido-DNJ derivatives is a worthy research 
objective. 
Figure 1:  Various potent GCS and GBA2 inhibitors 
 
 
From initial work on comparing the efficacy of DNJ and L-ido-DNJ derivatives as GCS/GBA2 
inhibitors, N-AMP DNJ (MZ-21, 1) and N-AMP L-ido-DNJ (MZ-31, 2) emerged as the most 
effective compounds. Both are potent GCS/GBA2 inhibitors and, as outlined above, whereas 
compound 1 has a considerable number of other glycosidases as off-targets, compound 2 is 
much more selective. More recent studies on a series of N-alkyl and N-aryl derivatives revealed 
N-penyloxymethylbiaryl DNJ (3) and its L-ido-DNJ derivative (4) as more potent inhibitors that 
retain the selectivity profile of their parent compounds, 1 and 2, respectively.2 In these studies, 
the impact on altering the nature of the nitrogen substituent has been studied in depth on DNJ, 
BIPHENYL-L-IDO DNJ DERIVATIVES AS DUAL GCS/GBA2 INHIBITORS  
88 
 
but less so on L-ido-DNJ, this while the latter class is considered more promising for the 
discovery of new LSD therapeutics.2 For this reason, it was decided to expand the number and 
variety of N-substituted, L-idose configured iminosugars. The results on the design, synthesis 
and evaluation of a set of such compounds as GCS/GBA1/GBA2 inhibitors in comparison with 
relevant literature compounds, including their D-glucose configured counterparts, are 
presented in this Chapter. 
Results and discussion  
Scheme 1: General approach to synthesize biphenyl substituted iminosugars 
 
Reagents and conditions: [a] K2CO3, DMF, 80 °C, 46%; [b] Pd(PPh3)4, NaOMe, EtOH, 65 °C, 18 h, 11%. 
The synthetic strategy employed to obtain functionalized biphenyl substituents is 
illustrated in Scheme 1 for the synthesis of protected catechol derivative 21. Following this 
strategy, first a large batch of bromobenzyl-L-ido-DNJ derivative (such as the para-bromobenzyl 
derivative 7) is made, which is then diversified into compound families using Suzuki cross-
coupling methodology with a variety of commercially available phenylboronates as the cross-
coupling counterpart. Thus, and following conditions as described in previous chapters,4 L-ido-
DNJ 5 is alkylated with bromide 6 to provide in acceptable yields and in a scalable fashion 
compound 7. Treatment of bromide 7 with catechol 9, a catalytic amount of Pd(Ph3)4 and 
sodium methoxide in ethanol provided after HPLC purification compound 21 in 11% yield. This 
yield is not impressive. Moreover, yields from the cross-coupling/purifications sequence 
involving different phenylboronates, yielding other library entries (see Figure 3 for their 




Nonwithstanding these yields, which were not optimized, sufficient quantities of material in 
excellent structural purity were obtained to perform enzyme inhibition assays, which was the 
primary objective of the research in this Chapter: are L-ido-DNJ derivatives more potent and 
selective than their D-gluco-counterparts in inhibiting GCS and GBA2 irrespective of the nature 
of the nitrogen substituent. 
Figure 3: Substituents for external phenyl ring modifications 
 
In order to obtain insight in what causes the low efficiency in the Suzuki reactions, HPLC 
traces were perused for potential side products that were formed during the reaction. From 
these studies it became apparent that compound 10 (Figure 4; when starting from DNJ) and 11 
(from L-ido-DNJ), the dehalogenated starting materials, were formed as major products. 
Dehalogenation of the aryl halide is a known side reaction in Suzuki cross couplings and can be 
suppressed by the addition of tertiary amine bases such as trimethylamine.5 
 Figure 4: Dehalogenated side products 
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In case needed (for instance when larger quantities of a given iminosugar are required) 
optimization of the cross-coupling event including the addition of such amines may be 
considered. Alternative literature procedures for the optimization of this key step includes 
modulating the amount of potassium carbonate used and the temperature at which the reaction 
is executed.6 
Inhibition activity 
As discussed above, an established trend is that L-idose configured iminosugars are more 
potent GCS inhibitors than their D-glucose configured counterparts. As can be seen (Figure 5), 
this trend in general also holds up after evaluation of the newly synthesized DNJ derivatives. 
There are however some notable exceptions to this rule: compounds 12, 16 and 17 are less 
potent GCS inhibitors than their corresponding DNJ derivatives (28, 29 and 30). The 
differences in potency are however too small to draw any structure-activity relationship 
conclusions from this observation. It can be generally concluded that the compound series 
contain many nanomolar GCS inhibitors and therefore many compounds that may be of interest 
for further perusal as in vivo GCS inhibitors. 
With the exception of 12 and 16 all compounds in the L-ido series inhibit GBA1 with IC50 
values ranging from 5 to 40 μM. These compounds are therefore rather potent inhibitors of 
GBA1, however there is a considerable window between GCS and GBA1 (GCS: nanomolar, GBA1: 
micromolar). This window is much more pronounced than the one in the D-gluco series, 
containing many nanomolar inhibitors of GBA1 (an enzyme one does not wish to inhibit, 
neither in relation to type 2 diabetes nor in relation to LSDs). Finally, all compounds inhibit 
GBA2 in the nanomolar range (IC50 0.8 – 17 nM), with ortho-F substituted 15 (IC50 = 0.8 nM) as 
the most potent compound of the series. Though less pronounced than seen for GCS, the L-ido-
compounds do seem to outperform their D-gluco counterparts in inhibition potency towards 
GBA2. Returning to GCS inhibition potency, one striking observation is that para-fluoride 13 
significantly more potent than para-chloride 12. This observation is opposite from what is 
observed in the D-gluco series (compare 28 and 31). 
Besides the construction of new L-ido-DNJ derivatives bearing known (for DNJ) N-
substituents the compounds synthesised in the framework of this Chapter also include a new 
functionality: thiophene derivatives 24-27 with the thiophene (appended through either of the 
two optional carbons) replacing the terminal phenyl ring in 3 and 4. Following the trend L-ido 
congeners 24 and 25 are 2 to 3 times more potent GCS inhibitors than the corresponding DNJ 





Figure 5: Structures and GCS, GBA1 and GBA2 IC50 values of the biphenyl analogue 
containing iminosugars 
*IC50 values of 29 – 40 are from the literature.2 
 
Overall, the introduction of different substituents at the biphenyl external ring has not led 
to inhibitors with significantly improved or decreased activity against GCS, GBA1 and GBA2, 
compared to the lead structures. When looking at selectivity, however, para-CF3 substituted 
compound 16 may be of interest, as it is the most selective GCS/GBA2 dual inhibitor when 
taking into account GBA1 as an undesired off-target. 
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Figure 6: Lipophilic ligand efficiency values (LipE) of D-gluco and L-ido series for 
GCS inhibition 
 
 To obtain some more insight into the potential relevance of the here-presented inhibitors 
for potential future in vivo application, their lipophilic ligand efficiency (LipE) was calculated 
(Figure 6). LipE is defined as pIC50 - LogP, which is a composite parameter often referred to 
when correlating the potency of a molecule towards an isolated target (or gleaned from an in 
vitro assay) to its potential druglikeness.7 A high LipE indicates the affinity of the inhibitor with 
the target enzyme tends to be driven by specific molecule-protein interaction, rather than a 
non-specific entropy-driven binding.7 It can be observed from Figure 6 that the L-ido series 
exhibits better performance in this index when the LogP value is low, whereas the D-glu series 
has a higher LipE value when the logP value is higher (see: 12/28, 16/29 and 17/30). From all 
the iminosugars discussed in this Chapter, compounds 21 and 22 seem to perform better than 
lead structure 4 in this evaluation. It should however be realized that this evaluation is not very 
precise, as for instance chiral information is not included and furthermore that the lipophilicity 
data is generated in silico, rather than by experimentation. 
Conclusion 
In this Chapter, 14 new L-ido-DNJ derivatives were designed and synthesized, with as key 
step a Suzuki-Miyaura cross coupling event. The results in this Chapter complement literature 


















compounds with D-gluco and L-ido configuration and bearing a large number of different N-
alkyl groups, alongside with GCS/GBA1/GBA2 inhibitory potencies obtained, now provide some 
hints as to what would make a N-substituted iminosugar a potent and/or selective GCS/GBA2 
inhibitor. For instance, as can be concluded from the inhibitors presented here, alteration of the 
terminal phenyl ring in a biphenyl substituent does little for activity/selectivity (but is also not 
detrimental). 
Figure 7: Potent internal phenyl ring modified L-ido iminosugar derivatives  
  
This is in contrast to the literature report on related compounds, but in which focus has 
been more on modulating the internal phenyl ring of the biphenyl moiety. For instance, L-ido-
DNJ derivatives 41 - 44 (Figure 7) turned out to be potent GCS/GBA2 inhibitors, more so than 
lead compound 4 as well as noniminosugar GCS inhibitors reported in the literature.2 One 
future direction may be to take those inner-ring substituents for potency/selectivity, and equip 
these with the most optimal terminal rings in terms of logP values, leading to, for instance, 
analogues 49–52 in (Figure 8) as potentially interesting targets for the future. 
Figure 8: Low logP modified biphenyl L-ido iminosugars   
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Experimental section  
Enzyme inhibition assays:  The potencies (IC50 values) of the N-alkyl-DNJ derivatives as GCS, 
GBA1 and GBA2 inhibitors were determined by exposing cells or enzyme preparations to an 
appropriated range of iminosugar concentrations. 
 
GCS: IC50 values for GCS activity were measured using living cells with NBD-ceramide as 
substrate.8 Briefly, cells were incubated with 50 nmol C6-NBD-ceramide (6-[N-methyl-N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)aminododecanoyl]sphingosine) in the presence of increasing 
compound concentrations. The cells were harvested after 2h followed by lipid extraction. The 
formed C6-NBD-glucosylceramide was quantified using a Molecular Dynamics Typhoon 
phosphor imaging device. IC50 values were determined from the titration curves. The 
experiment was performed twice. 
 
GBA1: IC50 values for lysosomal GBA1 were measured using 4-methylumbeliferyl-β-D-glucoside 
as substrate.9 Briefly, recombinant GBA1 was incubated with increasing compound 
concentrations for 30 min at 0 ℃. Enzyme activity was determined with 3.7 mM 4-
methylumbelliferyl-β-D-glucopyranoside in McIlvaine buffer (0.1 M citrate and 0.2 M phosphate 
buffer), pH 5.2, 0.1% Triton X-100 (v/v) and sodium taurocholate (0.2%, w/v). Assays were 
incubated at 37 ℃ for 30 min and quenched by the addition of glycine/NaOH (0.2 mL, pH 10.6). 
The amount of liberated 4-methylumbeliferyl was determined with a PerkinElmer Life Sciences 
LS30 fluorimeter, excitation wavelength 366 nm, emission wavelength 445 nm. Assays were 
performed in triplicate. 
 
GBA2: IC50 values for the non-lysosomal glucocerebrosidase (GBA2) were measured with 4-
methylumbeliferyl-β-D-glucoside as substrate.8 GBA2-rich membrane suspensions were 
prepared from enzyme-overexpressing HEK cells by sonicating, and the suspension was pre-
incubated for 30 min at 37 ℃ with conduritol-B-epoxide (1 mM, CBE, Sigma) to inhibit the 
lysosomal glucocerebrosidase (GBA1). The prepared GBA2-rich suspension was then incubated 
with increasing compound concentrations for another 30 min, and then incubated with 3.7 mM 
4-methylumbeliferyl-β-D-glucoside in McIlvaine buffer (0.1 M citrate and 0.2 M phosphate 
buffer), pH 5.8. Assays were incubated at 37 ℃ for 1 hour and quenched by the addition of 
glycine/NaOH (0.2 mL, pH 10.6). The amount of liberated 4-methylumbeliferyl was determined 
with a PerkinElmer Life Sciences LS30 fluorimeter, excitation wavelength 366 nm, emission 
wavelength 445 nm. Assays were performed in triplicate. 
 
General compound synthesis, purification and analysis methods: All solvents and reagents 
were obtained commercially and used as received unless stated otherwise. Reactions were 
executed at room temperature unless stated otherwise. Moisture sensitive reactions were 
performed under argon atmosphere. Water was removed from starting compounds by 
repetitive coevaporation with toluene. Solvents were removed by evaporation under reduced 
pressure. DCM, DMF, and THF were dried over activated 4Å molecular sieves for at least 12 
hours before use. Compounds were visualized during TLC analyses by UV (254 nm), and with 
the following staining solutions: aqueous solution of KMnO4 (5 g/L) and K2CO3 (25 g/L). 
Visualization of hemiacetals and glycosides was achieved by spraying with a solution of 20% 
H2SO4 in ethanol followed by charring at ≈ 200 ℃. Column chromatography purification was 
performed on silica gel (40-63 µm). 1H and 13C-APT NMR spectra were recorded on a Bruker AV 
400 (400/100 MHz), Bruker 600 (600/150 MHz) or Bruker 600 (850/215 MHz) spectrometer 
in CDCl3, MeOD or D2O. Chemical shifts are given in ppm (δ) relative to TMS as internal 
standard (1H NMR in CDCl3) or the signal of the deuterated solvent.10 Coupling constants (J) are 
given in Hz. High resolution mass spectra were recorded by direct injection (2 µL of a 2 µM 




Finnigan LTQ Orbitrap) equipped with an electrospray ion source with resolution R = 60000 at 
m/z 400 (mass range m/z = 150-2000). IR spectra were recorded on a Shimadzu FTIR-8300 
and are reported in cm-1. Optical rotation were measured on an automatic polarimeter of 
sodium D-line, at λ = 589 nm. Size-exclusion purifications were performed on an ÄKTA-
explorer, column size d = 26 mm, l = 60 mm, mobile phase NH4HCO3 (0.15 M) in H2O, flow 1.5 
mL/min. HPLC Purification were performed on a Prep LCMS, Gemini from Phenomenex B.V. (C-
18, 110 Å, 5 µm, 19 x 150 mm column). 
 
General procedure: Suzuki-Miyaura cross coupling: Solutions and stock solutions used were 
degassed with ultrasonic bath with an argon flow for at least 15 minutes. The reactions were 
carried out under argon protection. A stock solution of N-[5-(4-bromobenzyloxy)pentyl]-1-
deoxynojirimycin (1.2 M) in ethanol, a stock solution of boronic acid (1.5 M) in ethanol and a 
stock solution of Pd(PPh3)4 (5%) in ethanol were made. NaOMe (0.180 gram, 3.3 mmol) was 
added to the reaction vails containing an argon atmosphere, followed by the additions of  the 
stock solutions of N-[5-(4-bromobenzyloxy)pentyl]-1-deoxynojirimycin (1.2 M, 0.417 mL, 0.5 
mmol), boronic acid (1.5 M, 0.500 mL, 0.75 mmol) and Pd(PPh3)4 (2 mol%, 0.40mL). The 
reaction mixture was stirred at 65 °C for 18 h. After HPLC analysis indicated the complete 
consumption of starting material, the reaction mixture was diluted with ethanol filtered over 
Cilite and the volatiles were evaporated. The residue was purified by HPLC purification. Yields 
vary from 1% - 11%. 
 







To a mixture of 5-(4-bromobenzyloxy)pentane-1-ol (4.00 g, 14.6 
mmol) and triphenyl phosphine (5.80 g, 22.2 mmol) in DCM (150 
mL) was added CBr4 (7.35 g, 22.2 mmol) at 0 ℃. The reaction 
mixture was  stirred for 2 hours. After which TLC analysis showed the complete consumption of 
starting material, Celite was added and the volatiles were evaporated. The residue was purified 
with silica gel column (4:1 → 0:1, PE:toluene) to give 6 (3.20 g, 7.03 mmol, 50%) as yellow oil. 
RF = 0.70 (toluene). 1H NMR (400 MHz, CDCl3) δ 7.57 – 7.38 (m, 2H, HAr Bn), 7.24 – 7.11 (m, 2H, 
HAr Bn), 4.44 (s, 2H, H2-6), 3.46 (t, J = 6.3 Hz, 2H, H2-5), 3.40 (t, J = 6.8 Hz, 2H, H2-1), 1.97 – 1.80 
(m, 2H, H2-2), 1.71 – 1.58 (m, 2H, H2-4), 1.58 – 1.43 (m, 2H, H2-3). 13C NMR (100 MHz, CDCl3) δ 
137.6 (Cq Bn), 131.5 (CHAr Bn), 129.3 (CHAr Bn), 121.4 (Cq Bn), 72.2 (C-6), 70.2 (C-5), 33.9 (C-1), 
32.6 (C-2), 29.0 (C-4), 25.0 (C-3). IR/cm-1: 2935, 2856, 1487, 1356, 1093, 1010. 
 
N-[5-(4-Bromobenzyloxy)-pentyl]-L-ido-1-deoxynojirimycin (7): 
To a mixture of 6 (7.57g, 22.73 mmol) and K2CO3 (4.27, 30.90 
mmol) was added a solution of 5 (2.47g, 15.1 mmol) in DMF (75 
mL). This was stirred overnight at 80 ℃. After cooling to room 
temperature, the mixture was filtered and concentrated. The 
crude compound was purified with silica gel column (4:1 EtOAc: 
MeOH + 1% NH4OH → 6:4:1 EtOH:H2O:NH4OH) to give 7 in 46% yield (3.22g, 7.70 mmol). 1H 
NMR (400 MHz, MeOD) δ 7.47 (d, J = 8.1 Hz, 2H, HAr Bn), 7.25 (dd, J = 8.2, 3.5 Hz, 2H, HAr Bn), 
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4.43 (s, 2H, H2-6’), 3.84 (t, J = 5.3 Hz, 2H, H2-6), 3.77 – 3.66 (m, 1H, H-4), 3.59  – 3.53 (m, 1H, H-
2), 3.47 (t, J = 6.4 Hz, 2H, H2-5’), 3.42 (t, J = 8.5 Hz, 1H, H-3), 3.09 – 3.05 (m, 1H, H-5), 2.83 (dd, J 
= 12.3, 4.8 Hz, 1H, H-1a), 2.80 – 2.73 (m, 1H, H-1’a), 2.71 – 2.65 (m, 1H, H-1’b), 2.61 (dd, J = 12.4, 
9.7 Hz, 1H, H-1b), 1.80 – 1.47 (m, 4H, H2-2’, H2-4’), 1.38 (p, J = 7.7 Hz, 2H, H2-3’). 13C NMR (100 
MHz, MeOD) δ 139.1 (Cq Bn), 132.4 (CHAr Bn), 130.5 (CHAr Bn), 122.2 (Cq Bn), 75.5 (C-3), 72.9 
(C-6’), 72.6 (C-4), 71.4 (C-5’), 71.0 (C-2), 64.1 (C-5), 57.6 (C-6), 55.4 (C-1’), 52.8 (C-1), 30.5 (C-
2’), 28.1 (C-4’), 24.9 (C-3’). [α]20D = 10.4 (c = 1.00, MeOH). IR/cm-1: 3339, 1670, 1433, 1200, 
1134, 1070. HRMS: found 418.12236, 420.12032 [C18H29BrNO5+H]+, calculated for 
[C18H29BrNO5+H]+ 418.12237, 420.12030. 
 
N-[5-(4-Bromobenzyloxy)-pentyl]-1-deoxynojirimycin (8): 
8 (3.57 g, 8.57 mmol) was synthesized from 6 (2.00 g, 12.8 mmol) 
and DNJ (5.16 g, 15.4 mmol) according to the procedure described 
for the preparation of compound 8 as a white solid with 67% yield. 
RF = 0.45 (30% MeOH in EtOAc, 1% NH4OH). 1H NMR (400 MHz, 
MeOD) δ 7.55 – 7.47 (m, 2H, HAr Bn), 7.33 – 7.27 (m, 2H, HAr Bn), 
4.50 (s, 2H, H2-6’), 4.09 (dd, J = 12.3, 2.1 Hz, 1H, H-6a), 3.94 (dd, J = 12.5, 3.0 Hz, 1H, H-6b), 3.76 
– 3.70 (m, 1H, H-2), 3.62 (t, J = 9.5 Hz, 1H, H-4), 3.55 (t, J = 6.2 Hz, 2H, H2-5’), 3.49 – 3.38 (m, 2H, 
H-1a, H-3), 3.31 – 3.25 (m, 1H, H-1’a), 3.23 – 3.14 (m, 1H, H-1’b), 3.02 (dd, J = 11.7, 5.2 Hz, 1H, 
H-5), 2.95 (t, J = 11.5 Hz, 1H, H-1b), 1.88 – 1.75 (m, 2H, H2-2’), 1.73 – 1.69 (m, 2H, H2-4’), 1.55 – 
1.47 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 137.8 (Cq Bn), 131.1 (CHAr Bn), 129.3 (CHAr 
Bn), 120.9 (Cq Bn), 76.9 (C-3), 71.6 (C-6’), 69.8 (C-5’), 67.9 (C-4), 66.8 (C-2), 66.0 (C-5), 54.4 (C-
6), 53.8 (C-1), 52.7 (C-1’), 28.8 (C-4’), 23.2 (C-3’), 22.8 (C-2’). [α]20D = -0.2 (c = 1.00, MeOH). 
IR/cm-1: 3273, 1670, 1433, 1274, 1200, 1132, 1030, 1012. HRMS: found 418.12236, 420.12032 
[C18H29BrNO5+H]+, calculated for [C18H29BrNO5+H]+ 418.12237, 420.12030. 
 
 N-[5-((4’-Chloro[1,1’-biphenyl]-4-yl)-methoxy)-pentyl]-L-ido-1-deoxynojirimycin (12): 
12 (4.0 mg, 0.009 mmol, 2% yield) was synthesized 
according to the Suzuki-Miyaura cross coupling general 
procedure.  1H NMR (600 MHz, MeOD) δ 7.65 – 7.57 (m, 4H, 
HAr Bn2), 7.44 (ddd, J = 8.2, 4.5, 2.2 Hz, 4H, HAr Bn1), 4.55 (s, 
2H, H2-6’), 4.07 – 3.88 (m, 4H, H-4, H2-6, H-2), 3.84 (s, 1H, H-
3), 3.56 (t, J = 6.2 Hz, 2H, H2-5’), 3.54 – 3.39 (m, 2H, H-5. H-
1a), 3.35 – 3.23 (m, 3H, H-1b, H2-1’), 1.98 – 1.66 (m, 4H, H2-2’, H2-4’), 1.54 – 1.43 (m, 2H, H2-3’). 
13C NMR (150 MHz, MeOD) δ 140.7, 139.4, 134.4, (Cq BiPh), 130.0, 129.5, 127.9 (CAr BiPh), 73.6 
(C-6’), 72.3 (C-4), 71.0 (C-5’), 69.0 (C-2), 68.2 (C-3), 63.8 (C-5), 62.4 (C-6), 55.0 (C-1’), 54.2 (C-
1), 30.2 (C-4’), 24.6 (C-3’), 24.1 (C-2’). [α]20D = +3.33 (c = 0.06, MeOH).  IR/cm-1: 3319, 2920, 




13 (12.4 mg, 0.028 mmol, 6% yield) was synthesized 
according to the Suzuki-Miyaura cross coupling general 
procedure.   1H NMR (400 MHz, MeOD) δ 7.72 – 7.53 (m, 4H, 
HAr Bn1), 7.46 – 7.37 (m, 2H, HAr Bn2), 7.23 – 7.06 (m, 2H, HAr 
Bn2), 4.54 (s, 2H, H2-6’), 4.02 (s, 1H, H-4), 3.99 – 3.90 (m, 3H, 
H2-6, H-2), 3.85 (t, J = 4.0 Hz, H-3), 3.56 (t, J = 6.2 Hz, 2H, H2-
5’), 3.53 – 3.42 (m, 2H, H-5, H-1a), 3.35 – 3.30 (m, 3H, H-1b, H2-1’), 1.96 – 1.81 (m, 1H, H-2’a), 
1.73 – 1.69 (m, 3H, H-2’b, H2-4’), 1.52 – 1.48 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 165.1, 
162.7, 140.8, 138.9 (Cq BiPh), 129.8, 129.5, 127.9, 127.9, 116.6, 116.4, 116.4 (CAr BiPh), 73.6 (C-
6), 72.3 (C-4), 71.0 (C-5’), 68.9 (C-2), 68.0 (C-3), 63.8 (C-5), 61.4 (C-6), 55.0 (C-1’), 54.4 (C-1), 








14 (7.8 mg, 0.017 mmol, 3% yield) was synthesized according 
the Suzuki-Miyaura cross coupling general procedure. 1H 
NMR (400 MHz, MeOD) δ 8.16 – 7.41 (m, 8H, HAr BiPh), 4.58 
(s, 2H, H2-6’), 4.04 (br s, 1H, H-4), 4.00 – 3.96 (m, 3H, H2-6, H-
2), 3.89 (d, J = 4.0 Hz, 1H, H-3), 3.59 (t, J = 6.2 Hz, 2H, H2-5’), 
3.56 – 3.46 (m, 2H, H-5, H-1a), 3.41 – 3.32 (m, 3H, H-1b, H2-
1’), 2.00 – 1.64 (m, 4H, H2-2’, H2-4’), 1.55 – 1.51 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 
163.5, 143.2, 138.3 (Cq BiPh), 130.3 – 113.0 (CAr BiPh), 72.1 (C-6’), 70.9 (C-4), 69.7 (C-5’), 67.6 
(C-2), 66.6 (C-3), 62.4 (C-5), 60.0 (C-6), 53.7 (C-1’), 53.0 (C-1), 28.7 (C-4’), 23.2 (C-3’), 21.9 (C-
2’). [α]20D = +6.00 (c = 0.10, MeOH). IR/cm-1: 3362, 2924, 1676, 1437, 1204, 1134, 1074. HRMS: 




15 (9.1 mg, 0.021 mmol, 4% yield) was synthesized according to 
the Suzuki-Miyaura cross coupling general procedure.   1H NMR 
(400 MHz, MeOD) δ 7.59 – 7.16 (m, 8H, HAr BiPh), 4.59 (s, 2H, H2-
6’), 4.04 (br s, 1H, H-4), 4.01 – 3.93 (m, 3H, H2-6, H-2), 3.89 (t, J = 
3.7 Hz, 1H, H-3), 3.60 (t, J = 6.2 Hz, 2H, H2-5’), 3.57 – 3.45 (m, 2H, 
H-5, H-1a), 3.39 – 3.32 (m, 3H, H-1b, H2-1’), 1.98 – 1.70 (m, 4H, 
H2-2’, H2-4’), 1.56 – 1.52 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 162.3 – 131.8 (Cq BiPh), 
130.4 – 116.9 (CAr BiPh), 73.6 (C-6’), 72.4 (C-4), 71.0 (C-5’), 68.9 (C-2), 68.0 (C-3), 63.8 (C-5), 
61.4 (C-6), 55.1 (C-1’), 54.4 (C-1), 30.2 (C-4’), 24.6 (C-3’), 23.3 (C-2’). [α]20D = +3.64 (c = 0.22, 
MeOH). IR/cm-1: 3377, 2866, 2324, 1670, 1204, 1136, 1074. HRMS: found 434.23350 




16 (1.3 mg, 0.003 mmol, 1% yield) was synthesized 
according to the Suzuki-Miyaura cross coupling general 
procedure.   1H NMR (850 MHz, MeOD) δ 7.82 (d, J = 8.1 Hz, 
2H, HAr BiPh), 7.74 (d, J = 8.2 Hz, 2H, HAr BiPh), 7.70 – 7.59 
(m, 2H, HAr BiPh), 7.53 – 7.42 (m, 2H, HAr BiPh), 4.57 (s, 2H, 
H2-6’), 4.10 – 3.63 (m, 5H, H-4, H2-6, H-2, H-3), 3.57 (t, J = 
6.3 Hz, 2H, H2-5’), 3.49 – 3.38 (m, 2H, H-5, H-1a), 3.35 – 3.23 (m, 3H, H2-1’, H-1b),  2.02 – 1.56 
(m, 2H, H2-2’), 1.51 – 1.28 (m, 4H, H2-4’, H2-3’). 13C NMR (215 MHz, MeOD) δ 145.9 (C-7), 140.2, 
130.3, 129.5 (Cq BiPh), 128.5 – 126.8 (CAr BiPh), 73.5(C-6’), 72.3(C-4), 71.2(C-5’), 69.0(C-2), 
66.3(C-3), 63.9 (C-5), 55.1 (C-6), 52.9 (C-1‘), 52.3 (C-1), 33.1 (C-4’), 30.3 (C-3’), 24.7 (C-2’). 
[α]20D = +20.00 (c = 0.01, MeOH). IR/cm-1: 3402, 2930, 2349, 1683, 1506, 1203, 1130, 1070. 




17 (24.5 mg, 0.04 mmol, 8.9% yield) was synthesized 
according to the Suzuki-Miyaura cross coupling general 
procedure.   1H NMR (400 MHz, MeOD) δ 8.19 (d, J = 1.6 Hz, 
2H, HAr BiPh), 7.95 (s, 1H, HAr BiPh), 7.77 – 7.70 (m, 2H, H-
BiPh), 7.52 (d, J = 8.0 Hz, 2H, H-BiPh), 4.59 (s, 2H, H2-6’), 4.02 
(br s, 1H, H-4), 3.87 (t, J = 4.0 Hz, 1H, H-3), 3.58 (t, J = 6.2 Hz, 
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2H, H2-5’), 3.53 – 3.47 (m, 2H, H-5, H-1a), 3.37 – 3.31 (m, 3H, H-1b, H2-1’), 2.03 – 1.64 (m, 4H, 
H2-2’, H2-4’), 1.53 – 1.49 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 144.7, 141.0, 138.5, 133.5, 
133.2 (Cq BiPh, CF3), 129.7 – 121.8 (CAr BiPh), 73.4 (C-6’), 72.4 (C-4), 71.2 (C-5’), 69.0 (C-2), 68.0 
(C-3), 63.8 (C-5), 61.4 (C-6), 55.1 (C-1’), 54.4 (C-1), 30.2 (C-4’), 24.6 (C-3’), 23.3 (C-2’). [α]20D = 
+4.23 (c = 0.52, MeOH).  IR/cm-1: 3331, 2930, 2862, 1674, 1456, 1383, 1278, 1132, 1057. 
HRMS: found 552.21748 [C26H31F6NO5+H]+, calculated for [C26H31F6NO5+H]+ 552.21792. 
 
N-[5-((4’-Methoxy[1,1’-biphenyl]-4-yl)-methoxy)-pentyl]-L-ido-1-deoxynojirimycin (18): 
18 (4.6 mg, 0.01 mmol, 2% yield) was synthesized 
according to the Suzuki-Miyaura cross coupling general 
procedure.  1H NMR (400 MHz, MeOD) δ 7.59 – 7.51 (m, 4H, 
HAr BiPh), 7.41 – 7.35 (m, 2H, HAr BiPh), 7.04 – 6.93 (m, 2H, 
HAr BiPh), 4.53 (s, 2H, H2-6’), 4.01 (d, J = 3.0 Hz, 1H, H-4), 
3.99 – 3.89 (m, 3H, H2-6, H-2), 3.86 (d, J = 3.7 Hz, 1H, H-3), 
3.83 (s, 3H, OMe), 3.56 (t, J = 6.1 Hz, 2H, H2-5’), 3.54 – 3.43 (m, 2H, H-5, H-1a), 3.32 – 3.26 (m, 
3H, H-1b, H2-1’), 1.98 – 1.65 (m, 4H, H2-2’, H2-4’), 1.53 – 1.49 (m, 2H, H2-3’). 13C NMR (100 MHz, 
CDCl3) δ 143.3 – 138.1 (Cq BiPh), 129.5, – 115.3 (CAr BiPh), 73.7 (C-6’), 72.4 (C-4), 70.9 (C-5’), 
68.9 (C-2), 68.0 (C-3), 63.8 (C-5), 61.3 (C-6), 55.7 (C-7’), 55.1 (C-1’), 54.4 (C-1), 30.1 (C-4’), 24.6 
(C-3’), 23.2 (C-2’). [α]20D = -5.71 (c = 0.07, MeOH).  IR/cm-1: 3449, 2957, 2345, 2620, 1682, 




19 (11.6 mg, 0.026 mmol, 5% yield) was synthesized according 
to the Suzuki-Miyaura cross coupling general procedure.   1H 
NMR (400 MHz, MeOD) δ 7.50 – 7.44 (m, 2H, HAr BiPh), 7.35 (d, J 
= 8.1 Hz, 2H, HAr BiPh), 7.34 – 6.94 (m, 4H, HAr BiPh), 4.53 (s, 2H, 
H2-6’), 4.02 (br s, 1H, H-4), 3.98 – 3.93 (m, 3H, H2-6, H-2), 3.86 (t, 
J = 3.8 Hz, 1H, H-3), 3.78 (s, 3H, OMe), 3.56 (t, J = 6.2 Hz, 2H, H2-
5’), 3.54 – 3.44 (m, 2H, H-5, H-1a), 3.34 – 3.30 (m, 3H, H-1b, H2-
1’), 1.99 – 1.63 (m, 4H, H2-2’, H2-4’), 1.53 – 1.49 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 
157.9, 139.6, 138.2 (Cq BiPh), 131.6 – 112.6 (CAr BiPh), 73.8 (C-6’), 72.3 (C-4), 71.0 (C-5’), 68.9 
(C-2), 68.0 (C-3), 63.8 (C-5), 61.3 (C-6), 56.0 (C-7’), 55.0 (C-1’), 54.4 (C-1), 30.1 (C-4’), 24.6 (C-
3’), 23.2 (C-2’). [α]20D = +3.33 (c = 0.24, MeOH). IR/cm-1: 3323, 2943, 2857, 2311, 1674, 1487, 





20 (2.5 mg, 0.005 mmol, 1% yield) was synthesized 
according to the Suzuki-Miyaura cross coupling general 
procedure.   1H NMR (400 MHz, MeOD) δ 7.60 – 7.48 (m, 2H, 
HAr BiPh), 7.41 – 7.31 (m, 2H, HAr BiPh), 7.14 – 7.06 (m, 2H, 
HAr BiPh), 6.88 (d, J = 8.7 Hz, 1H, HAr BiPh), 5.98 (s, 2H, H2-
7’), 4.53 (s, 2H, H2-6’), 4.03 – 4.01 (m, 1H, H-4), 3.98 – 3.90 
(m, 3H, H2-6, H-2), 3.86 (t, J = 3.8 Hz, 1H, H-3), 3.55 (t, J = 6.2 
Hz, 2H, H2-5’), 3.53 – 3.44 (m, 2H, H-5, H-1a), 3.34 – 3.30 (m, 2H, H2-1’), 2.02 – 1.74 (m, 1H, H-
2’a), 1.74 – 1.65 (m, 3H, H-2’b, H2-4’), 1.56 – 1.44 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 
149.7, 141.7, 138.4, 136.4 (Cq BiPh), 129.4 – 102.5 (CAr BiPh), 102.5 (C-7’), 73.6 (C-6’), 72.3 (C-
4), 70.9 (C-5’), 68.9 (C-2), 68.1 (C-3), 63.8 (C-5), 61.4 (C-6), 55.1 (C-1’), 54.4 (C-1), 30.1 (C-4’), 









21 (26.4 mg, 0.06 mmol, 11% yield) was synthesized 
according to the Suzuki-Miyaura cross coupling general 
procedure.   1H NMR (400 MHz, MeOD) δ 7.55 – 7.47 (m, 
2H, HAr BiPh), 7.36 (d, J = 7.9 Hz, 2H, HAr BiPh), 7.08 (dd, J 
= 7.8, 1.6 Hz, 2H, HAr BiPh), 6.94 – 6.79 (m, 1H, HAr BiPh), 
4.51 (s, 2H, H2-6’), 4.26 (d, J = 1.3 Hz, 4H, H2-7’, H2-8’), 4.02 
(br s, 1H, H-4), 3.99 – 3.91 (m, 3H, H2-6, H-2), 3.87 (t, J = 3.7 Hz, 1H, H-3), 3.54 (t, J = 6.2 Hz, 2H, 
H2-5’), 3.51 – 3.41 (m, 2H, H-5, H-1a), 3.36 – 3.25 (m, 3H, H-1b, H2-1’), 1.91 – 1.62 (m, 4H, H2-2’, 
H2-4’), 1.50  – 1.46 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 145.2, 144.7, 141.3, 138.3, 135.4 
(Cq BiPh), 129.4 – 116.5 (CAr BiPh), 73.7 (C-6’), 72.4 (C-4), 70.9 (C-5’), 68.9 (C-2), 68.0 (C-3), 
65.7 (C-7’, C-8’), 63.8 (C-5), 61.3 (C-6), 55.1 (C-1’), 54.4 (C-1), 30.1 (C-4’), 24.6 (C-3’), 23.2 (C-2’). 
[α]20D = +5.20 (c = 0.50, MeOH). IR/cm-1: 3306, 2932, 2870, 1674, 1497, 1435, 1037, 1202, 1130, 




22 (15.9 mg, 0.032 mmol, 6% yield) was synthesized 
according to Suzuki-Miyamura cross coupling general 
procedure.  1H NMR (400 MHz, MeOD) δ 7.57 – 7.49 (m, 
2H, HAr BiPh), 7.38 (d, J = 8.0 Hz, 2H, HAr BiPh), 7.25 – 7.12 
(m, 2H, HAr BiPh), 7.01 (d, J = 8.2 Hz, 1H, HAr BiPh), 4.52 (s, 
2H, H2-6’), 4.19 (q, J = 5.3 Hz, 4H, H2-7’, H2-9’), 4.05 – 3.84 
(m, 5H, H-4, H2-6 H-2, H-3), 3.55 (t, J = 6.2 Hz, 2H, H2-5’), 
3.53 – 3.42 (m, 3H, H2-5, H-1a), 3.36 – 3.29 (m, 3H, H-1b, H2-1’), 2.18 (p, J = 5.5 Hz, 2H, H2-8’), 
1.95 – 1.80 (m, 1H, H-2’a), 1.79 – 1.62 (m, 3H, H-2’b, H2-4’), 1.51 – 1.47 (m, 2H, H2-3’). 13C NMR 
(100 MHz, MeOD) δ 153.0 – 137.6 (Cq BiPh), 129.4 – 121.0 (CAr BiPh), 73.6 (C-6’), 72.3 (C-4), 
72.0 (C-7’, C-9’), 71.0 (C-5’), 68.9 (C-2), 68.0 (C-3), 63.8 (C-5), 61.3 (C-6), 55.1 (C-1’), 54.4 (C-1), 
33.3 (C-8’), 30.1 (C-4’), 24.6 (C-3’), 23.2 (C-2’). [α]20D = +3.13 (c = 0.32, MeOH). IR/cm-1: 3381, 
2872, 2324, 1684, 1522, 1310, 1204, 1134, 1065. HRMS: found 488.26396 [C27H37NO7+H]+, 
calculated for [C27H37NO7+H]+ 488.26428. 
 
N-[5-((2’-Methyl[1,1’-biphenyl]-4-yl)-methoxy)-pentyl]-L-ido-1-deoxynojirimycin (23): 
23 (20.4 mg, 0.05 mmol, 10% yield) was synthesized according 
to the Suzuki-Miyaura cross coupling general procedure.   1H 
NMR (400 MHz, MeOD) δ 7.43 – 7.09 (m, 8H, HAr BiPh), 4.56 (s, 
2H, H2-6’), 4.03 (br s, 1H, H-4), 3.99 – 3.87 (m, 3H, H2-6, H-2), 
3.89 – 3.85 (m, 1H, H-3), 3.58 (t, J = 6.2 Hz, 2H, H2-5’), 3.54 – 
3.45 (m, 2H, H-5, H-1a), 3.40 – 3.29 (m, 3H, H-1b, H2-1’), 2.23 (s, 
3H, Me), 2.00 – 1.65 (m, 4H, H2-2’, H2-4’), 1.53 – 1.49 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) 
δ 142.9, 142.9, 138.4, 136.3 (Cq BiPh), 131.3 – 126.8 (CAr BiPh), 73.8 (C-6’), 72.3 (C-4), 71.1 (C-
5’), 68.9 (C-2), 68.0 (C-3), 63.8 (C-5), 61.3 (C-6), 55.1 (C-1’), 54.4 (C-1), 30.1 (C-4’), 24.6 (C-3’), 
23.3 (C-2’), 20.6 (C-7’). [α]20D = +6.25 (c = 0.45, MeOH). IR/cm-1: 3318, 1670, 1437, 1277, 1204, 
1074. HRMS: found 430.25863 [C25H35NO5+H]+, calculated for [C25H35NO5+H]+ 430.25880. 
 
N-[5-((4-(Thiophen-2-yl)benzyl]-4-yl)-methoxy)-pentyl]-L-ido-1-deoxynojirimycin (24): 
24 (2.2 mg, 0.005 mmol, 1% yield) was synthesized according to the Suzuki-Miyaura cross 
coupling general procedure.  1H NMR (850 MHz, MeOD) δ 7.66 – 7.58 (m, 2H, HAr BiPh), 7.40 – 
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7.32 (m, 4H, HAr BiPh), 7.09 (dd, J = 5.1, 3.6 Hz, 1H, HAr BiPh), 
4.52 (s, 2H, H2-6’), 4.02 (br s, 1H, H-4), 4.00 – 3.92 (m, 3H, H2-6, 
H-2), 3.86 (br s, 1H, H-3), 3.55 (t, J = 6.2 Hz, 2H, H2-5’), 3.53 – 
3.44 (m, 2H, H-5, H-1a), 3.39 – 3.32 (m, 3H, H-1b, H2-1’), 1.92 – 
1.73 (m, 2H, H2-2’), 1.73 – 1.69 (m, 2H, H2-4’), 1.52 – 1.48 (m, 
2H, H2-3’). 13C NMR (215 MHz, MeOD) δ 145.1, 139.1, 135.3 (Cq 
BiPh), 129.5 – 124.3 (CAr BiPh), 73.6 (C-6’), 72.4 (C-4), 71.0 (C-5’), 69.0 (C-2), 68.1 (C-3), 63.8 
(C-5), 61.4 (C-6), 55.1 (C-1’), 54.5 (C-1), 30.1 (C-4’), 24.6 (C-3’), 23.3 (C-2’). [α]20D = -3.57 (c = 
0.056, MeOH). IR/cm-1: 3366, 2924, 2326, 2872, 2326, 2207, 1684, 1506, 1202, 1134, 1101. 
HRMS: found 422.19949 [C22H31NO5S+H]+, calculated for [C22H31NO5S+H]+ 422.19957. 
 
 N-[5-((4-(Thiophen-3-yl)benzyl]-4-yl)-methoxy)-pentyl]-L-ido-1-deoxynojirimycin (25): 
25 (10.0 mg, 0.024 mmol, 5% yield) was synthesized according 
to Suzuki coupling general procedure. 1H NMR (400 MHz, 
MeOD) δ 7.69 – 7.59 (m, 3H, HAr BiPh), 7.48 – 7.44 (m, 2H, HAr 
BiPh), 7.37 (d, J = 8.0 Hz, 2H, HAr BiPh), 4.51 (s, 2H, H2-6’), 4.02 
(br s, 1H, H-4), 3.99 – 3.91 (m, 3H, H2-6, H-2), 3.86 (t, J = 3.7 Hz, 
1H, H-3), 3.55 (t, J = 6.1 Hz, 2H, H2-5’), 3.53 – 3.41 (m, 2H, H-5, 
H-1a), 3.31 – 3.15 (m, 3H, H-1b, H2-1’), 1.96 – 1.64 (m, 4H, H2-2’, H2-4’), 1.51 – 1.47 (m, 2H, H2-
3’). 13C NMR (100 MHz, MeOD) δ 141.8, 137.1, 135.3 (Cq BiPh), 128.1 – 119.9 (CAr BiPh), 72.3 (C-
6’), 70.9 (C-4), 69.5 (C-5’), 67.5 (C-2), 66.6 (C-3), 62.4 (C-5), 60.0 (C-6), 53.6 (C-1’), 53.0 (C-1), 
28.7 (C-4’), 23.2 (C-3’), 21.8 (C-2’). [α]20D = +9.00 (c = 0.20, MeOH).  IR/cm-1: 3319, 2926, 2862, 




26 (1.8 mg, 0.004 mmol, 1% yield) was synthesized according 
to the Suzuki-Miyaura cross coupling general procedure.   1H 
NMR (600 MHz, MeOD) δ 7.55 – 7.44 (m, 2H, HAr BiPh), 7.39 – 
7.17 (m, 5H, HAr BiPh), 4.47 (s, 2H, H2-6’), 4.10 (d, J = 12.4 Hz, 
1H, H-6a), 3.88 (dd, J = 12.5, 3.1 Hz, 1H, H-6b), 3.67 (ddd, J = 
11.5, 9.2, 5.0 Hz, 1H. H-2), 3.59 (t, J = 9.8 Hz, 1H, H-4), 3.53 (t, J = 
6.2 Hz, 2H, H2-5’), 3.44 (dd, J = 12.0, 4.9 Hz, 1H, H-1a), 3.39 – 3.35 (m, 1H, H-1’a), 3.36 (t, J = 9.2 
Hz, 1H, H-3), 3.22 – 3.14 (m, 1H, H-1’b), 3.02 (dd, J = 10.3, 2.9 Hz, 1H, H-5), 2.97 (t, J = 11.7 Hz, 
1H, H-1b), 1.89 – 1.73 (m, 2H, H2-2’), 1.72 – 1.66 (m, 2H, H2-4’), 1.52 – 1.48 (m, 2H, H2-3’). 13C 
NMR (150 MHz, MeOD) δ 140.1, 139.2 (Cq BiPh), 132.5 – 122.3 (CAr BiPh), 78.2 (C-3), 73.1 (C-
6’), 71.1 (C-5’), 68.8 (C-4), 67.8 (C-2), 67.4 (C-5), 54.9 (C-6), 54.8 (C-1), 54.3 (C-1’), 30.1 (C-4’), 
24.5 (C-3’), 23.9 (C-2’). [α]20D = -4.00 (c = 0.20, MeOH).  IR/cm-1: 3402, 2943, 2868, 2324, 2241, 




27 (2.5 mg, 0.006 mmol, 1% yield) was synthesized according 
to the Suzuki-Miyaura cross coupling general procedure.   1H 
NMR (850 MHz, MeOD) δ 7.67 – 7.59 (m, 3H, HAr BiPh), 7.50 – 
7.43 (m, 2H, HAr BiPh), 7.40 – 7.35 (m, 2H, HAr BiPh), 4.52 (s, 2H, 
H2-6’), 4.10 (d, J = 12.4 Hz, 1H, H-6a), 3.88 (dd, J = 12.5, 3.2 Hz, 
1H, H-6b), 3.66 (ddd, J = 11.3, 9.3, 4.9 Hz, 1H, H-2), 3.59 – 3.57 
(m, 1H, H-4), 3.56 (t, J = 6.2 Hz, 2H, H2-5’), 3.43 (dd, J = 12.1, 5.0 Hz, 1H, H-1a), 3.37 (dt, J = 12.8, 
4.9 Hz, 1H, H-1’a), 3.35 (t, J = 9.3 Hz, 1H, H-3), 3.19 (td, J = 12.5, 5.0 Hz, 1H, H-1’b), 3.01 (dd, J = 
10.4, 3.0 Hz, 1H, H-5), 2.97 (t, J = 11.7 Hz, 1H, H-1b), 1.86 – 1.73 (m, 2H, H2-2’), 1.72 – 1.68 (m, 




– 121.3 (CAr BiPh), 78.2 (C-3), 73.7 (C-6’), 70.9 (C-5’), 68.8 (C-4), 67.8 (C-2), 67.4 (C-5), 54.9 (C-
6), 54.8 (C-1), 54.3 (C-1’), 30.1 (C-4’), 24.5 (C-3’), 23.9 (C-2’). [α]20D = -15.00 (c = 0.20, MeOH). 
IR/cm-1: .3364, 2918, 2349, 1670, 1506, 1205, 1138. HRMS: found 422.19948 [C22H31NO5S+H]+, 
calculated for [C22H31NO5S+H]+ 422.19957. 
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Deoxynojirimycin (DNJ) and its congeners are inhibitors of a wide variety of glycosidases 
as well as some glycosyltransferases. N-alkyl DNJ derivatives have been identified as 
compounds with considerable therapeutic potential for the treatment of various diseases 
including diabetes and several lysosomal storage disorders (LSDs). Two characteristic 
iminosugars often included in studies aimed for the design of glycoprocessing enzymes are the 
natural product, DNJ, and its C-5 epimer, L-ido-DNJ.1 N-butyl-DNJ is a moderately potent 







glucosylceramide synthase (GCS) inhibitor and based on this virtue used in the clinic for the 
treatment of Gaucher disease in what is termed substrate reduction therapy. Enlarging the 
substituent on the DNJ nitrogen improves GCS inhibitory potency, but at the same time results 
in more potent off-target inhibition. Similarly substituted, L-ido-configured iminosugars appear 
to be much cleaner: they inhibit GCS with equal or (slightly) superior potency compared to 
their DNJ counterparts and are, with the exception of neutral glucosylceramidase (GBA2), 
remarkably more selective. These observations invite the question, which underlies the work 
described in this Chapter, whether hybrid piperidines bearing two α-geminal hydroxymethyl 
moieties (thus featuring both DNJ and L-ido-DNJ hydroxymethyls) would be valid GCS inhibitors, 
and if so, would be (even) more selective than existing N-alkyl-iminosugars.  
Figure 1 depicts the lead-iminosugars that led to the studies described here. N-AMP-DNJ (1, 
MZ-21) is a potent GCS/GBA1/GBA2 inhibitor, and its L-ido congener (2, MZ-31), has (slightly) 
improved GCS/GBA2 inhibitory potency offset by considerable loss in GBA1 inhibitory activity. 
N-AMP D-galacto DNJ (3) and N-AMP L-altro DNJ (4) are the C-4 epimers of N-AMP DNJ and N-
AMP L-ido-DNJ, respectively. Compound 3 is a moderately potent GCS inhibitor and a potent 
GBA2 inhibitor, and intestinal glycosidases are also inhibited by this compound. Epimer 4 in 
contrast is only a moderate GBA2 inhibitor with low or no inhibition of intestinal glycosidases, 
GCS and GBA1. 
Figure 1: IC50 values of N-AMP DNJ isosteres for GlcCer metabolizing enzymes 
 
*IC50 data from Wennekes el al.1 




These findings led to the design of a number of hybrid iminosugars bearing two geminal 
hydroxymethyl substituents, as depicted in Figure 2. The list of target compounds encompasses 
the configurational D-gluco-L-ido (6) and D-galacto-L-altro (7) pairs, but also a choice number of 
compounds emulating in configuration other pyranosides and that may be of interest in their 
own right (8, 9 and their N-alkyl derivatives). 
Figure 2: Structures of N-AMP α-geminal bishydroxymethyl iminosugars  
 
Results and discussion 
Synthesis of 5-C-hydroxymethyl-DNJ (6) 
Pawar et al. documented the synthesis of α-geminal bishydroxymethyl piperidines, which 
was adopted in the synthesis of D-gluco-L-ido configured compounds 6  and its C-2 and C-3 
epimers.2 In the first instance, the synthesis of D-gluco-L-ido DNJ (6) was undetaken following 
the literature procedure (Scheme 1).2 Correspondingly, D-diacetone glucose (D-DAG) was 
treated with sodium hydride and benzyl bromide to give 10. Protonolysis of 10 afforded diol 
11. Regioselective benzylation under the agency of dibutyltin oxide, sodium hydride and benzyl 
bromide afforded 12 in high yield. The secondary alcohol in 12 was oxidized using PCC to yield 
ketone 13. In situ formation of dichloromethane carbanion, from dichloromethane and lithium 
di-isopropyl amide, and subsequent addition to ketone 13 afforded methylene dichloride 14. 
An α-azido group was introduced at C-5 in 14 via a Jocic Reeve reaction to give 15. Azido-
aldehyde 15 was reduced using sodium borohydride to afford azido alcohol 16. Demasking of 
the isopropylidene protecting group, followed by hydrogenation and subsequent reductive 






Scheme 1: Synthesis of 5-C-hydroxymethyl-1-deoxynojirimycin (6)  
 
 
Reagents and conditions: [a] NaH, BnBr, DMF, 97%; [b] AcOH, H2O, 80%; [c] 1) Bu2SnO, toluene, 2) NaH, 
BnBr, 90%; [d] PCC, DCM, 53%; [e] LDA, DCM, THF, 55%; [f] NaN3, DMF, TBAI, 115 ℃, 69%; [g] NaBH4, 
89%; [h] TFA, H2O, 68%; [i] H2, Pd/C, 5 bar, 74%. 
Synthesis of 5-C-hydroxymethyl-1-deoxy-D-galactonojirimycin (7) 
It was anticipated that the chemical transformation depicted in Scheme 1 could also be 
applied on the C-4 epimer of diacetone glucose: diacetone galactose, which would give access to 
D-galacto-L-altro-iminosugar 7. Tosylation of DAG3 and subsequent β-elimination of tosylate 18 
gave glycal 194 in high yield (Scheme 2). Hydroboration and subsequent diastereoselective 
oxidation afforded the desired diacetone galactose 20 in good yield.5 Compound 20 was 
subjected to the transformations as outlined above for the synthesis of 6. The hydroxyl 
functionality in 20 was protected using benzyl bromide to give 21. Isopropylidene demasking 
of 21 with aqueous acidic acid afforded diol 22. Regioselective benzylation with the aid of 
dibutyltin oxide afforded 23. Alcohol 23 was oxidized with PCC to give ketone 24. The key step 
in this synthesis is the introduction of dichloromethylene onto the 5-ketone 24 to form 25, a 
reaction that proceeded in an even better yield than that on glucose isomer 14. Compound 25 
was next reacted with sodium azide in DMF at 115 ℃ to uneventfully give 26 in a yield of 93%.  
Aldehyde 26 was reduced to give alcohol 27, which underwent a TFA-water hydrolysis to 
remove the isopropyl protecting group after which the resulting intermediate 28 was exposed 




to 5 bar H2 atmosphere and a catalytic amount of palladium on carbon to remove the benzyls, 
reduce the azide to the amine and effect an ensuing intramolecular reductive amination to yield 
target iminosugar 7 (12% over 12 steps). 
 
Scheme 2: Synthesis of 5-C-hydroxymethyl-1-deoxy-D-galactonojirimycin (7) 
 
Reagents and conditions: [a] p-TsCl, pyridine, DCM, 60 ℃, 98%; [b] tBuOK, THF, 0 ℃, 91%; [c] 1) 
BH3∙THF, THF; 2) NaOH, H2O2, 75%; [d] NaH, BnBr, DMF; [e] AcOH, H2O, 86%, 2 steps; [f] 1) Bu2SnO, tol, 
2)TBABr, BnBr, 82%; [g] PCC, DCM, 92%; [h] LDA, DCM, -78 ℃, 74%; [i] NaN3, TBAI, DMF, 115 ℃, 93%; [j] 
NaBH4, MeOH, 0 ℃, 82%; [k] TFA, H2O, 0 ℃, 63%; [l] Pd/C, H2, EtOH, 5 bar, 91%. 
Synthesis of 5-C-hydroxymethyl-1-deoxy-D-mannonojirimycin (8) and 5-C-
hydroxymethyl-1-deoxy-D-allonojirimycin (9) 
The D-manno-L-gulo iminosugar 8 and D-allo-L-talo iminosugar 9 were synthesized as 
described by Pawar et al.2 The synthesis of 8 starts with TBATB catalyzed isopropylidenation of 
D-mannose to give 29.6 Benzylation of 29 gained 30 and subsequent acidic hydrolysis of the 
acetal protecting group afforded 31. Alcohol 31 underwent the 7-step transformation as 






Scheme 3: Synthesis of 5-C-hydroxymethyl-1-deoxy-D-mannonojirimycin (8) 
 
Reagents and conditions: [a] TBATB, acetone, 64%; [b] 18-crown-6, BnBr, KOH, THF, 75%; [c] AcOH, 
H2O, r.t., 81%; [d] 1) Bu2SnO, tol; 2) BnBr, TBABr, 76%; [e] PCC, DCM, 30 ℃, 88%; [f] LDA, THF, -78 ℃, 
66%; [g] NaN3, TBAI, DMF, 115 ℃, 87%; [h] NaBH4, MeOH, 0 ℃, 80%; [i] TFA, H2O, 0 ℃, 45%; [j] Pd/C, H2, 
EtOH, 5 bar, 82%. 
In a similar vein, diacetone allose 39, obtained via oxidation and stereoselective reduction 
from D-DAG, was transformed to produce compound 9 (Scheme 4). The C-3 alcohol of D-DAG 
was oxidized to form aldehyde 38, which was reduced by sodium borohydride to give diacetone 
D-allose 39 in 74% yield over the 2 steps. Compound 9 was prepared from 39 as described 
previously for the synthesis of 6 with an overall yield of 9% in 9 steps.  
With the four α-geminal bis-(hydroxymethyl) piperidines (6, 7, 8 and 9) in hand, the target 
hydrophobic iminosugars were prepared by treating 6 - 9 with bromides 48 – 55 (Scheme 5A; 
see for the final structures Figures 4, 5, 6 and 7). As an example, the synthesis of N-AMP D-
gluco-L-ido DNJ (61) is depicted in Scheme 5B. Treatment of D-gluco-L-ido DNJ (6) with bromide 
48 and potassium carbonate in DMF gave 61 in 11% yield (Scheme 5B). Yields of the N-alkyl 
derivatives vary from 2% to 46% after HPLC purification (see the experimental section for 
details). 
 




Scheme 4: 5-C-Hydroxymethyl-1-deoxy-D-allonojirimycin (9) 
 
Reagents and conditions: [a] PCC, DCM, 81%; [b] NaBH4, EtOAc, H2O, 92%; [c] NaH, BnBr, DMF, 90%; [d] 
AcOH, H2O, 46%; [e] 1) Bu2SnO, tol; 2) BnBr, TBABr, 76%; [f] PCC, DCM, 64%; [g] DCM, LDA, THF, -78 ℃, 
99%; [h] NaN3, DMF, 115 ℃, 71%; [i] NaBH4, MeOH, 0 ℃, 81%; [j] TFA, H2O, 0 ℃, 70%; [k] Pd/C, H2, EtOH, 
5 bar, 81%. 
Scheme 5: N-alkylation of α-geminal hydroxymethyl iminosugars 
 






D-Gluco-L-ido hybrid iminosugars 
Figure 3: Enzyme inhibition assay results: IC50 values, for D-gluco-L-ido DNJ and its N-
alkyl derivatives as inhibitors of GCS, GBA1 and GBA2, in comparision with the 
corresponding D-gluco-DNJ and L-ido-DNJ analogues 
 
 




The D-gluco-L-ido iminosugars (6, 56 - 62) were tested on their inhibitory potency against 
the glucosylceramide metabolizing enzymes, GCS, GBA1 and GBA2. The corresponding D-gluco 
(1, 63 - 69) and L-ido (2, 70 - 76) iminosugar derivatives were included as reference 
compounds to determine the effect of the additional hydroxymethyl group on the C-5 position. 
The results are tabulated in Figure 3. From the results it can be seen that the DNJ and L-ido-DNJ 
derivatives are without exception the more potent GCS inhibitors when compared with their D-
gluco-L-ido configured α-geminal bishydroxymethyl piperidine counterparts, irrespective of the 
nature of the N-alkyl substituent. In line with what was reported previously the L-ido 
iminosugars proved to be the more potent GCS inhibitor when compared with the D-gluco-
configured equivalent. Based on this result, it can be concluded that installment of an extra C-5 
hydroxymethyl group at the carbon already bearing such a substituent is detrimental for GCS 
inhibition. 
When looking at GBA1 inhibition values, it is remarkable that, whereas the hybrid 
iminosugars are all weaker inhibitors compared to the D-gluco configured molecules, they 
sometimes outperform their L-ido counterparts. This may indicate that the D-gluco 
configuration is preferred by GBA1, that an additional hydroxymethyl group may increase the 
steric hindrance and thus affect the inhibitory activity, but that this may be less detrimental 
than altering the configuration at C-5. 
The effect of adding an extra hydroxymethyl at C-5 on GBA2 inhibition is as was noted for 
GCS inhibitory activity: the D-gluco-L-ido hybrid iminosugars are still relatively potent GBA2 
inhibitors, but much less so than the corresponding D-gluco and L-ido compounds.  
D-Galacto-L-altro hybrid iminosugars 
In Figure 4, the inhibitory potencies towards GCS, GBA and GBA2 of the D-galacto-L-altro 
hybrid iminosugars (7, 77 - 83) as well as that of their and the parent compounds (D-galacto 
isomers, 3, 84 – 90; L-altro isomers, 4, 91 – 97) are depicted. The D-galacto-L-altro hybrids do 
inhibit GCS to some extend, however not at the concentrations at which the D-galacto and L-
altro iminosugars inhibit GCS. None of the compounds, with the exception of D-galacto AMP (3, 
IC50 GBA1 = 1 μM) inhibit GBA. In contrast, several of the D-galacto configured iminosugars 
inhibit GBA2 in the nanomolar range and are even more potent than the corresponding DNJ (i.e. 
64, 1 and 69) and L-ido-DNJ derivatives (i.e. 71, 2 and 76). The D-galacto-L-altro hybrid 
compounds, though, are only weak GBA2 inhibitors, if at all, and also here it appears that the 






Figure 4: Enzyme inhibition assay results: IC50 values, for D-galacto-L-altro-DNJ and its N-
alkyl derivatives as inhibitors of GCS, GBA1 and GBA2, in comparision with the 
corresponding D-galacto-DNJ and L-altro-DNJ analogues  
 
D-Manno-L-gulo iminosugars 
As shown in Figure 5, none of the D-manno-L-gulo hybrid iminosugars potently inhibit GCS. 
The most active GCS inhibitor in this series is the biphenyl derivative 104. Remarkably, 
however, the hybrid molecules do sometimes outperform their D-manno and L-gulo configured 




counterparts, in terms of GCS inhibitory potency (compare, for instance the GCS inhibitory 
potency of 102 with 110 and 118, and 103 with 111 and 109). The potency of this series as 
GBA1 and GBA2 inhibitors is modest at most. 
Figure 5: Enzyme inhibition assay results: IC50 values, for D-manno-L-gulo-DNJ and its N-
alkyl derivatives as inhibitors of GCS, GBA1 and GBA2, in comparision with the 






D-Allo-L-talo hybrid iminosugars 
Figure 6: Enzyme inhibition assay results: IC50 values, for D-allo-L-talo-DNJ and its N-
alkyl derivatives as inhibitors of GCS, GBA1 and GBA2, in comparision with the 
corresponding D-allo-DNJ and L-talo-DNJ analogues 
 
The results of the biological assays of the D-allo-L-talo hybrid iminosugar series (9, 121 - 
127), D-allo series (128 - 135) and L-talo series (136 - 143) are given in Figure 6. As can be 




seen, the series contains no GCS/GBA/GBA2 inhibitors with remarkable potency. Obviously, the 
rather drastic deviation of the glucose configuration is detrimental for inhibition of the three 
glucose-processing enzymes, and addition of an extra hydroxymethyl does not help. 
Conclusion 
In this Chapter, iminosugars that encompass both the D-glucose and L-idose structural 
properties in one molecule as well as its C-2, C-3 and C-4 epimers were synthesized. These four 
sets of hybrid compounds (6, 7, 8 and 9) were N-alkylated with various hydrophobic 
substitutes which produced a library of 28 N-alkylated derivatives. This set and their 
corresponding DNJ congeners have been tested as inhibitors for the GlcCer metabolic enzymes 
(GCS, GBA1 and GBA2).  
Figure 7: Enzyme inhibition assay results: IC50 values of the N-AMP iminosugar 
derivatives  
 
Generally, the hybrid compounds are weaker GCS inhibitors compared to both D-configured 
and L-configured iminosugars (Figure 7), with the D-manno-L-gulo compound 103 being an 





generally more potent than their corresponding L-compounds while less potent than the D-
compounds. This may indicate that the D-configuration at C-5 is more beneficial for the 
iminosugar to bind to GBA1, and that an additional hydroxymethyl has a negative effect in 
binding to the active site of the enzyme. There is no specific rule observed for how the extra 
hydroxymethyl group affects GBA or GBA2 activity, and general trends appear the same as for 
GCS activity. It should be noted that many of the compounds described here are of a 
configuration that is rather far removed from that of glucopyranose. It may therefore well be 
that the compound collections may contain inhibitors for glycoprocessing enzymes other than 
those assayed here. It would therefore be of interest to screen the compound collections against 
other glycosidases, including galactosidases and mannosidases that are of interest in their own 
right in biological and biomedical research. 
Experimental Section 
Enzyme inhibition assays:  The potencies (IC50 values) of the N-alkyl-DNJ derivatives as GCS, 
GBA1 and GBA2 inhibitors were determined by exposing cells or enzyme preparations to an 
appropriated range of iminosugar concentrations. 
 
GCS: IC50 values for GCS activity were measured using living cells with NBD-ceramide as 
substrate.7 Briefly, cells were incubated with 50 nmol C6-NBD-ceramide (6-[N-methyl-N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)aminododecanoyl]sphingosine) in the presence of increasing 
compound concentrations. The cells were harvested after 2h followed by lipid extraction. The 
formed C6-NBD-glucosylceramide was quantified using a Molecular Dynamics Typhoon 
phosphor imaging device. IC50 values were determined from the titration curves. The 
experiment was performed twice. 
 
GBA1: IC50 values for lysosomal GBA1 were measured using 4-methylumbeliferyl-β-D-glucoside 
as substrate.8 Briefly, recombinant GBA1 was incubated with increasing compound 
concentrations for 30 min at 0 ℃. Enzyme activity was determined with 3.7 mM 4-
methylumbelliferyl-β-D-glucopyranoside in McIlvaine buffer (0.1 M citrate and 0.2 M phosphate 
buffer), pH 5.2, 0.1% Triton X-100 (v/v) and sodium taurocholate (0.2%, w/v). Assays 
performed in triplicate were incubated at 37 ℃ for 30 min and quenched by the addition of 
glycine/NaOH (0.2 mL, pH 10.6). The amount of liberated 4-methylumbeliferyl was determined 
with a PerkinElmer Life Sciences LS30 fluorimeter, excitation wavelength 366 nm, emission 
wavelength 445 nm. 
 
GBA2: IC50 values for the non-lysosomal glucocerebrosidase (GBA2) were measured with 4-
methylumbeliferyl-β-D-glucoside as substrate.8 GBA2-rich membrane suspensions were 
prepared from enzyme-overexpressing HEK cells by sonicating, and the suspension was pre-
incubated for 30 min at 37 ℃ with conduritol-B-epoxide (1 mM, CBE, Sigma) to inhibit the 
lysosomal glucocerebrosidase (GBA1). The prepared GBA2-rich suspension was then incubated 
with increasing compound concentrations for another 30 min, and then incubated with 3.7 mM 
4-methylumbeliferyl-β-D-glucoside in McIlvaine buffer (0.1 M citrate and 0.2 M phosphate 
buffer), pH 5.8. Assays were incubated at 37 ℃ for 1 hour and quenched by the addition of 
glycine/NaOH (0.2 mL, pH 10.6). The amount of liberated 4-methylumbeliferyl was determined 




with a PerkinElmer Life Sciences LS30 fluorimeter, excitation wavelength 366 nm, emission 
wavelength 445 nm. Assays were performed in triplicate. 
 
General compound synthesis, purification and analysis methods: All solvents and reagents 
were obtained commercially and used as received unless stated otherwise. Reactions were 
executed at room temperature unless stated otherwise. Moisture sensitive reactions were 
performed under argon atmosphere. Water was removed from starting compounds by 
repetitive coevaporation with toluene. Solvents were removed by evaporation under reduced 
pressure. DCM, DMF, and THF were dried over activated 4Å molecular sieves for at least 12 
hours before use. Compounds were visualized during TLC analyses by UV (254 nm), and with 
the following staining solutions: aqueous solution of KMnO4 (5 g/L) and K2CO3 (25 g/L). 
Visualization of hemiacetals and glycosides was achieved by spraying with a solution of 20% 
H2SO4 in ethanol followed by charring at ≈ 200 ℃. Column chromatography purification was 
performed on silica gel (40-63 µm). 1H and 13C-APT NMR spectra were recorded on a Bruker AV 
400 (400/100 MHz) or Bruker 600 (600/150 MHz) spectrometer in CDCl3, MeOD or D2O. 
Chemical shifts are given in ppm (δ) relative to TMS as internal standard (1H NMR in CDCl3) or 
the signal of the deuterated solvent.9 Coupling constants (J) are given in Hz. High resolution 
mass spectra were recorded by direct injection (2 µL of a 2 µM solution in 
water/acetonitrile/tert-butanol 1:1:1 v/v/v) on a mass spectrometer (Thermo Finnigan LTQ 
Orbitrap) equipped with an electrospray ion source with resolution R = 60000 at m/z 400 
(mass range m/z = 150-2000). IR spectra were recorded on a Shimadzu FTIR-8300 and are 
reported in cm-1. Optical rotation were measured on an automatic polarimeter of sodium D-line, 
at λ = 589 nm. Size-exclusion purifications were performed on an ÄKTA-explorer, column size d 
= 26 mm, l = 60 mm, mobile phase NH4HCO3 (0.15 M) in H2O, flow 1.5 mL/min. HPLC 
Purification were performed on a Prep LCMS, Gemini from Phenomenex B.V. (C-18, 110 Å, 5 µm, 
19 x 150 mm column). 
 
General Procedure: Alkylation of iminosugars. To a mixture of the bromide chain (0.3 mmol, 
see Scheme 5A) and K2CO3 (0.4 mmol) was added a solution of the 5-hydroxymethyl 
nojirimycin derivative (0.2 mmol) in DMF (1 mL). The reaction suspension was stirred at 80 ℃ 
overnight. After cooling to room temperature, the mixture was filtered and concentrated. The 
crude compound was purified with HPLC.  
Figure 8: Proton and carbon NMR numbering of N-alkylated iminosugars 
 
Synthesis of 5-C-hydroxymethyl-1-deoxynojirimycin (6) 
3-O-Benzyl-1,2:5,6-di-O-isopropylidene-α-D-gluco-furanoside (10): 
BnBr (7.10 mL, 59.8 mmol) was added to a cooled (0 ℃) and stirred 
mixture of diacetone-D-glucose (13.0 g, 49.9 mmol) and NaH (60% on 
mineral oil, 6.00 g, 150 mmol) in DMF (150 mL). After 18 h, TLC analysis 
showed complete conversion of starting material. Methanol was added to 





(250 mL) and extracted with Et2O (3 x). The organic layers were combined and washed 
successively with sat. aq. NaHCO3 and water, dried (Na2SO4), filtered and concentrated. The 
crude product was purified by silica gel column chromatography (4:1, PE:EtOAc) to give pure 
10 (16.9 g, 48.2 mmol)  in yield of 97% as light yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.40 – 
7.25 (m, 5H, HAr Bn), 5.90 (d, J = 3.7 Hz, 1H, H-1), 4.72 – 4.55 (m, 3H, 2 x CHH Bn, H-2), 4.37 (dt, J 
= 7.8, 6.0 Hz, 1H, H-5), 4.16 – 4.10 (m, 2H, H-6a, H-4), 4.05 – 3.97 (m, 2H, H-6b, H-3), 1.50 (s, 3H, 
CH3), 1.43 (s, 3H, CH3), 1.38 (s, 3H, CH3), 1.31 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 137.7 (Cq 
Bn), 128.5, 128.0, 127.8 (CHAr Bn), 111.7, 108.9 (2 x Cq isopropyl), 105.2 (C-1), 82.6 (C-2), 81.6 
(C-3), 81.3 (C-4), 72.5 (C-5), 72.3 (CH2 Bn), 67.4 (C-6), 27.0, 26.9, 26.4, 25.6 (4 x CH3). 
 
3-O-Benzyl-1,2-O-isopropylidene-α-D-gluco-furanoside (11): 
10 (14.0 g, 40.0 mmol) was dissolved in a mixture of acetic acid (45 mL) 
and water (20 mL), and the reaction mixture was stirred for 72 h at r.t. 
After TLC analysis showed complete consumption of starting material, 
ethyl acetate (100 mL) was added. The organic layer was washed 
successively with sat. aq. NaHCO3, water and brine. The organic layer was dried (Na2SO4), 
filtrated and concentrated. The crude product was purified by silica gel column 
chromatography to gain 20 (9.92 g, 32.0 mmol) in 80% yield.  1H NMR (400 MHz, CDCl3) δ 7.40 
– 7.27 (m, 5H, HAr Bn), 5.91 (dd, J = 3.9, 1.5 Hz, 1H, H-1), 4.70 (dd, J = 11.8, 1.9 Hz, 1H, CHH Bn), 
4.60 (dd, J = 3.9, 1.5 Hz, 1H, H-2), 4.56 (d, J = 11.8 Hz, 1H, CHH Bn), 4.13 – 4.06 (m, 2H, H-3, H-4), 
4.02 (dd, J = 8.9, 4.8 Hz, 1H, H-5), 3.79 (d, J = 11.0 Hz, 1H, H-6a), 3.67 (dd, J = 11.6, 5.5 Hz, 1H, H-
6b), 1.47 (s, 3H, CH3), 1.30 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 137.3 (Cq Bn), 128.7, 128.2, 
127.9 (CHAr Bn), 111.9 (Cq isopropyl), 105.2 (C-1), 82.2 (C-2), 82.0 (C-3), 80.0 (C-4), 72.2 (C-5), 
69.2 (CH2 Bn), 64.7 (C-6), 26.8, 26.3 (2 x CH3). 
 
3,6-Di-O-benzyl-1,2-O-isopropylidene-α-D-gluco-furanoside (12): 
To a solution of 11 (8.29 g, 26.7 mmol) in toluene (250 mL) was added 
dibutyl tin oxide (10.0 g, 40.0 mmol). The reaction mixture was heated 
to reflux and stirred for 8 hours under Dean-Stark conditions. TBABr 
(1.03 g, 4.04 mmol) and benzyl bromide (6.36 mL, 53.6 mmol) were 
added to the solution. The reaction mixture was refluxed for another 18 h. The solvent was 
evaporated, and the residue was purified by silica gel column chromatography (5:1 → 3:1, 
PE:EtOAc) to give 12 (9.61 g, 24.0 mmol, yield 90%). 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.27 
(m, 10H, HAr Bn), 5.94 (d, J = 3.7 Hz, 1H, H-1), 4.68 (d, J = 11.7 Hz, 1H, CHH Bn), 4.59 – 4.47 (m, 
3H, 3 x CHH Bn), 4.61 (d, J = 3.6 Hz, 1H, H-2), 4.21 – 4.15 (m, 2H, H-3, H-5), 4.11 (d, J = 1.9 Hz, 
1H, H-4), 3.75 (d, J = 9.2 Hz, 1H, H-6a), 3.61 (d, J = 9.9 Hz, 1H, H-6b), 1.49 (s, 3H, CH3), 1.32 (s, 
3H, CH3). 13C NMR (100 MHz, CDCl3) δ 138.0, 137.3 (Cq Bn), 128.6, 128.5, 128.1, 127.8 (CHAr Bn), 
111.8 (Cq isopropyl), 105.1 (C-1), 82.3 (C-2), 82.1 (C-4), 79.8 (C-3), 73.5 (CH2 Bn), 72.4 (CH2 Bn), 
72.1 (C-6), 68.1 (C-5), 26.8, 26.3 (2 x CH3). 
 
1,2-O-Isopropyl-3,6-di-O-benzyl-α-D-xylo-hexofuranoside-5-ulose (13): 
12 (8.62 g, 21.5 mmol) dissolved in dry DCM (100 mL) was added to a 
suspension of pyridinium chlorochromate (PCC, 15.34 g, 71.1 mmol) and 
activated 4 Å molecular sieves in dry DCM (300 mL). The reaction 
mixture was stirred under argon atmosphere at 30 ℃ overnight. 2-
Propanol was then added to quench the reaction. Diethyl ether (200 mL) was added to dilute 
the dark brown suspension and the mixture was filtered through a pad of Celite. The filtrate 
was concentrated, and the residue was purified by silica gel column chromatography and to 
give pure 13 (4.54 g, 11.40 mmol, yield 53%).  1H NMR (400 MHz, CDCl3) δ 7.46 – 7.22 (m, 10H, 
HAr Bn), 6.05 (d, J = 3.6 Hz, 1H, H-1), 4.82 (d, J = 3.7 Hz, 1H, H-4), 4.62 (d, J = 3.6 Hz, 1H, H-2), 
4.60 (d, J = 12.0, 1H, CHH Bn), 4.59 (d, J = 12.0 Hz, CHH Bn), 4.50 (d, J = 11.8 Hz, 1H, CHH Bn), 
4.49 (d, J = 11.8 Hz, 1H, CHH Bn), 4.46 (d, J = 18.8 Hz, 1H, H-6a), 4.39 (d, J = 18.8 Hz, 1H, H-6b), 




4.38 (d, J = 3.7 Hz, 1H, H-3), 1.49 (s, 3H, CH3), 1.34 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 
204.6 (C=O), 137.4, 136.7 (Cq Bn), 128.6, 128.5, 128.2, 127.9 (CHAr Bn), 112.5 (Cq isopropyl), 




To a cooled (-78 ℃) solution of LDA (36 mmol, 18 mL, 2 M in THF) in dry 
THF (45 mL) was added DCM (18 mL). After 30 minutes, 13 (4.48 g, 11.3 
mmol) dissolved in DCM (18 mL) was added. After another 30 minutes 
temperature was allowed to rise to r.t. When TLC analysis indicated 
complete conversion of starting material, sat. aq. NH4Cl was added. The mixture was extracted 
with EtOAc (100 mL) and the organic layer was washed successively with water and brine, 
dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column 
chromatography (20:1 → 10:1, pentane:EtOAc) to gain 14 (3.00 g, 6.21 mmol, yield 55%), as a 
mixture of two inseparable diastereo-isomers at a ratio of 3:2. NMR data of the major 
diastereoisomer: 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.00 (m, 10H, HAr Bn), 6.11 (s, 1H, CHCl2), 
5.89 (d, J = 3.9 Hz, 1H, H-1), 4.58 (d, J = 3.9 Hz, 1H, H-2), 4.56 – 4.43 (m, 5H, H-4, 2 x CH2 Bn), 
4.36 (d, J = 3.0 Hz, 1H, H-4), 3.94 (d, J = 10.0 Hz, 1H, H-6a), 3.85 (d, J = 10.0 Hz, 1H, H-6b), 1.41 
(s, 3H, CH3), 1.25 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 137.9, 135.9 (Cq Bn), 128.8 – 127.7 
(CHAr Bn), 112.0 (Cq isopropyl), 103.7 (C-1), 84.9 (C-3), 81.5 (C-2), 79.7 (C-5), 75.8 (C-4), 73.8, 




 A mixture of 14 (2.69 g, 5.58 mmol), TBAI (1.07 g, 2.89 mmol) and NaN3 
(1.96 g, 30.0 mmol) in DMF (60 mL) was stirred at 115 ℃ for 18 h. After 
TLCMS analysis showed complete consumption of 14, the reaction was 
quenched by the addition of water (100 mL) and extracted with EtOAc 
(75 mL x 3). The combined organic layers were washed with water (2 x) and brine (2 x), dried 
(Na2SO4), filtered, and concentrated. The residue was purified by silica gel column 
chromatography (10:1, pentane:EtOAc) to give 15 (1.74 g, 3.85 mmol, yield 69%). It is a 
mixture of two inseparable diastereo-isomers at a ratio of 3:2. NMR data of the major 
diastereoisomer: 1H NMR (400 MHz, CDCl3) δ 9.69 (s, 1H, CHO), 7.47 – 7.30 (m, 10H, HAr Bn), 
5.93 (d, J = 3.6 Hz, 1H, H-1), 4.67 – 4.41 (m, 5H, H-4, 2 x CH2 Bn), 4.28 (d, J = 3.0 Hz, 1H, H-4), 
4.08 (d, J = 10.2 Hz, 1H, H-6a), 4.05 (d, J = 3.0 Hz, 1H, H-3), 3.86 (d, J = 10.2 Hz, 1H, H-6b), 1.48 
(s, 3H, CH3), 1.32 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 195.3 (C=O), 137.2, 136.3 (Cq Bn), 
128.6, 128.6, 128.3, 127.9, 127.6 (CHAr Bn), 112.3 (C-5), 105.2 (C-1), 81.9 (C-2), 81.4 (C-4), 81.1 




NaBH4 (0.33 g, 1.85 mmol) was added to a solution of 15 (1.68 g, 3.85 
mmol) in methanol (10 mL) at 0 ℃. The reaction mixture was stirred for 2 
hours at 0 ℃, and quenched by the addition of  sat. aq. NH4Cl. The volatiles 
were evaporated. The residue was extracted with EtOAc (3 x). The organic 
layer was washed with water and brine, dried (Na2SO4), filtered and 
concentrated. The crude product was purified by silica gel column chromatography (20:1 → 
10:1, pentane:EtOAc) to give 16 (1.56 g, 3.43 mmol, yield 89%), as a mixture of two inseparable 
diastereo-isomers at a ratio of 3:2. NMR data of the major diastereoisomer: 1H NMR (400 MHz, 
CDCl3) δ 7.38 – 7.24 (m, 10H, HAr Bn), 5.91 (d, J = 3.8 Hz, 1H, H-1), 4.63 (d, J = 11.5 Hz, 1H, CHH 
Bn), 4.56 (d, J = 3.5 Hz, 1H, H-2), 4.52 (d, J = 12.0 Hz, 1H, CHH Bn), 4.47 (d, J = 12.4 Hz, 1H, CHH 





3.87 (d, J = 11.5 Hz, 1H, H-6b), 3.75 (d, J = 10.0 Hz, 1H, CHHOH), 3.67 (d, J = 10.1 Hz, 1H, 
CHHOH), 1.46 (s, 3H, CH3), 1.30 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 137.6, 136.5 (Cq Bn), 
128.6, 128.6, 128.5, 128.3, 127.9, 127.8, 127.7 (CHAr Bn), 112.0 (Cq isopropyl), 104.4 (C-1), 82.2 
(C-4), 81.7 (C-2), 80.0 (C-3), 73.6, 72.1 (CH2 Bn), 71.2 (CH2OH), 66.0 (C-5), 63.6 (C-6), 26.8, 26.3 
(2 x CH3). 
 
5-Deoxy-5-azido-5-C-benzyloxymethyl-3-O-benzyl-D-gluco/β-L-ido-furanoside (17):  
16 (1.50 g, 3.29 mmol) was dissolved in a mixture of H2O (15 mL) and TFA 
(15 mL) at 0 ℃, the temperature was allowed to rise to r.t. and the mixture 
was stirred for 18 h. After TLC analysis indicated complete conversion of 
the starting material, TFA was removed by repetitive coevaporation with 
toluene. The reaction mixture was diluted with water (20 mL), extracted 
with EtOAc (90 mL) and washed with brine (2 x). The organic layer was dried (Na2SO4), filtered 
and concentrated. The crude product was purified by silica gel column chromatography to give 
17 (0.93 g, 2.24 mmol, yield 68%). It is a mixture of two inseparable diastereo-isomers at a 
ratio of 3:2. NMR data of the major diastereoisomer: 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.24 (m, 
10H, HAr Bn), 5.47 (d, J = 4.6 Hz, 1H, H-1), 4.49 – 4.30 (m, 4H, 2 x CH2 Bn), 4.21 (d, J = 2.8 Hz, 1H, 
H-3), 4.16 (dd, J = 4.0, 1.7 Hz, 1H, H-2), 3.99 (dd, J = 4.0, 1.6 Hz, 1H, H-4), 3.89 (d, J = 11.9 Hz, 1H, 
H-6a, 3.83 (d, J = 11.8 Hz, 1H, H-6b), 3.70 (d, J = 10.0 Hz, 1H, CHHOH), 3.67 (d, J = 10.2 Hz, 1H, 
CHHOH). 13C NMR (100 MHz, CDCl3) δ 137.6, 137.0 (Cq Bn), 128.7, 128.5, 128.2, 127.9, 127.8, 
127.8 (CHAr Bn), 103.2 (C-1), 84.2 (C-4), 77.2 (C-3), 74.1 (C-2), 72.5, 71.9 (2 x CH2 Bn), 70.4 
(CH2OH), 66.4 (C-5), 63.6 (C-6). 
 
5-C-Hydroxymethyl-1-deoxynojirimycin (6): 
 Pd/C (10%, 0.28 g) was added to a solution of 17 (1.17 g, 2.82 mmol) in 
ethanol (50 mL) and pH of the solution was adjusted to 1 with 1M HCl. The 
reaction mixture was exposed to 5 bar of hydrogen and kept shaking for 24 
hours. The reaction mixture was filtered over a pad of Celite and the filtrate 
was concentrated. The residue was purified by silica gel column 
chromatography (0% → 20% methanol in DCM + 1% NH4OH) to gain 6 as 
light yellow oil  (0.40 g, 2.09 mmol, yield 74%). 1H NMR (400 MHz, MeOD) δ 3.86 (d, J = 12.1 Hz, 
1H, H-6*a), 3.81 (d, J = 11.1 Hz, 1H, H-6a), 3.68 (d, J = 12.0 Hz, 1H, H-6*b), 3.67 (d, J = 11.1 Hz, 
1H, H-6b), 3.64 (d, J = 9.6 Hz, 1H, H-4), 3.56 (dd, J = 9.2, 8.8 Hz, 1H, H-3), 3.58 – 3.51 (m, 1H, H-
2), 3.07 (dd, J = 12.6, 4.6 Hz, 1H, H-1a), 2.86 – 2.78 (m, 1H, H-1b). 13C NMR (100 MHz, MeOD) δ 
74.7 (C-3), 71.3 (C-4), 70.1 (C-2), 62.0 (C-5), 61.8 (C-6), 57.3 (C-6*), 43.7 (C-1). [α]20D = -0.3 (c = 
0.54, MeOH). IR/cm-1: 3277, 2926, 1612, 1450, 1406, 1259, 1076, 1039, 933. HRMS: found 
194.10222 [C7H15NO5+H]+, calculated for [C7H15NO5+H]+ 194.10230. 
 
Synthesis of 5-C-Hydroxymethyl-1-deoxy-D-galactonojirimycin (7) 
3-O-(p-Toluenesulfonyl)-1,2:5,6-di-O-isopropylidene-α-D-gluco-furanoside (18): 
p-Toluenesulfonyl chloride (3.60 g, 1.88 mmol) was added to a solution of 
diacetone-D-glucose (2.50 g, 8.61 mmol) in pyridine (24 mL) and DCM (24 
mL). The reaction mixture was stirred overnight at a temperature of 60 ℃. 
The volatiles were removed, and the residue was dissolved in DCM (30 
mL), and the organic layer was washed with sat. aq. NaHCO3, dried 
(Na2SO4), filtered, concentrated and purified by silica gel column chromatography to give 18 
(3.50 g, 8.44 mmol, yield 98%). RF = 0.41 (5:3, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.84 (d, J 
= 8.3 Hz, 2H, HAr Ts), 7.34 (d, J = 8.1 Hz, 2H, HAr Ts), 5.92 (d, J = 3.6 Hz, 1H, H-1), 4.83 (d, J = 3.7 
Hz, 1H, H-2), 4.80 (d, J = 2.3 Hz, 1H, H-3), 4.07 – 3.96 (m, 3H, H-4, H-5, H-6a), 3.91 (dd, J = 8.2, 
3.9 Hz, 1H, H-6b), 2.46 (s, 3H, CH3 Ts), 1.48 (s, 3H, CH3), 1.31 (s, 3H, CH3), 1.20 (s, 3H, CH3), 1.15 
(s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 145.1, 132.7, 130.2, 129.7, 128.4, 128.0 (CAr Ts), 112.5 




(Cq isopropyl), 109.1 (Cq isopropyl), 105.1 (C-1), 83.3 (C-2), 82.1 (C-3), 79.9 (C-4), 71.8 (C-5), 
67.1 (C-6), 26.6, 26.2, 24.9, 21.7 (4 x CH3), 14.2 (CH3 Ts). 
 
1,2:5,6-Di-O-isopropylidene-3-α-D-glucal (19): 
Potassium tert-butoxide (6.30 g, 10.1 mmol) was added to a solution of 18 
(2.73 g, 6.59 mmol) in dried THF (40 mL) at 0 ℃, and the mixture was 
stirred at 0 ℃ under argon atmosphere for 5 hours. Water (100 mL) was 
added and the reaction mixture was extracted with DCM (2 x 50 mL). The 
combined organic layers were washed successively with water and brine, 
dried (Na2SO4), filtered, concentrated and the residue was purified by silica gel column 
chromatography (5:1, PE:EtOAc) to give 19 (1.45 g, 5.99 mmol, yield 91%). RF = 0.78 (5:1, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 6.09 (d, J = 5.2 Hz, 1H, H-1), 5.31 (ddd, J = 5.3, 2.3, 1.5 
Hz, 1H, H-2), 5.26 (dd, J = 2.4, 1.2 Hz, 1H, H-3), 4.60 (dd, J = 7.0, 5.6 Hz, 1H, H-5), 4.17 (d, J = 8.4 
Hz, 1H, H-6a), 3.99 (d, J = 8.5 Hz, 1H, H-6b), 1.48 (s, 6H, 2 x CH3), 1.45 (s, 3H, CH3), 1.40 (s, 3H, 
CH3). 13C NMR (100 MHz, CDCl3) δ 160.0 (C-4), 112.3 (Cq isopropyl), 110.3 (Cq isopropyl), 106.6 
(C-1), 99.0 (C-3), 83.4 (C-2), 71.3 (C-5), 67.0 (C-6), 28.2, 27.9, 26.2, 25.5 (4 x CH3). 
 
1,2:5,6-Di-O-isopropylidene-α-D-galacto-furanoside (20): 
 To a solution of 19 (0.49 g, 2.02 mmol) in THF (3 mL) was added 
BH3∙THF complex (1M, 2.5 mL, 2.5 mmol) at 0 ℃ under argon 
atmosphere. After 4 hours a mixture of aq. NaOH (2M, 0.9 mL) and 30% 
H2O2 (0.4 mL) was added to the reaction mixture. The reaction was 
stirred at r.t. for 1 hour, and the volatiles were evaporated. The residue 
was diluted with water (5 mL), and the water layer extracted with EtOAc (4 x 50 mL). The 
combined organic layers were dried (Na2SO4), filtered and evaporated. The crude product was 
crystallized from EtOAc and pentane to give 20 as a crystalline product (0.40 g, 1.53 mmol, 
75%). RF = 0.24 (5:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 5.88 (d, J = 3.9 Hz, 1H, H-1), 4.55 
(dd, J = 3.9, 1.4 Hz, 1H, H-2), 4.37 (q, J = 6.8 Hz, 1H, H-5), 4.13 (dd, J = 4.5, 1.3 Hz, 1H, H-3), 4.08 
(dd, J = 8.4, 6.6 Hz, 1H, H-6a), 3.88 (d, J = 6.8 Hz, 1H, H-4), 3.86 (dd, J = 8.0, 7.0 Hz, 1H, H-6b), 
1.55 (s, 3H, CH3), 1.46 (s, 3H, CH3), 1.38 (s, 3H, CH3), 1.36 (s, 3H, CH3). 13C NMR (100 MHz, 
CDCl3) δ 113.8, 110.0 (2 x Cq isopropyl), 105.1 (C-1), 87.7 (C-2), 86.0 (C-4), 76.3 (C-3), 75.5 (C-
4), 65.8 (C-6), 27.6, 26.9, 26.7, 25.4 (4 x CH3). 
 
3-O-Benzyl-1,2-O-isopropylidene-α-D-galacto-furanoside (22): 
To a solution of 20 (4.00 g, 15.4 mmol) in DMF (150 mL) at 0 ℃ under 
argon atmosphere, was added NaH (60% mineral oil, 1.85 g, 46.3 mmol). 
After 30 minutes, BnBr (40 mL, 33.7 mmol) was added. The reaction 
mixture was stirred at r.t. overnight. The excess NaH was quenched by the 
addition of methanol, and the volatiles were evaporated. The residue was dissolved in DCM, 
washed with water and brine, dried (Na2SO4), filtered and concentrated. The crude product 21 
(RF = 0.18, 5:3, PE:EtOAc) was dissolved in water (10 mL) and AcOH (60 mL). The reaction 
mixture was stirred at r.t. overnight. The volatiles were evaporated, and the residue was 
purified by silica gel column chromatography (3:2 → 1:1, PE:EtOAc) to give 22 (4.12 g, 13.2 
mmol, 86% yield over the 2 steps). RF = 0.82 (5:3, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.40 – 
7.30 (m, 5H, HAr Bn), 5.92 (d, J = 4.1 Hz, 1H, H-1), 4.69 (dd, J = 4.1, 1.1 Hz, 1H, H-2), 4.65 (d, J = 
11.8 Hz, 1H, CHH Bn), 4.57 (d, J = 11.8 Hz, 1H, CHH Bn), 4.14 (dd, J = 6.7, 3.5 Hz, 1H, H-4), 4.01 
(dd, J = 3.5, 1.1 Hz, 1H, H-3), 3.80 (ddd, J = 6.7, 4.8, 3.8 Hz, 1H, H-5), 3.70 (dd, J = 11.8, 3.8 Hz, 1H, 
H-6a), 3.59 (dd, J = 11.7, 4.8 Hz, 1H, H-6b), 1.53 (s, 3H, CH3), 1.35 (s, 3H, CH3). 13C NMR (100 
MHz, CDCl3) δ 137.1 (Cq Bn), 128.7, 128.3, 128.0 (CHAr Bn), 113.3 (Cq isopropyl), 105.7 (C-1), 







23 was synthesized from 22 (3.30 g, 10.6 mmol) in a yield of 82% (3.49 
g, 8.72 mmol), as a thick yellow oil, as described for the synthesis of 12. 
RF = 0.80 (9:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.30 (m, 
10H, HAr Bn), 5.95 (d, J = 4.2 Hz, 1H, H-1), 4.71 (d, J = 3.9 Hz, 1H, H-2), 
4.61 (d, J = 11.4 Hz, 1H, CHH Bn), 4.57 (s, 2H, CH2 Bn), 4.54 (d, J = 11.7 Hz, 1H,  CHH Bn)), 4.19 
(dd, J = 6.5, 3.4 Hz, 1H, H-4), 4.12 (dd, J = 3.4, 1.1 Hz, 1H, H-3), 3.98 (q, J = 5.8 Hz, 1H, H-5), 3.59 
(dd, J = 9.9, 5.7 Hz, 1H, H-6a), 3.55 (dd, J = 9.9, 5.3 Hz, 1H, H-6b), 1.57 (s, 3H, CH3), 1.38 (s, 3H, 
CH3). 13C NMR (100 MHz, CDCl3) δ 137.9, 137.2 (Cq Bn), 128.6, 128.5, 128.4, 128.1, 128.0, 127.8, 
127.8, 127.8 (CHAr Bn), 113.0 (Cq isopropyl), 105.5 (C-1), 85.6 (C-2), 85.2 (C-4), 83.1 (C-3), 73.6 
(CH2 Bn), 71.9 (CH2 Bn), 71.4 (C-6), 69.7 (C-5), 27.1, 26.4 (2 x CH3). 
 
3,6-Di-O-Benzyl-1,2-O-isopropylidene-α-D-arabino-hexofuranoside-5-ulose (24):  
24 was synthesized from 23 (3.50 g, 8.74 mmol) in a yield of 92% (3.20 g, 
8.04 mmol), as a thick yellow oil, as described for the synthesis of 13. RF = 
0.67 (10:3, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.27 (m, 10H, 
HAr Bn), 5.98 (d, J = 3.8 Hz, 1H, H-1), 4.70 (d, J = 18.4 Hz, 1H, CHH Bn), 4.65 
– 4.61 (m, 3H, H-2, H-3, CHH Bn), 4.60 – 4.56 (m, 3H, H2-6, CHH Bn), 4.52 
(d, J = 1.0 Hz, 1H, H-4), 4.37 (d, J = 18.4 Hz, 1H, CHH Bn), 1.31 (s, 3H, CH3), 1.25 (s, 3H, CH3).  13C 
NMR (100 MHz, CDCl3) δ 205.0 (C-5), 137.2 – 127.8 (CAr Bn), 112.3 (Cq isopropyl), 106.5 (C-1), 




 25 was synthesized from 24 (3.20 g, 8.03 mmol) in a yield of 74% (2.87 
g, 5.94 mmol) as a thick yellow oil as described for the synthesis of 14. RF 
= 0.52 (9:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.24 (m, 10H, 
HAr Bn), 5.95 – 5.93 (m, 1H, CHCl2), 5.80 (dd, J = 3.9, 1.6 Hz, 1H, H-1), 4.66 
(d, J = 11.6, 1H, CHH Bn), 4.63 (dd, J = 3.8, 1.4 Hz, 1H, H-2), 4.60 (d, J = 11.6, 1H, CHH Bn), 4.56 
(d, J = 1.7 Hz, 2H, CH2 Bn), 4.50 – 4.46 (m, 1H, H-3), 4.44 – 4.38 (m, 1H, H-4), 3.81 (m, 2H, H2-6), 
1.51 (s, 3H, CH3), 1.35 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 137.5 – 127.8 (CAr Bn), 114.1 (Cq 
isopropyl), 104.8 (C-1), 85.2 (C-2), 84.8 (C-4), 81.7 (C-3), 76.6 (C-5), 75.7 (CHCl2), 73.8 (CH2 Bn), 
72.3 (CH2 Bn), 70.1 (C-6), 27.2, 26.7 (2 x CH3). HRMS: found 505.11521 [C24H28Cl2O6+Na]+, 




26 was synthesized from 25 (2.90 g, 6.00 mmol) in a yield of 93% as a 
thick yellow oil as described for the synthesis of 15. RF = 0.52 (9:1, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 9.70 (s, 1H, CHO), 7.54 – 7.19 
(m, 10H, HAr Bn), 5.75 (d, J = 4.0 Hz, 1H, H-1), 4.69 (d, J = 11.3 Hz, 1H, 
CHH Bn), 4.64 (dd, J = 4.0, 1.5 Hz, 1H, H-2), 4.54 (d, J = 11.3 Hz, 1H, CHH 
Bn), 4.52 (d, J = 4.1 Hz, 2H, CH2 Bn), 4.14 (dd, J = 6.3, 1.5 Hz, 1H, H-3), 4.11 (d, J = 6.3 Hz, 1H, H-
4), 3.96 (d, J = 10.0 Hz, 1H, H-6a), 3.60 (d, J = 10.0 Hz, 1H, H-6b), 1.61 (s, 3H, CH3), 1.40 (s, 3H, 
CH3). 13C NMR (100 MHz, CDCl3) δ 196.8 (CHO), 136.9, 136.7 (Cq Bn), 128.5, 128.2, 128.1, 128.0, 
127.7 (CHAr Bn), 115.1 (Cq isopropyl), 104.6 (C-1), 85.4 (C-2), 82.0 (C-3), 81.9 (C-4), 73.8 (CH2 
Bn), 72.4 (CH2 Bn), 70.8 (C-5), 70.5 (C-6), 27.5, 27.1 (2 x CH3). HRMS: found 476.17913 
[C24H27N3O6+Na]+, calculated for [C24H27N3O6+Na]+ 476.19721. 
 







 27 was synthesized from 26 (2.50 g, 5.51 mmol) in a yield of 82% (2.06 
g, 4.52 mmol), as thick yellow oil, as described for the synthesis of 16. RF 
= 0.22 (9:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.18 (m, 10H, 
HAr Bn), 5.76 (d, J = 4.0 Hz, 1H, H-1), 4.67 (d, J = 11.3 Hz, 1H, CHH Bn), 
4.62 (dd, J = 4.1, 1.5 Hz, 1H, H-2), 4.50 (d, J = 12.0, 1H, CHH Bn), 4.49 (s, 
2H, CH2OH), 4.22 (dd, J = 6.4, 1.5 Hz, 1H, H-3), 3.99 (d, J = 12.0 Hz, 1H, H-6a), 3.95 (d, J = 6.4 Hz, 
1H, H-4), 3.93 (d, J = 11.9 Hz, 1H, H-6b), 4.04 – 3.86 (m, 3H, H-4, H2-6), 3.61 (d, J = 9.9 Hz, 1H, 
CHH Bn), 3.52 (d, J = 10.0 Hz, 1H, CHH Bn), 1.60 (s, 3H, CH3), 1.39 (s, 3H, CH3). 13C NMR (100 
MHz, CDCl3) δ 137.7 – 127.9 (CAr Bn), 115.2 (Cq isopropyl), 104.7 (C-1), 86.1 (C-2), 83.4 (C-4), 
82.4 (C-3), 74.0 (CH2OH), 72.7 (CH2 Bn), 71.4 (CH2 Bn), 66.1 (C-5), 63.9 (C-6), 27.8, 27.4 (2 x 
CH3). HRMS: found 478.19451 [C24H29N3O6+Na]+, calculated for [C24H29N3O6+Na]+ 478.19486. 
 
5-Deoxy-5-azido-5-C-benzyloxymethyl-3-O-benzyl-α-D-galacto/β-L-altro-furanoside (28): 
 28 was synthesized from 27 (2.08 g, 4.57 mmol) in a yield of 63% (1.31 g, 
2.88 mmol), as a thick yellow oil, as described for the synthesis of 17. 28 
was obtained as an inseparable mixture of diastereo isomers (ratio 1:0.9). 
NMR data of the major diastereoisomer: 1H NMR (400 MHz, CDCl3 ) δ 5.20 
(d, J = 3.9 Hz, 1H, H-1), 4.61 (d, J = 11.8 Hz, 1H, CHH Bn), 4.45 (d, J = 11.8 
Hz, 1H, CHH Bn), 4.43 (s, 2H, CH2OH),  4.07 (d, J = 3.8 Hz, 1H, H-3), 4.03 (t, J = 4.0 Hz, 1H, H-2), 
3.93 (dd, J = 11.8, 4.7 Hz, 1H, H-6a), 3.89 (d, J = 5.3 Hz, 1H, H-4), 3.85 (d, J = 11.8 Hz, 1H, H-6b), 
3.59 (d, J = 10.1 Hz, 1H, CHH Bn), 3.42 (d, J = 10.0 Hz, 1H, CHH Bn). 13C NMR (100 MHz, CDCl3) δ 
137.6, 137.4 (Cq Bn), 128.7, 128.7, 128.4, 128.4, 128.2, 128.2, 127.8, 127.8 (CHAr Bn), 97.1 (C-1), 
84.0 (C-3), 81.3 (C-4), 76.0 (C-2), 73.9 (CH2OH), 72.1 (CH2 Bn), 71.1 (CH2 Bn), 66.5 (C-5), 62.4 
(C-6). HRMS: found 438.16347 [M+Na]+, calculated for [+Na]+ 438.19486. 
 
5-C-Hydroxymethyl-1-deoxy-D-galactonojirimycin (7): 
7 was synthesized from 28 (1.00 g, 2.42 mmol) in a yield of 91% (0.42 g, 2.20 
mmol), as thick yellow oil, as described for the synthesis of 6. RF = 0.26 (1% 
NH4OH in MeOH). 1H NMR (400 MHz, MeOD) δ 3.99 (d, J = 3.3 Hz, 1H, H-4), 
3.87 (d, J = 11.3 Hz, 1H, H-6a), 3.83 (td, J = 7.8, 4.3 Hz, 1H, H-2), 3.75 (d, J = 
11.4 Hz, 1H, H-6*a), 3.71 (dd, J = 7.6, 3.3 Hz, 1H, H-3), 3.68 (d, J = 11.2 Hz, 1H, 
H-6b), 3.63 (d, J = 11.3 Hz, 1H, H-6*b), 3.13 (dd, J = 13.2, 4.3 Hz, 1H, H-1a), 2.71 
(dd, J = 13.2, 7.9 Hz, 1H, H-1b). 13C NMR (100 MHz, MeOD) δ 72.0 (C-3), 68.4 (C-4), 68.3 (C-2), 
61.9 (C-6), 60.9 (C-5), 59.7 (C-6*), 43.6 (C-1). [α]20D = +0.8 (c = 0.57, MeOH). IR/cm-1: 3275, 
2922, 2497, 1608, 1049, 1338, 1247, 1114, 1056, 1024. HRMS: found [C7H15NO5+H]+ 
194.10221, calculated for [C7H15NO5+H]+  194.10230. 
 
Synthesis of 5-C-hydroxymethyl-1-deoxy-D-mannonojirimycin (8) 
2,3:5,6-Di-O-isopropyl-α-D-manno-furanoside (29): 
To a solution of D-mannose (36.0 g, 180 mmol) in dry acetone (1000 mL) at 
r.t. was added tetrabutylammonium tribromide (TBATB, 1.97 g, 4.08 mmol).6 
The reaction was monitored by TLC analysis. After complete conversion of the 
starting material, acetone was removed on a rotary evaporator. Title 
compound 29 was isolated by crystallization (3:1, pentane:EtOAc, 30.2 g, 116 
mmol, yield 64%). RF = 0.40 (10:3, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 
5.36 (d, J = 2.7 Hz, 1H, H-1), 4.80 (dd, J = 5.9, 3.7 Hz, 1H, H-3), 4.60 (d, J = 5.9 
Hz, 1H, H-2), 4.40 (q, J = 4.0 Hz, 1H, H-5), 4.16 (dd, J = 7.2, 3.6 Hz, 1H, H-4), 4.07 (d, J = 5.9 Hz, 





(100 MHz, CDCl3) δ 112.3, 108.9 (2 x Cq isopropyl), 100.8 (C-1), 85.3 (C-2), 79.7 (C-4), 79.4 (C-
3), 73.1 (C-5), 66.2 (C-6), 26.5, 25.6, 24.9, 24.2 (4 x CH3). 
 
Benzyl-2,3:5,6-di-O-isopropyl-α-D-manno-furanoside (30): 
To a solution of 29 (1.28 g, 4.92 mmol) in THF (10 mL) was successively 
added freshly powdered potassium hydroxide (0.48 g, 8.56 mmol), 18-
crown-6 (0.055 g, 0.21 mmol) and benzyl bromide (0.67 mL, 0.96 g, 5.64 
mmol). The mixture was stirred at r.t. and the reaction was monitored by 
TLC analysis. After complete conversion of the starting material, the mixture 
was diluted with DCM and washed with water (3 x). The organic layer was 
dried (Na2SO4),  filtered and concentrated, and the residue was purified by 
silica gel column chromatography (9:1, PE:EtOAc) to gain 30 (1.29 g, 3.68 mmol, yield 75%), RF 
= 0. 70 (6:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.27 (m, 5H, HAr Bn), 5.08 (s, 1H, H-
1), 4.80 (dd, J = 5.9, 3.6 Hz, 1H, H-3), 4.67 (d, J = 5.9 Hz, 1H, H-2), 4.64 (d, J = 11.6 Hz, 1H, CHH 
Bn), 4.49 (d, J = 11.8 Hz, 1H, CHH Bn), 4.11 (ddd, J = 7.9, 6.3, 4.3 Hz, 1H, H-5), 4.14 (dd, J = 8.7, 
6.3 Hz, 1H, H-6a), 4.02 (dd, J = 8.8, 4.4 Hz, 1H, H-6b), 4.00 (dd, J = 8.0, 3.6 Hz, 1H, H-4), 1.46 (s, 
3H, CH3), 1.46 (s, 3H, CH3), 1.39 (s, 3H, CH3), 1.32 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 
137.4 (Cq Bn), 128.6 – 127.9 (CHAr Bn), 112.7, 109.4 (2 x Cq isopropyl), 105.7 (C-1), 85.2 (C-2), 
80.5 (C-4), 79.7 (C-3), 73.2 (C-5), 69.3 (CH2 Bn), 67.1 (C-6), 27.1, 26.0, 25.3, 24.6 (4 x CH3). 
 
 Benzyl-2,3-O-isopropyl-α-D-manno-furanoside (31): 
31 was synthesized from 30 (15.00 g, 42.84 mmol) in a yield of 81% (10.8 
g, 34.8 mmol) as described for the synthesis of 11. RF = 0.19 (5:3, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.26 (m, 5H, HAr Bn), 5.10 (s, 
1H, H-1), 4.85 (dd, J = 5.9, 3.6 Hz, 1H, H-3), 4.65 (d, J = 6.0 Hz, 1H, H-2), 4.62 
(d, J = 11.9 Hz, 1H, CHH Bn), 4.48 (d, J = 11.8 Hz, 1H, CHH Bn), 4.05 – 3.98 
(m, 1H, H-5), 3.95 (dd, J = 8.3, 3.6 Hz, 1H, H-4), 3.82 (dd, J = 11.5, 3.2 Hz, 1H, 
H-6a), 3.65 (dd, J = 11.5, 5.9 Hz, 1H, H-6b), 3.28 (s, 1H, OH), 2.96 (s, 1H, OH), 1.46 (s, 3H, CH3), 
1.32 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 137.2 (Cq Bn), 128.4, 128.0, 127.8 (CHAr Bn), 
112.6 (Cq isopropyl), 105.3 (C-1), 84.7 (C-2), 80.0 (C-3), 79.2 (C-4), 70.1 (C-5), 69.1 (CH2 Bn), 
64.3 (C-6), 28.8, 24.5 (2 x CH3). 
 
Benzyl-2,3-O-isopropyl-6-O-benzyl-α-D-manno-furanoside (32): 
32 was synthesized from 31 (10.7 g, 34.4 mmol) in a yield of 76% (10.5 g, 
26.2 mmol) as thick yellow oil, as described for the synthesis of 12. RF = 
0.64 (5:3, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.27 (m, 10H, 2 x 
HAr Bn), 5.09 (s, 1H, H-1), 4.87 (dd, J = 5.9, 3.7 Hz, 1H, H-3), 4.65 (d, J = 5.9 
Hz, 1H, H-2), 4.64 (d, J = 11.9 Hz, 1H, CHH Bn), 4.62 (d, J = 11.7 Hz, 1H, 
CHH Bn), 4.58 (d, J= 11.9 Hz 1H, CHH Bn), 4.44 (d, J= 11.7 Hz 1H, CHH Bn), 
4.15 (ddd, J = 8.4, 5.8, 3.3 Hz, 1H, H-5), 4.03 (dd, J = 8.3, 3.6 Hz, 1H, H-4), 3.73 (dd, J = 9.8, 3.3 Hz, 
1H, H-6a), 3.63 (dd, J = 9.8, 5.7 Hz, 1H, H-6b), 1.47 (s, 3H, CH3), 1.33 (s, 3H, CH3). 13C NMR (100 
MHz, CDCl3) δ 138.1, 137.4 (2 x Cq Bn), 128.6 – 127.8 (CHAr Bn), 112.7 (Cq isopropyl), 105.4 (C-
1), 85.0 (C-2), 80.2 (C-3), 79.1 (C-4), 73.6 (CH2 Bn), 71.9 (C-6), 69.1 (CH2 Bn), 69.0(C-5), 26.1, 
24.7(2 x CH3). 
 
Benzyl-2,3-O-isopropyl-6-O-benzyl-α-D-lyxo-hexofuranoside-5-ulose (33): 
33 (4.21 g, 10.5 mmol) was synthesized from 32 in a yield of 88% (3.66 g, 
9.18 mmol), as described for the synthesis of 13. RF = 0.63 (3:1, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.17 (m, 10H, HAr Bn ), 5.23 
(s, 1H, H-1), 5.11 (dd, J = 5.8, 4.2 Hz, 1H, H-3), 4.73 (d, J = 4.2 Hz, 1H, H-4), 
4.67 (d, J = 11.6 Hz, CHH Bn), 4.65 (d, J = 11.6 Hz, CHH Bn), 4.64 (d, J = 5.8 
Hz, 1H, H-2), 4.61 (d, J = 11.6 Hz, CHH Bn), 4.49 (d, J = 11.6 Hz, CHH Bn), 




4.35 (s, 2H, H2-6), 1.35 (s, 3H, CH3), 1.26 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 203.0 (C=O), 
137.2, 136.8 (2 x Cq Bn), 128.6 – 128.0 (CHAr Bn), 113.0 (Cq isopropyl), 105.4 (C-1), 84.3 (C-2), 
84.2 (C-4), 80.7 (C-3), 74.1, 73.4 (2 x CH2 Bn), 69.3 (C-6), 25.7, 24.5 (2 x CH3). 
 
Benzyl-2,3-O-isopropyl-6-O-benzyl-5-C-dichloromethyl-β-L-gulo-furanoside  (34): 
34 was synthesized from 33 in a yield of 66% (3.90 g, 8.34 mmol) as 
described for the synthesis of 14. RF = 0.53 (9:1, PE:EtOAc). 1H NMR (400 
MHz, CDCl3) δ 7.43 – 7.15 (m, 10H, HAr Bn), 6.19 (s, 1H, CHCl2), 5.17 (s, 1H, 
H-1), 5.05 (dd, J = 5.9, 3.4 Hz, 1H, H-3), 4.87 (s, 1H, -OH), 4.71 – 4.57 (m, 
4H, H-4, 3 x CHH Bn), 4.39 (d, J = 11.4 Hz, 1H, CHH Bn), 4.28 (d, J = 3.4 Hz, 
1H, H-2), 3.76 (d, J = 9.8 Hz, 1H, H-6a), 3.61 (d, J = 9.8 Hz, 1H, H-6b), 1.51 
(s, 3H, CH3), 1.34 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 138.0 – 127.8 (CAr Bn), 113.3 (Cq 
isopropyl), 105.0 (C-1), 85.0 (C-4), 81.7 (C-3), 77.9 (C-2), 73.9 (CH2 Bn), 73.3 (CHCl2), 70.8 (C-5), 




35 was synthesized from 34 (2.82 g, 5.84 mmol) in a yield of 87% (2.30 
g, 5.07 mmol), as described for the synthesis of 15. RF = 0.52 (9:1, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 9.74 (s, 1H, CHO), 7.39 – 7.28 (m, 
10H, HAr Bn), 5.18 (s, 1H, H-1), 4.84 (dd, J = 5.9, 3.4 Hz, 1H, H-3), 4.70 – 
4.60 (m, 4H, H-4, 3 x CHH Bn), 4.51 (d, J = 11.7 Hz, 1H, CHH Bn), 4.29 (d, J 
= 3.4 Hz, 1H, H-2), 3.90 (d, J = 10.2 Hz, 1H, H-6a), 3.82 (d, J = 10.2 Hz, 1H, 
H-6b), 1.45 (s, 3H, CH3), 1.32 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 195.8 (CHO), 137.2 (Cq 
Bn), 128.6 – 127.7 (CHAr Bn), 113.3 (Cq isopropyl), 105.6 (C-1), 84.6 (C-4), 80.4 (C-2), 79.2 (C-3), 




36 was synthesized from 35 (0.37 g, 0.82 mmol) in a yield of 80% (0.30 
g, 0.65 mmol) as two inseparable diastereomers as described for the 
synthesis of 16. RF = 0.22 (9:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 
7.40 – 7.27 (m, 10H, CHAr Bn), 5.09 (s, 1H, H-1), 4.77 (dd, J = 5.8, 3.3 Hz, 
1H, H-3), 4.64 (d, J = 11.9 Hz, 1H, CHH Bn), 4.63 (d, J = 5.8 Hz, H-4), 4.62 
(d, J = 11.6 Hz, 1H, CHH Bn), 4.55 (d, J = 11.9 Hz, 1H, CHH Bn), 4.45 (d, J = 
11.7 Hz, 1H, CHH Bn), 4.23 (d, J = 3.2 Hz, 1H, H-2), 3.91 (d, J = 2.1 Hz, 2H, 
CH2OH), 3.87 (d, J = 10.1 Hz, 1H, H-6a), 3.78 (d, J = 10.1 Hz, 1H, H-6b), 1.45 (s, 3H, CH3), 1.29 (s, 
3H, CH3). 13C NMR (100 MHz, CDCl3) δ 137.5, 137.4 (Cq Bn), 128.5 – 127.7 (CHAr Bn), 112.9 (Cq 
isopropyl), 104.8 (C-1), 85.1(C-4), 79.8 (C-2), 79. 5 (C-3), 73.8 (CH2 Bn), 70.9 (C-6), 69.3 (CH2 
Bn), 66.6 (Cq N3), 63.7 (CH2OH), 25.7, 24.3 (2 x CH3). 
 
 Benzyl-5-deoxy-5-azido-5-C-benzyloxymethyl-α-D-manno/β-L-gulo-furanoside (37): 
36 (0.19 g, 0.43 mmol) was dissolved in a mixture of H2O (0.6 mL) and 
TFA (1.8 mL) at 0 ℃, the temperature was allowed to rise to r.t. and the 
mixture was stirred for 18 h. After TLC analysis indicated complete 
conversion of the starting material, the reaction mixture was diluted 
with water (5 mL), extracted with EtOAc (20 mL) and washed with brine 
(2 x). The organic layer was dried (Na2SO4), filtered and concentrated. 
The crude product was purified by silica gel column chromatography to give 37 (0.08 g, 0.19 
mmol, yield 45%). RF = 0.16 (5:3, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.27 (m, 10H, 
CHAr Bn), 5.09 (d, J = 2.2 Hz, 1H, H-1), 4.66 (d, J = 11.6 Hz, 1H, CHH Bn), 4.60 (d, J = 11.7 Hz, 1H, 





4.1, 1.0 Hz, 1H, H-3), 4.14 (dd, J = 2.3, 5.3 Hz, 1H, H-2), 4.13 (dd, J = 4.0, 0.8 Hz, 1H, H-4), 3.94 (d, 
J = 11.6 Hz, 1H, H-6a), 3.84 (dd, J = 11.7, 0.8 Hz, 1H, H-6b), 3.75 (s, 2H, CH2OH). 13C NMR (100 
MHz, CDCl3) δ 137.6, 136.8 (Cq Bn), 128.7 – 127.8 (CHAr Bn), 107.2 (C-1), 79.7 (C-4), 77.1 (C-2), 
74.0 (CH2 Bn), 71.6 (C-3), 70.4 (CH2 Bn), 70.2 (CH2OH), 66.8 (C-5), 63.8 (C-6). 
 
 5-C-Hydroxymethyl-1-deoxy-D-mannonojirimycin (8): 
8 was synthesized from 37 (0.83 g, 2.0 mmol) in a yield of 82% (0.32 g, 1.64 
mmol) as described for the synthesis of 6. 1H NMR (400 MHz, MeOD) δ 4.17 
(ddd, J = 1.5, 3.0, 3.7 Hz, 1H, H-2), 4.10 (d, J = 9.2 Hz, 1H, H-4), 3.95 (d, J = 11.6 
Hz, 1H, H-6a), 3.94 (d, J = 12.6 Hz, 1H, H-6a’), 3.86 (dd, J = 9.2, 3.0 Hz, 1H, H-3), 
3.77 (d, J = 11.6 Hz, 1H, H-6b), 3.71 (d, J = 12.5 Hz, 1H, H-6b’), 3.40 (dd, J = 1.5, 
13.2 Hz, 1H, H-1a), 3.28 (dd, J = 3.7, 13.1 Hz, 1H, H-1b). 13C NMR (100 MHz, 
MeOD) δ 71.9 (C-3), 68.5 (C-4), 67.8 (C-2), 67.0 (C-5), 61.6 (C-6), 58.5 (C-6’), 45.7 (C-1). IR/cm-1: 
3307, 1636, 1451, 1229, 1073. HRMS: found 194.10223 [C7H15NO5+H]+, calculated for 
[C7H15NO5+H]+ 194.10230. 
 
Synthesis of 5-C-hydroxymethyl-1-deoxy-D-allonojirimycin (9) 
 1,2:5,6-Di-O-isopropylidene-α-D-allo-furanoside-3-ulose (38): 
To a mixture of diacetone-D-glucose (15.0 g, 57.7 mmol) in anhydrous 
DCM (350 mL) and activated 4Å molecular sieves at 0 ℃, was added 
pyridinium chlorochromate (PCC, 24.3 g, 112 mmol). The reaction 
mixture was stirred at r.t. overnight under argon atmosphere. The dark 
brown mixture was then filtered through a pad of silica gel, and the silica 
gel pad was rinsed with EtOAc (2 x 200 mL). The filtrate was concentrated and the residue was 
purified by silica gel column chromatography (5:1 → 2:1, PE:EtOAc) to gain 38 (12.1 g, 47.0 
mmol, yield 81%), RF = 0.2 (19:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 6.16 (d, J = 4.5 Hz, 1H, 
H-1), 4.41 (d, J = 4.6 Hz, 1H, H-2), 4.38 (d, J = 0.7 Hz, 1H, H-4), 4.37 (td, J = 2.5, 0.6 Hz, 1H, H-5), 
4.06 (d, J = 0.7 Hz, 1H, H-6a), 4.05 – 4.03 (m, 1H, H-6b), 1.48 (s, 3H, CH3), 1.45 (s, 3H, CH3), 1.36 
(s, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 208.9 (C=O), 114.3 (Cq isopropyl), 110.4 (Cq 
isopropyl), 103.1 (C-1), 78.9 (C-4), 77.2 (C-2), 76.4 (C-5), 64.3 (C-6), 27.6, 27.2, 26.0, 25.3 (4 x 
CH3). 
 
1,2:5,6-Di-O-isopropylidene-α-D-allo-furanoside (39):  
38 (12.1 g, 47.0 mmol) was dissolved in a mixture of water and ethanol 
(72 mL, 4:5). In small portions NaBH4 (8.70 g, 230 mmol) was added. 
After stirred for 7 hours, the reaction mixture was extracted with DCM (3 
x). The combined organic layers were washed with water and brine, dried 
(Na2SO4), filtered, concentrated and the residue was purified by silica gel 
column chromatography (5:1 → 3:2, PE:EtOAc), to give 39 (11.2 g, 43.1 mmol, yield 92%). RF = 
0.4 (1:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 5.82 (d, J = 3.8 Hz, 1H, H-1), 4.62 (dd, J = 5.2, 3.8 
Hz, 1H, H-2), 4.31 (td, J = 6.6, 4.7 Hz, 1H, H-5), 4.09 (dd, J = 8.5, 6.6 Hz, 1H, H-6a), 4.02 (dd, J = 
8.5, 6.6 Hz, 1H, H-6b), 3.82 (dd, J = 8.5, 4.7 Hz, 1H, H-4), 2.55 (br s, 1H, -OH), 1.58 (s, 3H, CH3), 
1.47 (s, 3H, CH3), 1.38 (d, J = 5.2 Hz, 6H, 2 x CH3). 13C NMR (100 MHz, CDCl3) δ 113.0 (Cq 
isopropyl), 110.0 (Cq isopropyl), 104.1 (C-1), 79.9 (C-4), 79.1 (C-2), 75.7 (C-5), 72.7 (C-3), 66.0 
(C-6), 26.7, 26.7, 26.5, 25.4 (4 x CH3). 
 
3-O-Benzyl-1,2:5,6-di-O-isopropylidene-α-D-allo-furanoside (40): 
NaH (60% on mineral oil, 0.042 g, 1.05 mmol) was added to a solution of 
39 (0.14 g, 0.54 mmol) in DMF (2 mL) at 0 ℃ under argon atmosphere. 
The mixture was stirred for 1 hour, subsequently, BnBr (0.1 mL, 0.84 
mmol) was added. The suspension was stirred overnight at r.t. The 




reaction was quenched by the addition of methanol (3 mL), and volatiles were evaporated. The 
residue was dissolved with EtOAc (10 mL), washed with brine (3 x), dried (Na2SO4), filtered, 
concentrated and purified by silica gel column chromatography to give 40 (0.17 g, 0.48 mmol, 
yield 90%). RF = 0.8 (1:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 5.76 (d, J = 3.7 Hz, 1H, H-1), 
4.78 (d, J = 11.7 Hz, 1H, CHH Bn), 4.60 (d, J = 11.7 Hz, 1H, CHH Bn), 4.59 (t, J = 4.2 Hz, 1H, H-2), 
4.37 (td, J = 7.0, 3.2 Hz, 1H, H-5), 4.15 (dd, J = 8.7, 3.2 Hz, 1H, H-4), 4.02 (dd, J = 8.3, 6.9 Hz, 1H, 
H-6a), 3.97 (dd, J = 8.3, 7.1 Hz, 1H, H-6b), 3.90 (d, J = 4.5 Hz, 1H, H-3), 1.60 (s, 3H, CH3), 1.40 (s, 
3H, CH3), 1.38 (s, 3H, CH3), 1.37 (s, 4H, CH3). 13C NMR (100 MHz, CDCl3) δ 137.5 (Cq Bn), 128.4, 
128.2, 128.0 (CHAr  Bn), 112.9 (Cq isopropyl), 109.6 (Cq isopropyl), 103.9 (H-1), 78.0 (C-4), 77.8 
(C-2), 77.5 (C-3), 74.8 (C-5), 72.2 (CH2 Bn), 65.0 (C-6), 26.8, 26.6, 26.2, 25.1 (4 x CH3). 
 
3-O-Benzyl-1,2-di-O-isopropylidene-α-D-allo-furanoside (41): 
41 was synthesized from 40 (9.0 g, 25.68 mmol) in a yield of 46% (3.67 
g, 11.8 mmol), as described for the synthesis of 11. RF = 0.15 (1:1, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.31 (m, 5H, HAr Bn), 5.79 
(d, J = 3.7 Hz, 1H, H-1), 4.81 (d, J = 11.3 Hz, 1H, CHH Bn), 4.63 (t, J = 4.1 
Hz, 1H, H-2), 4.58 (d, J = 11.3 Hz, 1H, CHH Bn), 4.13 (dd, J = 8.9, 3.4 Hz, 
1H, H-4), 4.07 – 4.00 (m, 1H, H-5), 3.96 (dd, J = 8.9, 4.4 Hz, 1H, H-3), 3.77 – 3.64 (m, 2H, H-6), 
1.62 (s, 3H, CH3), 1.39 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 136.7 (Cq Bn), 128.6, 128.4, 
128.3 (CHAr Bn), 113.2 (Cq isopropyl), 104.2 (C-1), 79.1 (C-4), 77.4 (C-2), 76.8 (C-3), 72.2 (CH2 
Bn), 70.1 (C-5), 63.1 (C-6), 26.8, 26.6 (2 x CH3). 
 
3,6-Di-O-Benzyl-1,2-di-O-isopropylidene-α-D-allo-furanose (42): 
42 was synthesized from 41 (0.45 g, 1.45 mmol) in a yield of 76% (0.44 
g, 1.10 mmol), as thick yellow oil, as described for the synthesis of 12. RF 
= 0.27 (10:3, PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.30 (m, 
10H, HAr Bn), 5.75 (d, J = 3.7 Hz, 1H, H-1), 4.74 (d, J = 11.6 Hz, 1H, CHH 
Bn), 4.57 – 4.54 (m, 3H, 2 x CHH Bn, H-2), 4.56 (d, J = 11.7 Hz, 1H, CHH 
Bn), 4.15 (m, 1H, H-5), 4.14 – 4.09 (m, 1H, H-4), 3.98 (dd, J = 8.7, 4.4 Hz, 1H, H-3), 3.60 – 3.55 (m, 
2H, H2-6), 1.61 (s, 3H, CH3), 1.37 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 138.0, 137.5 (Cq Bn), 
128.5 – 127.6 (CHAr Bn), 113.0 (Cq isopropyl), 104.2 (C-1), 78.5 (C-4), 77.7 (C-2), 77.1(C-3), 
73.4, 72.1 (CH2 Bn), 70.7 (C-6), 70.1 (C-5), 26.9, 26.7 (2 x CH3). 
 
1,2-O-Isopropyl-3,6-di-O-benzyl-α-D-ribo-hexofurano-5-ulose (43): 
43 was synthesized from 42 (14.0 g, 35.0 mmol) in a yield of 64% (8.91 
g, 22.4 mmol), as described for the synthesis of 13. RF = 0.4 (10:3, 
PE:EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.21 (m, 10H, HAr Bn), 
5.77 (d, J = 3.5 Hz, 1H, H-1), 4.72 (d, J = 12.0 Hz, 1H, CHH Bn), 4.63 – 4.55 
(m, 4H, 2 x CHH Bn, H-6, H-4), 4.54 – 4.52 (m, 1H, H-2), 4.31 (d, J = 5.0 
Hz, 2H, CH2 Bn), 3.82 (dd, J = 9.0, 4.3 Hz, 1H, H-3), 1.58 (s, 3H, CH3), 1.35 (s, 3H, CH3). 13C NMR 
(100 MHz, CDCl3) δ 203.8 (C=O), 137.1, 136.9 (Cq Bn), 128.6 – 128.0 (CHAr Bn), 113.7 (Cq), 104.6 




44 was synthesized from 43 (10.0 g, 25.1 mmol) in a yield of 99% (12.0 
g, 24.8 mmol) as two inseparable isomers (ratio 1:1) as described for 
the synthesis of 14. RF = 0.63 (5:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) 
δ 7.46 – 7.31 (m, 10H, HAr Bn), 6.12 (s, 1H, CHCl2), 5.78 (d, J = 3.6 Hz, 1H, 
H-1), 4.70 (d, J = 11.5 Hz, 1H, CHH Bn), 4.58 – 4.52 (m, 3H, H2-6, H-2), 
4.49 (d, J = 11.6 Hz, 1H, CHH Bn), 4.41 (d, J = 8.3 Hz, 1H, H-4), 4.12 (dd, J = 8.3, 4.4 Hz, 1H, H-3), 





CH3). 13C NMR (100 MHz, CDCl3) δ 137.3, 137.3 (Cq Bn), 128.5, 128.4, 128.4, 128.2, 128.1, 128.1, 
128.0, 127.9, 127.8, 127.8 (CHAr Bn), 113.5 (Cq isopropyl), 104.1 (C-1), 78.9 (C-4), 77.9 (C-2), 





45 was synthesized from 44 (12.0 g, 24.8 mmol) in a yield of 71% (7.99 
g, 17.6 mmol), as described for the synthesis of 15. RF = 0.25 (10:1, 
PE:EtOAc). 45 is an inseparable mixture of diastereomers (ratio = 5:3). 
NMR data of the major diastereomer: 1H NMR (400 MHz, CDCl3) δ 9.52 
(s, 1H, CHO), 7.50 – 7.20 (m, 10H, HAr Bn), 5.73 (d, J = 3.5 Hz, 1H, H-1), 
4.64 – 4.42 (m, 5H, 2 x CHH Bn, H2-6, H-2), 4.35 (d, J = 8.7 Hz, 1H, H-4), 4.12 (d, J = 10.0 Hz, 1H, 
CHH Bn), 3.99 (d, J = 10.0 Hz, 1H, CHH Bn), 3.97 (dd, J = 8.7, 4.3 Hz, 1H, H-3), 1.59 (s, 3H, CH3), 
1.35 (s, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 195.7 (CHO), 137.0, 136.7 (Cq Bn), 128.6 – 127.7 
(CHAr Bn), 113.6 (Cq isopropyl), 104.6 (C-1), 77.8 C-4), 77.2 (C-3), 76.9 (C-2), 73.8 (C-6), 72.4, 




46 was synthesized from 45 (7.46 g, 16.5 mmol) in a yield of 81% (6.06 
g, 13.3 mmol) as two inseparable diastereomers as described for the 
synthesis of 16. RF = 0.23 (9:1, PE:EtOAc). NMR-data of the major 
diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.30 (m, 10H, HAr Bn), 
5.82 (d, J = 3.7 Hz, 1H, H-1), 4.81 (d, J = 11.0 Hz, 1H, CHH Bn), 4.67 – 4.60 
(m, 3H, H2-6, H-2), 4.58 (d, J = 11.0 Hz, 1H, CHH Bn), 4.22 (d, J = 8.6 Hz, 1H, H-4), 4.11 – 4.08 (m, 
1H, H-3), 3.93 (d, J = 9.9 Hz, 1H, CHH Bn), 3.86 (d, J = 9.9 Hz, 1H, CHH Bn), 3.86 (d, J = 9.9 Hz, 1H, 
CHHOH), 3.67 (dd, J = 9.9, 3.7 Hz, 1H, CHHOH), 1.60 (s, 3H, CH3), 1.41 (s, 3H, CH3). 13C NMR (100 
MHz, CDCl3) δ 137.7, 136.4 (Cq Bn), 128.7 – 127.7 (CHAr Bn), 113.4 (Cq isopropyl), 104.3 (C-1), 
79.5 (C-4), 77.8 (C-3), 77.2 (C-2), 73.7 (C-6), 72.3, 69.9 (CH2 Bn), 66.6 (C-5), 62.3 (CH2OH), 26.9, 
26.7 (2 x CH3).  
 
5-Deoxy-5-azido-5-C-benzyloxymethyl-3-O-benzyl-α-D-allo/β-L-talo-furanoside (47):  
47 was synthesized from 46 (1.40 g, 3.07 mmol) in a yield of 70% (0.89 
g, 2.15 mmol), as two inseparable diastereoisomer (ratio = 5:3) as 
described for the synthesis of 17. RF = 0.15 (5:3, PE:EtOAc). NMR data of 
the major diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.31 (m, 
10H, HAr Bn), 5.29 (s, 1H, H-1), 4.71 – 4.38 (m, 5H, CH2 Bn, H2-6, H-2), 
4.30 – 4.23 (m, 1H, H-4), 4.08 – 4.03 (m, 1H, H-3), 3.81 – 3.73 (m, 2H, CH2 Bn), 3.69 – 3.51 (m, 
2H, CH2OH). 13C NMR (100 MHz, CDCl3) δ 137.6 – 127.7 (CHAr Bn), 96.9 (C-1), 81.5 (C-4), 77.9 
(C-2), 77.0 (C-3), 73.8 (C-6), 72.9 (CH2 Bn), 69.5 (CH2 Bn), 66.6 (C-5), 62.9 (CH2OH). 
 
5-C-Hydroxymethyl-1-deoxy-D-allonojirimycin (9): 
9 was synthesized from 47 (0.79 g, 1.90 mmol) in a yield of 81% (0.30 g, 1.54 
mmol) as described for the synthesis of 6. 1H NMR (400 MHz, MeOD) δ 4.02 
(d, J = 11.5 Hz, 1H, H-6a), 3.98 (t, J = 3.2 Hz, 1H, H-3), 3.81 (d, J = 3.2 Hz, 1H, H-
4), 3.75 – 3.71 (m, 1H, H-2), 3.73 (d, J = 10.8Hz, 1H, H-6*a), 3.67 (d, J = 11.6 Hz, 
1H, H-6b), 3.59 (d, J = 11.1 Hz, 1H, H-6*b), 3.03 (dd, J = 13.1, 8.2 Hz, 1H, H-1a), 
2.87 (dd, J = 13.1, 4.0 Hz, 1H, H-1b). 13C NMR (100 MHz, MeOD) δ 70.0 (C-3), 
69.5 (C-4), 68.3 (C-2), 61.3 (C-6), 60.8 (C-6*), 60.3 (C-5), 42.3 (C-1). [α]20D = +0.23 (c =1.31, 
MeOH).  IR/cm-1: 3263, 2900, 1607, 1450, 1413, 1257, 1033. HRMS: found 194.10218 [M+H]+, 
calculated for [C7H15NO5+H]+ 194.10230. 





N-Alkylated final compounds: 
5-C-Hydroxymethyl-N-butyl-1-deoxynojirimycin (56): 
 6 (0.10 mmol) and butyl bromide (0.16 mmol) was subjected to general 
alkylation procedure to provide 56 (0.5 mg, 0.002 mmol, yield 2%). 1H NMR 
(600 MHz, MeOD) δ 4.04 (d, J = 13.3 Hz, 1H, H-6a), 3.90 (d, J = 12.0 Hz, 1H, H-
6*a), 3.87 (d, J = 12.9 Hz, 1H, H-6b), 3.86 (t, J = 9.6 Hz, 1H, H-3), 3.78 (d, J = 
12.0 Hz, 1H, H-6*b), 3.76 – 3.72 (m, 1H, H-2), 3.68 (d, J = 10.0 Hz, 1H, H-4), 
3.59 – 3.51 (m, 2H, H-1a, H-1’a), 3.47 – 3.43 (m, 1H, H-1b), 3.14 (td, J = 12.3, 
5.0 Hz, 1H, H-1’b), 1.93 – 1.83 (m, 1H, H-2’a), 1.78 – 1.68 (m, 1H, H-2’b), 1.53 – 1.41 (m, 2H, H2-
3’), 1.04 (t, J = 7.4 Hz, 3H, H3-4’). 13C NMR (150 MHz, MeOD) δ 74.1 (C-3), 72.9 (C-5), 70.0 (C-4), 
67.9 (C-2), 56.8 (C-6*), 56.5 (C-6), 52.6 (C-1), 52.5 (C-1’), 27.9 (C-2’), 20.7 (C-3’), 13.5 (C-4’). 
IR/cm-1: 3471, 2970, 1738, 1442, 1365, 1216, 1139. [α]20D = -2.00 (c = 0.01, MeOH). HRMS: 
found 250.16502 [C11H23NO5+H]+, calculated for [C11H23NO5+H]+ 250.16490. 
 
5-C-Hydroxymethyl-N-nonyl-1-deoxynojirimycin (57): 
 6 (0.20 mmol) and nonyl bromide (0.31 mmol) was subjected to general 
alkylation procedure to provide 57 (5.0 mg, 0.016 mmol, yield 8%). 1H NMR 
(600 MHz, MeOD) δ 4.04 (d, J = 13.3 Hz, 1H, H-6a), 3.90 (d, J = 12.0 Hz, 1H, H-
6*a), 3.86 (d, J = 13.6 Hz, 1H, H-6b), 3.86 (t, J = 10.0 Hz, 1H, H-3), 3.77 (d, J = 
11.9 Hz, 1H, H-6*b), 3.78 – 3.71 (m, 1H, H-2), 3.68 (d, J = 10.0 Hz, 1H, H-4), 
3.58 – 3.50 (m, 2H, H-1a, H-1’a), 3.44 (t, J = 11.7 Hz, 1H, H-1b), 3.12 (td, J = 
12.3, 5.0 Hz, 1H, H-1’b), 1.96 – 1.83 (m, 1H, H-2’a), 1.80 – 1.70 (m, 1H, H-2’b), 1.47 – 1.25 (m, 
12H, H2-3’, H2-4’, H2-5’, H2-6’, H2-7’, H2-8’), 0.93 (t, J = 7.1 Hz, 3H, H3-9’). 13C NMR (150 MHz, 
MeOD) δ 74.0 (C-3), 72.9 (C-5), 70.0 (C-4), 67.9 (C-2), 56.8 (C-6*), 56.5 (C-6), 52.6 (C-1’), 52.6 
(C-1), 32.6 , 30.1, 29.9, 29.9, 27.4, 25.9, 23.3, 14.0 (C-2’ – C-9’). IR/cm-1: 3675, 2988, 2901, 1677, 
1394, 1226, 1056. [α]20D = -0.1 (c = 0.10, MeOH). HRMS: found 320.24321 [C16H33NO5+H]+, 
calculated for [C16H33NO5 +H] + 320.24315. 
 
5-C-Hydroxymethyl-N-[5-(hexyloxy)pentyl]-1-deoxynojirimycin (58): 
6 (0.20 mmol) and pentyloxyhexyl bromide (0.30 mmol) was subjected 
to general alkylation procedure to provide 58 (3.0 mg, 0.008 mmol, 
yield 4%). 1H NMR (600 MHz, MeOD) δ 4.02 (d, J = 13.3 Hz, 1H, H-6a), 
3.88 (d, J = 12.0 Hz, 1H, H-6*a), 3.84 (t, J = 9.6 Hz, 1H, H-3), 3.84 (d, J = 
13.2 Hz, 1H, H-6b), 3.75 (d, J = 11.9 Hz, 1H, H-6*b), 3.75 – 3.69 (m, 1H, 
H-2), 3.66 (d, J = 10.0 Hz, 1H, H-4), 3.56 – 3.50 (m, 2H, H-1a, H-1’a), 3.44 
– 3.40 (m, 1H, H-1b), 3.46 (t, J = 6.3 Hz, 2H, H2-5’), 3.43 (t, J = 6.7 Hz, 2H, H2-6’), 3.12 (td, J = 12.2, 
5.0 Hz, 1H, H-1’b), 1.94 – 1.86 (m, 1H, H-2’a), 1.81 – 1.69 (m, 1H, H-2’b), 1.68 – 1.60 (m, 2H, H2-
4’), 1.60 – 1.53 (m, 2H, H2-7’), 1.52 – 1.43 (m, 2H, H2-3’), 1.40 – 1.26 (m, 6H, H2-8’, H2-9’, H2-10’), 
0.91 (t, J = 6.9 Hz, 3H, H3-11’). 13C NMR (150 MHz, MeOD) δ 74.4 (C-3), 73.3 (C-5), 72.1 (C-6’), 
71.4 (C-5’), 70.4 (C-4), 68.2 (C-2), 57.2 (C-6), 56.9 (C-6*), 53.0 (C-1), 52.9 (C-1’), 32.9 (C-9’), 30.7 
(C-7’), 30.2 (C-4’), 27.0 (C-8’), 26.1 (C-2’), 24.6 (C-3’), 23.7 (C-10’), 14.4 (C-11’). IR/cm-1: 3316, 
2933, 1673, 1439, 1366, 1205, 1135. [α]20D = -1.00 (c = 0.06, MeOH). HRMS: found 364.26940 
[C18H37NO6+H]+, calculated for [C18H37NO6+H]+ 364.26936. 
 
5-C-Hydroxymethyl-N-[5-(nonyloxy)pentyl]-1-deoxynojirimycin (59): 
6 (0.20 mmol) and pentyloxynonyl bromide (0.30 mmol) was 
subjected to general alkylation procedure to provide 59 (2.4 mg, 0.006 
mmol, yield 3%). 1H NMR (600 MHz, MeOD) δ 4.02 (d, J = 13.3 Hz, 1H, 
H-6a), 3.88 (d, J = 12.0 Hz, 1H, H-6*a), 3.84 (t, J = 9.6 Hz, 1H, H-3), 3.84 





(m, 1H, H-2), 3.66 (d, J = 10.0 Hz, 1H, H-4), 3.57 – 3.49 (m, 2H, H-1a, H-1’a), 3.46 (t, J = 6.3 Hz, 
2H, H2-5’), 3.43 (t, J = 6.6 Hz, 2H, H2-6’), 3.44 – 3.40 (m, 1H, H-1b), 3.12 (td, J = 12.2, 5.0 Hz, 1H, 
H-1’b), 1.90 (ddt, J = 20.9, 12.1, 5.8 Hz, 1H, H-2’a), 1.75 (dtt, J = 22.4, 12.0, 5.1 Hz, 1H, H-2’b), 
1.68 – 1.61 (m, 2H, H2-4’), 1.59 – 1.53 (m, 2H, H2-7’), 1.53 – 1.42 (m, 2H, H2-3’), 1.40 – 1.23 (m, 
12H, H2-8’, H2-9’, H2-10’, H2-11’, H2-12’, H2-13’), 0.90 (t, J = 7.0 Hz, 3H, H3-14’). 13C NMR (150 
MHz, MeOD) δ 74.4 (C-3), 73.3 (C-5), 72.1 (C-6’), 71.4(C-5’), 70.4 (C-4), 68.2 (C-2), 57.2 (C-6), 
56.9 (C-6*), 53.0 (C-1), 52.9 (C-1’), 33.1 (C-9’), 30.8 (C-7’), 30.7, 30.6 30.4 (C-10’, C-11’, C-12’), 
30.2 (C-4’), 27.3 (C-8’), 26.1 (C-2’), 24.6 (C-3’), 23.7 (C-13’), 14.4 (C-14’). [α]20D = -0.63 (c = 0.05, 
MeOH). IR/cm-1: 3357, 2928, 1738, 1676, 1438, 1365, 1216, 1137, 801, 724, 527. HRMS: found 
406.31624 [C21H43NO6+H]+, calculated for [C21H43NO6+H]+ 406.31631.  
 
5-C-Hydroxymethyl-N-[5-(3,3-dimethyl-1-propyloxy)pentyl]-1-deoxynojirimycin (60): 
6 (0.10 mmol) and 1-bromo-5-(2,2-dimethyl-1-propoxy) pentane 
(0.15 mmol) was subjected to general alkylation procedure to 
provide 60 (1.1 mg, 0.0032 mmol, yield 3%).  1H NMR (600 MHz, 
MeOD) δ 4.02 (d, J = 13.3 Hz, 1H, H-6a), 3.88 (d, J = 12.0 Hz, 1H, H-
6*a), 3.84 (d, J = 13.3 Hz, 1H, H-6b), 3.75 (d, J = 12.0 Hz, 1H, H-6*b), 
3.86 – 3.81 (m, 1H, H-3), 3.75 – 3.69 (m, 1H, H-2), 3.65 (d, J = 10.0 Hz, 
1H, H-4), 3.56 – 3.50 (m, 2H, H-1a, H-1’a), 3.45 (t, J = 6.3 Hz, 2H, H2-
5’), 3.44 – 3.38 (m, 1H, H-1b), 3.12 (td, J = 12.2, 5.0 Hz, 1H, H-1’b), 3.08 (s, 2H, H2-6’),1.94 – 1.89 
(m, 1H, H-2’a), 1.77 – 1.73 (m, 1H, H-2’b), 1.69 – 1.65 (m, 2H, H2-3’), 1.61 – 1.42 (m, 2H, H2-4’), 
0.91 (s, 9H, 3 x CH3). 13C NMR (150 MHz, MeOD) δ 82.6 (C-6’), 74.4 (C-3), 73.3 (C-5), 72.0 (C-5’), 
70.4 (C-4), 68.2 (C-2), 57.2 (C-6), 56.9 (C-6*), 53.0 (C-1), 53.0 (C-1’), 32.9 (Cq), 30.3 (C-4’), 27.1 
(C-2’), 26.2 (C-3’), 24.6 (3 x CH3). [α]20D = -1.36 (c = 0.02, MeOH). IR/cm-1: 3460, 3016, 2970, 




6 (0.20 mmol) and 5-(adamantan-1-yl-methoxy)pentyl bromide 
(0.29 mmol) was subjected to general alkylation procedure to 
provide 61 (9.1 mg, 0.022 mmol, yield 11%). 1H NMR (600 MHz, 
MeOD) δ 4.02 (d, J = 13.4 Hz, 1H, H-6a), 3.88 (d, J = 12.2 Hz, 1H, H-
6b), 3.85 (d, J = 13.8 Hz, H-6*a),  3.86 – 3.82 (m, 1H, H-3), 3.76 (d, 
J = 12.2 Hz, 1H, H-6*b), 3.76 – 3.72 (m, 1H, H-2), 3.66 (d, J = 10.0 
Hz, 1H, H-4), 3.55 – 3.50 (m, 2H, H-1a, H-1’a), 3.42 (t, J = 6.3 Hz, 2H, H2-5’), 3.43 – 3.39 (m, 1H, 
H- 1b) 3.16 – 3.08 (m, 1H, H-1’b), 2.99 (s, 2H, H2-6’), 1.94 (p, J = 3.0 Hz, 3H, 3 x CH ada), 1.94 – 
1.90 (m, 1H, H-2’a), 1.77 – 1.66 (m, 7H, 3 x CH2 ada, H-2’b), 1.63 (m, 2H, H2-4’), 1.56 (d, J = 2.9 
Hz, 6H, 3 x CH2 ada), 1.53 – 1.41 (m, 2H, H2-3’). 13C NMR (150 MHz, MeOD) δ 83.1 (C-6’), 74.4 (C-
3), 73.2 (C-5), 72.1 (C-5’), 70.4 (C-4), 68.2 (C-2), 57.2 (C-6), 56.9 (C-6*), 53.0 (C-1’), 52.9 (C-1), 
40.8 (CH2 ada), 38.3 (CH2 ada), 35.1 (Cq ada), 30.1 (C-4’), 29.7 (CH ada), 26.1 (C-2’), 24.6 (C-3’). 
[α]20D =  -0.77 (c = 0.18, MeOH). IR/cm-1: 3346, 2902, 2848, 1738, 1673, 1448, 1365, 1205, 
1136. HRMS: found 428.30048 [C23H41NO6+H]+, calculated for [C23H41NO6+H]+ 428.30066. 
 
5-C-Hydroxymethyl-N-[(biphenyl-4-yl-methoxy)-pentyl]-1-deoxynojirimycin (62): 
6 (0.20 mmol) and (biphenyl-4-yl-methoxy)pentyl 
bromide (0.30 mmol) was subjected to general alkylation 
procedure to provide 62 (40.8 mg, 0.092 mmol, yield 
46%). 1H NMR (600 MHz, MeOD) δ 7.63 (dd, J = 8.3, 1.7 
Hz, 4H, HAr BiPh), 7.48 – 7.41 (m, 4H, HAr BiPh), 7.39 – 7.32 
(m, 1H, HAr BiPh), 4.58 (s, 2H, H2-6’), 4.03 (d, J = 13.3 Hz, 
1H, H-6a), 3.90 (d, J = 12.1 Hz, 1H, H-6*a), 3.86 (d, J = 10.1 Hz, 1H, H-3), 3.86 (d, J = 13.2 Hz, 1H, 
H-6b), 3.77 (d, J = 12 Hz, 1H, H-6*b), 3.77 – 3.63 (m, 1H, H-2), 3.68 (d, J = 10.0 Hz, 1H, H-4), 3.59 




(t, J = 6.2 Hz, 2H, H2-5’), 3.57 – 3.51 (m, 2H, H-1a, H-1’a), 3.44 (t, J = 11.8 Hz, 1H, H-1b), 3.15 (td, J 
= 12.2, 5.0 Hz, 1H, H-1’b), 2.01 – 1.86 (m, 1H, H-2’a), 1.84 – 1.76 (m, 1H, H-2’b), 1.76 – 1.69 (m, 
2H, H2-4’), 1.64 – 1.45 (m, 2H, H2-3’a). 13C NMR (150 MHz, MeOD) δ 141.7, 141.5 (Cq BiPh), 
138.5 – 127.5 (CAr BiPh), 74.1 (C-3), 73.3 (C-6’), 72.9 (C-5), 70.6 (C-5’), 70.1 (C-4), 67.9 (C-2), 
56.8 (C-6), 56.5 (C-6*), 52.6 (C-1), 52.6 (C-2), 29.8 (C-4’), 25.7 (C-2’), 24.3 (C-3’). [α]20D = -0.1 (c 
= 0.82, MeOH). IR/cm-1: 3361, 3016, 2970, 1738, 1675, 1440, 1365, 1205, 1134. HRMS: found 
446.25357 [C25H35NO6+H]+, calculated for [C25H35NO6+H]+ 446.25371.  
 
5-C-Hydroxymethyl-N-butyl-1-deoxy-D-galactonojirimycin (77): 
7 (0.20 mmol) and butyl bromide (0.30 mmol) was subjected to general 
alkylation procedure to provide 77 (11.2 mg, 0.044 mmol, yield 22%). 1H 
NMR (600 MHz, MeOD) δ 4.27 (d, J = 3.4 Hz, 1H, H-4), 4.24 (d, J = 14.0 Hz, 1H, 
H-6a), 4.00 (td, J = 4.8, 1.8 Hz, 1H, H-2), 3.98 (d, J = 11.4 Hz, 1H, H-6*a), 3.94 
(t, J = 4.1 Hz, 1H, H-3), 3.89 (d, J = 12 Hz, 1H, H-6*b), 3.89 (d, J = 14.4 Hz, 1H, 
H-6b), 3.76 (dd, J = 13.1, 1.6 Hz, 1H, H-1a), 3.62 (ddd, J = 13.1, 10.1, 6.6 Hz, 
1H, 1’a), 3.42 (dd, J = 13.8, 3.6 Hz, 1H, H-1b), 3.24 – 3.17 (m, 1H, H-1’b), 1.89 – 1.79 (m, 1H, H-
2’a), 1.74 – 1.64 (m, 1H, H-2’b), 1.52 – 1.36 (m, 2H, H2-3’), 1.01 (t, J = 7.4 Hz, 3H, H3-4’). 13C NMR 
(150 MHz, MeOD) δ 73.6 (C-5), 70.2 (C-3), 66.8 (C-2), 65.1 (C-4), 56.9 (C-6*), 56.5 (C-6), 51.8 (C-
1’), 49.5 (C-1), 28.5 (C-2’), 20.0 (C-3’), 13.5 (C-4’). [α]20D = +0.04 (c = 0.22, MeOH). IR/cm-1: 
3271, 2968, 2879, 1674, 1435, 1201, 1134, 1082. HRMS: found 250.16488 [C11H23NO5+H]+, 
calculated for [C11H23NO5 +H]+ 250.16490. 
 
5-C-Hydroxymethyl-N-nonyl-1-deoxy-D-galactonojirimycin (78): 
 7 (0.20 mmol) and nonyl bromide (0.30 mmol) was subjected to general 
alkylation procedure to provide 78 (11.8 mg, 0.036 mmol, yield 18%). 1H 
NMR (400 MHz, MeOD) δ 4.30 (d, J = 3.3 Hz, 1H, H-4), 4.27 (d, J = 14.0 Hz, 1H, 
H-6a), 4.04 – 4.00 (m, 1H, H-2), 4.00 (d, J = 11.9 Hz, 1H, H-6*a), 3.98 – 3.95 
(m, 1H, H-3), 3.91 (d, J = 11.5 Hz, 1H, H-6*b), 3.91 (d, J = 14.2 Hz, 1H, H-6b), 
3.78 (dd, J = 13.0, 1.6 Hz, 1H, H-1a), 3.63 (ddd, J = 13.0, 10.0, 6.7 Hz, 1H, H-
1’a), 3.43 (dd, J = 13.1, 3.4 Hz, 1H, H-1b), 3.23 (ddd, J = 13.6, 9.6, 4.9 Hz, 1H, H-1’b), 1.96 – 1.82 
(m, 1H, H-2’a), 1.80 – 1.66 (m, 1H, H-2’b), 1.51 – 1.28 (m, 12H, H2-3’, H2-4’, H2-5’, H2-6’, H2-7’, H2-
8’), 0.93 (t, J = 7.1 Hz, 3H, H3-9’). 13C NMR (100 MHz, MeOD) δ 72.6 (C-5), 69.2 (C-3), 65.8 (C-2), 
64.1 (C-4), 55.8 (C-6*), 55.4 (C-6), 51.0 (C-1’), 48.4 (C-1), 31.6, 29.1, 28.9, 28.8, 25.7, 25.4, 22.3 
(C-2’ – C-8’), 13.0 (C-9’). [α]20D = +0.0 (c = 0.24, MeOH). IR/cm-1: 3336, 2928, 1738, 1673, 1438, 




7 (0.20 mmol) and pentyloxyhexyl bromide (0.30 mmol) was subjected 
to general alkylation procedure to provide 79 (15.3 mg, 0.042 mmol, 
yield 21%). 1H NMR (400 MHz, MeOD) δ 4.30 (d, J = 3.3 Hz, 1H, H-4), 
4.26 (d, J = 14.0 Hz, 1H, H-6a), 4.05 – 4.02 (m, 1H, H-2), 4.00 (d, J = 12.0 
Hz, 1H, H-6*a), 3.98 – 3.95 (m, 1H, H-3), 3.92 (d, J = 11.7 Hz, 1H, H-6*b), 
3.91 (d, J = 14.1 Hz, 1H, H-6b), 3.79 (dd, J = 13.1, 1.3 Hz, 1H, H-1a), 3.64 
(ddd, J = 13.2, 10.1, 6.6 Hz, 1H, H-1’a), 3.48 (t, J = 6.3 Hz, 2H, H2-5’), 3.45 (t, J = 6.6 Hz, 2H, H2-6’), 
3.43 (dd, J = 13.2, 3.5 Hz, 1H, H-1b), 3.24 (ddd, J = 13.0, 9.7, 4.4 Hz, 1H, H-1’b), 1.99 – 1.85 (m, 
1H, H-2’a), 1.85 – 1.71 (m, 1H, H-2’b), 1.71 – 1.62 (m, 2H, H2-4’), 1.57 (dt, J = 7.9, 6.6 Hz, 2H, H2-
7’), 1.54 – 1.43 (m, 2H, H2-3’), 1.42 – 1.28 (m, 6H, H2-8’, H2-9’, H2-10’), 0.93 (t, J = 7.1 Hz, 3H, H3-
11’). 13C NMR (150 MHz, MeOD) δ 71.8 (C-6’), 71.1 (C-5’), 70.5 (C-3),  66.8 (C-2), 65.3 (C-4), 58.4 
(C-6*),  57.1(C-6), 52.2 (C-1’), 49.8 (C-1), 32.6 (C-10’), 30.5 (C-7’), 29.9 (C-4’), 26.7 (C-8’), 26.3 





2860, 1670, 1458, 1431, 1201, 1132, 1082. HRMS: found 364.26934 [C18H37NO6+H]+, calculated 
for [C18H37NO6 +H]+ 364.26936. 
 
5-C-Hydroxymethyl-N-[5-(nonyloxy)pentyl]-1-deoxy-D-galactonojirimycin (80): 
7 (0.20 mmol) and pentyloxynonyl bromide (0.30 mmol) was subjected 
to general alkylation procedure to provide 80 (11.5 mg, 0.028 mmol, 
yield 14%). 1H NMR (400 MHz, MeOD) δ 4.29 (d, J = 3.3 Hz, 1H, H-4), 
4.26 (d, J = 14.0 Hz, 1H, H-6a), 4.03 – 4.01 (m, 1H, H-2), 4.00 (d, J = 11.8 
Hz, 1H, H-6*a), 3.97 – 3.94 (m, 1H, H-3), 3.91 (d, J = 11.2 Hz, 1H, H-6*b), 
3.91 (d, J = 14.2 Hz, 1H, H-6b), 3.79 (dd, J = 13.1, 1.6 Hz, 1H, H-1a), 3.69 
– 3.56 (m, 1H, H-1’a), 3.47 (t, J = 6.2 Hz, 2H, H2-5’), 3.44 (t, J = 6.6 Hz, 2H, H2-6’), 3.45 – 3.42 (m, 
1H, H-1b), 3.23 (ddd, J = 14.1, 9.8, 4.4 Hz, 1H, H-1’b), 1.99 – 1.85 (m, 1H, H-2’a), 1.80 – 1.72 (m, 
1H, H-2’b), 1.65 (dt, J = 8.1, 6.1 Hz, 2H, H2-4’), 1.60 – 1.53 (m, 2H, H2-7’), 1.53 – 1.41 (m, 2H, H2-
3’), 1.39 – 1.26 (m, 12H, H2-8’, H2-9’, H2-10’, H2-11’, H2-12’, H2-13’), 0.93 (t, J = 6.8 Hz, 3H, H3-
14’). 13C NMR (100 MHz, MeOD) δ 72.6 (C-5), 70.7 (C-6’), 69.9 (C-5’), 69.2 (C-3), 65.8 (C-2), 64.2 
(C-4), 55.9 (C-6*), 55.5 (C-6), 50.9 (C-1’), 48.6 (C-1), 31.6 (C-9’), 29.4 (C-7’), 29.3, 29.2, 29.0 (C-
10’, C-11’, C-12’), 28.7 (C-4’), 25.9 (C-8’), 25.2 (C-2’), 22.6 (C-3’), 22.3 (C-13’), 13.0 (C-14’). 
IR/cm-1: 3675, 3353, 2971, 2924, 1674, 1394, 1203, 1067. [α]20D = +0.1 (c = 0.23, MeOH). 




7 (0.20 mmol) and 1-bromo-5-(2,2-dimethyl-1-propoxy) pentane 
(0.30 mmol) was subjected to general alkylation procedure to 
provide 81 (14.3 mg, 0.04 mmol,  yield 20%). 1H NMR (400 MHz, 
MeOD) δ 4.30 (d, J = 3.3 Hz, 1H, H-4), 4.27 (d, J = 14.1 Hz, 1H, H-6a), 
4.02 (td, J = 3.6, 1.6 Hz, 1H, H-2), 4.00 (d, J = 11.6 Hz, 1H, H-6*a), 3.97 
(t, J = 3.6 Hz, 1H, H-3), 3.92 (d, J = 11.2 Hz, 1H, H-6*b), 3.91 (d, J = 14.0 
Hz, 1H, H-6b), 3.79 (dd, J = 13.1, 1.7 Hz, 1H, H-1a), 3.64 (ddd, J = 13.1, 10.1, 6.7 Hz, 1H, H-1’a), 
3.47 (t, J = 6.1 Hz, 2H, H2-5’), 3.44 (dd, J = 13.2, 3.2 Hz, 1H, H-1b), 3.28 – 3.20 (m, 1H, H-1’b), 3.10 
(s, 2H, H2-6’), 2.03 – 1.88 (m, 1H, H-2’a), 1.85 – 1.74 (m, 1H, H-2’b), 1.71 – 1.63 (m, 2H, H2-4’), 
1.61 – 1.42 (m, 2H, H2-3’), 0.93 (s, 9H, 3 x CH3). 13C NMR (100 MHz, MeOD) δ 81.1 (C-6’), 72.6 (C-
5), 70.6 (C-5’), 69.2 (C-3), 65.8 (C-2), 64.1 (C-4), 55.9 (C-6*), 55.5 (C-6), 50.9 (C-1’), 48.5 (C-1), 
31.5 (C-7’), 28.8 (C-4’), 25.7 (CH3), 25.3 (C-2’), 22.7 (C-3’). [α]20D = -0.1, (c = 0.29, MeOH). IR/cm-
1: 3675, 3327, 2971, 1673, 1393, 1202, 1066. HRMS: found 350.25364 [C17H35NO6+H]+, 




7 (0.20 mmol) and 5-(adamantan-1-yl-methoxy)pentyl bromide 
(0.30 mmol) was subjected to general alkylation procedure to 
provide 82 (36.5 mg, 0.09 mmol, yield 43%). 1H NMR (400 MHz, 
MeOD) δ 4.28 (d, J = 3.0 Hz, 1H, H-4), 4.25 (d, J = 13.5 Hz, 1H, H-
6a), 4.02 – 3.98 (m, 1H, H-2), 3.99 (d, J = 12.5 Hz, 1H, H-6*a), 3.95 
(t, J = 3.9 Hz, 1H, H-3), 3.90 (d, J = 11.8 Hz, 1H, H-6*b), 3.90 (d, J = 
13.7 Hz, 1H, H-6b), 3.77 (d, J = 12.9 Hz, 1H, H-1a), 3.62 (dt, J = 17.4, 8.1 Hz, 1H, H-1’a), 3.53 – 
3.44 (m, 1H, H-1b), 3.42 (t, J = 6.1 Hz, 1H, H-5’), 3.28 – 3.16 (m, 1H, H-1’b), 2.98 (s, 2H, H2-6’), 
1.95 (t, J = 3.0 Hz, 3H, 3 x CH ada), 1.90 – 1.80 (m, 1H, H-2’a), 1.82 – 1.65 (m, 6H, 3 x CH2 ada), 
1.72 – 1.61 (m, 1H, H-2’b), 1.68 – 1.61 (m, 2H, H2-4’), 1.57 (d, J = 2.8 Hz, 6H, 3 x CH2 ada), 1.55 – 
1.39 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 81.7 (C-6’), 72.6 (C-5), 70.7 (C-5’), 69.2 (C-3), 
65.4 (C-2), 64.1 (C-4), 55.8 (C-6*), 55.4 (C-6), 50.9 (C-1’), 47.7 (C-1), 39.4 (CH2 ada), 36.9 (CH2 
ada), 33.7 (Cq ada), 28.7 (C-4’), 28.3 (CH ada), 25.3 (C-2’), 22.7 (C-3’). [α]20D = +0.2 (c = 0.73, 




MeOH). IR/cm-1: 3248, 2902, 2848, 1674, 1447, 1361, 1319, 1199, 1139, 1084, 1011. HRMS: 




7 (0.20 mmol) and (biphenyl-4-yl-methoxy)pentyl 
bromide (0.30 mmol) was subjected to general alkylation 
procedure to provide 83 (18.6 mg, 0.04 mmol, yield 20%). 
1H NMR (400 MHz, MeOD) δ 7.68 – 7.60 (m, 4H, HAr BiPh), 
7.52 – 7.41 (m, 4H, HAr BiPh), 7.39 – 7.32 (m, 1H, HAr 
BiPh), 4.57 (s, 2H, H2-6’), 4.31 (d, J = 3.3 Hz, 1H, H-4), 4.26 
(d, J = 14.0 Hz, 1H, H-6a), 4.02 – 3.99 (m, 1H, H-2), 4.00 (d, J = 11.7 Hz, 1H, H-6*a), 3.98 – 3.95 
(m, 1H, H-3), 3.92 (d, J = 11.9 Hz, 1H, H-6*b), 3.91 (d, J = 14.1 Hz, 1H, H-6b), 3.76 (d, J = 13.0 Hz, 
1H, H-1a), 3.69 – 3.61 (m, 1H, H-1’a), 3.58 (t, J = 6.1 Hz, 2H, H2-5’), 3.41 (dd, J = 13.0, 3.4 Hz, 1H, 
H-1b), 3.28 – 3.20 (m, 1H, H-1’b), 1.99 – 1.84 (m, 1H, H-2’a), 1.83 – 1.75 (m, 1H, H-2’b), 1.73 (dt, 
J = 7.9, 6.1 Hz, 2H, H2-4’), 1.65 – 1.43 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 132.0 – 128.6 
(CAr BiPh), 74.9 (C-5), 74.5 (C-6’), 71.7 (C-5’), 71.4 (C-3), 68.0 (C-2), 66.4 (C-4), 58.1 (C-6*), 57.7 
(C-6), 53.1 (C-1’), 50.8 (C-1), 30.9 (C-4’), 27.4 (C-2’), 24.9 (C-3’). [α]20D = +0.8 (c = 0.37, MeOH). 
IR/cm-1: 3675, 3313, 2971, 1671, 1407, 1278, 1200, 1077, 1132. HRMS: found 446.25342 
[C25H35NO6+H]+, calculated for [C25H35NO6+H]+ 446.25371.  
 
5-C-Hydroxymethyl-N-butyl-1-deoxy-D-mannonojirimycin (98): 
8 (0.20 mmol) and butyl bromide (0.30 mmol) was subjected to general 
alkylation procedure to provide 98 (12.6 mg, 0.05 mmol, yield 25%). 1H 
NMR (400 MHz, MeOD) δ 4.16 (td, J = 3.6, 1.2 Hz, 1H, H-2), 4.15 (d, J = 10 Hz, 
1H, H-4) 4.06 (d, J = 13.2 Hz, 1H, H-6a), 4.04 (dd, J = 9.6, 3.0 Hz, 1H, H-3), 
3.92 (dd, J = 12.8, 0.8 Hz, 1H, H-1a), 3.90 (d, J = 13.2 Hz, 1H, H-6b), 3.87 (d, J 
= 12 Hz, 1H, H-6*a), 3.73 (d, J = 11.7 Hz, 1H, H-6*b), 3.61 (dd, J = 12.8, 3.6 Hz, 
1H, H-1b), 3.60 – 3.53 (m, 1H, H-1’a), 3.23 (ddd, J = 13.3, 9.7, 4.6 Hz, 1H, H-1’b), 1.96 – 1.82 (m, 
1H, H-2’a), 1.74 (m, 1H, H-2’b), 1.52 – 1.44 (m, 2H, H2-3’), 1.05 (t, J = 7.3 Hz, 3H, H3-4’). 13C NMR 
(100 MHz, MeOD) δ 74.7 (C-5), 72.0 (C-3), 69.4 (C-4), 67.9 (C-2), 58.4 (C-6*), 58.1 (C-6), 55.1 (C-
1), 52.6 (C-1’), 29.6 (C-2’), 21.3 (C-3’), 14.8 (C-4’). [α]20D = -19.8 (c = 0.25, MeOH). IR/cm-1: 3675, 




8 (0.20 mmol) and nonyl bromide (0.30 mmol) was subjected to general 
alkylation procedure to provide 99 (16.3 mg, 0.052 mmol, yield 26%). 1H 
NMR (400 MHz, MeOD) δ 4.14 (d, J = 9.6 Hz, 1H, H-4), 4.13 (d, J = 3.6 Hz, 1H, 
H-2), 4.05 (d, J = 13.2 Hz, 1H, H-6a), 4.04 (dd, J = 9.6, 3.2 Hz, 1H, H-3), 3.90 (d, 
J = 13.2 Hz, 1H, H-1a), 3.88 (d, J = 13.2 Hz, 1H, H-6b), 3.87 (d, J = 12 Hz, 1H, 
H-6*a), 3.72 (d, J = 11.7 Hz, 1H, H-6*b), 3.59 (dd, J = 13.2, 3.6 Hz, 1H, H-1b), 
3.58 – 3.52 (m, 1H, H-1’a), 3.27 – 3.16 (m, 1H, 1’b), 1.95 – 1.84 (m, 1H, H-2’a), 1.80 – 1.70 (m, 
1H, H-2’b), 1.53 – 1.23 (m, 12H, H2-3’ – H2-8’), 0.90 (t, J = 7.0 Hz, 3H, H3-9’). 13C NMR (100 MHz, 
MeOD) δ 72.4 (C-5), 69.7 (C-3), 67.1 (C-4), 65.7 (C-2), 56.2 (C-6), 55.8 (C-6*), 52.8 (C-1), 50.5 (C-
1’), 31.6, 29.1, 28.9, 28.8, 25.7, 25.3, 22.3 (C-2’ – C-8’), 13.0 (C-9’). [α]20D = -15.9 (c = 0.33, 
MeOH). IR/cm-1: 3352, 2928, 2859, 1670, 1435, 1200, 1134, 1038. HRMS: found 320.24306 
[C16H33NO5+H]+, calculated for [C16H33NO5+H]+ 320.24315. 
 
5-C-Hydroxymethyl-N-hexylpentyl-1-deoxy-D-mannonojirimycin (100): 
8 (0.20 mmol) and pentyloxyhexyl bromide (0.31 mmol) was subjected to general alkylation 





(d, J = 9,6 Hz, 1H, H-4), 4.14 (d, J = 4.0 Hz, 1H, H-2), 4.05 (d, J = 13.2 Hz, 
1H, H-6a), 4.04 (dd, J = 9.6, 3.0 Hz, 1H, H-3), 3.91 (d, J = 12 Hz, 1H, H-1a), 
3.89 (d, J = 13.2 Hz, 1H, H-6b), 3.87 (d, J = 12 Hz, 1H, H-6*a), 3.72 (d, J = 
11.7 Hz, 1H, H-6*b), 3.60 (dd, J = 12.8, 3.2 Hz, 1H, H-1b), 3.60 – 3.51 (m, 
1H, H-1’a), 3.48 (t, J = 6.2 Hz, 2H, H2-5’), 3.45 (t, J = 6.6 Hz, 2H, H2-6’), 
3.26 – 3.19 (m, 1H, H-1’b), 2.01 – 1.72 (m, 2H, H2-2’), 1.72 – 1.63 (m, 2H, 
H2-4’), 1.63 – 1.53 (m, 2H, H2-7’), 1.56 – 1.44 (m, 2H, H2-3’), 1.43 – 1.29 (m, 6H, H2-8’, H2-9’, H2-
10’), 0.93 (t, J = 6.7 Hz, 3H, H3-11’). 13C NMR (100 MHz, MeOD) δ 72.4 (C-5), 70.7 (C-6’), 69.9 (C-
5’), 69.7 (C-3), 67.1 (C-4), 65.7 (C-2), 56.2 (C-6*), 55.8 (C-6), 52.9 (C-1), 50.4 (C-1’), 31.5 (C-9’), 
29.4 (C-7’), 28.7 (C-4’), 25.6 (C-8’), 25.1 (C-2’), 22.6 (C-3’), 22.3 (C-10’), 13.0 (C-11’). [α]20D = -
15.0 (c = 0.28, MeOH). IR/cm-1: 3327, 2930, 2860, 1672, 1464, 1431, 1377, 1202, 1134, 1040. 
HRMS: found 364.27001 [C18H37NO6+H]+, calculated for [C18H37NO6+H]+ 364.26936. 
 
5-C-Hydroxymethyl-N-nonylpentyl-1-deoxy-D-mannonojirimycin (101):  
8 (0.20 mmol) pentyloxynonyl bromide (0.30 mmol) was subjected to 
general alkylation procedure to provide 101 (14.2 mg, 0.034 mmol, 
yield 17%). 1H NMR (400 MHz, MeOD) δ 3.98 (d, J = 9.9 Hz, 1H, H-4), 
3.97 (d, J = 4.0 Hz, 1H, H-2), 3.93 – 3.87 (m, 1H, H-3), 3.91 (d, J = 12.5 Hz, 
1H, H-6a), 3.86 (d, J = 12.4 Hz, 1H, H-6b), 3.84 (d, J = 11.4 Hz, 1H, H-6*a), 
3.72 (d, J = 11.3 Hz, 1H, H-6*b), 3.47 (t, J = 6.6 Hz, 2H, H2-5’), 3.45 (t, J = 
6.7 Hz, 2H, H2-6’), 3.53 – 3.42 (m, 1H, H-1a), 3.28 – 3.12 (m, 2H, H-1b, H-1’a), 2.82 – 2.58 (m, 1H, 
H-1’b), 1.78 – 1.53 (m, 6H, H2-2’, H2-4’, H2-7’), 1.51 – 1.20 (m, 14H, H2-3’, H2-8’, H2-9’, H2-10’, H2-
11’, H2-12’, H2-13’), 0.91 (t, J = 6.9 Hz, 3H, H3-14’). 13C NMR (100 MHz, MeOD) δ 72.9 (C-6’),72.8 
(C-5), 72.5 (C-5’), 70.8 (C-3), 68.9 (C-2), 67.5 (C-4), 53.7 (C-1), 51.6 (C-1’), 33.9 (C-9’), 31.7, 31.6, 
31.6, 31.5, 31.4, 31.3, 28.1, 25.5, 24.6 (C-2’, C-3’, C-4’, C-7’, C-8’, C-10’, C-11’, C-12’, C-13’), 15.3 
(C-14’). [α]20D = -15.5 (c = 0.28, MeOH). IR/cm-1: 3357, 2928, 1738, 1676, 1438, 1365, 1216, 




8 (0.20 mmol) and 1-bromo-5-(2,2-dimethyl-1-propoxy)pentane 
(0.30 mmol) was subjected to general alkylation procedure to 
provide 102 (11.7 mg,  0.034 mmol, yield 17%). 1H NMR (400 MHz, 
MeOD) δ 4.14 (d, J = 9.6 Hz, 1H, H-4), 4.14 (dd, J = 3.1, 1.1 Hz, 1H, H-
2), 4.05 (d, J = 13.6 Hz, 1H, H-6a), 4.04 (dd, J = 9.9, 3.1 Hz, 1H, H-3), 
3.92 (d, J = 12.8 Hz, 1H, H-1b), 3.89 (d, J = 13.2 Hz, 1H, H-6b), 3.87 (d, J 
= 11.2 Hz, 1H, H-6*a), 3.72 (d, J = 11.7 Hz, 1H, H-6*b), 3.61 (dd, J = 12.6, 3.5 Hz, 1H, H-1a), 3.58 – 
3.53 (m, 2H, H2-1’a), 3.48 (t, J = 6.1 Hz, 2H, H2-5’), 3.29 – 3.19 (m, 1H, H-1’b), 3.11 (s, 2H, H2-6’), 
1.94 (m, 1H, H-2’a), 1.87 – 1.73 (m, 1H, H-2’b), 1.73 – 1.64 (m, 2H, H2-3’), 1.54 (m , 2H, H2-4’), 
0.94 (s, 9H, 3 x CH3). 13C NMR (100 MHz, MeOD) δ 83.4 (C-6’), 73.5 (C-5), )72.9 (C-5’), 72.0 (C-
3), 69.4 (C-4), 67.9 (C-2), 58.4, 58.1 (C-6, C-6*), 55.1 (C-1), 52.7 (C-1’), 33.8 (C-7’) 31.1 (C-3’), 
28.0 (3 x CH3), 27.4 (C-2’), 25.0 (C-4’). [α]20D = -15.4 (c = 0.23, MeOH). IR/cm-1: 3675, 2988, 





8 (0.20 mmol) and 5-(adamantan-1-yl-methoxy)pentyl bromide 
(0.30 mmol) was subjected to general alkylation procedure to 
provide 103 (10.5 mg, 0.024 mmol, yield 12%). 1H NMR (400 
MHz, MeOD) δ 4.14 (d, J = 9.6, 1H, H-4), 4.15 – 4.14 (m, 1H, H-2), 
4.06 (d, J = 13.2, 1H, H-6a), 4.04 (dd, J = 9.6, 2.8, 1H, H-3), 3.92 




(dd, J = 13.2, 1.2, 1H, H-1b), 3.89 (d, J = 13.6, 1H, H-6b), 3.88 (d, J = 11.6, 1H, H-6*a), 3.73 (d, J = 
11.7, 1H, H-6*b), 3.61 (dd, J = 12.9, 3.4 Hz, 1H, H-1a), 3.62 – 3.52 (m, 1H, H-1’a), 3.45 (t, J = 6.1 
Hz, 2H, H2-5'), 3.23 (ddd, J = 13.4, 9.9, 4.6 Hz, 1H, H-1’b), 1.98 (br s, 3H, CH ada), 1.96 – 1.89 (m, 
1H, H-2’a), 1.85 – 1.75 (m, 1H, H-2’b), 1.83 – 1.68 (m, 6H, 3 x CH2 ada), 1.70 – 1.63 (m, 2H, H2-
4’), 1.59 (d, J = 2.8 Hz, 6H, 3 x CH2 ada), 1.57 – 1.48 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 
84.0 (C-6’), 74.7 (C-5), 73.0 (C-5’), 72.0 (C-3), 69.4 (C-4), 67.9 (C-2), 58.4 (C-6*), 58.1 (C-6), 53.8 
(C-1), 52.7 (C-1’), 41.7 (CH2 ada), 39.2 (CH2 ada), 36.0 (Cq ada), 31.0 (C-4’), 30.6 (CH ada), 27.5 
(C-2’), 25.0 (C-3’). [α]20D = -13.3 (c = 0.21, MeOH). IR/cm-1: 3675, 3330, 2901, 1673, 1450, 1203, 




8 (0.20 mmol) and (biphenyl-4-yl-methoxy)pentyl 
bromide (0.32 mmol) was subjected to general alkylation 
procedure to provide 104 (17.1 mg, 0.038 mmol, yield 
19%). 1H NMR (400 MHz, MeOD) δ 7.64 (m, 4H, HAr BiPh), 
7.50 – 7.40 (m, 4H, HAr BiPh), 7.40 – 7.29 (m, 1H, HAr BiPh), 
4.58 (s, 2H, H2-6’), 4.14 (d, J = 9.8 Hz, 1H, H-4), 4.15 - 4.11 
(t, J = 3.2 Hz, 1H, H-2), 4.04 (d, J = 13.2, 1H, H-6a), 4.03 (dd, J = 10.0, 2.8, 1H, H-3), 3.89 (d, J = 
13.2, 1H, H-6b), 3.87 (d, J = 12.0, 1H, H-6*a ), 3.87 (m, 1H, H-1a) 3.71 (d, J = 11.6, 1H, H-6*b ), 
3.65 – 3.54 (m, 1H, H-1’a), 3.59 (t, J = 5.8 Hz, 2H, H2-5’), 3.64 - 3.55 (m, 1H, H-1b), 3.28 – 3.17 (m, 
1H, H-1’b), 2.01 – 1.86 (m, 1H, H-2’a), 1.86 – 1.77 (m, 1H, H-2’b), 1.78 – 1.70 (m, 2H, H-4’), 1.68 
– 1.46 (m, 2H, H-3’). 13C NMR (100 MHz, MeOD) δ 140.5, 137.5 (Cq BiPh), 129.7, 128.7, 128.5, 
128.1, 127.0, 126.6, 126.5 (CAr BiPh), 72.4 (C-5), 72.2 (C-6’), 69.7 (C-3), 69.5 (C-5’), 67.1 (C-4), 
65.7 (C-2), 56.2 (C-6*), 55.8 (C-6), 52.8 (C-1), 50.4 (C-1’), 28.7 (C-2’), 25.0 (C-3’), 22.7 (C-4’). 
[α]20D = -14.6 (c = 0.34, MeOH). IR/cm-1: 3675, 3323, 2971, 1674, 1407, 1202, 1133, 1076. 
HRMS: found 446.25345 [C25H35NO6+H]+, calculated for [C25H35NO6+H]+ 446.25371. 
 
5-C-Hydroxymethyl-N-butyl-1-deoxy-D-allonojirimycin (121): 
9 (0.20 mmol) and butyl bromide (0.30 mmol) was subjected to general 
alkylation procedure to provide 121 (6.2 mg, 0.025 mmol, yield 12%). 1H 
NMR (600 MHz, MeOD) δ 4.18 (d, J = 14.2 Hz, 1H, H-6a), 4.08 (t, J = 2.9 Hz, 
1H, H-3), 3.97 (d, J = 12.1 Hz, 1H, H-6*a), 3.94 – 3.90 (m, 1H, H-2), 3.89 (d, J = 
12.6 Hz, 1H, H-6*b), 3.89 (d, J = 2.7 Hz, 1H, H-4), 3.87 (d, J = 14.2 Hz, 1H, H-
6b), 3.61 (ddd, J = 13.0, 11.9, 5.0 Hz, 1H, H-1’), 3.36 – 3.34 (m, 2H, H2-1), 1.92 
– 1.80 (m, 1H, H-2’a), 1.76 – 1.59 (m, 1H, H-2’b), 1.54 – 1.33 (m, 2H, H2-3’), 1.01 (t, J = 7.4 Hz, 3H, 
H3-4’). 13C NMR (150 MHz, MeOD) δ 72.6 (C-5), 71.8 (C-3), 67.5 (C-4), 65.1 (C-2), 57.0 (C-6), 
57.0 (C-6*), 53.0 (C-1’), 49.0 (C-1), 28.4 (C-2’), 21.1 (C-3’), 13.9 (C-4’). [α]20D = -0.2 (c = 0.12, 
MeOH). IR/cm-1: 3352, 2970, 2879, 1674, 1430, 1201, 1136, 1056. HRMS: found 250.16502 
[C11H23NO5+H]+, calculated for [C11H23NO5+H]+ 250.16490. 
 
5-C-Hydroxymethyl-N-nonyl-1-deoxy-D-allonojirimycin (122): 
9 (0.20 mmol) and nonyl bromide (0.30 mmol) was subjected to general 
alkylation procedure with to provide 122 (8.3 mg, 0.026 mmol, yield 13%). 1H 
NMR (400 MHz, MeOD) δ 4.21 (d, J = 14.3 Hz, 1H, H-6a), 4.10 (t, J = 2.9 Hz, 1H, 
H-3), 3.99 (d, J = 12.1 Hz, 1H, H-6*a), 3.95 (dd, J = 6.5, 3.1 Hz, 1H, H-2), 3.92 (d, 
J = 12.4 Hz, 1H, H-6*b), 3.91 (d, J = 2.4 Hz, 1H, H-4), 3.89 (d, J = 14 Hz, 1H, H-
6b), 3.63 (td, J = 12.4, 5.0 Hz, 1H, H-1’a), 3.42 – 3.35 (m, 2H, H2-1), 3.14 (dt, J = 
12.5, 6.3 Hz, 1H, H-1’b), 1.98 – 1.66 (m, 2H, H2-2’), 1.46 – 1.33 (m, 12H, H2-3’ - H2-8’), 0.94 (t, J = 
7.1 Hz, 3H, H3-9’). 13C NMR (100 MHz, MeOD) δ 71.2 (C-5), 70.3 (C-3), 66.1 (C-4), 63.7 (C-2), 
55.6 (C-6), 55.6 (C-6*), 51.8 (C-1’), 47.5 (C-1), 31.6, 29.1, 28.9, 28.8, 26.4, 25.0, 22.3 (C-2’ - C-8’), 









9 (0.20 mmol) and pentyloxyhexyl bromide (0.30 mmol) was subjected 
to general alkylation procedure to provide 123 (5.0 mg, 0.014 mmol, 
yield 7%). 1H NMR (600 MHz, MeOD) δ 4.21 (d, J = 14.2 Hz, 1H, H-6a), 
4.10 (t, J = 2.8 Hz, 1H, H-3), 3.99 (d, J = 12.1 Hz, 1H, H-6*a), 3.96 – 3.93 
(m, 2H, H2-2), 3.91 (d, J = 12.4 Hz, 1H, H-6*b), 3.91 (d, J = 2.7 Hz, 1H, H-
4), 3.89 (d, J = 14.3 Hz, 1H, H-6b), 3.68 – 3.59 (m, 1H, H-1’a), 3.48 (t, J = 
6.3 Hz, 2H, H2-5’), 3.46 (t, J = 6.6 Hz, 2H, H2-6’), 3.40 – 3.36 (m, 2H, H2-1), 3.15 (td, J = 12.4, 5.0 
Hz, 1H, H-1’b), 1.96 – 1.90 (m, 1H, H-2’a), 1.80 – 1.71 (m, 1H, H-2’b), 1.68 – 1.66 (m, 2H, H2-4’), 
1.60 – 1.56 (m, 2H, H2-7’), 1.55 – 1.44 (m, 2H, H2-3’), 1.42 – 1.30 (m, 6H, H2-8’, H2-9’, H2-10’), 
0.93 (t, J = 6.9 Hz, 3H, H3-11’). 13C NMR (150 MHz, MeOD) δ 72.3 (C-5), 71.7 (C-6’), 71.4 (C-3), 
71.0 (C-5’), 67.1 (C-4), 64.7 (C-2), 56.6 (C-6), 56.6 (C-6*), 52.7 (C-1’), 48.5 (C-1), 31.9 (C-9’), 30.3 
(C-7’), 29.8 (C-4’), 26.6 (C-8’), 25.8 (C-2’), 24.2 (C-3’), 23.3 (C-10’), 14.0 (C-11’). [α]20D = +0.0 (c = 
0.10, MeOH). IR/cm-1: 3352, 2929, 2860, 1751, 1676, 1431, 1371, 1205, 1132, 1080. HRMS: 
found 264.26942 [C18H37NO6+H]+, calculated for [C18H37NO6+H]+ 264.26936. 
 
5-C-Hydroxymethyl-N-nonyloxypentyl-1-deoxy-D-allonojirimycin (124): 
9 (0.20 mmol) and pentyloxynonyl bromide (0.30 mmol) was subjected 
to general alkylation procedure to provide 124 (3.3 mg, 0.008 mmol, 
yield 4%). 1H NMR (600 MHz, MeOD) δ 4.21 (d, J = 14.3 Hz, 1H, H-6a), 
4.10 (t, J = 2.9 Hz, 1H, H-3), 3.99 (d, J = 12.1 Hz, 1H, H-6*a), 3.96 – 3.93 
(m, 1H, H-2), 3.91 (d, J = 12 Hz, 1H, H-6*b), 3.91 (d, J = 2.4 Hz, 1H, H-4), 
3.89 (d, J = 14.4 Hz, 1H, H-6b), 3.67 – 3.60 (m, 1H, H-1’a), 3.48 (t, J = 6.3 
Hz, 2H, H2-5’), 3.46 (t, J = 6.6 Hz, 2H, H2-6’), 3.39 – 3.33 (m, 2H, H2-1), 3.15 (td, J = 12.5, 5.0 Hz, 
1H, H-1’b), 1.99 – 1.88 (m, 1H, H-2’a), 1.84 – 1.72 (m, 1H, H-2’b), 1.68 – 1.66 (m, 2H, H2-4'), 1.58 
(dt, J = 8.0, 6.4 Hz, 2H, H2-7’), 1.55 – 1.45 (m, 2H, H2-3’), 1.41 – 1.27 (m, 12H, H2-8’ – H2-13’), 
0.93 (t, J = 7.1 Hz, 3H, H3-14’). 13C NMR (150 MHz, MeOD) δ 72.3 (C-5), 71.7 (C-6’), 71.4 (C-3), 
71.0 (C-5’), 67.1 (C-4), 64.7 (C-2), 56.6 (C-6), 56.6 (C-6*), 52.7 (C-1’), 49.5 (C-1), 32.7 (C-9’), 30.4 
(C-7’), 30.3, 30.2, 30.0 (C-10’, C-11’, C-12’), 29.8 (C-4’), 26.9 (C-8’), 25.8 (C-2’), 24.2 (C-3’), 23.3 
(C-13’), 14.1 (C-14’). [α]20D = -0.2 (c = 0.07, MeOH). IR/cm-1: 3292, 2924, 2856, 1676, 1425, 





9 (0.20 mmol) and 1-bromo-5-(2,2-dimethyl-1-propoxy)pentane 
(0.31 mmol) was subjected to general alkylation procedure with to 
provide 125 (13.8 mg, 0.04 mmol, yield 20%). 1H NMR (400 MHz, 
MeOD) δ 4.21 (d, J = 14.3 Hz, 1H, H-6a), 4.11 (t, J = 2.9 Hz, 1H, H-3), 
4.00 (d, J = 12.1 Hz, 1H, H-6*a), 3.98 – 3.94 (m, 1H. H-2), 3.92 (d, J = 
12.4 Hz, 1H, H-6*b), 3.92 (d, J = 3.2 Hz, 1H, H-4), 3.90 (d, J = 14.8 Hz, 
1H, H-6b), 3.65 (td, J = 12.4, 5.0 Hz, 1H, H-1’a), 3.47 (t, J = 6.2 Hz, 2H, 
H2-5’), 3.42 – 3.38 (m, 2H, H2-1), 3.22 – 3.13 (m, 1H, H-1’b), 3.10 (s, 2H, H2-6’), 2.01 – 1.89 (m, 
1H, H-2’a), 1.88 – 1.73 (m, 1H, H-2’b), 1.67 (dt, J = 7.9, 6.4 Hz, 2H, H2-4’), 1.58 – 1.48 (m, 2H, H2-
3’), 0.93 (s, 9H, 3 x CH3). 13C NMR (100 MHz, MeOD) δ 81.1 (C-6’), 71.3 (C-5), 70.6 (C-5’), 70.3 
(C-3), 66.2 (C-4), 63.7 (C-2), 55.7, 55.7 (C-6, C-6*), 51.7 (C-1’), 47.2 (C-1), 31.5 (C-7’), 28.9 (C-4’), 
25.8 (CH3), 24.8 (C-2’), 23.3 (C-3’). [α]20D = -0.3 (c = 0.28, MeOH). IR/cm-1: 3675, 2971, 1672, 
1393, 1202, 1066. HRMS: found 350.25347 [C17H35NO6+H]+, calculated for [C17H35NO6+H]+ 
350.25371.  







9 (0.20 mmol) and 5-(adamantan-1-yl-methoxy)pentyl bromide 
(0.29 mmol) was subjected to general alkylation procedure to 
provide 126 (9.5 mg, 0.022 mmol, yield 11%). 1H NMR (400 MHz, 
MeOD) δ 4.21 (d, J = 14.2 Hz, 1H, H-6a), 4.10 (t, J = 2.9 Hz, 1H, H-
3), 3.98 (d, J = 12.4 Hz, 1H, H-6*a), 3.96 – 3.92 (m, 1H, H2-2), 3.91 
(d, J = 12.4 Hz, 1H, H-6*b), 3.91 (d, J = 2.8 Hz, 1H, H-4), 3.90 (d, J = 
14 Hz, 1H, H-6b), 3.64 (td, J = 12.3, 4.9 Hz, 1H, H-1’a), 3.44 (t, J = 6.2 Hz, 2H, H2-5’), 3.41 – 3.35 
(m, 2H, H2-1), 3.22 – 3.10 (m, 1H, H-1’b), 1.97 (t, J = 3.2 Hz, 3H, 3 x CH ada), 1.97 – 1.90 (m, 1H, 
H2-2’a), 1.80 – 1.68 (m, 6H, 3 x CH2 ada), 1.74 – 1.69 (m, 1H, H-2’b), 1.70 – 1.62 (m, 2H, H2-4’), 
1.59 (d, J = 2.9 Hz, 6H, 3 x CH2 ada), 1.56 – 1.44 (m, 2H, H-3’). 13C NMR (100 MHz, MeOD) δ 81.7 
(C-6’), 71.3 (C-5), 70.7 (C-5’), 70.3 (C-3), 66.1 (C-4), 63.7 (C-2), 55.6 (C-6), 55.6 (C-6*) 51.7 (C-
1’), 48.3 (C-1), 39.4 (CH2 ada), 36.9 (CH2 ada), 33.8 (Cq ada), 28.8 (C-4’), 28.3 (CH ada), 24.8 (C-
2’), 23.3 (C-3’). [α]20D = -0.1 (c = 0.19, MeOH). IR/cm-1: 3675, 2988, 1673, 1394, 1205, 1131, 




9 (0.20 mmol) and (biphenyl-4-yl-methoxy)pentyl 
bromide (0.30 mmol) was subjected to general alkylation 
procedure to provide 127 (2.8 mg, 0.0062 mmol, yield 
3%). 1H NMR (600 MHz, MeOD) δ 7.65 – 7.57 (m, 4H, HAr 
BiPh), 7.43 (d, J = 8.0 Hz, 4H, HAr BiPh), 7.34 (d, J = 7.4 Hz, 
1H, HAr BiPh), 4.56 (s, 2H, H-6’), 4.17 (d, J = 14.3 Hz, 1H, H-
6a), 4.07 (t, J = 2.9 Hz, 1H, H-3), 3.96 (d, J = 12.2 Hz, 1H, H-6b), 3.92 – 3.89 (m, 1H, H-2), 3.90 (d, 
J = 14.4 Hz, 1H, H-6*a), 3.88 (d, J = 3 Hz, 1H, H-4), 3.86 (d, J = 13.8 Hz, 1H, H-6*b), 3.64 – 3.59 (m, 
1H, H-1’a), 3.56 (t, J = 3.56, 2H, H2-5’), 3.37 – 3.32 (m, 2H, H2-1),  3.17 – 3.10 (m, 1H, H-1’b), 1.97 
– 1.88 (m, 1H, H-2’a), 1.80 – 1.73 (m, 1H, H-2’b), 1.74 – 1.68 (m, 2H, H2-4’), 1.59 – 1.46 (m, 2H, 
H2-3’). 13C NMR (150 MHz, MeOD) δ 142.1, 141.9 (Cq Bn), 138.8, 129.9, 129.4, 128.4, 128.0, 
127.9 (CAr BiPh), 73.7 (C-6’), 71.8 (C-3), 71.0 (C-5’), 67.5 (C-4), 65.1 (C-2), 62.6 (C-5), 57.0 (C-6), 
56.9 (C-6*), 53.1 (C-1’), 49.9 (C-1), 30.2 (C-4’), 26.2 (C-2’), 24.7 (C-3’). [α]20D = +0.54 (c = 0.06, 
MeOH). IR/cm-1: 3337, 2928, 2863, 1738, 1673, 1442, 1365, 1205, 1130. HRMS: found 
[C25H35NO6+H]+ 446.25357, calculated for [C25H35NO6+H]+  446.25371. 
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This Thesis describes the design, synthesis and evaluation as glycoprocessing enzyme 
inhibitors of focused libraries of iminosugars. In the studies described, 1-deoxynojirimycin 
(DNJ), the archetypal iminosugar, and its known N-alkylated derivatives, served as starting 
points. DNJ modifications presented here include alteration of the substitution pattern of the 
piperidine core structure; variation in the N substituent, or a combination of the two. Biological 
evaluation of the synthesized compounds focused on the glycoprocessing enzymes involved in 
glucosylceramide metabolism: glucosylceramide synthase (GCS), lysosomal glucosylceramidase 
(GBA1) and neutral glucosylceramidase (GBA2), and in all examples presented the inhibitory 
potency of newly synthesized compounds are compared with that of literature compounds. 






In Chapter 1 the current and potential applications of iminosugars in biomedicine are 
introduced. Given the importance of this class of compounds, numerous synthetic strategies 
have been reported over the decades, thus allowing the synthesis of natural compounds that 
are hard to access in large quantities and/or purity from nature, but also to expand the 
structural diversity. Chapter 2 reviews some particularly versatile synthetic strategies for the 
construction of DNJ, including strategies involving a double reductive amination as a key step – 
a key step that also features in several routes of synthesis as presented in this Thesis. 
Glycosylated DNJs comprise a relatively less well explored class of iminosugars when 
compared to monosaccharidic DNJs. In Chapter 3 an efficient method is described for the 
synthesis of glycosylated DNJ derivatives starting from the corresponding disaccharides. Five 
different glycosylated DNJ structures were successfully constructed (1 – 5, Figure 1) following a 
route comprising selective liberation of the anomeric center of the reducing glucose in the 
starting disaccharides followed by reduction to the diol, oxidation to the 5-keto aldehyde and 
double reductive amination. 
Figure 1: Glycosylated 1-deoxynojirimycin (1 - 5) constructed in Chapter 3 
 
N-alkyl derivatives of some of these glycosylated iminosugars (see for the synthesized 
structures Table 1) were prepared as depicted in scheme 1. As an example, reductive amination 
of the per-O-benzyl protected iminodisaccharide 6 with sodium cyanoborohydride as the 
reducing agent and including the appropriate aldehyde provides, after global deprotection, 
hydroxyethyl derivative 10 (Scheme 1A; see for experimental details the experimental section 
at the end of this Chapter). Alternatively, fully deprotected iminodisaccharide 2 can be 
subjected to butyl bromide and potassium carbonate in DMF to yield N-butyl-
iminodisaccharide 19 (Scheme 1B). A combination of both approaches should enable the 
synthesis of the complete panel as depicted in Table 1. 
 




Scheme 1: N-Alkylation strategies of glycosylated DNJ derivatives (9 - 28) 
 
Reagents and conditions: [a] AcOH, NaCHBH3, MeOH, DCM, 64%; [b] Pd/C, H2, DMF/MeOH, 91%; [c] 
K2CO3, DMF, 85 °C, 58%. 
Table 1: Code of the synthesized N-alkyl glycosylated DNJ derivatives 
 Melibio DNJ (1) Malto DNJ (2) Lacto DNJ (3) Cellobio DNJ (4) 
N-hydroxyethyl  
 
[a]  9, [b] 10 N.S. N.S. N.S. 
N-butyl 
 
[a] 11, [b] N.S. [a] 18, [b] 19 N.S. [c] 23 
N-nonyl 
 
[a] 12, [b] 13 [a] 20, [b] N.S. N.S. [c] 24 
N-5-(hexyloxy)pentyl 
 
N.S. N.S. [c] 21 [c] 25 
N-5-(nonyloxy)pentyl 
 
[c] 14 N.S. N.S. [c] 26 
N-(biphenyl-4-yl-
methoxy)pentyl 
[c] 15 N.S. N.S. [c] 27 
N-5-(adamantan-1-yl-
methoxy)pentyl 
[c] 16 N.S. [c] 22 N.S. 
N-5-(3,3-dimethyl-1-
propyloxy)pentyl 
[c] 17 N.S. N.S. [c] 28 
*N.S.: not synthesized or purified. 
*[a],[b],[c]: synthesized via conditions a, b or c described in scheme 1. 
 
GBA2 selective inhibitors are desirable commodities both for fundamental biological 
studies on the physiological role of GBA2 and as potential clinical candidates, in case GBA2 
turns out to be a relevant drug target (as is currently considered in relation to the lysosomal 





inhibitors described in the literature have overlapping activities on either of the two other 
GlcCer metabolism relating enzymes, GCS and GBA1. Chapter 4 discusses the design and 
synthesis of N-alkyl DNJ derivatives as potential GBA2 selective inhibitors. A focused library 
composed of N-pentyloxy neopentyl isosteres iminosugars was built and evaluated, and 
compound 29 (Figure 2) was found to be the most selective GBA2 inhibitor of the investigated 
series. 
Figure 2: Most promising GBA2 selective inhibitor from Chapter 4 
 
 
Studies on configurational iminosugars have revealed that D-ido-configured DNJ derivatives 
possess remarkable GBA2 selectivity. As depicted in Figure 3, D-ido-configured, N-alkyl 
derivative 32 is a low nanomolar GBA2 inhibitor. The compound is even more potent than the 
known GBA2 inhibitors 30 and 31, and is also more selective (32: IC50 GCS/IC50 GBA2 1750, IC50 
GBA1/IC50 GBA2 92071; 30: IC50 GCS/IC50 GBA2 1020, IC50 GBA1/IC50 GBA2 1252). 
Figure 3: Structure and inhibitory activity of D-gluco, L-ido and D-ido iminosugars  
 
Hence, D-ido structural iminosugar is a promising starting point for further research on 
GBA2 selective inhibitors, for instance by variation of the N-alkyl substituent as has been the 
object of study in Chapter 4 (leading to, for instance, compound 33, Figure 4). 
Figure 4: Structure of designed GBA2 selective inhibitor 
 





Iminosugars with dual GCS/GBA2 inhibitory activity are promising leads for drug 
development for the treatment of several lysosomal storage disorders. In Chapter 5, 16 N-alkyl 
D-glucose configured and L-idose configured DNJ derivatives were designed, synthesized and 
evaluated on their efficacy as dual GCS/GBA2 inhibitors. Regrettably, no outstanding new 
inhibitor was identified. Amongst the compounds evaluated, the one carrying a para-
trifluorometyl substituted N-biphenyl moiety (L-ido-DNJ 34) proved to be the most GCS/GBA2 
selective compound of the series (selectivity as set against GBA1 inhibitory activity), whereas 
derivatives with a low logP value (such as 35) deserve future attention as well because of their 
suspected improved (compared to 34) in vivo activity. 
Figure 5: Most promising GCS/GBA2 inhibitors from Chapter 5 
 
As also highlighted in Chapter 5, future research might focus on modification of the inner 
benzene moiety of the biphenyl substituent in the L-idose configured and D-glucose configured 
DNJ derivatives (for instance, 36 – 39, Figure 6), or even modification of both benzenes (for 
instance, 40 – 47).  
Chapter 6 discusses the design and synthesis of a focused library comprising four 
configurational isomeric bis-hydroxymethyl iminosugars (48 – 51, Figure 7). These core 
structures were decorated with different aliphatic chains and the complete library was 
assessed on their inhibitory potential against GCS, GBA1 and GBA2. The additional (compared 
to the parent iminosugars) hydroxymethyl group does not bring extra potency and neither 
selectivity against the target enzymes. 
 Lack of potency towards the target enzymes may be due to steric factors, and one way to 
overcome this, but that would keep the symmetrical carbon at C-5 intactly, would be to 
condense the two hydroxyls to form an oxetane (as in 52 – 55, Figure 8). Oxetane groups are 
common functional groups in medicinal chemistry and confer to drugs/drug candidates 






Figure 6: Relevant D-gluco and L-idose configured DNJ derivatives carrying a modified 
biphenyl functional group 
     
Figure 7: 5-Bis-hydroxymethyl DNJ compounds (48 - 51) described in Chapter 6 
 









Scheme 2: Designed synthesis route for 1,5-dideoxy-1,5-imino-5-oxetane-D-xylitol 
 
Reagents and conditions: [a] 1) TBSCl, TEA, DMAP, DCM; 2) PCC, DCM; 3) LDA, DCM, THF; 4) NaN3, DMF, 
115 °C; [b] NaBH4; [c] CBr4, PPh3, DCM; [d] TBAF, THF; [e] NaOH, H2O, MeOH; [f] TFA, H2O; [g] H2, Pd/C. 
 
A potential route of synthesis towards compound 52 is presented in Scheme 2. The 
synthesis is based on diacetone-D-glucose (D-DAG), and standard protecting group 
manipulations have yielded compound 56. The additional carbon and nitrogen could be 
introduced following a strategy similar to that described in Chapter 6 (from D-DAG to 57). The 
newly introduced hydroxylmethyl group (58) may be transformed to a bromide via an Appel 
reaction, and the bromide substituted by the liberated (59 to 60) OH-6 to form oxetane (61). 
The anomeric center in 61 is then to be exposed (to give 62) using the TFA/water system after 
which reduction of the azide to the amine, reductive amination onto the anomeric aldehyde and 
concomitant debenzylation should yield 52.  
In previous studies, the inhibitory activity against GCS, GBA1 and GBA2 of a series of 1,2-
dideoxynojirimycin derivatives was tested (for example, compounds 67 – 70, Figure 9). As is 
evident from the depicted (Figure 9) IC50 values, the lack of a C-2 hydroxyl results in a loss of 
GCS inhibitory activity (compare the GCS inhibitory activity of 63 and 67; 64 and 68; 65 and 69; 






Figure 9: IC50 values of N-AMP iminosugars  
*IC50 values are from the literature1 
 
In order to investigate the importance of C-3 OH, 1,3-dideoxynojirimycin derivatives have 
been synthesized and evaluated on their potency to inhibit GCS (e.g. 71 and 72, Figure 10). It 
appears that removal of C-3 OH in DNJ (with the remaining chiral centers as in the parent 
iminosugar, deoxynojirimycin) largely abolishes GCS inhibitory activity (compare GCS 
inhibitory activity of 71 and 63, 72 and 89). It would be useful to have the full set of 
configurational isomers of 71 (three stereocenters – 6 stereoisomers in total besides 71 and 72) 
in hand to establish their inhibitory potency against GCS but also GBA1 and GBA2, and synthetic 
methodology needs to be developed for this purpose. 




















Looking closer at the IC50 values obtained for GCS inhibition as described in Chapter 6, it 
becomes apparent that D-glucose configured iminosugars (for instance, 63, Figure 11) and L-
idose configured iminosugars (for instance, 65) and their C-4 epimers (for instance, D-galactose 
configured 64 and L-altrose configured 66) are all able to act as GCS inhibitors. It can thus be 
concluded that all compounds tested and that display significant GCS inhibitory activity share 
one common characteristic: the (2S, 3R) configuration of the diol system (with both hydroxyls 
present): all relevant GCS inhibitors are found in either the D-glucose, L-idose, D-galactose or L-
altrose iminosugar series.  
In order to unambiguously confirm this structure-activity-relationship, the efficacy of all 16 
DNJ congeners bearing the same N-alkyl substituent should be evaluated side-by-side on GCS, 
GBA1 and GBA2. Initial results towards this goal are presented in Figure 11 and concern some 
first inhibitory data on the complete set of 16 configurational isomers of N-
adamantanemethoxypentyl-deoxynojirimycin. It can be seen that D-gluco AMP (63), L-ido AMP 
(65), D-galacto AMP (64) and L-altro AMP (66), which all have the (2S, 3R) configuration, but 
none of the other configurational isomers, exhibit potent GCS inhibitory activity (0.1 μM - 0.2 
μM). The synthesis details of compounds 73, 74, 76, 77, 79 and 84 can be found in the 
experimental part. 
Looking at the inhibition potency of GBA1 and GBA2 as exerted by the 12 configurational 
isosters introduced in Figure 11, and comparing with the four lead isosteres, D-ido derivative 
74 stands out as a promising GBA2 selective inhibitor. In order to fully capitalize on the 
potential of configurational and functional DNJ isosters as selective inhibitors for GCS, GBA or 
GBA2 as well as for unrelated glycoprocessing enzymes, it would be advantageous to have 
access to a focused and comprehensive library. Such a library should ideally contain all 16 
configurational isomers as well as encompass all alkyl and aryl substituents found on individual 
DNJ isomers in the literature and that are found to have a beneficial effect, whether on enzyme 
inhibition potency/selectivity or on pharmacological behavior. Initial synthesis efforts have 
been conducted towards this goal and the resulting configurational and functional DNJ 
derivatives – alongside with initial GCS/GBA1/GBA2 inhibitory properties such as have been 




































Figure 15:  IC50 values of DNJ derivatives with 2R, 3S configuration 
       
One literature study, describes the synthesis and evaluation of 1,6-dideoxynojirimycin 
(175) and xylose-DNJ (176).1 Compared to DNJ derivative 63 (Figure 16) both compounds 




proved to be less potent as GCS inhibitors, with the xylose-configured one less active than the 
quinuvose-configured one. This result suggests that the functional group at C-6 contributes to 
GCS inhibitory activity.  
Figure 16: IC50 values of DNJ-AMP, 6-deoxy-DNJ AMP and 6-dehydroxy-DNJ-AMP 
 
*IC50 data from the literature1 
Based on the data above, substitution of the C6-OH in 63 with an electron-withdrawing 
functional group may yield a conceptually new, potent and potentially selective GCS inhibitor. 
Fluorine is a widely used hydroxyl isostere2 that has about the same size and is comparatively 
more electron-withdrawing, and substituting C6-OH in 63 with fluorine therefore appeared an 
attractive strategy. 
Figure 17: IC50 values of DNJ and 6-deoxy-6-fluoro-DNJ derivatives 
  
However, 6-deoxy-6-fluoro-AMP-DNJ (181, Figure 17) turned out to be a comparatively 





side-by-side comparison (compare compounds 177 – 183 with their 6-hydroxy counterparts) 
and GBA1/GBA2 inhibition potency appears affected by the OH-to-F substitution as well. A 
tentative conclusion may be that the hydrogen-bond-donating properties of the C6-OH (and not 
so much the hydrogen-bond accepting properties – though arguably a fluorine partakes in 
neither) are what makes DNJ derivatives bearing this substituent more potent against the three 
enzymes tested. Nevertheless, the developed methodology to introduce a fluorine at C-6 allows 
for synthesis of C6-fluorine-modified, configurational DNJ isomers as well, and it may well be 
that the O6-for-F substitution is beneficial for DNJ derivatives targeting glycoprocessing 
enzymes other than the ones subject of this Thesis. 
 
Experimental Section 
Enzyme inhibition assays:  The inhibitory potencies (IC50 values) of the final compounds for 
GCS, GBA1 and GBA2 were determined by exposing cells or enzyme preparations to an 
appropriated range of iminosugar concentrations. 
 
GCS: IC50 values for GCS activity were measured using living cells with NBD-ceramide as 
substrate.3 Briefly, cells were incubated with 50 nmol C6-NBD-ceramide (6-[N-methyl-N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)aminododecanoyl]sphingosine) in the presence of increasing 
compound concentrations. The cells were harvested after 2h followed by lipid extraction. The 
formed C6-NBD-glucosylceramide was quantified using a Molecular Dynamics Typhoon 
phosphor imaging device. IC50 values were determined from the titration curves. The 
experiment was performed twice. 
 
GBA1: IC50 values for lysosomal GBA1 were measured using 4-methylumbeliferyl-β-D-glucoside 
as substrate.4 Briefly, recombinant GBA1 was incubated with increasing compound 
concentrations for 30 min at 0 ℃. Enzyme activity was determined with 3.7 mM 4-
methylumbelliferyl-β-D-glucopyranoside in McIlvaine buffer (0.1 M citrate and 0.2 M phosphate 
buffer), pH 5.2, 0.1% Triton X-100 (v/v) and 0.2% (w/v) sodium taurocholate. Assays 
performed in triplicate were incubated at 37 ℃ for 30 min and quenched by the addition of 
glycine/NaOH (0.2 mL, pH 10.6). The amount of liberated 4-methylumbeliferyl was determined 
with a PerkinElmer Life Sciences LS30 fluorimeter, excitation wavelength 366 nm, emission 
wavelength 445 nm. 
 
GBA2: IC50 values for the non-lysosomal glucocerebrosidase (GBA2) were measured with the 4-
methylumbeliferyl-β-D-glucoside as substrate.4 GBA2-rich membrane suspensions were 
prepared from enzyme-overexpressing HEK cells by sonicating, and the suspension was pre-
incubated for 30 min at 37 ℃ with conduritol-B-epoxide (1 mM, CBE, Sigma) to inhibit the 
lysosomal glucocerebrosidase (GBA1). The prepared GBA2-rich suspension was then incubated 
with increasing compound concentrations for another 30 min, and then incubated with 3.7 mM 
4-methylumbeliferyl-β-D-glucoside in McIlvaine buffer (0.1 M citrate and 0.2 M phosphate 
buffer), pH 5.8. Assays were incubated at 37 ℃ for 1 hour and quenched by the addition of 
glycine/NaOH (0.2 mL, pH 10.6). The amount of liberated 4-methylumbeliferyl was determined 
with a PerkinElmer Life Sciences LS30 fluorimeter, excitation wavelength 366 nm, emission 
wavelength 445 nm. Assays were performed in triplicate. 
 




General methods: All solvents and reagents were obtained commercially and used as received 
unless stated otherwise. Reactions were executed at room temperature unless stated 
otherwise. Moisture sensitive reactions were performed under argon atmosphere. Water was 
removed from starting compounds by repetitive coevaporation with toluene. Solvents were 
removed by evaporation under reduced pressure. DCM, DMF, and THF were dried over 
activated 4Å molecular sieves for at least 12 hours before use. Compounds were visualized 
during TLC analyses by UV (254 nm), and with the following staining solutions: aqueous 
solution of KMnO4 (5 g/L) and K2CO3 (25 g/L). Visualization of hemiacetals and glycosides was 
achieved by spraying with a solution of 20% H2SO4 in ethanol followed by charring at ≈ 200 ℃. 
Column chromatography purification was performed on silica gel (40-63 µm). 1H and 13C-APT 
NMR spectra were recorded on a Bruker AV 400 (400/100 MHz) or Bruker 600 (600/150 MHz) 
spectrometer in CDCl3, MeOD or D2O. Chemical shifts are given in ppm (δ) relative to TMS as 
internal standard (1H NMR in CDCl3) or the signal of the deuterated solvent.5 Coupling 
constants (J) are given in Hz. High resolution mass spectra were recorded by direct injection (2 
µL of a 2 µM solution in water/acetonitrile/tert-butanol 1:1:1 v/v/v) on a mass spectrometer 
(Thermo Finnigan LTQ Orbitrap) equipped with an electrospray ion source with resolution R = 
60000 at m/z 400 (mass range m/z = 150-2000). IR spectra were recorded on a Shimadzu 
FTIR-8300 and are reported in cm-1. Optical rotation were measured on an automatic 
polarimeter of sodium D-line, at λ =589 nm. Size-exclusion purifications were performed on an 
ÄKTA-explorer provided by GE-Healthcare polymere HW-40S from Toyopearl, column size  d = 
26 mm; l = 60 mm, mobile phase NH4HCO3 (0.15 M) in H2O, flow 1.5 mL/min. HPLC Purification 
were performed on a Prep LCMS, Gemini from Phenomenex B.V. (C-18, 110 Å, 5 µm, 19 x 150 
mm column). 
 
General Procedure A: Alkylation of iminosugars. To a mixture of the 1-bromo-5-alkyloxy-
pentane (1.5 eq) and di-isopropylethylamine  (DiPEA, 3 eq) was added a solution of iminosugar 
(1 eq) in DMF (0.2M). The reaction mixture was stirred overnight at 70 ℃. After cooling to 
room temperature, the mixture was filtered and concentrated. The crude compound was 
purified using silica gel column chromatography (0% → 20% methanol in DCM + 1% NH4OH).  
 
General Procedure B: Alkylation of iminosugars. To a mixture of the bromide chain (1.5 eq) 
and K2CO3 (3eq) was added a solution of the (glycosylated) iminosugar (1eq) in DMF (0.2 M). 
The reaction suspension was stirred at 85 ℃ for 18 hours. After cooling to room temperature, 
the mixture was filtered and concentrated. The crude compound was purified with HPLC.  
 
General Procedure C: Alkylation of protected glycosylated iminosugars. Glycosylated 
disaccharide iminosugar (0.2 mmol), aldehyde chain (0.3 mmol), AcOH (1.6 mmol), NaCNBH3 
(0.8 mmol), Na2SO4 (desiccant) and MeOH (2 mL) was mixed at 0 ℃ and stirred overnight, 
allowing the temperature to reach r.t. After TLC analysis showed the completely consumption 
of starting material (4:1, PE:EtOAc), the mixture was filtered and concentrated. The residue 
was dissolved in DCM (15 mL) and washed with aq. NaHCO3 (10%), dried (Na2SO4), filtered and 
concentrated. The residue was purified using silica gel column chromatography (19:1 → 9:1→ 
17:3 → 4:1, PE:EtOAc). 
 
General Procedure D: Catalytic Hydrogenation of protected glycosylated N-alkyl DNJ.  
Protected glycosylated DNJ derivative (1eq) was dissolved in MeOH/DMF (1 mM, 2:1; v:v), and 
the solution was flushed with argon (3 x).  After which a catalytic amount of Pd/C (20%) was 
added. The mixture was kept shaking under H2 atmosphere (4 bar) overnight. After TLC 







Synthesis of alkylated glycosylated-1-deoxynojirimycin 





A mixture of DCM/MeOH (1:1, v:v, 15 mL) and melibio-DNJ (0.19 g, 
0.20 mmol) was cooled in an ice bath.  AcOH (92 µL, 1.6 mmol, 8 eq 
in 1 mL MeOH), 2-(benzyloxy)acetaldehyde (48.1 mg, 0.32 mmol, 
1.6 eq in 1 mL DCM) and NaCNBH3 (50.3 mg, 0.8 mmol, 4 eq) were 
added in respective order. The mixture was stirred overnight 
allowing warming up to r.t. After evaporating the volatiles, DCM (20 
mL) was added to the residue and the organic layer was washed with sat. aq. NaHCO3 (15 mL), 
dried (Na2SO4) filtered and concentrated. The residue was purified on silica gel column (9:1 → 
4:1, PE:EtOAc) to gain 9 in 64% yield (140 mg, 0.128 mmol). RF = 0.54 (7:3, PE:EtOAc). 1H NMR 
(400 MHz, CDCl3) 7.41 – 7.11 (m, 40H, HAr Bn), 4.99 (d, J = 3.9 Hz, 1H, H-1’), 4.96 – 4.23 (m, 
16H, 8 x CH2 Bn), 4.02 (dd, J = 9.3, 3.5 Hz, 1H, H-2’), 3.98 – 3.83 (m, 5H, H-3’, H-4, H-4, H2-6’), 
3.61 – 3.47 (m, 6H, H-2, H2-2”, H-3, H-5’, H-6a), 3.43 (dd, J = 9.0, 5.7 Hz, 1H, H-6b), 3.20 (dd, J = 
11.5, 4.5 Hz, 1H, H-1a), 3.03 (dt, J = 11.0, 5.5 Hz, 1H, H-1”a), 2.89 (dt, J = 14.2, 5.2 Hz, 1H, H-1”b), 
2.53 (d, J = 7.4 Hz, 1H, H-5), 2.32 (t, J = 10.8 Hz, 1H, H-1b). 13C NMR (100 MHz, CDCl3) 139.1 – 
138.1 (Cq Bn), 128.6 – 127.5 (CHAr Bn), 98.3 (C-1’), 87.3 (C-3), 78.6 (C-2), 78.5 (C-4), 76.7 (C-2’), 
75.4, 75.2 (2 x CH2 Bn), 75.0 (C-3’), 74.9, 73.5, 73.1, 73.1, 72.9, 72.8 (6 x CH2 Bn), 69.9 (C-4’), 
68.8 (C-6), 67.6 (C-2”), 65.7 (C-6’), 64.9 (C-5), 55.2 (C-1), 52.0 (C-1”). []20D  = +31.8 (c = 1.0, 
CHCl3). IR/cm-1: 3029, 2911, 2852, 1496, 1453, 1321, 1207, 1093, 1061, 1027. 
 
6-O-(α-D-Galactopyranosyl)-N-hydroxyethyl-1-deoxynojirimycin (10): 
9 (0.13 g, 0.12 mmol) was subjected to the general procurer D to 
generate 10 (40.1 mg, 0.109 mmol) in a yield of 91%.  1H NMR (400 
MHz, CDCl3) 4.82 (d, J = 3.6 Hz, 1H, H-1’), 4.30 (d, J = 11.0 Hz, 1H, H-
6a), 4.17 (dd, J = 10.9, 1.8 Hz, 1H, H-6b), 3.92 (d, J = 2.7 Hz, 1H, H-4’), 
3.85 (t, J = 6.1 Hz, 1H, H-5’), 3.78 (dd, J = 10.1, 3.0 Hz, 1H, H-2’), 3.75 
(dd, J = 7.4, 3.6 Hz, 2H, H2-2”), 3.73 (dd, J = 7.5, 4.0 Hz, 1H, H-3’), 3.70 
(dd, J = 6.0, 3.1 Hz, 2H, H2-6’), 3.64 (dd, J = 10.9, 2.2 Hz, 1H, H-6a), 3.52 (ddd, J = 10.6, 9.4, 4.9 Hz, 
1H, H-2), 3.43 (t, J = 9.4 Hz, 1H, H-4), 3.18 (t, J = 9.1 Hz, 1H, H-3), 3.15 (dd, J = 11.5, 4.8 Hz, 1H, H-
1b), 2.96 (dt, J = 13.7, 6.2 Hz, 1H, H-1b”), 2.78 (dt, J = 13.9, 5.7 Hz, 1H, H-1a”), 2.46 (dd, J = 9.7, 
2.4 Hz, 1H, H-5), 2.43 (dd, J = 11.4, 10.7 Hz, 1H, H-1a). 13C NMR (100 MHz, CDCl3) 100.3 (C-1’), 
80.4 (C-3), 72.4 (C-5’), 71.7 (C-2’), 71.4 (C-4), 70.9 (C-4’), 70.7 (C-3’), 70.6 (C-2), 66.1 (C-5), 63.6 
(C-6), 62.5 (C-6’), 58.8 (C-2”), 58.3 (C-1), 55.0 (C-1”). []20D  = +68.4 (c = 0.5, MeOH). IR/cm
-1: 
3256, 2894, 1558, 1409, 1343, 1151, 1081, 1038. HRMS: found 370.17082 [C14H28NO10+H]+, 
calculated for [C14H28NO10+H]+  370.17077. 
 
2,3,4-Tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)-N-butyl-1-
deoxynojirimycin (11).  
Protected melibio-DNJ (0.19 g, 0.2 mmol) was subjected to the 
general procedure C to generate 11 (0.18 g, 0.18 mmol) in a yield of 
90%. 1H NMR (400 MHz, CDCl3) 7.40 – 7.14 (m, 35H, HAr Bn), 5.03 
(d, J = 3.2 Hz, 1H H-1’), 4.99 – 4.27 (m, 14H, 7 x CH2 Bn), 4.04 (dd, J = 




10.2, 2.8 Hz, 1H, H-2’), 4.00 – 3.92 (m, 3H, H-3’, H-4’, H-5’), 3.89 (dd, J = 11.8, 3.4 Hz, 1H, H-6a), 
3.83 (dd, J = 11.7, 1.5 Hz, 1H, H-6b), 3.62 – 3.42 (m, 5H, H-2, H-3, H-4, H2-6’), 3.08 (dd, J = 11.3, 
4.6 Hz, 1H, H-1a), 2.78 (m, 1H, H-1”a), 2.55 (m, 1H, H-1”a), 2.39 (d, J = 9.3 Hz, 1H, H-5), 2.15 (t, J 
= 10.7, 1H, H-1”b), 1.32 – 1.42 (m, 2H, H2-2”), 1.15 – 1.25 (m, 2H, H2-3”), 0.85 (t, J = 7.3 Hz, 3H, 
H3-4”). 13C NMR (100 MHz, CDCl3)  139.2 – 138.1 (7 x Cq Bn), 128.5 – 127.5 (CHAr Bn), 98.2 (C-
1’), 87.4 (C-3), 78.8 (C-4), 78.8 (C-2), 78.7 (C-3’), 76.8 (C-2’), 75.3 (CH2 Bn), 75.2 (C-4’), 74,9, 
73.5, 73.0, 72.8, (CH2 Bn), 69.9 (C-5’), 68.9 (C-6’), 65.0 (C-5), 65.0 (C-6), 54.4 (C-1), 52.8 (C-1”), 
26.6 (C-2”), 20.8 (C-3”), 14.2 (C-4”). []20D  = +11.8 (c = 1.0, CHCl3). IR/cm-1: 3030, 2924, 2870, 
1497, 1454, 1362, 1207, 1092, 1059, 1028. HRMS: found 1012.53571 [C21H41NO9+H]+, 




Protected melibio-DNJ (0.19 g, 0.2 mmol) was subjected to the general 
procedure C to generate 12 (0.20 g, 0.19 mmol) in a yield of 93%. 1H-
NMR (400 MHz, CDCl3) 7.37 – 7.08 (m, 35H, HAr Bn), 5.75 (d, J = 3.3 
Hz, 1H, H-1’), 5.03 – 4.23 (m, 14H, 7 x CH2 Bn), 4.11 (t, J = 8.2 Hz, 1H, H-
4’), 3.99 (t, J = 9.2 Hz, 1H, H-4), 3.83 – 3.57 (m, 6H, H-2’, H-3, H-3’, H-5’, 
H-6a, H-6’a), 3.56 – 3.48 (m, 3H, H-2, H-6b, H-6’b), 3.08 (dd, J = 11.1, 4.7 
Hz, 1H, H-1’a), 2.58 – 2.48 (m, 3H, H2-1”, H-5), 2.33 (t, J = 10.7 Hz, 1H, H-1’b), 1.47 – 1.15 (m, 
12H, H2-2” – H2-7”), 1.12 – 1.02 (m, 2H, H2-8”), 0.89 (t, J = 6.9 Hz, 3H, H3-9”). 13C-NMR (100 MHz, 
CDCl3) 139.1 – 137.8 (Cq Bn), 128.4 – 126.8 (CHAr Bn), 95.8 (C-1’), 86.3 (C-3), 82.1 (C-4), 79.7 
(C-2), 78.6 (C-3’), 77.7 (C-2’), 75.6, 74.9, 73.6, 73.0, 72.9, 72.8, 72.4 (7 x CH2 Bn), 72.1 (C-4’), 
70.9 (C-5’), 68.2 (C-6’), 65.8 (C-6), 63.0 (C-5), 53.4 (C-1), 52.6 (C-1”), 32.0, 29.6, 29.6, 29.3, 27.4, 
24.1, 22.8, 14.2 (C-2’’ – C-9’’).  []20D  = +30.4 (c = 2.1, CHCl3). IR/cm-1: 3063, 3030, 2922, 2855, 
1497, 1454, 1359, 1207, 1091, 1059, 1028.  
 
6-O-(α-D-Galactopyranosyl)-N-nonyl-1-deoxynojirimycin (13): 
12 was subjected to the general procedure D to generate 13 (25.4 mg, 
0.06 mmol) in a yield of 89%. 1H NMR (400 MHz, MeOD) δ 4.92 (d, J = 
3.9 Hz, 1H, H-1’), 4.33 (d, J = 11.7 Hz, 1H, H-6a), 3.91 (d, J = 3.5 Hz, 1H, 
H-3’), 3.89 (d, J = 3.8 Hz, 1H, H-2’), 3.81 (t, J = 5.9 Hz, 1H, H-5’), 3.74 (d, J 
= 3.3 Hz, 1H, H-4’), 3.71 (d, J = 6.0 Hz, 2H, H2-6’), 3.68 (dd, J = 10.6, 5.8 
Hz, 1H, H-6b), 3.67 (t, J = 11.6 Hz, 1H, H-2), 3.62 (t, J = 9.8 Hz, 1H, H-4), 
3.54 (dd, J = 12.1, 4.8 Hz, 1H, H-1a), 3.37 (t, J = 9.2 Hz, 1H, H-3), 3.33  – 3.29 (m, 1H, H-1’’a), 3.26 
(d, J = 10.0 Hz, 1H, H-5), 3.13 (td, J = 12.5, 5.5 Hz, 1H, H-1’’b), 3.03 (t, J = 11.7 Hz, 1H, H-1b), 1.77 
– 1.71 (m, 2H, H2-2’’), 1.46 – 1.22 (m, 12H, H2-3’’, H2-4’, H2-5’’, H2-6’’, H2-7’’, H2-8’’), 0.91 (t, J = 
7.0 Hz, 3H, H3-9’’). 13C NMR (100 MHz, MeOD) δ 100.0 (C-1’), 78.2 (C-3), 72.8 (C-5’), 71.3 (C-4’), 
70.8 (C-3’), 70.0 (C-2’), 69.0 (C-4), 68.0 (C-2), 66.2 (C-5), 62.5 (C-6’), 60.3 (C-6), 55.1 (C-1), 54.4 
(C-1’’), 33.0, 30.5, 30.3, 30.3, 27.7, 24.2, 23.7 (C-2’’- C-8’’), 14.4 (C-9’’). HRMS: found 452.28500 
[C21H41NO9+H]+, calculated for [C21H41NO9+H]+  452.28541. 
 
6-O-(α-D-Galactopyranosyl)-N-[5-(nonyloxy)pentyl]-1-deoxynojirimycin (14): 
 Melibio-DNJ (1, 32.0 mg, 0.1 mmol) was subjected to the general 
procedure B to generate 14 (16.9 mg, 0.04 mmol) in a yield of 32%. 
1H-NMR (400 MHz, MeOD) 4.91 (d, J = 4.6 Hz, 1H, H-1’), 4.30 (d, J 
= 11.4 Hz, 1H, H-6’a), 3.93 – 3.89 (m, 1H, H-4’), 3.91 – 3.83 (m, 1H, 
H-4), 3.82 (t, J = 6.1 Hz, 1H, H-5’), 3.76 – 3.70 (m, 3H, H2-6, H-6’b), 
3.69 – 3.57 (m, 2H, H-2, H-3’), 3.52 – 3.40 (m, 6H, H2-1’’, H2-6”, H2-
5”), 3.36 (d, J = 9.1 Hz, 1H, H-3), 3.28 – 3.20 (m, 1H, H-1a), 3.19 – 3.04 (m, 2H, H-1b, H-5), 1.81 – 
1.71 (m, 2H, H2-2”), 1.68 – 1.60 (m, 2H, H2-4”), 1.60 – 1.52 (m, 2H, H2-7”), 1.50 – 1.40 (m, 2H, H2-





13C NMR (100 MHz, MeOD) 100.1 (C-1’), 78.3 (C-3), 72.7 (C-5’), 72.1 (C-6’’), 71.5 (C-5’’), 71.3 
(C-2’), 70.8 (C-4), 70.1 (C-4’), 69.3 (C-3’), 68.3 (C-2), 66.0 (C-5), 62.5 (C-6), 60.6 (C-6’), 55.3 (C-
1’’), 54.3 (C-1), 33.1, 30.8, 30.7, 30.6, 30.4, 30.2, 27.3, 24.6, 23.9, 23.7 (C-2” – C-4’’, C-7’’ – C-13’’), 
14.5 (C-14”). []20D  = +48.2 (c = 0.34, MeOH). IR/cm-1: 3350, 2926, 2855, 1672, 1458, 1431, 
1366, 1204, 1134, 1080, 1042. HRMS: found 538.35812 [C26H51NO10+H]+, calculated for 




Melibio-DNJ (1) was subjected to the general procedure A to 
generate 15 (7.5 mg, 0.01 mmol) in a yield of 13%. 1H NMR (600 
MHz, MeOD) δ 7.64 – 7.62 (m, 4H, HAr BiPh), 7.48 – 7.43 (m, 4H, HAr 
BiPh), 7.38 – 7.33 (m, 1H, HAr BiPh), 4.94 (d, J = 4.0 Hz, 1H, H-1’), 
4.57 (s, 2H, H2-6’’), 4.33 (d, J = 11.7 Hz, 1H, H-6’a), 3.93 (d, J = 2.8 
Hz, 1H, H-4), 3.91 (dd, J = 10.0, 3.9 Hz, 1H, H-4’), 3.83 (t, J = 6.1 Hz, 
1H, H-5’), 3.75 (dd, J = 10.1, 3.4 Hz, 1H, H-2’), 3.73 (d, J = 6.0 Hz, 2H, H2-6), 3.69 (dd, J = 11.7, 2.8 
Hz, 1H, H-6’b), 3.70 – 3.66 (m, 1H, H-2), 3.64 (dd, J = 10.3, 9.2 Hz, 1H, H-3’), 3.59 (t, J = 6.2 Hz, 
2H, H-5’’), 3.55 (dd, J = 12.1, 4.9 Hz, 1H, H-1a), 3.38 (t, J = 9.2 Hz, 1H, H-3), 3.37 – 3.34 (m, 1H, H-
1’’a), 3.27 (d, J = 11.1 Hz, 1H, H-5), 3.17 (td, J = 12.5, 5.1 Hz, 1H, H-1’’b), 3.05 (t, J = 11.8 Hz, 1H, 
H-1b), 1.91 – 1.76 (m, 2H, H2-2’’), 1.76 – 1.69 (m, 2H, H2-4''), 1.58 – 1.49 (m, 2H, H2-3’’). 13C NMR 
(150 MHz, MeOD) δ 140.6 – 126.4 (CAr), 98.6 (C-1’), 76.8 (C-3), 72.3 (C-6’’), 71.3 (C-5’), 69.8 (C-
2’), 69.6 (C-5’’), 69.3 (C-4), 68.6 (C-4’), 67.6 (C-3’), 66.5 (C-2), 64.7 (C-5), 61.1 (C-6), 58.9 (C-6’), 
53.7 (C-1), 52.9 (C-1’’), 28.7 (C-4’’), 23.2 (C-3’’), 22.5 (C-2’’). []20D  = +41.4 (c = 0.5, MeOH); 
IR/cm-1: 3550, 3062, 2302, 1716, 1699, 1558, 1521, 1506, 1489, 1394, 1338, 1203, 1139, 1080, 





Melibio-DNJ (1) was subjected to the general procedure A 
to generate 16 (5.6 mg, 0.01 mmol) in a yield of 10%.  1H 
NMR (600 MHz, MeOD) δ 4.95 (d, J = 3.9 Hz, 1H, H-1’), 4.35 
(d, J = 11.7 Hz, 1H, H-6’a), 3.94 (dd, J = 3.4, 1.0 Hz, 1H, H-4), 
3.91 (dd, J = 10.0, 3.9 Hz, 1H, H-4’), 3.83 (t, J = 6.1 Hz, 1H, 
H-5’), 3.76 (dd, J = 10.1, 3.3 Hz, 1H, H-2’), 3.73 (d, J = 6.1 
Hz, 2H, H2-6), 3.72 – 3.67 (m, 2H, H-6’b, H-2), 3.65 (t, J = 
9.9 Hz, 1H, H-3), 3.56 (dd, J = 12.1, 4.9 Hz, 1H, H-1a), 3.44 (t, J = 6.2 Hz, 2H, H2-5’’), 3.39 (t, J = 9.3 
Hz, 1H, H-3), 3.36 – 3.34 (m, 1H, H-1’’a), 3.28 (d, J = 10.5 Hz, 1H, H-5), 3.17 (td, J = 12.5, 5.0 Hz, 
1H, H-1’’b), 3.06 (t, J = 11.8 Hz, 1H, H-1b), 2.98 (s, 2H, H2-6’’), 1.97 (t, J = 3.1 Hz, 3H, 3 x CH ada), 
1.89 – 1.72 (m, 2H, H-2’’), 1.81 –1.68 (m, 6H, CH2 ada), 1.68 – 1.64 (m, 2H, H2-4’’), 1.58 (d, J = 2.9 
Hz, 6H, 3 x CH2 ada), 1.52 – 1.47 (m, 2H, H2-3’’). 13C NMR (150 MHz, MeOD) δ 100.2 (C-1’), 83.3 
(C-6’’), 78.3 (C-3), 72.9 (C-5’), 72.3 (C-5’’), 71.4 (C-2’), 70.9 (C-4), 70.1 (C-4’), 69.1 (C-3’), 68.1 
(C-2), 66.2 (C-5), 62.6 (C-6), 60.4 (C-6’), 55.2 (C-1), 54.4 (C-1’’), 41.0 (CH2 ada), 38.4 (CH2 ada), 
35.2 (Cq ada), 30.3 (C-4’’), 29.8 (CH ada), 24.7 (C-3’’), 24.0 (C-2’’). []20D  = +31.5 (c = 0.2, MeOH). 
IR/cm-1: 3385, 3161, 2374, 2349, 2320, 2063, 1683, 1558, 1506, 1436, 1207, 1138, 1082, 1039. 




 Melibio-DNJ (1, 32.5 mg, 0.1 mmol) was subjected to the general procedure B to generate 17 
(13.0 mg, 27.0 mmol) in a yield of 27%. 1H NMR (400 MHz, MeOD) 4.93 (d, J = 3.8 Hz, 1H, H-
1’), 4.33 (d, J = 11.6 Hz, 1H, H-6’a), 3.93 – 3.87 (m, 2H, H-4, H-4’), 3.81 (t, J = 6.0 Hz, 1H, H-5’), 




3.78 – 3.68 (m, 3H, H-2’, H2-6), 3.69 – 3.59 (m, 2H, H-2, H-3’), 3.55 
(dd, J = 12.0, 4.7 Hz, 1H, H-1a), 3.45 (t, J = 6.2 Hz, 2H, H2-5”), 3.40 – 
3.32 (m, 2H, H-3, H-1”a), 3.26 (d, J = 9.7 Hz, 1H, H-5), 3.15 (td, J = 
12.5, 5.1 Hz, 1H, H-1”b), 3.08 (s, 2H, H2-6’’), 3.04 (t, J = 11.8 Hz, 1H, 
H-1b), 1.88 – 1.71 (m, 2H, H2-2”), 1.71 – 1.62 (m, 2H, H2-4”), 1.50  – 
1.43 (m, 2H, H2-3”), 0.91 (s, 9H, H3-8’’, H3-9’’, H3-10’’). 13C NMR (100 
MHz, MeOD) 100.0 (C-1’), 82.6 (C-6’’), 78.2 (C-3), 72.8 (C-5’), 72.1 (C-5”), 71.3 (C-2’), 70.8 (C-
4), 70.0 (C-4’), 69.0 (C-3’), 68.0 (C-2), 66.2 (C-5), 62.5 (C-6), 60.3 (C-6’), 55.1 (C-1), 54.4 (C-1”), 
32.9 (C-7’’), 30.2 (C-4”), 27.1 (C3-8’’, C3-9’’, C3-10’’), 24.5 (C-3”), 24.0 (C-2”). []20D  = +43.8 (c = 
0.26, MeOH).  IR/cm-1: 3329, 2951, 2864, 1372, 1427, 1358, 1202, 1134, 1080, 1040. HRMS: 
found 482.29552 [C22H43NO10+H]+, calculated for [C22H43NO10+H]+  482.29597. 
 
2,3,6-Tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl)-N-butyl-1-
deoxynojirimycin (18):  
Protected Malto-DNJ (0.19 g, 0.2 mmol) was subjected to the 
general procedure C to generate 18 (0.12 g, 0.12 mmol) in a yield 
of 66%. RF = 0.40 (4:1, PE:EtOAc). 1H NMR (400 MHz, CDCl3) 
7.35 – 7.09 (m, 35H, HAr Bn), 5.74 (d, J = 3.4 Hz, 1H, H-1), 5.00 – 
4.26 (m, 14H, 7 x CH2 Bn), 4.10 (t, J = 8.2 Hz, 1H, H-4), 3.98 (t, J = 
9.3 Hz, 1H, H-3’), 3.80 (t, J = 9.6 Hz, 1H, H-5’), 3.76 – 3.58 (m, 5H, H-2, H-3, H-4’, H-6a, H-6’a), 
3.55 – 3.50  (m, 3H, H-2’, H-6b, H-6’b), 3.08 (dd, J = 11.1, 4.7 Hz, 1H, H-1a), 2.57 – 2.50 (m, 3H, 
H2-1”, H-5), 2.33 (t, J = 10.7 Hz, 1H, H-1b), 1.30 (m, 2H, H2-2”), 1.15 – 1.05 (m, 2H, H2-3”), 0.82 (t, 
J = 7.3 Hz, 3H, H3-4”).  13C NMR (100 MHz, CDCl3) 139.1 – 137.8 (7 x Cq Bn), 128.4 – 126.8 (CHAr 
Bn), 95.9 (C-1’), 86.3 (C-3), 82.2 (C-3’), 79.7 (C-2’), 78.6 (C-2), 77.7 (C-4’), 75.6 – 72.4 (7 x CH2 
Bn), 72.3 (C-4), 70.9 (C-5’), 68.2 (C-6), 65.9 (C-6’), 63.1 (C-5), 53.4 (C-1), 52.4 (C-1”), 26.4 (C-2”), 
20.6 (C-3”), 14.1 (C-4”). []20D  = +15.6 (c = 1.0, CHCl3). IR/cm-1: 3063, 3030, 2922, 2964, 1497, 
1453, 1363, 1092, 1073, 1028. HRMS: found 1012.53472 [C65H74NO9+H]+, calculated for 
[C65H74NO9+H]+  1012.53581.  
 
4-O-(α-D-Glucopyranosyl)-N-butyl-1-deoxynojirimycin (19):  
Malto-DNJ (18, 0.19 g, 0.2 mmol) was subjected to the general 
procedure C to generate 19 (26.1 mg, 0.07 mmol) as a white solid in 
58% yield. 1H-NMR (400 MHz, MeOD) δ 5.13 (d, J = 3.8 Hz, 1H, H-1’), 
3.92 (dd, J = 12.2, 2.4 Hz, 1H, H-6a), 3.88 (dd, J = 12.2, 2.1 Hz, 1H, H-
6b), 3.84 (dd, J = 11.6, 2.1 Hz, 1H, H-6a'), 3.74 (ddd, J = 9.8, 5.9, 2.0 
Hz, 1H, H-5’), 3.66 (dd, J = 11.6, 6.0 Hz, 1H, H-6b’), 3.63 (t, J = 9.3 Hz, 1H, H-3’), 3.52 (t, J = 9.2 Hz, 
1H, H-4), 3.51 (dd, J = 9.8, 4.9 Hz, 1H, H-2), 3.47 (dd, J = 9.7, 3.8 Hz, 1H, H-2’), 3.37 (t, J =9.1 Hz, 
1H, H-3), 3.27 (dd, J = 9.9, 9.0 Hz, 1H, H-4’), 2.97 (dd, J = 11.0, 4.7 Hz, 1H, H-1a), 2.79 (m, 1H, H-
1’’a), 2.63 (m, 1H, H-1’’b), 2.20 (dd, J = 11.3, 1.7 Hz, 1H, H-5), 2.19 (m, 1H, H-1b), 1.49 – 1.42 (m, 
2H, H2-2’’), 1.35 – 1.29 (m, 2H, H2-3’’), 0.95 (t, J = 7.3 Hz, 3H, H3-4’’). 13C NMR (100 MHz, MeOD) 
103.5 (C-1’), 84.0 (C-2), 80.4 (C-3), 75.1 (C-3’), 74.8 (C-5’), 74.3 (C-2’), 71.6 (C-4’), 70.2 (C-4), 
66.1 (C-5), 62.8 (C-6’), 58.5 (C-6), 57.5 (C-1), 53.4 (C-1”), 27.3 (C-2”), 21.8 (C-3”), 14.4 (C-4”). 
[]20D  = +42.1 (c = 0.76, MeOH).  IR/cm-1: 3309, 2961, 2932, 2479, 1636, 1456, 1373, 1146, 




deoxynojirimycin (20).  
Protected malto-DNJ (0.19 g, 0.2 mmol) was subjected to the 
general procedure C to generate 20 (0.13 g, 0.12 mmol) in a 





PE:EtOAc). 1H NMR (400 MHz, CDCl3) 7.31 – 7.10 (m, 35H, HAr Bn), 5.75 (d, J = 3.3 Hz, 1H, H-
1), 5.01 – 4.26 (m, 14H, 7 x CH2 Bn), 4.11 (t, J = 8.2 Hz, 1H, H-4), 3.99 (t, J = 9.2 Hz, 1H, H-3’), 3.80 
(t, J = 9.2 Hz, 1H, H-5’), 3.76 – 3.58 (m, 5H, H-2, H-3, H-4’, H-6a, H-6’a), 3.55 – 3.50 (m, 3H, H-2’, 
H-6b, H-6’b), 3.08 (dd, J = 11.1, 4.7 Hz, 1H, H-1a), 2.57 – 2.50 (m, 3H, H2-1’’, H-5), 2.33 (t, J = 10.7 
Hz, 1H, H-1b), 1.47-1.13 (m, 12H, H2-2” – H2-7”), 1.12 – 1.02 (m, 2H, H2-8”), 0.88 (t, J = 8.1, Hz, 
3H, H3-9”). 13C NMR (100 MHz, CDCl3) 139.1 – 137.8 (Cq Bn), 128.4 – 126.8 (CHAr Bn), 95.8 (C-
1’), 86.3 (C-3), 82.1 (C-3’), 79.7 (C-2’), 78.6 (C-2), 77.7 (C-4’), 75.6 – 72.4 (7 x CH2 Bn), 72.1 (C-
4), 70 .9 (C-5’), 68.2 (C-6), 65.8 (C-6’), 63.0 (C-5), 53.4 (C-1), 32.0, 30.0, 29.6, 29.6, 29.3, 29.2, 
27.4, 24.1, 22.8 (C-2’’ – C-8’’), 14.2 (C-9’’). []20D  = +16.0 (c = 1.02, CHCl3). IR/cm-1: 2954, 2925, 
2853, 1539, 1506, 1093, 1073, 1028. 
 
4-O-(β-D-Galactopyranosyl)-N-[5-(hexyloxy)pentyl]-1-deoxynojirimycin (21): 
Lacto-DNJ was subjected to the general procedure A to 
generate 21 (5.6 mg, 0.01 mmol) in a yield of 11%. 1H 
NMR (600 MHz, MeOD) δ 4.54 (d, J = 7.7 Hz, 1H, H-1’), 4.42 
(d, J = 13.0 Hz, 1H, H-6a), 3.99 (d, J = 13.0 Hz, 1H, H-6b), 
3.92 (dd, J = 3.3, 1.0 Hz, 1H, H-4’), 3.92 – 3.87 (m, 1H, H-4), 3.88 (dd, J = 11.5, 7.7 Hz, 1H, H-6’a), 
3.86 – 3.83 (m, 1H, H-3), 3.81 (dd, J = 11.4, 4.4 Hz, 1H, H-6’b), 3.70 (q, J = 7.0 Hz, 1H, H-5’), 3.68 
(dd, J = 12.3, 7.7 Hz, 1H, H-2’), 3.64 (t, J = 9.2 Hz, 1H, H-2), 3.59 (dd, J = 9.7, 3.3 Hz, 1H, H-3’), 3.55 
(t, J = 6.2 Hz, 2H, H2-5’’), 3.55 – 3.51 (m, 1H, H-1a), 3.52 (t, J = 6.6 Hz, 2H, H2-6’’), 3.49 – 3.45 (m, 
1H, H-1’’a). 3.36 (d, J = 10.0 Hz, 1H, H-5), 3.33 – 3.26 (m, 1H, H-1’’b), 3.13 (t, J = 11.7 Hz, 1H, H-
1b), 1.95 – 1.80 (m, 2H, H2-2’’), 1.76 – 1.72 (m, 2H, H2-4’’), 1.68 – 1.62 (m, 2H, H2-7’’), 1.62 – 1.52 
(m, 2H, H2-3’’), 1.49 – 1.36 (m, 6H, H2-8’’, H2-9’’, H2-10’’), 1.00 (t, J = 6.9 Hz, 3H, H3-11’’). 13C NMR 
(150 MHz, MeOD) δ 106.1 (C-1’), 78.8 (C-4), 78.2 (C-5), 77.3 (C-2), 75.7 (C-3’), 73.4 (C-2’), 72.9 
(C-6’’), 72.2 (C-5’’), 71.1 (C-4’), 68.4 (C-3), 67.1 (C-5), 63.4 (C-6’), 55.3 (C-1), 55.1 (C-1’’), 55.1 
(C-6), 33.7 (C-9’’), 31.6 (C-7’’), 31.0 (C-4’’), 27.8 (C-8’’), 25.3 (C-3’’), 24.8 (C-2’’), 24.5 (C-10’’), 
15.3 (C-11’’). []20D  = -4.0 (c = 0.2, MeOH). IR/cm-1: 3395, 2956, 2872, 1670, 1435, 1201, 1142, 





Lacto-DNJ (3) was subjected to the general procedure A to 
generate 22 (6.72 mg, 0.01 mmol) in a yield of 12%. 1H 
NMR (400 MHz, MeOD) δ 4.54 (d, J = 7.7 Hz, 1H, H-1’), 4.42 
(d, J = 12.9 Hz, 1H, H-6a), 3.99 (d, J = 12.3 Hz, 1H, H-6b), 
3.91 (dd, J = 3.3, 1.1 Hz, 1H, H-4’), 3.90 – 3.82 (m, 2H, H-4, H-3), 3.88 (dd, J = 11.4, 7.7 Hz, 1H, H-
6’a), 3.80 (dd, J = 11.5, 4.4 Hz, 1H, H-6’b), 3.69 (ddd, J = 7.6, 4.3, 1.1 Hz, 1H, H-5’), 3.67 (dd, J = 
8.3, 7.6 Hz, 1H, H-2’), 3.64 – 3.59 (m, 1H, H-2), 3.58 (dd, J = 9.8, 3.3 Hz, 1H, H-3’), 3.57 – 3.51 (m, 
1H, H-1a), 3.51 (t, J = 6.1 Hz, 2H, H-5’’), 3.49 – 3.45 (m, 1H, H-1’’a), 3.37 – 3.26 (m, 2H, H-5, H-
1’’b), 3.13 (t, J = 11.7 Hz, 1H, H-1b), 3.07 (s, 2H, H2-6’’), 2.06 – 2.02 (m, 3H, 3 x CH ada), 1.96 – 
1.69 (m, 10H, H2-4’’, 3 x CH2 ada), 1.68 – 1.63 (m, 6H, 3 x CH2 ada), 1.63 – 1.51 (m, 2H, H2-3’’). 
13C NMR (100 MHz, MeOD) δ 105.8 (C-1’), 84.0 (C-6’’), 78.8 (C-4’), 78.2 (C-5’), 76.9 (C-2), 75.7 
(C-3’), 73.4 (C-2’), 72.9 (C-5’’), 71.1 (C-4), 68.4 (C-3), 67.1 (C-5), 63.4 (C-6’), 54.8 (C-6), 54.9 (C-
1), 54.9 (C-1’’), 41.7 (CH2-ada), 39.2 (CH2-ada), 36.0 (Cq-ada), 31.0 (C-2’’), 30.6 (CH-ada), 27.3 
(C-3’’), 25.4 (C-4’’). []20D  = -17.0 (c = 0.2, MeOH). IR/cm-1: 3391, 2903, 2849, 1674, 1435, 1204, 




Cellibio-DNJ (4) was subjected to the general procedure A to 
generate 23 (6.5 mg, 0.02 mmol) in a yield of 17%. 1H NMR (400 




MHz, MeOD) δ 4.59 (d, J = 7.8 Hz, 1H, H-1’), 4.37 (dd, J = 12.9, 1.7 Hz, 1H, H-6a), 4.00 (dd, J = 
12.9, 2.8 Hz, 1H, H-6b), 3.99 (dd, J = 11.8, 2.1 Hz, 1H, H-6’a), 3.87 (dd, J = 10.0, 9.0 Hz, 1H, H-4), 
3.83 (ddd, J = 11.0, 9.1, 4.9 Hz, 1H, H-2), 3.75 (dd, J = 11.8, 6.0 Hz, 1H, H-6’b), 3.61 (t, J = 9.0 Hz, 
1H, H-3), 3.53 – 3.33 (m, 6H, H-1a, H-1’’a, H-2’, H-3’, H-4’, H-5’), 3.30 – 3.18 (m, 2H, H-5, H-1’’b), 
3.03 (t, J = 11.5 Hz, 1H, H-1b), 1.87 – 1.71 (m, 2H, H2-2’’), 1.57 – 1.45 (m, 2H, H2-3’’), 1.10 (t, J = 
7.4 Hz, 3H, H3-4’’). 13C NMR (100 MHz, MeOD) δ 105.6 (C-1’), 79.6 (C-4), 79.2 (C-3’), 78.7 (C-5’), 
77.4 (C-3), 75.8 (C-2’), 72.2 (C-4’), 68.8 (C-2), 67.1 (C-5), 63.3 (C-6’), 55.8 (C-6), 55.5 (C-1), 54.7 
(C-1’’), 27.2 (C-2’’), 21.9 (C-3’’), 14.8 (C-4’’). []20D  = -17.0 (c = 0.2, MeOH). HRMS: found 
382.20752 [C16H31NO9+H]+, calculated for [C16H31NO9+H]+  382.20716. 
 
 4-O-(β-D-Glucopyranosyl)-N-nonyl-1-deoxynojirimycin (24): 
Cellobio-DNJ (4) was subjected to the general procedure 
A to generate 24 (3.6 mg, 0.01 mmol) in a yield of 8%. 1H 
NMR (600 MHz, MeOD) δ 4.51 (d, J = 7.8 Hz, 1H, H-1’), 
4.36 (d, J = 12.9 Hz, 1H, H-6a), 3.92 (dd, J = 11.8, 2.2 Hz, 
1H, H-6’a), 3.90 (dd, J = 12.6, 2.4 Hz, 1H, H-6b), 3.81 (t, J = 9.7 Hz, 1H, H-4), 3.76 (td, J = 11.3, 5.3 
Hz, 1H, H-2), 3.68 (dd, J = 11.8, 6.2 Hz, 1H, H-6’b), 3.55 (t, J = 9.1 Hz, 1H, H-3), 3.47 (dd, J = 12.2, 
5.0 Hz, 1H, H-1a), 3.42 – 3.26 (m, 6H, H-1’’a, H-2’, H-3’, H-4’, H-5’, H-5), 3.25 – 3.18 (m, 1H, H-
1’’b), 3.05 (t, J = 11.7 Hz, 1H, H-1b), 1.84 – 1.69 (m, 2H, H2-2’’), 1.50 – 1.26 (m, 12H, H2-3’’ – H2-
8’’), 0.93 (t, J = 7.0, 3H, H3-9’’). 13C NMR (150 MHz, MeOD) δ 104.4 (C-1’), 78.0 (C-5’), 77.8 (C-4), 
77.5 (C-3’), 75.9 (C-3), 74.5 (C-2’), 70.9 (C-4’), 67.2 (C-2), 65.8 (C-5), 62.0 (C-6’), 53.9 (C-1’’), 
53.9 (C-1), 53.7 (C-6), 32.6, 30.1, 29.9, 29.8, 27.2, 23.7, 23.3 (C-2’’ – C-8’’), 14.0 (C-9’’). []20D  = 
+9.0 (c = 0.2, MeOH). IR/cm-1: 3337, 2923, 1669, 1203, 1135, 1073. HRMS: found 452.28500 
[C21H41NO9+H]+, calculated for [C21H41NO9+H]+  452.28541. 
 
4-O-(β-D-Glucopyranosyl)-N-[5-(hexyloxy)pentyl]-1-deoxynojirimycin (25): 
Cellobio-DNJ (4) was subjected to the general procedure 
A to generate 25 (5.5 mg, 0.01 mmol) in a yield of 11%. 
1H NMR (600 MHz, MeOD) δ 4.58 (d, J = 7.8 Hz, 1H, H-1’), 
4.42 (d, J = 13.0 Hz, 1H, H-6a), 3.99 (dd, J = 11.8, 2.2 Hz, 
1H, H-6’a), 3.98 (d, J = 12.1 Hz, 1H, H-6b), 3.87 (t, J = 9.7 Hz, 1H, H-4), 3.83 (ddd, J = 11.1, 10.6, 
4.9 Hz, 1H, H-2), 3.75 (dd, J = 11.9, 6.2 Hz, 1H, H-6’b), 3.55 (t, J = 6.3 Hz, 2H, H2-6’’), 3.55 – 3.51 
(m, 1H, H-1a), 3.52 (t, J = 6.6 Hz, 2H, H2-5’’), 3.49 – 3.44 (m, 1H, H-1’’a), 3.46 (t, J = 9.0 Hz, 1H, H-
3’), 3.45 (ddd, J = 9.1, 6.2, 2.3 Hz, 1H, H-5’), 3.39 (t, J = 9.4 Hz, 1H, H-4’), 3.36 (dd, J = 9.1, 7.9 Hz, 
1H, H-2’), 3.35 – 3.26 (m, 2H, H-5, H-1’’b), 3.11 (t, J = 11.4 Hz, 1H, H-1b), 1.94 – 1.77 (m, 2H, H2-
2’’), 1.78 – 1.71 (m, 2H, H2-4’’), 1.67 – 1.63 (m, 2H, H2-7’’), 1.60 – 1.53 (m, 2H, H2-3’’), 1.48 – 1.34 
(m, 6H, H2-8’’, H2-9’’, H2-10’’), 1.00 (t, J = 6.9 Hz, 3H, H3-11’’). 13C NMR (150 MHz, MeOD) δ 105.6 
(C-1’), 79.2 (C-5’), 78.8 (C-4, C-3’), 77.2 (C-3), 75.8 (C-2’), 73.0 (C-5’’), 72.2 (C-6’’), 72.1(C-4’), 
68.5(C-2), 67.1 (C-5), 63.3 (C-6’), 55.3 (C-1), 55.0 (C-1’), 55.0 (C-6), 33.7 (C-9’’), 31.6 (C-7’’), 31.0 
(C-4’’), 27.8 (C-8’’), 25.4 (C-3’’), 24.8 (C-2’’), 24.6 (C-10’’), 15.3 (C-11’’). []20D  = +0.3 (c = 1.0, 
MeOH). IR/cm-1: 3298, 2874, 2511, 1635, 1456, 1317, 1015. HRMS: found 496.31124 
[C23H45NO10+H]+, calculated for [C23H45NO10+H]+  496.31162. 
 
4-O-(β-D-Glucopyranosyl)-N-[5-(nonyloxy)pentyl]-1-deoxynojirimycin  (26): 
Cellobio-DNJ (4) was subjected to the general procedure 
A to generate 26 (4.8 mg, 0.01 mmol) in a yield of 9%. 1H 
NMR (600 MHz, MeOD) δ 4.51 (d, J = 7.8 Hz, 1H, H-1’), 
4.34 (d, J = 12.6 Hz, 1H, H-6a), 3.92 (dd, J = 11.8, 2.3 Hz, 
1H, H-6’a), 3.84 – 3.73 (m, 2H, H-4, H-2), 3.68 (dd, J = 11.8, 6.2 Hz, 1H, H-6’b), 3.54 (t, J = 8.9 Hz, 
1H, H-3), 3.48 (t, J = 6.3 Hz, 2H, H2-5’’), 3.45 (t, J = 6.6 Hz, 2H, H2-6’’), 3.49 – 3.45 (m, 1H, H-1a), 
3.40 – 3.18 (m, 7H, H-1’’a, H-1’’b, H-2’, H-3’, H-4’, H-5’, H-5), 1.85 – 1.73 (m, 2H, H2-2’’), 1.71 – 





H2-8’’ – H2-13’’), 0.92 (t, J = 7.0 Hz, 3H, H3-14’’). 13C NMR (150 MHz, MeOD) δ 103.4 (C-1’), 77.0 
(C-4), 76.8 (C-5’), 76.5 (C-3’), 75.2 (C-3), 73.5 (C-2’), 70.7 (C-6’’), 70.0 (C-5’’), 69.9 (C-4’), 61.0 
(C-2), 53.1 (C-6’), 52.9 (C-1), 52.7 (C-6), 48.0 (C-1’’), 31.6, 29.4, 29.3, 29.2, 29.0, 28.8, 25.9, 23.1, 
22.5, 22.3, 13.0 (C-2’’ – 4’’, C-7’’ – C-14’’).  []20D = -7.0 (c = 0.1, MeOH). IR/cm-1: 3383, 2933, 




Cellobio-DNJ (4) was subjected to the general 
procedure A and generated 27 (8.7 mg, 0.02 
mmol) in a yield of 15%. 1H NMR (600 MHz, 
MeOD) δ 7.66 – 7.29 (m, 9H, HAr BiPh), 4.57 (s, 
2H, H2-6’’), 4.50 (d, J = 7.9 Hz, 1H, H-1’), 4.34 (d, J 
= 12.9 Hz, 1H, H-6a), 3.91 (dd, J = 11.8, 2.2 Hz, 1H, H-6’a), 3.90 (d, J = 13.5 Hz, 1H, H-6b), 3.82 – 
3.73 (m, 2H, H-2, H-4), 3.68 (dd, J = 11.8, 6.2 Hz, 1H, H-6’b), 3.59 (t, J = 6.2 Hz, 2H, H2-5’’), 3.56 – 
3.51 (m, 1H, H-3), 3.49 – 3.43 (m, 1H, H-1a), 3.43 – 3.16 (m, 7H, H-1’’a, H-1’’b, H-2’, H-3’, H-4’, H-
5’, H-5), 3.02 (t, J = 11.7 Hz, 1H, H-1b), 1.86 – 1.77 (m, 2H, H2-2’’), 1.76 – 1.70 (m, 2H, H2-3’’), 
1.60 – 1.48 (m, 2H, H2-4’’). 13C NMR (150 MHz, MeOD) δ 141.7 – 127.6 (CAr BiPh), 104.3 (C-1’), 
78.0 (C-4), 77.7 (C-5’), 77.5 (C-3’), 76.0 (C-3), 74.5 (C-2’), 73.3 (C-6’’), 70.9 (C-4’), 70.5 (C-5’’), 
67.3 (C-2), 65.8 (C-5), 62.0 (C-6), 54.3 (C-1), 54.1 (C-6), 53.8 (C-1’’), 29.7 (C-4’’), 24.2 (C-3’’), 
23.5 (C-2’’). []20D  = +0.5 (c = 0.2, MeOH). IR/cm-1: 3368, 2318, 1674, 1205, 1134, 1080. HRMS: 




Cellobio-DNJ (4) was subjected to the general procedure 
A and generated 28 (4.8 mg, 0.01 mmol) in a yield of 
10%. 1H NMR (400 MHz, MeOD) δ 4.58 (d, J = 7.8 Hz, 1H, 
H-1’), 4.30 (dd, J = 12.4, 1.7 Hz, 1H, H-6’a), 3.98 (dd, J = 
12.1, 4.5 Hz, 1H, H-6a), 3.98 (d, J = 12.0 Hz, 1H, H-6’b), 3.81 (t, J = 9.6 Hz, 1H, H-4), 3.81 – 3.73 
(m, 1H, H-2), 3.75 (dd, J = 11.9, 6.0 Hz, 1H, H-6b), 3.53 (t, J = 9.6 Hz, 2H, H2-5’’), 3.50 – 3.45 (m, 
2H, H-3, H-5’), 3.45 – 3.41 (m, 2H, H-4’, H-2’), 3.35 (dd, J = 9.0, 7.8 Hz, 1H, H-1a), 3.29 – 3.19 (m, 
1H, H-1’’a), 3.17 (s, 2H, H2-6’’), 3.14 – 3.03 (m, 1H, H-1’’b), 3.00 (d, J = 9.3 Hz, 1H, H-5), 2.81 (t, J 
= 11.5 Hz, 1H, H-1b), 1.86 – 1.68 (m, 4H, H2-2’’, H2-3’’), 1.63 – 1.48 (m, 2H, H2-4’’), 1.00 (s, 9H, 
H3-8’’, H3-9’’, H3-10’’). 13C NMR (100 MHz, MeOD) δ 105.6 (C-1’), 83.4 (C-6’’), 80.6 (C-4), 79.1 (C-
5’), 78.8 (C-3), 78.0 (C-3’), 75.9 (C-2’), 73.0 (C-5’’), 72.2 (C-4’), 69.6 (C-2), 67.1 (C-5), 63.3 (C-6), 
56.2 (C-6’), 54.7 (C-1), 54.1 (C-1’’), 33.8 (C-7’’), 31.2 (C-2’’), 28.0 (C-8’’, 9’’, 10’’), 25.7 (C-4’’), 25.3 
(C-3’’). []20D  = +0.5 (c = 1.0, MeOH). IR/cm-1: 3308, 2980, 2875, 2349, 1635, 1080, 1031. 
HRMS: found 482.29552 [C22H43NO10+H]+, calculated for [C22H43NO10+H]+  482.29597. 
 
Synthesis of N-Alkylated DNJ and DNJ congeners 
Figure 19: Proton and carbon NMR numbering of iminosugars  
 






1H NMR (400 MHz, MeOD) δ 3.92 (dd, J = 10.9, 3.1 Hz, 1H, H-6a), 3.67 (dd, J = 
10.9, 6.5 Hz, 1H, H-6b), 3.49 (ddd, J = 10.6, 8.7, 5.1 Hz, 1H, H-2), 3.28 (t, J = 8.1 
Hz, 1H, H-3), 3.24 (t, J = 9.1 Hz, 1H, H-4), 3.18 (dd, J = 12.1, 5.1 Hz, 1H, H-1a), 
2.54 (ddd, J = 9.4, 6.4, 3.1 Hz, 1H, H-5), 2.52 (dd, J = 12.1, 10.7 Hz, 1H, H-1b). 13C 
NMR (100 MHz, MeOD) δ 81.5 (C-3), 74.2 (C-4), 73.5 (C-2), 64.0 (C-6), 63.7 (C-
5), 51.9 (C-1). 
 
N-Benzyloxyethyl-1-deoxynojirimycin (90): 
DNJ (85) was subjected to the general procedure A and generated 90 
(12.4 mg, 0.04 mmol) in a yield of 38%. 1H NMR (400 MHz, MeOD) δ 
7.45 – 7.33 (m, 5H, HAr Bn), 4.61 (s, 2H, CH2 Bn), 4.02 (dd, J = 12.1, 2.7 
Hz, 1H, H-6a), 3.92 (dd, J = 12.1, 2.8 Hz, 1H, H-6b), 3.73 – 3.69 (m, 2H, 
H2-2’), 3.55 (ddd, J = 10.5, 9.1, 4.8 Hz, 1H, H-2), 3.45 (t, J = 9.3 Hz, 1H, H-
4), 3.23 (t, J = 9.1 Hz, 1H, H-3), 3.19 – 3.13 (m, 1H, H-1’a), 3.15 (dd, J = 
10.5, 5.1 Hz, 1H, H-1a), 2.84 (dt, J = 14.5, 4.6 Hz, 1H, H-1’b), 2.38 (dd, J = 11.3, 10.5 Hz, 1H, H-1b), 
2.30 (dt, J = 9.5, 2.7 Hz, 1H, H-5). 13C NMR (100 MHz, MeOD) δ 131.3 – 129.6 (CAr), 81.3 (C-3), 
75.0 (CH2 Bn), 72.6 (C-4), 71.5 (C-2), 69.4 (C-2’), 68.5 (C-5), 60.2 (C-6), 59.3 (C-1), 53.4 (C-1’). 
HRMS: found 298.16505 [C15H23NO5+H]+, calculated for [C15H23NO5+H]+ 298.16490.          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
N-Hydroxyethyl-1-deoxynojirimycin (90a): 
90 (60 mg, 0.2 mmol) was dissolved in 5 mL ethanol and the pH of the solvent 
was adjusted to 2 with aqueous HCl (1M). After the solution was flushed with 
argon (3 x), a catalytic amount of Pd/C (10%) was added. The reaction mixture 
was exposed to H2 atmosphere (3 bar) for 18 hours. TLC analysis showed 
completely consumption of 90. The reaction mixture was filtered over a pad of 
Celite and the filtrate was concentrated. The residue was purified by silica gel column 
chromatography (0% → 20% methanol in DCM + 1% NH4OH) to give 90a as a colorless oil in a 
of yield 65% (27 mg, 0.13 mmol). 1H NMR (400 MHz, MeOD) δ 4.21 (dd, J = 12.6, 0.9 Hz, 1H, H-
6a), 4.08 (dd, J = 12.6, 2.9 Hz, 1H, H-6b), 4.05 (t, J = 5.1 Hz, 2H, H2-2’), 3.82 (ddd, J = 11.2, 9.3, 4.9 
Hz, 1H, H-2), 3.74 (dd, J = 12.1, 4.9 Hz, 1H, H-1a), 3.71 (dd, J = 10.4, 9.2 Hz, 1H, H-4), 3.70 – 3.63 
(m, 1H, H-1’a), 3.47 (t, J = 9.2 Hz, 1H, H-3), 3.46 – 3.41 (m, 1H, H-1’a), 3.26 (d, J = 10.9 Hz, 1H, H-
5), 3.20 (t, J = 11.7 Hz, 1H, H-1b). 13C NMR (100 MHz, MeOD) δ 79.0 (C-3), 69.7 (C-4), 69.3 (C-5), 
68.6 (C-2), 57.7 (C-2’), 57.0 (C-1’), 56.5 (C-1), 56.0 (C-6). [α]20D = -42.0 (c = 0.2, MeOH). HRMS: 
found 208.11795 [C8H17NO5+H]+, calculated for [C8H17NO5+H]+ 208.11795. 
 
N-Benzyloxyethyl-L-ido-1-deoxynojimycin (97): 
L-ido-DNJ was subjected to the general procedure A and generated 97 
(21 mg, 0.07 mmol) in a yield of 12%. 1H NMR (400 MHz, MeOD) δ 7.50 – 
7.29 (m, 5H, HAr Bn), 4.62 (s, 2H, CH2 Bn), 4.03 (d, J =11.2, 6.4 Hz, 1H, H-
6a), 3.87 (dd, J = 10.8, 6.4 Hz, 1H, H-6b), 3.80 (dd, J = 8.9, 5.3 Hz, 1H, H-4), 
3.70 (t, J = 5.6 Hz, 2H, H2-2’), 3.63 (ddd, J = 12.7, 8.9, 5.1 Hz, 1H, H-2), 
3.45 (t, J = 8.5 Hz, 1H, H-3), 3.17 (m, J = 5.6 Hz, 1H, H-5), 3.11 (t, J = 5.6 
Hz, 1H, H-1’a), 3.04 (t, J = 5.6 Hz, 1H, H-1’b), 2.97 (dd, J = 12.7, 4.9 Hz, 1H, H-1a), 2.75 (dd, J = 
12.6, 9.7 Hz, 1H, H-1b). 13C NMR (100 MHz, MeOD) δ 140.5 – 129.0 (CHAr Bn), 76.7 (C-3), 75.0 
(CH2 Bn), 73.3 (C-4), 71.9 (C-2), 70.7 (C-2’), 65.7 (C-5), 58.8 (C-6), 56.2 (C-1’), 53.7 (C-1). [α]20D 
= -18.0 (c = 0.5, MeOH). IR/cm-1: 3331, 2864, 1653, 1456, 1362, 1059, 1027. HRMS: found 









2,3,4-Tri-O-benzyl-L-manno-1-deoxynojimycin (0.84 g, 1.94 mmol) was 
dissolved in ethanol (100 mL) and pH of the solution was adjusted to 2 with 
aqueous HCl (1M). The solvent was flushed with argon (3 x), a catalytic amount 
of Pd/C (10%) was added, and the reaction mixture was exposed to H2 
atmosphere (2 bar) for 18 hours. After TLC analysis showed completely 
consumption of the starting compound, the reaction mixture was filtered over a pad of Celite 
and the filtrate was concentrated. The residue was purified by silica gel column 
chromatography (0% → 20% methanol in DCM + 1% NH4OH) to give 129 (0.19 g, 1.14 mmol) 
in a yield of 59%. 1H NMR (400 MHz, CDCl3) δ 4.12 (s, 1H, H-2), 4.02 (d, J = 12.0 Hz, 1H, H-6a), 
3.86 (d, J = 12.4 Hz, 1H, H-6b), 3.84 (d, J = 10.8 Hz, 1H, H-4), 3.63 (d, J = 9.6 Hz, 1H, H-3), 3.36 (d, 
J = 13.2 Hz, 1H, H-1a), 3.25 (d, J = 13.6 Hz, 1H, H-1b), 3.12 – 3.07 (m, 1H, H-5). 13C NMR (100 
MHz, CDCl3) δ 73.0 (C-3), 66.2 (C-4), 66.2 (C-2), 61.0 (C-5), 58.2 (C-6), 34.1 (C-1). [α]20D = +4.3 (c 
= 1.0, MeOH). IR/cm-1: 3348, 2924, 1653, 1448, 1144, 1081, 1047. HRMS: found 164.09167 
[C6H13NO4+H]+, calculated for [C6H13NO4+H]+ 164.09173. 
 
N-Butyl- L-manno-1-deoxynojimycin (130): 
129 was subjected to the general procedure A and generated 130  (18 mg, 0.04 
mmol) in a yield of 42%. 1H NMR (400 MHz, MeOD) δ 4.21 (ddd, J = 3.9, 3.2, 1.5 
Hz, H-2), 4.17 (dd, J = 12.7, 2.9 Hz, 1H, H-6a), 4.05 (dd, J = 12.9, 2.8 Hz, 1H, H-
6b), 4.04 (t, J = 9.5 Hz, 1H, H-4), 3.66 (dd, J = 9.2, 3.0 Hz, 1H, H-3), 3.55 (dd, J = 
12.9, 3.7 Hz, 1H, H-1a), 3.47 (d, J = 13.0 Hz, 1H, H-1b), 3.44 – 3.35 (m, 2H, H2-1’), 
3.14 (dt, J = 9.9, 3.0 Hz, 1H, H-5), 1.94 – 1.72 (m, 2H, H2-2’), 1.54 – 1.50 (m, 2H, H2-3’), 1.10 (t, J = 
7.4 Hz, 3H, H3-4’). 13C NMR (100 MHz, MeOD) δ 75.0 (C-3), 68.6 (C-5), 68.0 (C-2), 67.8 (C-4), 
56.9 (C-6), 56.9 (C-1), 55.2 (C-1’), 26.6 (C-2’), 21.8 (C-3’), 14.8 (C-4’). [α]20D = -7.2 (c = 1.0, 
MeOH). IR/cm-1: 3244, 2954, 2872, 2619, 1635, 1435, 1259, 1076, 1020. HRMS: found 
220.15434 [C10H21NO4+H]+, calculated for [C10H21NO4+H]+ 220.15433. 
 
N-Nonyl- L-manno-1-deoxynojimycin (131): 
129 was subjected to the general procedure A and generated 131 (10 mg, 
0.03 mmol) in a yield of 17%. 1H NMR (400 MHz, MeOD) δ 4.00 (dd, J = 11.8, 
2.6 Hz, 1H, H-6a), 3.96 – 3.92 (m, 1H, H-2), 3.95 (dd, J = 11.7, 2.9 Hz, 1H, H-
6b), 3.78 (t, J = 9.1 Hz, 1H, H-4), 3.42 (dd, J = 9.0, 3.4 Hz, 1H, H-3), 3.11 (dd, J 
= 12.3, 3.9 Hz, 1H, H-1a), 2.95 – 2.83 (m, 1H, H-1’a), 2.80 – 2.70 (m, 1H, H-
1’b), 2.66 (d, J = 12.3 Hz, 1H, H-1b), 2.32  – 2.28 (m, 1H, H-5), 1.65 – 1.51 (m, 
2H, H2-2’), 1.47 – 1.32 (m, 12H, H2-3’ – H2-8’), 0.94 (t, J = 7.1 Hz, 3H, H3-9’). 13C NMR (100 MHz, 
MeOD) δ 77.2 (C-3), 70.2 (C-4), 70.2 (C-2), 67.9 (C-5), 59.7 (C-6), 57.3 (C-1), 54.8 (C-1’), 33.9, 
31.6, 31.5, 31.3, 29.4, 26.0, 24.6 (C-2’ – C-8’), 15.3 (C-9’). [α]20D = +6.0 (c = 1.0, MeOH). IR/cm-1: 
3392, 2924, 2857, 2503, 1635, 1435, 1273, 1082. HRMS: found 290.23291 [C15H31NO4+H]+, 
calculated for [C15H31NO4+H]+ 290.23258. 
 
N-[5-(Hexyloxy)pentyl]- L-manno-1-deoxynojimycin (132) 
129 was subjected to the general procedure A and generated 132 (27 
mg, 0.08 mmol) in a yield of 41%. 1H NMR (400 MHz, MeOD) δ 3.92 (dd, 
J = 4.7, 2.7 Hz, 2H, H2-6), 3.90 – 3.86 (m, 1H, H-2), 3.72 (t, J = 9.1 Hz, 1H, 
H-4), 3.36 (dd, J = 8.8, 3.1 Hz, 1H, H-3), 3.06 (dd, J = 12.4, 3.9 Hz, 1H, H-
1a), 2.92 – 2.78 (m, 1H, H-1’a), 2.75 – 2.65 (m, 1H, H-1’b), 2.61 (d, J = 
12.4 Hz, 1H, H-1b), 2.25 (d, J = 9.0 Hz, 1H, H-5), 1.74 – 1.27 (m, 14H, H2-
2’, H2-3’, H2-4’, H2-7’, H2-8’, H2-9’, H2-10’), 0.93 (t, J = 7.1 Hz, 3H, H3-11’).  13C NMR (100 MHz, 
MeOD) δ 77.2 (C-3), 72.8 (C-6’), 72.6 (C-5’), 70.2 (C-2), 70.2 (C-4), 67.9 (C-5), 59.7 (C-6), 57.2 
(C-1), 54.7 (C-1’), 33.7, 31.6, 31.4, 27.8, 26.0, 25.8, 24.6 (C-2’ – C-4’, C-7’ – C-10’), 15.3 (C-11’). 




[α]20D = +31.5 (c = 1.0, MeOH). IR/cm-1: 3392, 2932, 2867, 1684, 1456, 1373, 1099. HRMS: 
found 334.25936 [C17H35NO5+H]+, calculated for [C17H35NO5+H]+ 334.25880. 
 
 N-[5-(3,3-Dimethyl-1-propyloxy)pentyl]- L-manno-1-deoxynojimycin (133): 
129 was subjected to the general procedure A and generated 133 (15 
mg, 0.05 mmol) in a yield of 24%. 1H NMR (400 MHz, MeOD) δ 4.00 
(dd, J = 11.9, 2.8 Hz, 1H, H-6a), 3.96 (dd, J = 11.7, 2.9 Hz, 1H, H-6b), 
3.95 – 3.92 (m, 1H, H-2), 3.78 (t, J = 9.1 Hz, 1H, H-4), 3.51 (t, J = 6.4 Hz, 
2H, H-5’), 3.42 (dd, J = 8.5, 3.4 Hz, 1H, H-3), 3.16 (s, 2H, H2-6’), 3.11 
(dd, J = 12.4, 3.9 Hz, 1H, H-1a), 2.98 – 2.81 (m, 1H, H-1’a), 2.81 – 2.69 
(m, 1H, H-1’b), 2.65 (d, J = 12.3 Hz, 1H, H-1b), 2.29 (d, J = 8.9 Hz, 1H, 
H-5), 1.73 – 1.66 (m, 2H, H2-4’), 1.65 – 1.56 (m, 2H, H2-2’), 1.51 – 1.37 (m, 2H, H2-3’), 0.99 (s, 9H, 
H3-8’, H3-9’, H3-10’). 13C NMR (100 MHz, MeOD) δ 81.1 (C-6’), 75.0 (C-3), 71.0 (C-5’), 68.0 (C-2), 
68.0 (C-4), 65.6 (C-5), 57.5 (C-6), 55.0 (C-1), 52.5 (C-1’), 31.5 (C-4’), 29.2 (C-7’), 25.7 (C-
8’,9’,10’), 23.8 (C-3’), 23.5 (C-2’). [α]20D = +34.0 (c = 0.2, MeOH). IR/cm-1: 3390, 2955, 2507, 
1645, 1435, 1273, 1089. HRMS: found 320.24339 [C16H33NO5+H]+, calculated for 
[C16H33NO5+H]+ 320.24315. 
 
N-[5-(Adamantan-1-yl-methoxy)pentyl]- L-manno-1-deoxynojimycin (84): 
129 was subjected to the general procedure A and generated 84 
(14 mg, 0.04 mmol) in a yield of 18%. 1H NMR (600 MHz, MeOD) 
δ 4.22 – 4.19 (m, 1H, H-2), 4.16 (dd, J = 12.7, 3.3 Hz, 1H, H-6a), 
4.05 (dd, J = 12.7, 2.9 Hz, 1H, H-6b), 4.02 (t, J = 9.3 Hz, 1H, H-4), 
3.69 – 3.62 (m, 1H, H-3), 3.60 (t, J = 7.3 Hz, 2H, H2-5’), 3.57 (s, 2H, 
H2-6’), 3.53 (dd, J = 12.8, 4.0 Hz, 1H, H-1a), 3.47 – 3.41 (m, 3H, H2-1’, H-1b), 3.12 (br s, 1H, H-5), 
2.07 – 1.98 (m, 3H, 3 x CH ada), 1.95 – 1.91 (m, 2H, H2-2’), 1.87 – 1.80 (m, 3H, 3 x CH2 ada), 1.80 
– 1.70 (m, 7H, 3 x CH2 ada, C-4’), 1.65 (d, J = 2.8 Hz, 6H, 3 x CH2 ada), 1.46 (t, J = 7.4 Hz, 2H, H2-
3’). 13C NMR (150 MHz, MeOD) δ 75.1 (C-3), 71.7 (C-6’), 68.8 (C-5’), 68.6 (C-5), 68.0 (C-2), 68.0 
(C-4), 56.7 (C-6), 56.6 (C-1), 55.0 (C-1’), 45.7 (C-3’),  44.7 (CH2 ada), 39.0 (CH2 ada), 33.6 (Cq 
ada), 31.0 (CH ada), 28.7 (C-2’). IR/cm-1: 3393, 2901, 2830, 1684, 1506, 1456, 1418, 1396, 
1373, 1078. [α]20D = +13.8 (c = 0.5, MeOH). HRMS: found 398.28949 [C22H39NO5+H]+, calculated 
for [C22H39NO5+H]+ 398.29010. 
 
N-[(Biphenyl-4-yl-methoxy)pentyl]- L-manno-1-deoxynojimycin (134): 
 129 was subjected to the general procedure A and 
generated 134 (15 mg, 0.04 mmol) in a yield of 18%. 1H 
NMR (400 MHz, MeOD) δ 7.66 – 7.30 (m, 9H, HAr BiPh), 
4.45 (s, 2H, H2-6’), 3.97 (dd, J = 11.7, 2.7 Hz, 1H, H-6a), 
3.94 (dd, J = 11.7, 2.9 Hz, 1H, H-6b), 3.91 (dd, J = 3.7, 2.0 
Hz, 1H, H-2), 3.75 (t, J = 9.1 Hz, 1H, H-4), 3.48 (t, J = 6.4 Hz, 2H, H2-5’), 3.38 (d, J = 3.4 Hz, 1H, H-
3), 3.05 (dd, J = 12.3, 3.9 Hz, 1H, H-1a), 2.84 (dt, J = 13.4, 8.5 Hz, 1H, H-1’a), 2.68 (dt, J = 13.4, 8.2 
Hz, 1H, H-1’b), 2.57 (dd, J = 12.3, 1.8 Hz, 1H, H-1b), 2.22 (dt, J = 9.3, 2.7 Hz, 1H, H-5), 1.67 – 1.63 
(m, 2H, H2-4’), 1.57 – 1.54 (m, 2H, H2-2’), 1.45 – 1.34 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 
144.4 – 129.1 (CAr BiPh), 77.4 (C-3), 72.7 (C-6’), 72.3 (C-5’), 70.4 (C-2), 70.4 (C-4), 67.8 (C-5), 
59.9 (C-6), 57.3 (C-1), 54.6 (C-1’), 31.4 (C-4’), 26.1 (C-3’), 25.9 (C-2’). [α]20D = +17.4 (c = 0.5, 
MeOH). IR/cm-1: 3321, 2941, 2866, 2349, 2326, 1636, 1558, 1506, 1456, 1202, 1088, 744. 
HRMS: found 416.24303 [C24H33NO5+H]+, calculated for [C24H33NO5+H]+ 416.24315. 
 
N-Benzyloxyethyl- L-manno-1-deoxynojimycin (135): 
129 was subjected to the general procedure A and generated 135 (30 
mg, 0.10 mmol) in a yield of 17%. 1H NMR (400 MHz, MeOD) δ 7.58 – 





4.09 (dd, J = 12.7, 2.9 Hz, 1H, H-6a), 4.03 (dd, J = 12.7, 3.0 Hz, 1H, H-6b), 4.01 – 3.97 (m, 1H, H-
2’b), 4.12 (dd, J = 3.8, 1.4 Hz, 1H, H-2), 3.94 (t, J = 9.2, 1H, H-4), 3.69 – 3.61 (m, 1H, 1H, H-1’a), 
3.60 (dd, J = 9.1, 3.0 Hz, 1H, H-3), 3.34 – 3.29 (m, 1H, H-1’b), 3.18 (dd, J = 12.9, 4.0 Hz, H-1a), 
3.09 (d, J = 9.6 Hz, 1H, H-5), 2.93 (d, J = 12.7 Hz, 1H, H-1b). 13C NMR (100 MHz, MeOD) δ 137.5 – 
127.7 (CAr Bn), 72.9 (CH2 Bn), 72.2 (C-3), 66.6 (C-5), 66.2 (C-4), 66.1 (C-2), 56.0 (C-2’), 55.0 (C-
6), 53.2 (C-1), 52.1 (C-1’). [α]20D = +8.8 (c = 1.0, MeOH). IR/cm-1: 3381, 2913, 1653, 1212, 1101, 
1079, 1027. HRMS: found 298.16505 [C15H23NO5+H]+, calculated for [C15H23NO5+H]+ 
298.16490. 
 
N-[5-(Nonyloxy)pentyl]- L-manno-1-deoxynojimycin (136): 
129 was subjected to the general procedure A and generated 136 (22 
mg, 0.06 mmol) in a yield 29%. 1H NMR (400 MHz, MeOD) δ 4.16 (s, 1H, 
H-2), 4.11 (dd, J = 12.8, 2.8 Hz, 1H, H-6a), 3.99 (dd, J = 12.6, 2.7 Hz, 1H, 
H-6b), 3.97 (t, J = 9.5 Hz, 1H, H-4), 3.61 (dd, J = 9.3, 3.0 Hz, 1H, H-3), 3.51 
– 3.36 (m, 2H, H2-1), 3.35 – 3.31 (m, 2H, H2-1’), 3.48 (t, J = 6.4 Hz, 2H, H2-
5’), 3.46 (t, J = 6.6 Hz, 2H, H2-6’), 3.13 – 3.06 (m, 1H, H-5), 1.89 – 1.73 (m, 
2H, H2-2’), 1.70 – 1.66 (m, 2H, H2-4’), 1.61 – 1.58  (m, 2H, H2-7’), 1.52  – 1.48 (m, 2H, H2-3’), 1.43 
– 1.27 (m, 12H, H2-8’ – H2-13’), 0.93 (t, J = 7.0 Hz, 3H, H3-14’). 13C NMR (100 MHz, MeOD) δ 75.0 
(C-3), 72.9 (C-6’), 72.2 (C-5’), 68.6 (C-5), 68.0 (C-2), 67.8 (C-4), 56.9 (C-1), 56.9 (C-6), 55.3 (C-
1’), 33.9, 31.6, 31.6, 31.5, 31.3, 31.0, 28.1, 25.3, 24.6 (C-2’ – C-4’, C-7’ – C-13’), 15.3 (C-14’). [α]20D 
= +9.8 (c = 1.0, MeOH). IR/cm-1: 3200, 2870, 2509, 1456, 1398, 1317, 1246, 1101. HRMS: found 
376.30575 [C20H41NO5+H]+, calculated for [C20H41NO5+H]+ 376.30575. 
 
N-Hydroxyethyl- L-manno-1-deoxynojimycin (137) 
137 (4 mg, 0.02 mmol) was synthesized as described for the preparation of 
compound for 90a in a yield of 40%. 1H NMR (400 MHz, MeOD) δ 3.93 (td, J = 
3.8, 1.8 Hz, 1H, H-2), 3.89 (dd, J = 11.1, 4.5 Hz, 1H, H-6a), 3.82 (dd, J = 11.1, 3.1 
Hz, 1H, H-6b), 3.79 (dd, J = 11.5, 4.5 Hz, 1H, H-2’a), 3.72 (t, J = 9.8 Hz, 1H, H-4) 
3.69 (dd, J = 11.7, 4.8 Hz, 1H, H-2’b), 3.50 (dd, J = 9.3, 3.2 Hz, 1H, H-3), 3.15 (dd, 
J = 12.6, 4.0 Hz, 1H, H-1a), 3.10 (dd, J = 13.9, 2.8 Hz, 1H, H-1’a), 2.85 (dd, J = 
13.9, 1.6 Hz, 1H, H-1’b), 2.63 – 2.56 (m, 1H, H-1b), 2.49 (ddd, J = 9.9, 4.5, 3.1 Hz, 1H, H-5). 13C 
NMR (100 MHz, MeOD) δ 77.5 (C-3), 70.7 (C-2), 70.3 (C-4), 63.6 (C-5), 62.8 (C-6), 60.8 (C-2’), 
56.3 (C-1), 51.2 (C-1’). HRMS: found 208.11791 [C8H17NO5+H]+, calculated for [C8H17NO5+H]+ 
208.11795 
 
2,3,4-Tri-O-benzyl- D-manno-1-deoxynojimycin (138a): 
2,3,4-Tri-O-benzyl-5-tert-butyldimethylsilyl-O-D-manno-1-deoxynojimycin 
(0.84 g, 1.25 mmol)  was dissolved in THF (8 mL) at r.t.. TBAF (1M in THF, 
3.6 mL) was added to the solution under argon protection. The reaction 
mixture was stirred overnight, diluted with DCM, washed with water and 
brine, dried (Na2SO4) filtered and concentrated. The residual syrup was 
purified with silica gel column chromatography (20:1, DCM:MeOH) to give the protected 138a 
(0.39 g, 0.9 mmol) with 72% yield. RF = 0.45 (10:1, DCM:MeOH). 1H NMR (600 MHz, CDCl3) δ 
7.47 – 7.27 (m, 15H, HAr Bn), 4.95 (d, J = 11.0 Hz, 1H, CHH Bn), 4.70 (d, J = 3.6 Hz, 2H, CH2 Bn), 
4.66 – 4.58 (m, 3H, 3 x CHH Bn), 3.82 (dd, J = 11.0, 3.4 Hz, 1H, H-6a), 3.80 (dd, J = 3.1, 1.3 Hz, 1H, 
H-2), 3.74 (t, J = 9.4 Hz, 1H, H-4), 3.62 (dd, J = 11.0, 5.9 Hz, 1H, H-6b), 3.53 (dd, J = 9.1, 2.9 Hz, 
1H, H-3), 3.16 (dd, J = 14.2, 3.1 Hz, 1H, H-1a), 2.59 (ddd, J = 9.4, 5.8, 3.4 Hz, 1H, H-5), 2.51 (dd, J = 
14.3, 1.4 Hz, 1H, H-1b), 2.41 (s, 1H, -OH). 13C NMR (150 MHz, CDCl3) δ 139.5 – 128.6 (CAr Bn), 
85.0 (C-3), 78.0 (C-4), 76.2 (CH2 Bn), 74.6 (C-2), 72.9 (CH2 Bn), 72.6 (CH2 Bn), 63.5 (C-6), 62.4 
(C-5), 47.7 (C-1).  
 





138a (0.39 g, 0.9 mmol) was dissolved in ethanol (50 mL), and pH of the 
solution was adjusted to 2 with aqueous HCl (1M). After the solvent flushed 
with argon (3 x), a catalyst amount of Pd/C (10%) was added. The reaction 
mixture was exposed to H2 atmosphere (2 bar) for 18 hours. After TLC 
analysis showed completely consumption 138a, the reaction mixture was 
filtered over a pad of Celite and the filtrate was concentrated. The residue was purified by silica 
gel column chromatography (0% → 20% methanol in DCM + 1% NH4OH) to give 138 in a yield 
of 60% (0.09 g, 0.54 mmol). 1H NMR (400 MHz, MeOD) δ 4.16 (td, J = 3.1, 1.6 Hz, 1H, H-2), 4.02 
(dd, J = 11.8, 3.3 Hz, 1H, H-6a), 3.84 (dd, J = 10.3, 9.3 Hz, 1H, H-4), 3.83 (dd, J = 11.9, 7.0 Hz, 1H, 
H-1b), 3.61 (dd, J = 9.2, 3.0 Hz, 1H, H-3), 3.35 (dd, J = 13.5, 3.2 Hz, 1H, H-1a), 3.24 (dd, J = 13.2, 
1.6 Hz, 1H, H-1b), 3.08 (ddd, J = 10.3, 7.0, 3.3 Hz, 1H, H-5). 13C NMR (100 MHz, MeOD) δ 75.3 (C-
3), 68.4 (C-4), 68.4 (C-2), 63.3 (C-5), 60.5 (C-6), 49.8 (C-1).  
 
N-[5-(Hexyloxy)pentyl]-D-manno-1-deoxynojimycin (142): 
138 was subjected to the general procedure A and generated 142 (6.4 
mg, 0.02 mmol) in a yield of 7%. 1H NMR (400 MHz, MeOD) δ 4.05 – 4.03 
(m, 1H, H-2), 4.03 (dd, J = 12.2, 3.1 Hz, 1H, H-6a), 3.95 (dd, J = 12.3, 2.9 
Hz, 1H, H-6b), 3.86 (t, J = 9.2 Hz, 1H, H-4), 3.55 – 3.49 (m, 1H, H-3), 3.48 
(t, J = 6.4 Hz, 2H, H2-5’), 3.46 (t, J = 6.6 Hz, 2H, H2-6’), 3.33 – 3.27 (m, 2H, 
H2-1’), 3.18 – 2.99 (m, 2H, H2-1), 1.78 – 1.27 (m, 14H, H2-2’, H2-3’, H2-4’, 
H2-7’, H2-8’, H2-9’, H2-10’), 0.93 (t, J = 7.0 Hz, 3H, H3-11’). 13C NMR (100 MHz, MeOD) δ 75.8 (C-
3), 72.9 (C-6’), 72.4 (C-5’), 68.3 (C-4), 68.3 (C-2), 58.0 (C-6), 56.6 (C-1’), 54.9 (C-1), 33.7, 31.6, 
31.2, 27.8, 25.6, 25.2, 24.6 (C-2’ – C-4’, C-7’ – C-10’), 15.2 (C-11’). IR/cm-1: 3302, 2930, 2858, 




138 was subjected to the general procedure A and generated 145 (4.8 
mg, 0.015 mmol) in a yield of 5%. 1H NMR (400 MHz, MeOD) δ 7.48 – 
7.31 (m, 5H, HAr Bn), 4.53 (s, 2H, CH2 Bn) 4.33 (d, J = 13.2 Hz, 1H, H-2’a), 
4.18 (dd, J = 11.8, 2.9 Hz, 1H). 4.03 (dd, J = 11.9, 2.8 Hz, 1H, H-6a), 3.97 
(dd, J = 11.9, 2.7 Hz, 1H, H-6b), 3.90 (td, J = 3.7, 1.7 Hz, 1H, H-2), 3.75 (t, J 
= 9.1 Hz, 1H, H-4), 3.45 – 3.41 (m, 2H, H-2’b, H-3), 3.15 (dd, J = 12.5, 3.8 
Hz, 1H, H-1a), 3.23 – 3.14 (m, 1H, H-1’a), 2.97 – 2.90 (m, 1H, H-1’b), 2.72 (dd, J = 12.4, 1.6 Hz, 
1H, H-1b), 2.37 (dt, J = 9.0, 2.7 Hz, 1H, H-5). 13C NMR (100 MHz, MeOD) δ 140.4 – 129.6 (CAr Bn), 
77.3 (C-3), 75.1 (CH2 Bn), 70.3 (C-2), 70.2 (C-4), 68.3 (C-5), 60.3 (C-6), 59.1 (C-2’), 57.9 (C-1), 
53.7 (C-1’). IR/cm-1: 3360, 2504, 1636, 1558, 1506, 1456, 1435, 1271, 1207, 1082, 1051. HRMS: 
found 298.16504 [C15H23NO5+H]+, calculated for [C15H23NO5+H]+ 298.16490. 
 
L-Gulo-1-deoxynojimycin (146): 
146 (0.15 g, 0.90 mmol) was synthesized as described for the preparation of 
compound 138 in a yield of 59%. 1H NMR (400 MHz, MeOD) δ 4.22 (ddd, J = 
11.5, 5.1, 2.7 Hz, 1H, H-2), 4.02 (dd, J = 4.6, 1.6 Hz, 1H, H-4), 3.99 (dd, J = 4.5, 2.8 
Hz, 1H, H-3), 3.85 (dd, J = 11.8, 5.5 Hz, 1H, H-6a), 3.81 (dd, J = 11.8, 8.2 Hz, 1H, 
H-6b), 3.47 (ddd, J = 7.6, 5.5, 1.6 Hz, 1H, H-5), 3.18 (dd, J = 11.8, 5.1 Hz, 1H, H-
1a), 3.08 (t, J = 11.7 Hz, 1H, H-1b).  13C NMR (100 MHz, MeOD) δ 69.0 (C-3), 67.4 (C-4), 62.6 (C-
2), 59.2 (C-6), 55.6 (C-5), 42.7 (C-1). [α]20D = -24.8 (c = 1.0, MeOH). IR/cm-1: 3350, 3034, 1634, 








146 was subjected to the general procedure A and generated 147 (7 mg, 0.03 
mmol) in a yield of 35%. 1H NMR (600 MHz, MeOD) δ 4.16 – 4.12 (m, 1H, H-2), 
4.06 (dd, J = 4.9, 2.4 Hz, 1H, H-4), 3.97 (dd, J = 11.9, 5.0 Hz, 1H, H-6a), 3.94 (d, J = 
5.0 Hz, 1H, H-6b), 3.89 (dd, J = 4.7, 3.1 Hz, 1H, H-3), 3.15 – 2.81 (m, 5H, H-5, H2-
1’, H2-1), 1.76 – 1.60 (m, 2H, H2-2’), 1.46 – 1.42 (m, 2H, H2-3’), 1.06 (t, J = 7.4 Hz, 
3H, H3-4’). 13C NMR (150 MHz, MeOD) δ 73.5 (C-4), 72.4 (C-3), 66.9 (C-2), 62.1 (C-6), 62.0 (C-5), 
55.5 (C-1’), 53.3 (C-1), 26.3 (C-2’), 22.4 (C-3’), 15.1 (C-4’). [α]20D = +55.0 (c = 0.1, MeOH). IR/cm-
1: 3335, 2974, 2928, 2900, 2349, 1636, 1456, 1379, 1271, 1083, 1043. HRMS: found 220.15440 
[C10H21NO4+H]+, calculated for [C10H21NO4+H]+ 220.15433. 
 
N-Nonyl-L-gulo-1-deoxynojimycin (148): 
146 was subjected to the general procedure A and generated 148 (8 mg, 
0.03 mmol) in a yield of 31%. 1H NMR (400 MHz, MeOD) δ 4.22 (ddd, J = 9.0, 
6.3, 2.9 Hz, 1H, H-2), 4.11 (dd, J = 4.7, 2.1 Hz, 1H, H-4), 4.01 (dd, J = 12.0, 4.7 
Hz, 1H, H-6a), 3.97 (dd, J =12.0, 5.0 Hz, 1H, H-6b), 3.93 (dd, J = 4.6, 2.9 Hz, 
1H, H-3), 3.34 (td, J = 4.8, 2.2 Hz, 1H, H-5), 3.18 (ddd, J = 9.5, 6.7, 2.3 Hz, 2H, 
H2-1’), 3.15 – 3.10 (m, 2H, H2-1), 1.93 – 1.69 (m, 2H, H2-2’), 1.54 – 1.33 (m, 
12H, H2-3’ – H2-8’), 0.93 (t, J = 7.0 Hz, 3H, H3-9’). 13C NMR (100 MHz, MeOD) δ 72.6 (C-4), 71.2 
(C-3), 65.3 (C-2), 62.0 (C-5), 61.3 (C-6), 55.0 (C-1’), 52.0 (C-1), 33.4, 30.8, 30.8, 28.3, 28.3, 24.3 
(C-2’ – C-8’), 14.9 (C-9’). [α]20D = +14.4 (c = 0.5, MeOH). IR/cm-1: 3336, 2925, 2854, 1653, 1468, 




146 was subjected to the general procedure A and generated 149 (9 mg, 
0.03 mmol) in a yield of 30%. 1H NMR (400 MHz, MeOD) δ 4.14 (ddd, J = 
10.2, 4.5, 3.0 Hz, 1H, H-2), 4.06 (dd, J = 4.8, 2.3 Hz, 1H, H-4), 3.98 (dd, J = 
11.7, 4.7 Hz, 1H, H-6a), 3.94 (d, J = 12.0, 4.5 Hz, 1H), 3.89 (dd, J = 4.7, 3.1 
Hz, 1H, H-3), 3.53 (t, J = 6.5 Hz, 2H, H2-5’), 3.51 (t, J = 6.6 Hz, 2H, H2-6’) , 
3.23 – 2.85 (m, 5H, H-5, H2-1’, H2-1), 1.90 – 1.31 (m, 14H, H2-2’, H2-3’, 
H2-4’, H2-7’, H2-8’, H2-9’, H2-10’), 0.94 (t, J = 7.0 Hz, 3H, H3-11’). 13C NMR (100 MHz, MeOD) δ 
73.0 (C-4), 72.8 (C-6’), 72.4 (C-5’), 72.1 (C-3), 66.8 (C-2), 62.0 (C-6), 62.0 (C-5), 55.5 (C-1’), 53.1 
(C-1), 33.4, 31.2, 31.1, 27.6, 25.4, 25.2, 24.3 (C-2’ – C-4’, C-7’ – C-10’), 15.0 (C-11’). [α]20D = +27.0 
(c = 0.1, MeOH). IR/cm-1: 3380, 2987, 2872, 2376, 1635, 1506, 1456, 1394, 1229, 1076. HRMS: 
found 334.25886 [C17H35NO5+H]+, calculated for [C17H35NO5+H]+ 334.25880. 
 
N-[5-(Nonyloxy)pentyl]-L-gulo-1-deoxynojimycin (150): 
146 was subjected to the general procedure A and generated 150 (8 mg, 
0.02 mmol) in a yield of 24%. 1H NMR (400 MHz, MeOD) δ 4.28 (ddd, J = 
11.1, 5.2, 2.8 Hz, 1H, H-2), 4.17 (dd, J = 4.4, 1.7 Hz, 1H, H-4), 4.06 (dd, J = 
12.9, 4.1 Hz, 1H, H-6a), 4.01 (dd, J = 12.9, 4.8 Hz, 1H, H-6b), 3.97 (dd, J = 
4.1, 3.0 Hz, 1H, H-3), 3.58 – 3.55 (m, 1H, H-5), 3.55 (t, J = 5.5 Hz, 2H, H2-
5’), 3.52 (t, J = 6.3 Hz, 2H, H2-6’), 3.39 – 3.30 (m, 2H, H2-1’), 3.31 – 3.20 
(m, 2H, H2-1), 3.71 – 3.64 (m, 2H, H2-2’), 2.01 – 1.81 (m, 2H, H2-7’), 1.77 – 1.70 (m, 2H, H2-4’), 
1.71 – 1.62 (m, 2H, H2-3’), 1.63 – 1.48 (m, 12H, H2-8’, H2-9’, H2-10’, H2-11’, H2-12’, H2-13’), 0.94 
(t, J = 7.0 Hz, 3H, H3-14’). 13C NMR (100 MHz, MeOD) δ 73.2 (C-4), 72.9 (C-6’), 72.3 (C-5’), 70.9 
(C-3), 65.0 (C-2), 62.6 (C-5), 62.0 (C-6), 55.8 (C-1’), 52.1 (C-1), 33.9, 31.9, 31.6, 31.6, 31.5, 31.3, 
31.0, 28.1, 25.4, 23.9 (C-2’ –C-4’, C-7’ – C-13’), 15.2 (C-14’). IR/cm-1: 3308, 2927, 2872, 2313, 
1636, 1456, 1394, 1204, 1057. [α]20D = +6.5 (c = 0.2, MeOH). HRMS: found 376.30576 
[C20H41NO5+H]+, calculated for [C20H41NO5+H]+ 376.30575. 
 





146 was subjected to the general procedure A and generated 151 (8 mg, 
0.03 mmol) in a yield of 28%. 1H NMR (600 MHz, MeOD) δ 4.09 (dd, J = 
9.0, 4.8 Hz, 1H, H-2), 4.03 (td, J = 4.4, 2.1 Hz, 1H, H-4),  3.94 (dd, J = 11.7, 
5.2 Hz, 1H, H-6a), 3.90 (dd, J = 11.6, 4.8 Hz, 1H, H-6b), 3.86 (dd, J = 4.8, 
3.2 Hz, 1H, H-3), 3.51 (t, J = 6.4 Hz, 2H, H2-5’), 3.16 (s, 2H, H2-6’), 2.99 – 
2.75 (m, 5H, H-5, H2-1’, H2-1), 1.79 – 1.62 (m, 4H, H2-4’, H2-2’), 1.50 – 
1.41 (m, 2H, H2-3’), 0.99 (s, 9H, H3-8’, H3-9’, H3-10’). 13C NMR (150 MHz, MeOD) δ 83.4 (C-6’), 
73.6 (C-4), 73.2 (C-5’), 72.7 (C-3), 67.9 (C-2), 62.4 (C-6), 61.8 (C-5), 55.7 (C-1’), 53.6 (C-1), 33.8 
(C-7’), 31.4 (C-4’), 28.0 (C-8’, C-9’, C-10’), 26.1 (C-2’), 25.4 (C-3’). [α]20D = +29.0 (c = 0.1, MeOH). 
IR/cm-1: 3422, 2953, 2900, 2866, 2374, 2349, 2312, 1683, 1506, 1394, 1373, 1317, 1074. 
HRMS: found 320.24327 [C16H33NO5+H]+, calculated for [C16H33NO5+H]+ 320.24315. 
 
N-Benzyloxyethyl-L-gulo-1-deoxynojimycin (152a): 
146 was subjected to the general procedure A and generated 152a (13 
mg, 0.04 mmol) in a yield of 22%. 1H NMR (400 MHz, MeOD) δ 7.52 – 
7.29 (m, 5H, HAr Bn), 4.63 (s, 2H, CH2 Bn), 4.01 – 3.99 (m, 1H, H-2), 3.95 
(dd, J = 11.7, 4.9 Hz, 1H, H-6a), 3.90 (dd, J = 11.7, 5.4 Hz, 1H, H-6b), 3.84 
(td, J = 5.0, 2.6 Hz, 1H, H-3), 3.76 (dd, J = 5.2, 3.5 Hz, 1H, H-4), 3.59 (d, J = 
13.5 Hz, 1H, H-2’a), 3.24 – 3.12 (m, 1H, H-1’a), 3.07 – 3.00 (m, 2H, H-1’b, 
H-2’b), 2.91 (t, J = 5.3 Hz, 1H, H-5), 2.76 (dd, J = 11.4, 4.3 Hz, 1H, H-1a), 2.46 (dd, J = 11.1, 9.6 Hz, 
1H, H-1b). 13C NMR (100 MHz, MeOD) δ 131.9 – 129.6 (CHAr Bn), 75.1 (CH2 Bn), 73.5 (C-3), 69.0 
(C-4), 68.4 (C-2), 63.1 (C-5), 62.2 (C-6), 60.0 (C-2’), 54.4 (C-1’), 53.4 (C-1). [α]20D = +35.2 (c = 0.5, 
MeOH).  IR/cm-1: 3345, 2924, 1653, 1506, 1457, 1201, 1074, 1037. HRMS: found 298.16500 
[C15H23NO5+H]+, calculated for [C15H23NO5+H]+ 298.16490. 
 
N-[5-(Adamantan-1-yl-methoxy)pentyl]-L-gulo-1-deoxynojimycin (79): 
146 was subjected to the general procedure A and generated 79 
(7 mg, 0.02 mmol) in a yield of 19%. 1H NMR (400 MHz, MeOD) δ 
4.16 (ddd, J = 10.1, 4.8, 3.0 Hz, 1H, H-2), 4.07 (dd, J = 4.7, 2.3 Hz, 
1H, H-4), 3.90 (dd, J = 4.7, 3.1 Hz, 1H, H-3), 3.99 (dd, J = 12.0, 4.9 
Hz, 1H, ), 3.94 (dd, J = 12.0, 4.8 Hz, 1H), 3.59 (t, J = 7.3 Hz, 2H, H2-
5’), 3.54 (t, J = 6.2 Hz, 2H, H2-6’), 3.14 (td, J = 4.7, 2.0 Hz, 1H, H-5), 3.11 – 3.02 (m, 2H, H2-1’), 3.00 
(dd, J = 11.2, 4.9 Hz, 1H, H-1a), 2.93 (t, J = 10.7 Hz, 1H, H-1b), 2.04 – 2.02 (m, 3H, 3 x CH ada), 
1.89 – 1.72 (m, 8H, 3 x CH2 ada, H2-2’), 1.72 – 1.61 (m, 8H, 3 x CH2 ada, H2-3’), 1.46 (td, J = 7.3, 
3.4 Hz, 2H, H-4’). 13C NMR (100 MHz, MeOD) δ 73.4 (C-4), 72.2 (C-3), 72.2 (C-6’), 68.7 (C-5’), 
66.5 (C-2), 62.0 (C-5), 61.6 (C-6), 55.4 (C-1’), 53.1 (C-1), 45.6 (C-4’), 44.7 (CH2 ada), 39.1 (CH2 
ada), 33.7 (Cq ada), 31.0 (CH ada), 29.2 (C-3’), 20.5 (C-2’). [α]20D = +18.0 (c = 0.1, MeOH). IR/cm-
1: 3300, 2978, 2901, 2349, 1635, 1489, 1259, 1082, 1045, 878. HRMS: found 398.29004 
[C22H39NO5+H]+, calculated for [C22H39NO5+H]+ 398.29010. 
 
N-Benzyloxyethyl-D-ido-1-deoxynojimycin (157): 
D-ido-DNJ was subjected to the general procedure A and generated 157 
(44.8 mg, 0.15 mmol) in a yield of 25%. 1H NMR (400 MHz, MeOD) δ 
7.47 – 7.30 (m, 5H, HAr Bn), 4.62 (s, 2H, CH2 Bn), 4.00 (dd, J = 11.6, 9.6 
Hz, 1H, H-6a), 3.92 (dd, J = 11.6, 8.8 Hz, 1H, H-6b), 3.81 (dd, J = 8.9, 5.3 
Hz, 1H, H-4), 3.69 (t, J = 5.7 Hz, 2H, H2-2’), 3.67 – 3.61 (m, 1H, H-2), 3.45 
(t, J = 8.5 Hz, 1H, H-3), 3.17 (q, J = 5.5 Hz, 1H, H-5), 3.11 (t, J = 5.6 Hz, 1H, 
H-1’a), 3.03 (t, J = 5.6 Hz, 1H, H-1’b), 2.97 (dd, J = 13.0, 5.1 Hz, 1H, H-1a), 2.74 (dd, J = 11.9, 9.1 
Hz, 1H, H-1b). 13C NMR (100 MHz, MeOD) δ 140.4 – 128.9 (CAr Bn), 76.7 (C-3), 75.0 (CH2 Bn), 





2950, 1653, 1456, 1362, 1272, 1209, 1058, 1027, 735. [α]20D = +18.0 (c = 1.0, MeOH). HRMS: 
found 298.16501 [C15H23NO5+H]+, calculated for [C15H23NO5+H]+ 298.16490. 
 
N-Hydroxyethyl-D-ido-1-deoxynojimycin (158): 
158 (12.1 mg, 0.06 mmol) was synthesized as described for the preparation of 
compound 90a in a yield of 30%. 1H NMR (400 MHz, MeOD) δ 4.15 (br s, 1H, H-
3), 4.13 – 3.95 (m, 5H, H2-6 H-2’a, H-2, H-4), 3.91 (dd, J = 11.9, 5.1 Hz, 1H, H-
2’b), 3.78 (t, J = 5.0 Hz, 1H, H-5), 3.72 (d, J = 13.5 Hz, 1H, H-1a), 3.58 – 3.49 (m, 
1H, H-1b), 3.46 (d, J = 13.3 Hz, 1H, H-1’a), 3.34 (dd, J = 13.4, 2.4 Hz, 1H, H-1’b). 
13C NMR (100 MHz, MeOD) δ 72.8 (C-3), 69.9 (C-4), 68.7 (C-2), 65.5 (C-5), 61.4 (C-2’), 57.4 (C-6), 
57.4 (C-1), 47.7 (C-1’). [α]20D = -6.0 (c = 0.2, MeOH). IR/cm-1: 3421, 2987, 2901, 2374, 1684, 1558, 




 D-ido-DNJ (153) was subjected to the general procedure A and 
generated 159 (36.2 mg, 0.10 mmol) in a yield of 20%. 1H NMR (400 
MHz, MeOD) δ 3.94 (dd, J = 11.5, 4.8 Hz, 1H, H-6a), 3.90 (dd, J = 11.4, 6.4 
Hz, 1H, H-6b), 3.78 (dd, J = 8.8, 5.2 Hz, 1H, H-4), 3.62 (ddd, J = 9.4, 8.0, 
4.9 Hz, 1H, H-2), 3.52 (t, J = 6.5 Hz, 2H, H2-5’), 3.51 (t, J = 6.6 Hz, 2H, H2-
6’), 3.46 (t, J = 8.4 Hz, 1H, H-3), 3.15 – 3.08 (m, 1H, H-5), 2.89 (dd, J = 
12.4, 4.8 Hz, 1H, H-1a), 2.86 – 2.83 (m, 1H, H-1’a), 2.79 – 2.70 (m, 1H, H-1’b), 2.67 (dd, J = 12.4, 
9.5 Hz, 1H, H-1b), 1.75 – 1.54 (m, 6H, H2-2’, H2-4’, H2-7’), 1.53 – 1.26 (m, 14H, H2-3’, H2-8’, H2-9’, 
H2-10’, H2-11’, H2-12’, H2-13’), 0.93 (t, J = 7.0 Hz, 3H, H3-14’). 13C NMR (100 MHz, MeOD) δ 76.7 
(C-3), 73.6 (C-4), 72.8 (C-6’), 72.7 (C-5’), 72.1 (C-2), 65.2 (C-5), 58.5 (C-6), 56.4 (C-1’), 53.7 (C-
1), 33.9, 31.6, 31.6, 31.5, 31.3, 29.3, 28.1, 25.8, 24.6 (C-2’  –  C-4’, C-7’ – C-13’), 15.3 (C-14’). 




 D-ido-DNJ (153) was subjected to the general procedure A and 
generated 160 (40.8 mg, 0.12 mmol) in a yield of 20%. 1H NMR (400 
MHz, MeOD) δ 4.20 – 3.86 (m, 5H, H-2, H2-6, H-4, H-3), 3.64 (br s, 1H, H-
5), 3.57 – 3.53 (m, 1H, H-1a), 3.55 (t, J = 6.3 Hz, 1H, H-5’), 3.52 (t, J = 6.6 
Hz, 2H, H2-6’), 3.49 – 3.40 (m, 3H, H2-1’, H-1b), 2.07 – 1.78 (m, 2H, H2-
2’), 1.78 – 1.69 (m, 2H, H2-4’), 1.66 – 1.64 (m, 2H, H2-7’), 1.60 – 1.51 (m, 
2H, H2-3’), 1.50 – 1.28 (m, 6H, H2-8’, H2-9’, H2-10’), 0.93 (t, J = 7.0 Hz, 3H, H3-11’). 13C NMR (100 
MHz, MeOD) δ 73.0 (C-2), 72.9 (C-6’), 72.3 (C-5’), 69.7 (C-4), 68.9 (C-3), 64.7 (C-5), 62.2 (C-6), 
56.2 (C-1’), 55.9 (C-1), 33.7 , 31.6, 31.0, 27.8, 25.3, 25.3, 24.5 (C-2’ – C-4’, C-7’ – C-10’), 15.3 (C-
11’). [α]20D = -4.2 (c = 1.0, MeOH). IR/cm-1: 3385, 2932, 2859, 1628, 1435, 1269, 1096, 1067. 
HRMS: found 334.25887 [C17H35NO5+H]+, calculated for [C17H35NO5+H]+ 334.25880. 
 
L-Gluco-1-deoxynojimycin (161): 
 1H NMR (400 MHz, MeOD) δ 3.93 (dd, J = 11.8, 3.3 Hz, 1H, H-6a), 3.85 (dd, J = 
11.8, 5.5 Hz, 1H, H-6b), 3.69 (ddd, J = 11.4, 9.1, 5.1 Hz, 1H, H-2), 3.51 (dd, J = 
10.4, 9.0 Hz, 1H, H-4), 3.38 (t, J = 9.1 Hz, 1H, H-3), 3.34 (dd, J = 12.4, 5.1 Hz, H-
1a), 3.06 (ddd, J = 10.4, 5.5, 3.3 Hz, 1H, H-5), 2.87 (dd, J = 12.4, 11.4 Hz, 1H, H-
1b). 13C NMR (100 MHz, MeOD) δ 77.1 (C-3), 68.3 (C-4), 67.5(C-2), 60.5 (C-5), 
57.9 (C-6), 46.4 (C-1). [α]20D  = -34.8 (c = 1.0, MeOH). IR/cm-1: 3315, 2945, 2497, 1616, 1417, 
1093, 1043, 1022. HRMS: found 164.09172 [C6H13NO4+H]+, calculated for [C6H13NO4+H]+ 
164.09173. 
 





161 was subjected to the general procedure A and generated 162 (53.9 mg, 0.25 
mmol) in a yield of 40%. 1H NMR (400 MHz, MeOD) δ 4.12 (dd, J = 12.5, 1.9 Hz, 
1H, H-6a), 3.94 (dd, J = 12.5, 3.1 Hz, 1H, H-6b), 3.73 (ddd, J = 11.2, 9.2, 4.9 Hz, 1H, 
H-2), 3.62 (dd, J = 10.3, 9.2 Hz, 1H, H-4), 3.47 (dd, J = 12.1, 4.9 Hz, 1H, H-1), 3.40 
(t, J = 9.3 Hz, 1H, H-3), 3.33 (m, 1H, H-1’a), 3.22 (dt, J = 12.7, 6.5 Hz, 1H, H-1’b), 
3.06 (d, J = 10.2 Hz, 1H, H-5), 2.99 (t, J = 11.7 Hz, 1H, H-1b), 1.78 – 17.4 (m, 2H, H2-2’), 1.47 – 
1.45 (m, 2H, H2-3’), 1.04 (t, J = 7.4 Hz, 3H, H3-4’). 13C NMR (100 MHz, MeOD) δ 76.8 (C-3), 66.5 
(C-4), 67.6 (C-2), 66.1 (C-5), 53.7 (C-6), 52.4 (C-1), 52.7 (C-1’), 24.9 (C-2’), 19.6 (C-3’), 12.6 (C-
4’). IR/cm-1: 3320, 3038, 2962, 2873, 1653, 1398, 1099, 1086, 1050, 1028, 936, 886. [α]20D  = 




 161 was subjected to the general procedure A and generated 163 (63.5 
mmol, 0.22 mmol) in a yield of 37%. 1H NMR (400 MHz, MeOD) δ 4.10 (d, J = 
12.5 Hz, 1H, H-6a), 3.92 (dd, J = 12.4, 3.0 Hz, 1H, H-6b), 3.69 (td, J = 10.3, 4.7 
Hz, 1H, H-2), 3.59 (t, J = 9.7 Hz, 1H, H-4), 3.42 (dd, J = 12.1, 4.7 Hz, 1H, H-1a), 
3.37 (t, J = 9.2 Hz, 1H, H-3), 3.32 – 3.24 (m, 1H, H-1’a), 3.20 – 3.10 (m, 1H, H-
1’b), 3.02 – 2.84 (m, 2H, H-5, H-1b), 1.88 – 1.61 (m, 2H, H2-2’), 1.51 – 1.24 (m, 
12H, H2-3’, H2-4’, H2-5’, H2-6’, H2-7’, H2-8’), 0.93 (t, J = 7.0 Hz, 3H, H3-9’). 13C NMR (100 MHz, 
MeOD) 77.0 (C-3), 67.7 (C-4), 66.7 (C-2), 66.0 (C-5), 54.0 (C-6), 53.7 (C-1), 52.8 (C-1’), 31.6, 
29.1, 28.9, 28.9, 26.4, 22.9, 22.3 (C-2’- C-8’), 13.0 (C-9’). [α]20D = +4.3 (c = 1.0, MeOH). IR/cm-1: 
3333, 2924, 2855, 1456, 1374, 1085, 1026, 952, 886, 721. HRMS: found 290.23260 
[C15H31NO4+H]+, calculated for [C15H31NO4+H]+ 290.23258. 
 
N-[5-(adamantan-1-yl-methoxy)pentyl]-L-gluco-1-deoxynojimycin (76): 
161 was subjected to the general procedure A and generated 76 
(11 mg, 0.03 mmol) in a yield of 14%. 1H NMR (400 MHz, MeOD) 
δ 3.96 (d, J = 2.7 Hz, 2H, H2-6), 3.58 (ddd, J = 10.6, 9.1, 4.9 Hz, 1H, 
H-2), 3.48 (t, J = 6.4 Hz, 2H, H2-5’), 3.40 (t, J = 9.2 Hz, 1H, H-4), 
3.24 (t, J = 9.1 Hz, 1H, H-3), 3.12 (dd, J = 11.3, 4.9 Hz, 1H, H-1a), 
2.94 (ddd, J = 13.4, 9.6, 6.7 Hz, 1H, H-1’a), 2.74 (ddd, J = 13.3, 9.4, 6.1 Hz, 1H, H-1’b), 2.35 (t, J = 
11.0 Hz, 1H, H-1b), 2.30 (dt, J = 9.6, 2.8 Hz, 1H, H-5), 2.05 – 2.03 (m, 3H, 3 x CH ada), 1.89 – 1.74 
(m, 6H, 3 x CH2 ada), 1.65 (d, J = 2.8 Hz, 6H, 3 x CH2 ada ), 1.72 – 1.59 (m, 4H, H2-2’, H2-4’), 1.54 – 
1.37 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 83.9 (C-6’), 81.2 (C-3), 73.3 (C-5’), 72.6 (C-4), 
71.3 (C-2), 68.2 (C-5), 59.8 (C-6), 58.3 (C-1), 54.7 (C-1’), 41.7 (CH2  ada), 39.2 (CH2  ada), 36.0 (Cq 
ada), 31.4 (C-4’), 30.6 (CH ada), 26.1 (C-2’), 25.8 (C-3’). [α]20D = +6.4 (c = 0.5, MeOH). HRMS: 
found 398.28980 [C22H39NO5+H]+, calculated for [C22H39NO5+H]+ 398.29010 
 
N-[(Biphenyl-4-yl-methoxy)pentyl]-L-gluco-1-deoxynojimycin (164): 
161 was subjected to the general procedure A and 
generated 164 (28 mg, 0.07 mmol) in a yield of 22%. 1H 
NMR (400 MHz, MeOD) δ 7.64 – 7.29 (m, 9H, HAr BiPh), 
3.95 (dd, J = 12.0, 2.6 Hz, 1H, H-6a), 3.91 (dd, J = 12.0, 2.8 
Hz, 1H, H-6b), 3.57 (ddd, J = 10.5, 9.1, 4.8 Hz, 1H, H-2), 
3.48 – 3.43 (m, 2H, H2-5’), 3.45 (t, J = 9.3 Hz, 1H, H-4), 3.23 (t, J = 9.1 Hz, 1H, H-3), 3.07 (dd, J = 
11.2, 4.9 Hz, 1H, H-1a), 2.86 (dt, J = 13.4, 7.5 Hz, 1H, H-1’a), 2.65 (dt, J = 15.4, 6.9 Hz, 1H, H-1’b), 
2.26 (t, J = 10.8 Hz, 1H, H-1b), 2.19 (dt, J = 9.5, 2.8 Hz, 1H, H-5), 1.64 (p, J = 7.0 Hz, 2H, H2-4’), 
1.56 (p, J = 7.8 Hz, 2H, H2-2’), 1.41 – 1.37 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 144.4 – 
129.1 (CAr BiPh), 81.4 (C-3), 72.8 (C-4), 72.6 (C-6’), 72.3 (C-5’), 71.6 (C-2), 68.1 (C-5), 60.3 (C-6), 





1479, 1456, 1362, 1268, 1198, 1156, 1085, 1034, 1009. [α]20D = -31.7 (c = 1, MeOH). HRMS: 
found 416.24299 [C24H33NO5+H]+, calculated for [C24H33NO5+H]+ 416.24315. 
 
N-Benzyloxyethyl -L-gluco-1-deoxynojimycin (165): 
161 was subjected to the general procedure A and generated 165 (13 
mg, 0.04 mmol) in a yield of 15%. 1H NMR (400 MHz, MeOD) δ 7.51 – 
7.26 (m, 5H, HAr Bn), 4.62 (s, 2H, CH2 Bn), 3.99 (dd, J = 11.5, 9.9 Hz, 1H, 
H-6a), 3.91 (t, J = 11.4 Hz, 1H, H-6b), 3.81 (dd, J = 8.9, 5.3 Hz, 1H, H-4), 
3.70 (t, J = 5.7 Hz, 2H, H2-2’), 3.66 – 3.58 (m, 1H, H-2), 3.46 (t, J = 8.5 Hz, 
1H, H-3), 3.18 (dd, J = 11.7, 5.3 Hz, 1H, H-5), 3.13 (dd, J = 13.8, 5.6 Hz, H-
1’a), 3.03 (dd, J = 13.7, 5.6 Hz, H-1’b), 2.98 (dd, J = 12.7, 4.9 Hz, 1H, H-1a), (dd, J = 12.5, 9.7 Hz, 
1H, H-1b). 13C NMR (100 MHz, MeOD) δ 140.4 – 129.6 (CAr Bn), 76.6 (C-3), 75.0 (CH2 Bn), 73.3 
(C-4), 71.9 (C-2), 70.4 (C-2’), 65.7 (C-5), 58.8 (C-6), 56.1 (C-1’), 52.7 (C-1). IR/cm-1: 3328, 2878, 
1670, 1456, 1362, 1261, 1203, 1136, 1059, 1027.  [α]20D = -9.3 (c = 1.0, MeOH). HRMS: found 
298.16502 [C15H23NO5+H]+, calculated for [C15H23NO5+H]+ 298.16490. 
 
N-Hydroxyethyl-L-gluco-1-deoxynojimycin (166): 
 166 (14 mg, 0.07 mmol) was synthesized as described for the preparation of 
compound 90a in a yield of 47%. 1H NMR (400 MHz, MeOD) δ 4.17 – 4.11 (m, 
1H, H-3), 4.11 – 3.98 (m, 3H, H2-6, H-2’a),  4.07 (ddd, J = 10.4, 6.7, 3.6 Hz, 1H, H-
2), 3.99 – 3.93 (m, 1H, H-4), 3.88 (dd, J = 11.7, 4.8 Hz, 1H, H-2’b), 3.75 – 3.66 (m, 
1H, H-1a), 3.58 – 3.48 (m, 2H, H-5, H-1b), 3.45 (dd, J = 13.1, 2.1 Hz, 1H, H-1’a), 
3.32 (dd, J = 13.4, 3.3 Hz, 1H, H-1’b). 13C NMR (100 MHz, MeOD) δ 73.1 (C-3), 
70.1 (C-4), 69.3 (C-2), 61.6 (C-2’), 59.2 (C-5), 57.5 (C-6), 57.4 (C-1), 47.8 (C-1’). IR/cm-1: 3272, 




161 was subjected to the general procedure A and generated 167 (31 
mg, 0.08 mmol) in a yield of 26%. 1H NMR (400 MHz, MeOD) δ 4.21 (d, J 
= 12.5 Hz, 1H, H-6a), 4.00 (dd, J = 12.5, 3.2 Hz, 1H, H-6b), 3.80 (ddd, J = 
11.2, 9.3, 4.9 Hz, 1H, H-2), 3.70 (dd, J = 10.5 Hz, 1H, H-4), 3.54 (t, J = 12.7 
Hz, 2H, H-5’), 3.53 (t, J = 12.6 Hz, 2H, H2-6’), 3.60 – 3.43 (m, 3H, H-1a, H-
1’a, H-3), 3.31 (td, J = 12.6, 5.3 Hz, 1H, H-1’b), 3.17 (dd, J = 10.3, 2.8 Hz, 
H-5, 1H), 3.10 (dd, J = 12.2, 11.2 Hz, 1H, H-1b), 1.96 – 1.81 (m, 2H, H2-2’), 1.79 – 1.69 (m, 2H, H2-
7’), 1.69 – 1.61 (m, 2H, H2-4’), 1.59 – 1.50 (m, 2H, H2-3’), 1.50 – 1.30 (m, 12H, H2-8’ – H2-13’), 
0.94 (t, J = 7.0 Hz, 3H, H3-14’). 13C NMR (100 MHz, MeOD) δ 78.9 (C-3), 72.9 (C-6’), 72.2 (C-5’), 
69.7 (C-4), 68.7 (C-2), 68.3 (C-5), 55.7 (C-6), 55.7 (C-1), 55.2 (C-1’), 49.9, 33.9, 31.6, 31.6, 31.5, 
31.3, 31.0, 28.1, 25.4, 24.8, 24.6  (C-2’ – C-4’, C-7’ – C-13’), 15.3 (C-14’). [α]20D = +1.6 (c = 1, 
MeOH). IR/cm-1:3327, 2955, 2854, 1628, 1456, 1101, 1028. HRMS: found 376.30587 
[C20H41NO5+H]+, calculated for [C20H41NO5+H]+ 376.30575. 
 
N-[5-(Hexyloxy)pentyl]-L-gluco-1-deoxynojimycin (168): 
161 was subjected to the general procedure A and generated 168 (12 
mg, 0.04 mmol) in a yield of 10%. 1H NMR (400 MHz, MeOD) δ 4.02 (dd, 
J = 12.2, 2.5 Hz, 1H, H-6a), 3.97 (dd, J = 12.1, 2.8 Hz, 1H, H-6b), 3.64 
(ddd, J = 10.7, 7.6, 4.6 Hz, 1H, H-2), 3.52 (t, J = 6.4 Hz, 2H, H-5’), 3.51 (t, J 
= 6.6 Hz, 2H, H2-6’), 3.56 – 3.52 (m, 1H, H-4), 3.31 (t, J = 9.1 Hz, 1H, H-3), 
3.23 (dd, J = 11.6, 4.9 Hz, 1H, H-1a), 3.14 – 3.00 (m, 1H, H-1’a), 2.96 – 
2.82 (m, 1H, H-1’b), 2.61 – 2.45 (m, 2H, H-1b, H-5), 1.77 – 1.59 (m, 6H, H2-2’, H2-7’, H2-4’), 1.54 – 
1.34 (m, 8H, H2-3’, H2-8’, H2-9’, H2-10’), 0.94 (t, J = 7.0 Hz, 3H, H3-11’). 13C NMR (100 MHz, 
MeOD) δ 80.6 (C-3), 72.8 (C-6’), 72.5 (C-5’), 71.7 (C-4), 70.6 (C-2), 68.2 (C-5), 58.9 (C-6), 57.6 




(C-1), 54.7 (C-1’), 33.7, 31.6, 31.3, 27.8, 25.8, 25.5, 24.5 (C-2’ – C-4’, C-7’ – 10’), 15.3 (C-11’). 
[α]20D = +9.0 (c = 0.2, MeOH). IR/cm-1: 3361, 2933, 2860, 1670, 1456, 1375, 1202, 1101, 1034. 
HRMS: found 334.25897 [C17H35NO5+H]+, calculated for [C17H35NO5+H]+ 334.25880. 
 
N-[5-(3,3-Dimethyl-1-propyloxy)pentyl]-L-gluco-1-deoxynojimycin (169): 
161 was subjected to the general procedure A and generated 169 
(63 mg, 0.19 mmol) in a yield of 33%. 1H NMR (400 MHz, MeOD) δ 
4.06 (dd, J = 12.2, 2.2 Hz, 1H, H-6a), 3.98 (dd, J = 12.2, 3.0 Hz, 1H, H-
6b), 3.67 (td, J = 10.5, 9.9, 4.8 Hz, 1H, H-2), 3.56 (t, J = 9.7 Hz, 1H, H-
4), 3.53 (t, J = 6.3 Hz, 2H, H2-5’), 3.34 (t, J = 9.1 Hz, 1H, H-3), 3.38 – 
3.27 (m, 1H, H-1a), 3.16 (s, 2H, H2-6’), 3.16 (br s, 1H, H-1’a), 2.67 (br 
s, 2H, H-1b, H-5), 1.85 – 1.66 (m, 4H, H2-2’, H2-4’), 1.59 – 1.43 (m, 2H, 
H2-3’), 0.93 (s, 9H, H3-8’, H3-9’, H3-10’). 13C NMR (100 MHz, MeOD) δ 83.4 (C-6’), 80.3 (C-3), 73.1 
(C-5’), 71.3 (C-4), 70.2 (C-2), 68.2 (C-5), 58.6 (C-6), 56.3 (C-1), 54.8 (C-1’), 33.8 (C-7’), 31.3 (C-
4’), 28.0 (C-8’,C-9’,C-10’), 25.8 (C-3’), 25.4 (C-2’). [α]20D = +7.2 (c = 1, MeOH). IR/cm-1: 3280, 
2951, 2862, 1734, 1637, 1458, 1387, 1362, 1113, 1032. HRMS: found 320.24339 
[C16H33NO5+H]+, calculated for [C16H33NO5+H]+ 320.24315. 
 
C-6 fluorinated DNJ derivatives 
N-Butyl-1,6-dideoxy-6-fluoro-1,5-imino-D-glucitol (177):  
1-Bromobutane (0.375 mmol) was subjected to general procedure A with 
1,5,6-trideoxy-6-fluoro-1,5-imino-D-glucitol (0.25 mmol) to provide 177.  1H 
NMR (400 MHz, MeOD) δ 5.04 (qd, J = 12.0, 2.4 Hz, 1H, H-6a), 4.92 – 4.88 (m, 
1H, H-6b), 3.74 (td, J = 10.6, 10.1, 4.7 Hz, 1H, H-2), 3.65 – 3.56 (m, 1H, H-4), 
3.54 (dd, J = 12.2, 4.8 Hz, 1H, H-1a), 3.44 (t, J = 9.2 Hz, 1H, H-3), 3.41 – 3.32 
(m, 2H, H-1’a, H-5), 3.23 (td, J = 12.2, 5.2 Hz, 1H, H-1’b), 3.04 (t, J = 11.6 Hz, 1H, H-1b), 1.81  – 
1.66 (m, 2H, H2-2’), 1.48  – 1.40 (m, 2H, H2-3’), 1.00 (t, J = 7.4 Hz, 3H, H3-4’). 13C NMR (100 MHz, 
MeOD) δ 78.6 (d, JCF = 170.0 Hz, C-6), 77.0 (C-3), 68.5 (C-4), 67.7 (C-2), 66.4 (d, JCF = 17.7 Hz, C-
5), 55.1 (C-1), 54.6 (C-1’), 26.2 (C-2’), 20.8 (C-3’), 13.8 (C-4’). IR/cm-1: 3208, 2909, 1663, 1437, 
1184, 1132, 1055, 1024. HRMS: found 222.14995 [C10H20FNO3+H]+, calculated for 
[C10H20FNO3+H]+ 222.15000. 
 
N-Nonyl-1,6-dideoxy-6-fluoro-1,5-imino-D-glucitol (178):  
1-Bromononane (0.375 mmol) was subjected to general procedure A with 
1,5,6-trideoxy-6-fluoro-1,5-imino-D-glucitol (0.25 mmol) to provide 178. 1H 
NMR (400 MHz, MeOD) δ 5.05 (ddd, J = 12.8, 12.3, 2.4 Hz, 1H, H-6a), 4.97 – 
4.90 (m, 1H, H-6b), 3.72 (ddd, J = 10.5, 10.0, 4.7 Hz, 1H, H-2), 3.59 (t, J = 9.5 Hz, 
1H, H-4), 3.52 (dd, J = 12.2, 4.8 Hz, 1H, H-1a), 3.43 (t, J = 8.9 Hz, 1H, H-3), 3.40 
– 3.34 (m, 2H, H-1’a, H-5), 3.21 (td, J = 12.4, 5.4 Hz, 1H, H-1’b), 3.03 (t, J = 11.6 
Hz, 1H, H-1b), 1.80 – 1.70 (m, 2H, H2-2’), 1.47 – 1.19 (m, 12H, H2-3’, H2-4’, H2-5’, H2-6’, H2-7’, H2-
8’), 0.90 (t, J = 6.6 Hz, 3H, H3-9’). 13C NMR (100 MHz, MeOD) δ 78.6 (d, JCF = 168.8 Hz, C-6), 77.1 
(C-3), 68.6, 68.5 (C-4), 67.8 (C-2), 66.4 (d, JCF = 17.8 Hz, C-5), 54.8 (C-1), 54.4 (C-1’), 32.9, 30.4, 
30.2, 30.2, 27.6, 24.3, 23.6 (C-2’ – C-8’), 14.4 (C-9’). IR/cm-1: 3244, 2926, 2857, 1666, 1456, 
1435, 1200, 1184, 1086, 1022. HRMS: found 292.22803 [C15H30FNO3+H]+, calculated for 
[C15H30FNO3+H]+ 292.22825. 
 
 N-[5-(Hexyloxy)pentyl]-1,6-dideoxy-6-fluoro-1,5-imino-D-glucitol (179):  
Pentyloxyhexyl bromide (0.375 mmol) was subjected to general 
procedure A with 1,5,6-trideoxy-6-fluoro-1,5-imino-D-glucitol (0.25 
mmol) to provide 179. 1H NMR (400 MHz, MeOD) δ 5.11 – 4.89 (m, 2H, 





4), 3.50 (dd, J = 12.2, 4.8 Hz, 1H, H-1a), 3.46 (t, J = 6.2 Hz, 2H, H2-5’), 3.43 (t, J = 6.6 Hz, 2H, H2-
6’), 3.41 – 3.29 (m, 3H, H-3, H-1’a, H-5), 3.21 (td, J = 12.2, 5.1 Hz, 1H, H-1’b), 3.00 (t, J = 11.5 Hz, 
1H, H-1b), 1.84 – 1.74 (m, 2H, H2-2’), 1.69 – 1.60 (m, 2H, H2-4’), 1.58 – 1.53 (m, 2H, H2-7’), 1.48 – 
1.45 (m, 2H, H2-3’), 1.40 – 1.23 (m, 6H, H2-8’, H2-9’, H2-10’), 0.93 (t, J = 7.0 Hz, 3H, H3-11’). 13C 
NMR (100 MHz, MeOD) δ 78.6 (d, JCF = 174.4 Hz, C-6), 72.1 (C-6’), 71.4 (C-5’), 68.7 (C-4), 67.9 
(C-2), 66.4 (d, JCF = 17.7 Hz, C-5), 54.7 (C-1), 54.6 (C-1’), 32.8, 30.7, 30.1, 26.9, 24.4, 24.2, 23.6 (C-
2’ – C-4’, C-7’ – C-10’), 14.4 (C-11’). IR/cm-1: 3310, 2934, 2860, 2800, 1670, 1456, 1435, 1377, 
1204, 1134, 1022, 839, 800, 723.  HRMS: found 336.25416 [C17H34FNO4+H]+, calculated for 
[C17H34FNO4+H]+ 336.25446. 
 
N-[5-(3,3-Dimethyl-1-propyloxy)pentyl]-1,6-dideoxy-6-fluoro-1,5-imino-D-glucitol (180):  
1-Bromo-5-(2,2-dimethyl-1-propoxy) pentane (0.375 mmol) was 
subjected to general procedure A with 1,5,6-trideoxy-6-fluoro-1,5-
imino-D-glucitol (0.25 mmol) to provide 180.  1H NMR (400 MHz, 
MeOD) δ 5.11 – 4.86 (m, 2H, H2-6), 3.71 (td, J = 10.5, 4.7 Hz, 1H, H-2), 
3.59 (t, J = 9.2 Hz, 1H, H-4), 3.52 (dd, J = 12.2, 4.8 Hz, 1H, H-1a), 3.45 (t, 
J = 6.2 Hz, 2H, H2-5’), 3.43 – 3.34 (m, 3H, H-1’a, H-3, H-5), 3.23 (ddd, J = 
12.7, 12.3, 5.2 Hz, 1H, H-1b), 3.08 (s, 2H, H2-6’), 3.03 (t, J = 11.6 Hz, 1H, H-1b), 1.90 – 1.70 (m, 
2H, H2-2’), 1.65 (dt, J = 8.0, 6.4 Hz, 2H, H2-4’), 1.54 – 1.36 (m, 2H, H2-3’), 0.90 (s, 9H, H3-8’, H3-9’, 
H3-10’). 13C NMR (100 MHz, MeOD) δ 82.5 (C-6’), 78.48 (d, JCF = 174.2 Hz, C-6) 78.1 (C-3), 72.0 
(C-5’), 68.6 (C-4), 67.8 (C-2), 66.38 (d, JCF = 17.8 Hz, C-5), 54.8 (C-1), 54.7 (C-1’), 32.9 (C-7’), 30.1 
(C-4’), 27.1 (C-8’, 9’, 10’), 24.9 (C-3’), 24.4 (C-2’). IR/cm-1: 3302, 2955, 2866, 1670, 1435, 1387, 




5-(Adamantan-1-yl-methoxy)pentyl bromide (0.375 mmol) was 
subjected to general procedure A with 1,5,6-trideoxy-6-fluoro-
1,5-imino-D-glucitol (0.25 mmol) to provide 181. 1H NMR (400 
MHz, MeOD) δ 3.70 (td, J = 10.5, 4.7 Hz, 1H, H-2), 3.54 (t, J = 9.5 
Hz, 1H, H-4), 3.44 (dd, J = 12.4, 5.0 Hz, 1H, H-1a), 3.39 (t, J = 9.1 
Hz, 1H, H-3), 3.31 (t, J = 6.2 Hz, 2H, H2-5’), 3.33 – 3.20 (m, 2H, H-5, H-1’a), 3.13 (ddd, J = 12.8, 
12.3, 5.3 Hz, 1H, H-1’b), 2.93 (t, J = 11.6 Hz, 1H, H-1b), 2.88 (s, 2H, H2-6’), 1.85 (t, J = 3.4 Hz, 3H, 3 
x CH ada), 1.76 – 1.63 (m, 2H, H2-2’), 1.65 – 1.52 (m, 8H, 3 x CH2 ada, H2-4’), 1.44 (d, J = 3.0 Hz, 
6H, 3 x CH2 ada), 1.41 – 1.23 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 82.7 (C-6’), 78.6 (d, JCF 
= 170.7 Hz, C-6), 77.0 (C-3), 71.7 (C-5’), 68.1 (C-4), 67.1 (C-2), 65.97 (d, JCF = 17.8 Hz, C-5), 54.5 
(C-1), 54.5 (C-1’), 40.4 (CH2 ada), 37.9 (CH2 ada), 34.8 (Cq ada), 29.6 (C-4’), 29.2 (CH ada), 24.0 
(C-3’), 23.6 (C-2’). IR/cm-1: 3354, 2901, 2847, 2590, 1651, 1446, 1205, 1184, 1140, 1018. 
HRMS: found 400.28468 [C22H38FNO4+H]+, calculated for [C22H38FNO4+H]+ 400.28576. 
 
N-[(Biphenyl-4-yl-methoxy)pentyl]-6-fluoro-1,5-imino-D-glucitol (182): 
(Biphenyl-4-yl-methoxy)-pentyl bromide (0.375 mmol) 
was subjected to general procedure A with 1,5,6-trideoxy-
6-fluoro-1,5-imino-D-glucitol (0.25 mmol) to provide 182. 
1H NMR (400 MHz, MeOD) δ 7.61 (d, J = 7.9 Hz, 4H, HAr 
BiPh), 7.47 – 7.31 (m, 5H, HAr BiPh), 5.12 – 4.75 (m, 2H, H2-
6), 4.55 (s, 2H, H2-6’), 3.70 (td, J = 10.0, 4.5 Hz, 1H, H-2), 3.57 (t, J = 6.2 Hz, 2H, H2-5’), 3.51 (dd, J 
= 12.2, 4.9 Hz, 1H, H-4), 3.45 – 3.30 (m, 3H, H-1a, H-3, H-1’a), 3.23 (ddd, J = 13.1, 12.5, 5.7 Hz, 
1H, H-1’b), 3.02 (t, J = 11.6 Hz, 1H, H-1b), 1.89 – 1.75 (m, 2H, H2-2’), 1.76 – 1.66 (m, 2H, H2-4’), 
1.61 – 1.44 (m, 2H, H2-3’). 13C NMR (100 MHz, MeOD) δ 142.0, 138.7 (Cq BiPh), 129.9 – 127.9 
(CAr BiPh), 78.4 (d, JCF = 169.5 Hz, C-6), 77.9 (C-3), 73.7 (C-6’), 71.0 (C-5’), 68.5 (C-4), 67.8 (C-2), 
66.3 (d, JCF = 17.7 Hz, C-5), 54.9 (C-1), 54.7 (C-1’), 30.0 (C-4’), 24.5 (C-3’), 24.0 (C-2’). IR/cm-1: 




3304, 2918, 2864, 1672, 1487, 1435, 1364, 1203, 1134, 1022, 841. HRMS: found 418.23818 
[C24H32FNO4+H]+, calculated for [C24H32FNO4+H]+ 418.23881. 
 
N-(Benzyloxy)ethyl-1,6-dideoxy-6-fluoro-1,5-imino-D-glucitol (183):  
(2-Benzyloxy)ethyl bromide (0.375 mmol) was subjected to general 
procedure A with 1,5,6-trideoxy-6-fluoro-1,5-imino-D-glucitol (0.25 
mmol) to provide 183. 1H NMR (400 MHz, MeOD) δ 7.38 – 7.25 (m, 5H, 
HAr Bn), 5.25 – 4.90 (m, 2H, H2-6), 4.59 (s, 2H, CH2 Bn), 3.85 (t, J = 4.9 Hz, 
2H, H2-2’), 3.78 – 3.61 (m, 2H, H-2, H-1’a), 3.60 – 3.55 (m, 2H, H-4, H-
1a), 3.49 (dt, J = 14.1, 4.9 Hz, 1H, H-1’b), 3.39 (t, J = 9.0 Hz, 1H, H-3), 3.05 
(t, J = 11.6 Hz, 1H, H-1b). 13C NMR (100 MHz, MeOD) δ 138.5 (Cq Bn), 129.6 – 129.2 (CHAr Bn), 
78.8 (d, JCF = 169.1 Hz, C-6), 74.4 (C-3’), 68.5 (C-4), 67.8 (C-2), 66.2 (d, JCF = 17.6 Hz, C-5), 64.6 
(C-2’), 55.6 (C-1), 54.2 (C-1’). IR/cm-1: 3235, 2874, 1670, 1456, 1437, 1364, 1202, 1134, 1026. 
HRMS: found 300.16042 [C15H22FNO4+H]+, calculated for [C15H22FNO4+H]+ 300.16056. 
 
N-(Nonyloxy)pentyl-1,6-dideoxy-6-fluoro-1,5-imino-D-glucitol (184):  
Pentyloxynonyl bromide was subjected to general procedure A with 
1,5,6-trideoxy-6-fluoro-1,5-imino-D-glucitol (0.25 mmol) to provide 184. 
1H NMR (400 MHz, Methanol-d4) δ 5.05 (ddd, J = 11.0, 10.2, 2.3 Hz, 1H, H-
6a), 4.99 – 4.92 (m, 1H, H-6b), 3.71 (ddd, J = 10.9, 9.0, 4.8 Hz, 1H, H-2), 
3.59 (t, J = 9.6 Hz, 1H, H-4), 3.52 (dd, J = 12.2, 4.8 Hz, 1H, H-1a), 3.46 (t, J = 
6.1 Hz, 2H, H2-5’), 3.43 (t, J = 6.5 Hz, 2H, H2-6’), 3.40 – 3.30 (m, 3H, H-3, H-
1’a, H-5), 3.22 (ddd, J = 12.7, 12.3, 5.2 Hz, 1H, H-1’b), 3.02 (t, J = 11.6 Hz, 1H, H-1b), 1.89 – 1.69 
(m, 2H, H2-2’), 1.73 – 1.62 (m, 2H, H2-4’), 1.63 – 1.53 (m, 2H, H2-7’), 1.53 – 1.42 (m, 2H, H2-3’), 
1.38 – 1.23 (m, 12H, H2-8’, H2-9’, H2-10’, H2-11’, H2-12’, H2-13’), 0.90 (t, J = 6.8 Hz, 3H, H2-14’). 
13C NMR (100 MHz, MeOD) δ 78.6 (d, J = 168.3 Hz, C-6), 72.1 (C-6’), 71.4 (C-5’), 77.2 (C-3), 68.6 
(C-4), 67.8 (C-2), 66.4 (d, J = 17.7 Hz, C-5), 55.1 (C-1), 54.7 (C-1’), 33.0, 30.7, 30.6, 30.4, 30.1, 
27.2, 24.4, 24.1, 23.7 (C-2’ – C-4’, C-7’ – C-13’), 14.4 (C-14’). IR/cm-1: 3294, 2926, 2855, 1670, 
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DNJ 分子的合成策略，着重讨论了双还原胺化（double reductive amination）在合成过程中发
挥的关键作用。本论文中提出的几个合成路线都以其作为关键步骤。 
 
与单糖 DNJ 相比，目前其糖基化衍生物尚未受到明显关注。第 3 章阐述了从相应二糖开




GBA2 选择性抑制剂不仅是研究 GBA2 生物功能的理想工具分子，还是潜在的临床候选
药物。研究认为 GBA2 与溶酶体贮积症（lysosomal storage disorders，高雪氏病（Gaucher 
disease）和 C 型尼曼氏病（Niemann-Pick type C disease）密切相关。第 4 章关注了 N-烷基
化 DNJ 衍生物的设计和合成，构建了由 N-戊氧基新戊基异构体亚胺糖组成的化合物库，并对

















亚胺糖衍生物 C-5 氧杂环丁烷亚胺糖的合成路线。初步评估了亚胺糖 C-2 和 C-3 结构对于其
作为 GCS 抑制剂活性的重要性：（2S,3R）立体构型可能是亚胺糖拥有 GCS 抑制活性的必要
条件。此外，通过分析氟原子取代 6 号位羟基对 DNJ 活性的影响，结果表明引入电负性更高




List of Publications 
 
1. Lahav, D.; Liu, B.(Joint first author); van den Berg, R.J.B.H.N.; van den Nieuwendijk, A.M.C.H.; 
Wennekes, T.; Ghisaidoobe, A.; Breen, I.; Ferraz, M.; Kuo, C. L.; Wu, L.; Geurink, P.; Ovaa, H.; van der 
Marel, G.; van der Stelt, M.; Boot, R.; Davies, G.; Aerts, J.; Overkleeft, H. A fluorescence polarization 
activity-based protein profiling assay in the discovery of potent, selective inhibitors for human non-
lysosomal glucosylceramidase. JACS. accepted 22 Sept. 2017. 
 
2. Cao, S.; Liu, B.; Cheng, B. Z.; Lu, F. P.; Wang, Y. P.; Li, Y. Mechanisms of Zn(II) binded to collagen 
and its effect on the capacity of eco-friendly Zn-Cr combination tanning system. J. Hazard. Mater. 
2017, 321, 203-209. 
 
3. Cao, S.; Xin, Q.; Zhou, S.; Xue, B.; Liu, B.; Lu, F.; Wang, Y.; Li, Y.  Amyloliquefaciens TCCC 11319, a 
new Cr(III)-tolerant bacterium for future chromium tanned leather shavings disposal.  RSC Adv. 13 
Jan 2017, acceptied.  
 
4. Cao, S.; Zeng, Y. H.; Cheng, B. Z.; Zhang, W. H.; Liu, B. Effect of pH on Al/Zr-binding sites between 
collagen fibers in tanning process. J. Am. Leather Chem. As. 2016, 111, 242-249. 
 
5. Cao, S.;  Cheng, B. Z.; Liu, B.; He, X. Effect of mixed metal tanning using zinc and titanium with 
suitable masking agents. J. Soc. Leath. Tech. Chem. 2015, 99, 120-123.   
 
 
6. Cao, S.; Cheng, B. Z.; Wang, Q. O.; Liu, B. Characterization and mechanism of zinc salts as tanning 






Bing Liu was born on January 13th 1989 in Puyang, Henan, China. During her High School 
years, she got interested in Chemistry. After the College Entry Examinations, she enrolled at the 
College of Chemistry and Material Science at Shandong Agricultural University. Here she 
obtained her Bachelor’s Degree in Applied Chemistry. During this time she also took on English 
Literature as a second major, which resulted in another Bachelor’s Degree obtained in 2009.  
After completing her bachelor studies, she entered the College of Life Science at Beijing 
Normal University. Here she followed a major in Biochemistry and Molecular Biology. She 
obtained her Master’s Degree in 2012, under the supervision of Prof. Xiang Benqiong and Prof. 
Wei Qun.  
Following this she applied for a PhD study at Leiden University in 2012. In December of 
that year she started her study in the Bio-Organic Synthesis Group under the supervision of 
Prof. Dr. Herman S. Overkleeft and Dr. Richard J. B. H. N. van den Berg. She was awarded a 
scholarship by the CSC (China Scholarship Council) in 2013, which lasted until 2016. Her PhD 
study was focussed on the iminosugars as inhibitors for glucosylceramide processing enzymes. 
Her research consisted of the synthesis and the evaluation of the activity of various iminosugar 
compound libraries.   
 
